U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Sanders GD, Lowenstern A, Borre E, et al. Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Oct. (Comparative Effectiveness Reviews, No. 214.)

Cover of Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update

Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update [Internet].

Show details

Appendix DList of Excluded Studies

All studies listed below were reviewed in their full-text version and excluded for the reasons cited. Reasons for exclusion signify only the usefulness of the articles for this study and are not intended as criticisms of the articles. Not all of the same exclusion reasons were used for the 2017 update as were used for the 2012 report. The 2017 excluded studies are all listed before the 2012 excluded studies.

Not a full publication, publication retracted/withdrawn, full text not obtainable, or full text not obtainable in English-2017

  1. Alemán A and Ioli P. Comparative efficacy and cost-effectiveness of new oral anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. Neurologia Argentina 2013;5(4):228–232.
  2. Ardashev AV, Zheliakov EG, Dupliakov DV, et al. [Long-term results of radiofrequency catheter ablation of long-lasting persistent atrial fibrillation: five years of follow-up]. Kardiologiia 2013;53(6):4–11. PMID: 23953039 [PubMed: 23953039]
  3. Bai Y, Liu N, Bai R, et al. [Impacts of radiofrequency ablation on quality of life of atrial fibrillation patients with low CHA2DS2-VASc score]. Zhonghua Nei Ke Za Zhi 2016;55(4):278–82. PMID: 27030615 [PubMed: 27030615]
  4. Belousov YB, Mareev VY, Yavelov IS, et al. Pharmacoeconomic evaluation of dabigatran vs warfarin in cardiovascular events prevention in patients with non-valvular atrial fibrillation. Rational Pharmacotherapy in Cardiology 2012;8(1):37–44.
  5. Bi WJ, Li Y, Ren WD, et al. Application of CHADS2 score in prediction of left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Chinese Journal of Medical Imaging Technology 2013;29(3):398–401.
  6. Chang CJ, Chen YT, Liu CS, et al. Atrial Fibrillation Increases the Risk of Peripheral Arterial Disease With Relative Complications and Mortality: A Population-Based Cohort Study. Medicine (Baltimore) 2016;95(9):e3002. PMID: 26945422. [PMC free article: PMC4782906] [PubMed: 26945422]
  7. Chatzimavridou-Grigoriadou V, Kanavidis P and Mathioudakis AG. Valvular-CHADS-VASc as a safer alternative to CHADS-VASc score. International Journal of Cardiology 2016;221:1051–1052. [PubMed: 27447814]
  8. Corbalan R, Conejeros C, Rey C, et al. [Features, management and prognosis of Chilean patients with non valvular atrial fibrillation: GARFIELD AF registry]. Rev Med Chil 2017;145(8):963–971. Digital Object Identifier: 10.4067/s0034-98872017000800963. PMID: 29189853. [PubMed: 29189853] [CrossRef]
  9. Cortés-Ramírez JM, De Jesús Cortés-de La Torre JM, Cortés-de La Torre RA, et al. Atrial Fibrillation. Stratification, Treatmentwith Anticoagulants and Following. Medicina Interna de Mexico 2014;30(2):133–139.
  10. De Caterina R and Abbate R. [The AVERROES study]. G Ital Cardiol (Rome) 2011;12(9):551–5. PMID: 21892215. [PubMed: 21892215]
  11. De Caterina R, Renda G, Sangiuolo R, et al. [Management of thromboembolic risk in patients with atrial fibrillation in Italy: baseline data from the PREFER in AF European Registry]. G Ital Cardiol (Rome) 2014;15(2):99–109. PMID: 24625849. [PubMed: 24625849]
  12. Deambrosis P, Bettiol A, Bolcato J, et al. Thromboprophylaxis in patients with atrial fibrillation: A real practice analysis. Global and Regional Health Technology Assessment 2016;3(1):16–22.
  13. Di Lullo L, Barbera V, Bellasi A, et al. [NOACs and Chronic kidney disease]. G Ital Nefrol 2017;34:(Suppl 69):188–204. PMID: 28682039. [PubMed: 28682039]
  14. Di Lullo L, Barbera V, Bellasi A, et al. [Non vitamin-K dependent oral anticoagulants (NOACs) in chronic kidney disease patients with non-valvular atrial fibrillation]. G Ital Nefrol 2017;34(2):58–73. PMID: 28682563. [PubMed: 28682563]
  15. Di Pasquale G and Riva L. Edoxaban in atrial fibrillation: The ENGAGE AF-TIMI 48 trial. Giornale Italiano di Cardiologia 2014;15(12):22S–26S.
  16. Di Toro D, Hadid C, Gallino S, et al. Application and comparison of the chads2 and cha2ds2-vasc risk scores in a population with atrial fibrillation. Revista Argentina de Cardiologia 2013;81(6).
  17. Diener HC. Severe bleeding from anticoagulation with warfarin often. Medizinische Monatsschrift fur Pharmazeuten 2013;36(4):157.
  18. Dürschmied D, Moser M and Bode C. Newest data and practical experience with new oral anticoagulants (NOAK) - Which patients benefit from these drugs?. Klinikarzt 2013;42(SUPPL. 1):9–14.
  19. Erlikh AD, Kharchenko MS, Barbarash OL, et al. [Adherence to guidelines on management of acute coronary syndrome in Russian hospitals and outcomes of hospitalization (data from the RECORD-2 Registry)]. Kardiologiia 2013;53(1):14–22. PMID: 23548345. [PubMed: 23548345]
  20. Erlikh AD, Tkachenko KG and Gratsiansky NA. Management and outcomes in acute coronary syndrome with atrial fibrillation in “on-invasive” clinic. Russian Journal of Cardiology 2017;141(1):89–94. Digital Object Identifier: 10.15829/1560-4071-2017-1-89-94. [CrossRef]
  21. Fareau S, Baumstarck K, Farcet A, et al. [Quality of life of elderly people on oral anticoagulant for atrial fibrillation: VKA versus direct oral anticoagulants]. Geriatr Psychol Neuropsychiatr Vieil 2015;13(1):45–54. PMID: 25786423. [PubMed: 25786423]
  22. Fernández A, Rodríguez A, Sénior JM, et al. Short-term safety and efficacy of left atrial appendage closure using WATCHMAN® device for non-valvular atrial fibrillation in patients with a high risk of bleeding. Revista Colombiana de Cardiologia 2017;24(4):369–375. Digital Object Identifier: 10.1016/j.rccar.2016.10.048. [CrossRef]
  23. Fitch K, Broulette J, Pyenson B, et al. Erratum: utilization of anticoagulation therapy in medicare patients with nonvalvular atrial fibrillation. Am Health Drug Benefits 2012;5(3):157–68. PMID: 24991318. [PMC free article: PMC4046469] [PubMed: 24991318]
  24. Furman NV, Graifer IV, Reshet’ko OV, et al. [Gender related characteristics of clinical status and pharmacotherapy of patients with paroxysmal and persistent atrial fibrillation]. Kardiologiia 2013;53(2):30–7. PMID: 23548388. [PubMed: 23548388]
  25. Gao X, Yang YM, Zhu J, et al. [Dabigatran versus warfarin for the prevention of stroke in Chinese patients with nonvalvular atrial fibrillation: Chinese subpopulation analysis of RE-LY]. Zhonghua Xin Xue Guan Bing Za Zhi 2016;44(11):929–934. PMID: 27903389. [PubMed: 27903389]
  26. García-Villarreal OA and Heredia-Delgado JA. Left atrial appendage in rheumatic mitral valve disease: The main source of embolism in atrial fibrillation. Archivos de Cardiologia de Mexico 2017;87(4):286–291. Digital Object Identifier: 10.1016/j.acmx.2016.11.007. [PubMed: 27986559] [CrossRef]
  27. Gloekler S, Hajredini B, Rycerz S, et al. [Left atrial appendage clusure in nonvalvular atrial fibrillation: Clinical evidence 2017]. Herzschrittmacherther Elektrophysiol 2017;28(4):366–380. Digital Object Identifier: 10.1007/s00399-017-0536-9. PMID: 29143099. [PubMed: 29143099] [CrossRef]
  28. Gómez-Peña L, Nápoles CD, Torres EP, et al. Risk of cerebrovascular disease in atrial fibrillation. Lenin Hospital, January 2006 - December 2007. Revista Ecuatoriana de Neurologia 2011;20(1-3):50–54
  29. Gorzelak P, Zyzak S, Krewko L, et al. [Frequency of use of oral vitamin K antagonists in patients with atrial fibrillation and cognitive function disturbances]. Pol Merkur Lekarski 2014;36(215):302–6. PMID: 24964505. [PubMed: 24964505]
  30. Grajfer IV, Kuvshinova LE, Dolotovskaya PV, et al. Risk of thromboembolic complications and antithrombotic therapy in in-patients with permanent and recurrent atrial fibrillation in real clinical practice. Rational Pharmacotherapy in Cardiology 2012;8(5):675–680.
  31. Guo X, Zhang Y, Xu G, et al. [The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China]. Zhonghua Nei Ke Za Zhi 2014;53(5):371–4. PMID: 25146403. [PubMed: 25146403]
  32. Huang LT, Han Z, Ye ZS, et al. The relationship between CHADS2 score and prognosis in acute ischemic stroke patients with nonvalvular atrial fibrillation. Chinese Journal of Neurology 2012;45(3):169–173
  33. Janský P. Apixaban is more effective than warfarin in reduction of the incidence of strokes and bleeding in patients with atrial fibrillation irrespective of their risk profiles: Subanalysis of ARISTOTLE trial. Interni Medicina pro Praxi 2013;15(8-9):269–272.
  34. Jorge E, Pereira FS, Baptista R, et al. [Anticoagulation in elderly patients with atrial fibrillation: from the guidelines to the daily medical practice]. Acta Med Port 2011;24: Suppl 2:293–300. PMID: 22849915. [PubMed: 22849915]
  35. Katsiki N and Mikhailidis DP. Antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease. Cardiology Review 2015;31(2).
  36. Kim SW, Yoon SJ, Choi JY, et al. OS 27-05 FRAILTY ASSESSMENT IN OLDER ATRIAL FIBRILLATION PATIENTS. J Hypertens 2016;34 Suppl 1 - ISH 2016 Abstract Book:e250. PMID: 27754141.
  37. Koroleva LY, Kolesnichenko IV, Nosov VP, et al. The anticoagulation in patients with atrial fibrillation: Rivaroxaban and warfarin. Rational Pharmacotherapy in Cardiology 2016;12(5):553–557.
  38. Leschke M, Hess S, Weber E, et al. Stroke prevention with rivaroxaban in routine clinical practice - current study data concerning stroke prophylaxis in patients with non-valvular atrial fibrillation in Germany. Klinikarzt 2017;46(3):104–110.
  39. Li H, Li Y, Wei L, et al. Comparison of transesophageal echocardiography and dual source CT in diagnosis of left atrial appendage thrombus in atrial fibrillation patients and analysis of related clinical data. Chinese Journal of Medical Imaging Technology 2016;32(12):1871–1875.
  40. Li J, Guo YT and Wang CJ. [Clinical features and risk factors of stroke/thromboembolism and bleeding in the elderly patients with atrial fibrillation]. Zhonghua Xin Xue Guan Bing Za Zhi 2013;41(11):927–30. PMID: 24370219. [PubMed: 24370219]
  41. Liu BJ, Qu ZS, Zhao YW, et al. Significance of B-type natriuretic peptide in choice of antithrombotic therapy for acute cerebral infarction patients with atrial fibrillation. Journal of Shanghai Jiaotong University (Medical Science) 2017;37(1):85–88.
  42. Lopes RD, Alings M, Connolly SJ, et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J 2017;189:137–145. PMID: 28625370. [PubMed: 28625370]
  43. Lopez Soto A, Formiga F, Bosch X, et al. [Prevalence of atrial fibrillation and related factors in hospitalized old patients: ESFINGE study]. Med Clin (Barc) 2012;138(6):231–7. PMID: 21940001. [PubMed: 21940001]
  44. Malek F. Rivaroxaban use in prevention of stroke in patients with non-valvular atrial fibrillation in clinical practice, results of observational studies and our experience. Vnitrni Lekarstvi 2016;62(10):814–819. [PubMed: 27900868]
  45. Mas JL. Atrial fibrillation: Thromboembolic complications. Archives of Cardiovascular Diseases Supplements 2013;5(2):125–131.
  46. Mavri A and Štalc M. Dabigatran and rivaroxaban in the patients with atrial fibrillation and venous thrombembolism: Our first clinical experience. Zdravniski Vestnik 2014;83(12):849–856
  47. McHorney C, Crivera C, Laliberté F, et al. Adherence to non-VKA oral anticoagulant medications based on the pharmacy quality alliance measure. Circulation 2015;132. [PubMed: 26393483]
  48. Mergenthaler U, Kostev K, Moosmang S, et al. [Stroke prevention in atrial fibrillation in Germany. Situational analysis of treatment reality based on retrospective data]. MMW Fortschr Med 2017;159:(Suppl 7):26–32. Digital Object Identifier: 10.1007/s15006-017-0341-8. PMID: 29204949. [PubMed: 29204949] [CrossRef]
  49. Misirli CH, Mayda Domaç F, Özkan D, et al. Women sex importance in stroke patients with atrial fibrillation. Turk Serebrovaskuler Hastaliklar Dergisi 2014;20(2):47–51.
  50. Mokracek A, Kurfirst V, Bulava A, et al. [Closure of the left atrial appendage by means of the AtriClip System]. Vnitr Lek 2017;63(1):31–35. PMID: 28225286. [PubMed: 28225286]
  51. Monreal-Bosch M, Soulard S, Crespo C, et al. [Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain]. Rev Neurol 2017;64(6):247–256. PMID: 28272725. [PubMed: 28272725]
  52. Oto A, Aytemir K, Okutucu S, et al. [Percutaneous closure of the left atrial appendage: a new option for the prevention of thromboembolic stroke]. Turk Kardiyol Dern Ars 2011;39(8):668–74. PMID: 22257805. [PubMed: 22257805]
  53. Overbeck P. [Anticoagulation in atrial fibrillation. Standard in stroke prevention is eliminated]. MMW Fortschr Med 2011;153(37):12. PMID: 21950180. [PubMed: 21950180]
  54. Passman R. Time in therapeutic range inwarfarin-treated patients is very good good enough?. JAMA - Journal of the American Medical Association 2016;316(8):872–873. [PubMed: 27552620]
  55. Patti G, Colonna P, Pelliccia F, et al. Comparability of efficacy and safety results among phase III trials of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Giornale Italiano di Cardiologia 2017;18(3):175–179 [PubMed: 28398375]
  56. Peeterbroeck J, Danguy C, Lelubre C, et al. Bleeding complications with oral anticoagulants in the elderly: an observational study. Geriatr Psychol Neuropsychiatr Vieil 2016;14(4):406–412. PMID: 27507064. [PubMed: 27507064]
  57. Pelissero E, Giuggia M, Todaro MC, et al. [Combined left atrial appendage percutaneous closure and atrial fibrillation ablation: a single center experience]. G Ital Cardiol (Rome) 2017;18(12):11–17. Digital Object Identifier: 10.1714/2835.28627. PMID: 29297907. [PubMed: 29297907] [CrossRef]
  58. Pelissero E, Giuggia M, Todaro MC, et al. Combined procedure of left atrial appendage percutaneous closure and atrial fibrillation ablation: Experience of a single center. Giornale Italiano di Cardiologia 2017;18(12):11S–17S. Digital Object Identifier: 10.1714/2835.28627. [PubMed: 29297907] [CrossRef]
  59. Perez-Ortega I, Moniche-Alvarez F, Jimenez-Hernandez MD, et al. [Cardioembolic stroke in atrial fibrillation and new anticoagulation criteria: a therapeutic dare]. Rev Neurol 2012;55(2):74–80. PMID: 22760766. [PubMed: 22760766]
  60. Pfister R, Schneider CA and Erdmann E. Atrial fibrillation in diabetic patients with macrovascular disease - PROactive analysis. Diabetes, Stoffwechsel und Herz 2012;21(4):225–229.
  61. Postulła M and Kosior D. XANTUS, a prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Kardiologia Polska 2015;73:71–75.
  62. Ravasio R, Pedone MP and Ratti M. Cost efficacy analysis of new oral anticoagulant for stroke prevention in non-valvular atrial fibrillation in Italy. PharmacoEconomics - Italian Research Articles 2014;16(2-3):1–10.
  63. Renda G, Patti G, Sangiuolo R, et al. [Management of thromboembolic risk in patients with atrial fibrillation in Italy: follow-up data from the PREFER in AF European Registry]. G Ital Cardiol (Rome) 2016;17(11):922–931. PMID: 27996998. [PubMed: 27996998]
  64. Rudakova AV and Tatarskii BA. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation]. Kardiologiia 2014;54(7):43–52. PMID: 25177813. [PubMed: 25177813]
  65. Sanchez Soriano RM, Albero Molina MD, Chamorro Fernandez CI, et al. Long-term prognostic impact of anticoagulation on patients with atrial fibrillation undergoing hemodialysis. Nefrologia 2018. Digital Object Identifier: 10.1016/j.nefro.2017.11.026. PMID: 29426785. [PubMed: 29426785] [CrossRef]
  66. Shavarov A, Yusupov A, Kiyakbaev G, et al. 5A.06: CORRELATION OF THROMBOEMBOLIC RISK WITH GLOBAL LEFT ATRIAL STRAIN IN HYPERTENSIVE PATIENTS WITH ATRIAL FIBRILLATION. J Hypertens 2015;33: Suppl 1:e65. PMID: 26102888.
  67. Shevelev VI and Kanorskii SG. [Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation]. Kardiologiia 2012;52(7):56–60. PMID: 22839715. [PubMed: 22839715]
  68. Shevelev VI and Kanorsky SG. [Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation]. Klin Med (Mosk) 2012;90(10):60–3. PMID: 23285766. [PubMed: 23285766]
  69. Shlyakhto EV, Ezhov AV, Zenin SA, et al. Clinical portrait of the atrial fibrillation patient in Russian federation. Data from the global registry gloria af. Russian Journal of Cardiology 2017;149(9):21–27. Digital Object Identifier: 10.15829/1560-4071-2017-9-21-27. [CrossRef]
  70. Sokolova AA, Zhilenko AV, Tsarev IL, et al. Practical concerns of anticoagulation in nonvalvular atrial fibrillation: A university clinics registry. Russian Journal of Cardiology 2015;125(9):32–37
  71. Sokolova AA, Zhilenko AV, Tsarev IL, et al. Predictors of the risk of hemorrhagic events in patients with atrial fibrillation receiving longterm therapy with direct oral anticoagulants. Rational Pharmacotherapy in Cardiology 2017;13(6):756–763. Digital Object Identifier: 10.20996/1819-6446-2017-13-6-756-763. [CrossRef]
  72. Song SF, Zhou XH, Ruozha B, et al. [A study on the evaluation of anticoagulation status comparing of CHADS2 versus CHA2DS2-VASc scores in patients with non valvular atrial fibrillation in Xinjiang area]. Zhonghua Nei Ke Za Zhi 2016;55(9):684–8. PMID: 27586975. [PubMed: 27586975]
  73. Straube F, Dorwarth U, Schmidt M, et al. [Treatment of atrial fibrillation - status quo]. Dtsch Med Wochenschr 2012;137(14):738–44. PMID: 22454206. [PubMed: 22454206]
  74. Tao XL, Zhang XR, Xiong B, et al. Values of three scoring systems in predicting left atrial thrombus in patients with non-valvular atrial fibrillation. Academic Journal of Second Military Medical University 2014;35(6):644–650.
  75. Terroba-Chambi CJ and Scherle-Matamoros CE. Safety of oral anticoagulation in stroke patients with atrial non valvular fibrillation. Neurologia Argentina 2013;5(3):158–163
  76. Vazquez-Acosta JA, Ramirez-Gutierrez AE, Cerecedo-Rosendo MA, et al. [Characterisation of thromboembolic risk in a mexican population with non-valvular atrial fibrillation and its effect on anticoagulation (MAYA Study)]. Gac Med Mex 2016;152(4):473–8. PMID: 27595250. [PubMed: 27595250]
  77. Wang J, Yang Y, Zhu J, et al. [An analysis of risk factors for stroke in atrial fibrillation and hypertension patients]. Zhonghua Nei Ke Za Zhi 2014;53(4):269–72. PMID: 24857298. [PubMed: 24857298]
  78. Wang J, Yang YM, Zhu J, et al. [Analysis of risk factors for all cause-mortality in Chinese emergency atrial fibrillation patients]. Zhonghua Yi Xue Za Zhi 2013;93(36):2871–5. PMID: 24373398. [PubMed: 24373398]
  79. Wang J, Yang YM, Zhu J, et al. [The impact of hypertension history and baseline blood pressure levels on the cardiovascular outcomes in Chinese emergency atrial fibrillation patients]. Zhonghua Xin Xue Guan Bing Za Zhi 2013;41(11):911–5. PMID: 24370216. [PubMed: 24370216]
  80. Wu S, Yang YM, Zhu J, et al. [Analysis of clinical characteristics and risk of stroke and death within 1 year of patients with nonvalvular atrial fibrillation combined with diabetes mellitus]. Zhonghua Yi Xue Za Zhi 2016;96(26):2044–8. PMID: 27468614. [PubMed: 27468614]
  81. Xiang W, Wang Y, Liu F, et al. [Comparison between CHADS2 score and CHA2DS2-VASc score on assessing the risk of ischemic stroke in patients with nonvalvular atrial fibrillation]. Zhonghua Xin Xue Guan Bing Za Zhi 2014;42(5):389–91. PMID: 25042916. [PubMed: 25042916]
  82. Yamashita T, Fukaya T, Kuroki D, et al. Comparison of the length of stay in patients hospitalized and initiated with dabigatran or warfarin for a concomitant non-valvular atrial fibrillation in real-world Japanese therapeutic practice (SHORT-J). Therapeutic Research 2017;38(4):377–391.
  83. You S, Han Q, Xiao G, et al. [The role of THRIVE score in prediction of outcomes of acute ischemic stroke patients with atrial fibrillation]. Zhonghua Nei Ke Za Zhi 2014;53(7):532–6. PMID: 25264007. [PubMed: 25264007]
  84. Zycińska K, Wiktorowicz M, Pływaczewska M, et al. Present and future of oral anticoagulants in clinical practice. Family Medicine and Primary Care Review 2013;15(2):210–212.
  85. Zyryanov SK and Pereverzev AP. Efficacy and safety of the novel oral anticoagulants for prevention of stroke and systemic embolism in atrial fibrillation. Russian Journal of Cardiology 2017;146(6):158–163. Digital Object Identifier: 10.15829/1560-4071-2017-6-158-163. [CrossRef]

Does not meet study design or sample size requirements-2017

  1. Aakre CA, McLeod CJ, Cha SS, et al. Comparison of clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation. Stroke 2014;45(2):426–31. PMID: 24309585. [PubMed: 24309585]
  2. Abu-Assi E, Otero-Ravina F, Allut Vidal G, et al. Comparison of the reliability and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation. Int J Cardiol 2013;166(1):205–9. PMID: 22104995. [PubMed: 22104995]
  3. Al-Khalili F, Lindström C and Benson L. Adherence to anticoagulant treatment with apixaban and rivaroxaban in a real-world setting. Clinical Trials and Regulatory Science in Cardiology 2016;18:1–4.
  4. Al-Khalili F, Lindstrom C and Benson L. The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic. Curr Med Res Opin 2016;32(4):779–85. PMID: 26765366. [PubMed: 26765366]
  5. Almutairi AR, Zhou L, Gellad WF, et al. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Clin Ther 2017;39(7):1456–1478.e36. Digital Object Identifier: 10.1016/j.clinthera.2017.05.358. PMID: 28668628. [PubMed: 28668628] [CrossRef]
  6. Araújo I, Fonseca C, Cardiga R, et al. CHA2DS2-VASc and HASBLED scores: Implications for thromboembolic prophylaxis in the elderly with atrial fibrillation. European Geriatric Medicine 2013;4(2):67–72.
  7. Arnao V, Agnelli G and Paciaroni M. Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation. Intern Emerg Med 2015;10(5):555–60. PMID: 25862436. [PubMed: 25862436]
  8. Asmarats L and Rodes-Cabau J. Percutaneous Left Atrial Appendage Closure: Current Devices and Clinical Outcomes. Circ Cardiovasc Interv 2017;10(11). Digital Object Identifier: 10.1161/circinterventions.117.005359. PMID: 29146668. [PubMed: 29146668] [CrossRef]
  9. Athanasakis K, Boubouchairopoulou N, Karampli E, et al. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective. Am J Cardiovasc Drugs 2017;17(2):123–133. PMID: 27882517. [PubMed: 27882517]
  10. Athanasakis K, Karampli E, Tsounis D, et al. Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting. Clin Drug Investig 2015;35(11):693–705. PMID: 26385756. [PubMed: 26385756]
  11. Azemi T, Rabdiya VM, Ayirala SR, et al. Left atrial strain is reduced in patients with atrial fibrillation, stroke or TIA, and low risk CHADS(2) scores. J Am Soc Echocardiogr 2012;25(12):1327–32. PMID: 23067897. [PubMed: 23067897]
  12. Barra S, Providencia R, Faustino C, et al. Performance of the Cockcroft-Gault, MDRD and CKD-EPI Formulae in Non-Valvular Atrial Fibrillation: Which one Should be Used for Risk Stratification?. J Atr Fibrillation 2013;6(3):896. PMID: 28496890. [PMC free article: PMC5153032] [PubMed: 28496890]
  13. Bautista J, Bella A, Chaudhari A, et al. Advanced chronic kidney disease in non-valvular atrial fibrillation: extending the utility of R2CHADS2 to patients with advanced renal failure. Clin Kidney J 2015;8(2):226–31. PMID: 25815182. [PMC free article: PMC4370306] [PubMed: 25815182]
  14. Belavic JM. Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation. Nurse Pract 2011;36(9):6–7. PMID: 21857210. [PubMed: 21857210]
  15. Belgaid DR, Khan Z, Zaidi M, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial. Int J Cardiol 2016;219:177–9. PMID: 27343417. [PubMed: 27343417]
  16. Benzimra M, Bonnamour B, Duracinsky M, et al. Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation. Patient Prefer Adherence 2018;12:79–87. Digital Object Identifier: 10.2147/ppa.s131158. PMID: 29379275. [PMC free article: PMC5757966] [PubMed: 29379275] [CrossRef]
  17. Bergmann MW. LAA occluder device for stroke prevention: Data on WATCHMAN and other LAA occluders. Trends in Cardiovascular Medicine 2017. [PubMed: 28461140]
  18. Bertoletti L, Ollier E, Duvillard C, et al. Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism. Pharmacological Research 2017;118:33–42. [PubMed: 27350265]
  19. Bilha SC, Burlacu A, Siriopol D, et al. Primary Prevention of Stroke in Chronic Kidney Disease Patients: A Scientific Update. Cerebrovasc Dis 2018;45(1-2):33–41. Digital Object Identifier: 10.1159/000486016. PMID: 29316564. [PubMed: 29316564] [CrossRef]
  20. Blann AD, Banerjee A, Lane DA, et al. Net clinical benefit of edoxaban versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study. Int J Cardiol 2015;201:693–8. PMID: 26379097. [PubMed: 26379097]
  21. Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J 2014;35(8):508–16. PMID: 24334432. [PMC free article: PMC3930873] [PubMed: 24334432]
  22. Bratland B and Hornnes MB. Warfarin therapy for atrial fibrillation in general practice-is bleeding risk underestimated?. Tidsskr Nor Laegeforen 2014;134(2):175–9. PMID: 24477151. [PubMed: 24477151]
  23. Cannon CP, Gropper S, Bhatt DL, et al. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Clin Cardiol 2016;39(10):555–564. PMID: 27565018. [PMC free article: PMC5108471] [PubMed: 27565018]
  24. Carmo J, Ferreira J, Costa F, et al. Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: A meta-analysis of randomized trials. Int J Cardiol 2017;244:196–201. Digital Object Identifier: 10.1016/j.ijcard.2017.06.004. PMID: 28679480. [PubMed: 28679480] [CrossRef]
  25. Clemens A, Fraessdorf M and Friedman J. Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag 2013;9:599–615. PMID: 24143109. [PMC free article: PMC3798206] [PubMed: 24143109]
  26. Connolly SJ, Wallentin L and Yusuf S. Additional events in the RE-LY trial. N Engl J Med 2014;371(15):1464–5. Digital Object Identifier: 10.1056/NEJMc1407908. PMID: 25251519. [PubMed: 25251519] [CrossRef]
  27. Coppens M, Eikelboom JW, Hart RG, et al. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J 2013;34(3):170–6. PMID: 23018151. [PubMed: 23018151]
  28. Costa J, Fiorentino F, Caldeira D, et al. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal. Rev Port Cardiol 2015;34(12):723–37. PMID: 26616542. [PubMed: 26616542]
  29. Dahal K, Kunwar S, Rijal J, et al. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. Chest 2016;149(4):951–9. PMID: 26378611. [PubMed: 26378611]
  30. Dalmau Llorca MR, Gonçalves AQ, Forcadell Drago E, et al. A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation. Medicine (United States) 2018;97(3). Digital Object Identifier: 10.1097/MD.0000000000009578. [PMC free article: PMC5779750] [PubMed: 29504981] [CrossRef]
  31. Dzeshka MS and Lip GY. Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation. Expert Opin Drug Saf 2015;14(1):45–62. PMID: 25341529. [PubMed: 25341529]
  32. Dzeshka MS, Shantsila A, Shantsila E, et al. Atrial Fibrillation and Hypertension. Hypertension 2017;70(5):854–861. Digital Object Identifier: 10.1161/HYPERTENSIONAHA.117.08934. [PubMed: 28893897] [CrossRef]
  33. Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, et al. Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in ‘real-world’ atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. Int J Cardiol 2017. Digital Object Identifier: 10.1016/j.ijcard.2017.11.087. PMID: 29248163. [PubMed: 29248163] [CrossRef]
  34. Ezekowitz MD, Pollack CV, Sanders P, et al. Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. Am Heart J 2016;179:59–68. PMID: 27595680. [PubMed: 27595680]
  35. Fanikos J, Burnett AE, Mahan CE, et al. Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism. Am J Med 2017;130(10):1137–1143. Digital Object Identifier: 10.1016/j.amjmed.2017.06.004. PMID: 28687262. [PubMed: 28687262] [CrossRef]
  36. Fatima S, Holbrook A, Schulman S, et al. Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation. Thromb Res 2016;145:143–8. PMID: 27388221. [PubMed: 27388221]
  37. Galvani G, Grassetto A, Sterlicchio S, et al. Cost-Effectiveness of Dabigatran Exilate in Treatment of Atrial Fibrillation. J Atr Fibrillation 2015;7(6):5–9. PMID: 27957165. [PMC free article: PMC4956364] [PubMed: 27957165]
  38. Gao F, Shen H, Wang ZJ, et al. Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention. Contemp Clin Trials 2015;43:129–32. PMID: 26003433. [PubMed: 26003433]
  39. Ghadban R, Flaker G, Katta N, et al. Anti-thrombotic therapy for atrial fibrillation in patients with chronic kidney disease: Current views. Hemodial Int 2017;21: Suppl 2:S47–s56. Digital Object Identifier: 10.1111/hdi.12600. PMID: 29064182. [PubMed: 29064182] [CrossRef]
  40. Gibson CM, Mehran R, Bode C, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J 2015;169(4):472–8.e5. PMID: 25819853. [PubMed: 25819853]
  41. Giorgi MA, Caroli C, Giglio ND, et al. Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina. Health Econ Rev 2015;5(1):52. PMID: 26112219. [PMC free article: PMC4480270] [PubMed: 26112219]
  42. Guo Y, Pisters R, Apostolakis S, et al. Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: would the novel oral anticoagulants have an impact?. Int J Cardiol 2013;168(1):515–22. PMID: 23103146. [PubMed: 23103146]
  43. Harel Z, Sholzberg M, Shah PS, et al. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. J Am Soc Nephrol 2014;25(3):431–42. PMID: 24385595. [PMC free article: PMC3935586] [PubMed: 24385595]
  44. Hart RG, Eikelboom JW and Pearce LA. Sex, stroke, and atrial fibrillation. Arch Neurol 2012;69(12):1641–3. PMID: 23007639. [PubMed: 23007639]
  45. Hatori Y, Sakai H, Kunishima T, et al. Rationale and design of ASSAF-K (A study of the safety and efficacy of anticoagulant therapy in the treatment of atrial fibrillation in Kanagawa). J Arrhythm 2017;33(2):111–116. PMID: 28416976. [PMC free article: PMC5388051] [PubMed: 28416976]
  46. He J, Tse G, Korantzopoulos P, et al. P-Wave Indices and Risk of Ischemic Stroke: A Systematic Review and Meta-Analysis. Stroke 2017;48(8):2066–2072. Digital Object Identifier: 10.1161/strokeaha.117.017293. PMID: 28679858. [PubMed: 28679858] [CrossRef]
  47. Hohnloser SH and Diener HC. Dabigatran for stroke prevention in atrial fibrillation. Hamostaseologie 2012;32(3):216–20. PMID: 22739760. [PubMed: 22739760]
  48. Holmes DR, Reddy VY, Buchbinder M, et al. The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial. Am Heart J 2017;189:68–74. PMID: 28625383. [PubMed: 28625383]
  49. Holt TA, Hunter TD, Gunnarsson C, et al. Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. Br J Gen Pract 2012;62(603):e710–7. PMID: 23265231. [PMC free article: PMC3459779] [PubMed: 23265231]
  50. Hong KS, Kwon SU, Lee SH, et al. Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol 2017;74(10):1206–1215. Digital Object Identifier: 10.1001/jamaneurol.2017.2161. PMID: 28892526. [PMC free article: PMC5710243] [PubMed: 28892526] [CrossRef]
  51. Hsu JC, Hsieh CY, Yang YH, et al. Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis. PLoS One 2015;10(4):e0124806. PMID: 25897861. [PMC free article: PMC4405347] [PubMed: 25897861]
  52. Hu YF, Liu CJ, Chang PMH, et al. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. International Journal of Cardiology 2013;165(2):355–394. [PubMed: 22989607]
  53. Ishii M, Ogawa H, Unoki T, et al. Relationship of Hypertension and Systolic Blood Pressure With the Risk of Stroke or Bleeding in Patients With Atrial Fibrillation: The Fushimi AF Registry. Am J Hypertens 2017. PMID: 28575205. [PubMed: 28575205]
  54. Itzhaki O, Zadok B and Eisen A. Use of non-vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus. Diabet Med 2018. Digital Object Identifier: 10.1111/dme.13600. PMID: 29438571. [PubMed: 29438571] [CrossRef]
  55. Jones DA, Tchétché D, Forrest J, et al. The SURTAVI study: TAVI for patients with intermediate risk. EuroIntervention 2017;13(5):e617–e620. Digital Object Identifier: 10.4244/EIJV13I5A97. [PubMed: 28781252] [CrossRef]
  56. Jover E, Roldan V, Gallego P, et al. Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation. Rev Esp Cardiol (Engl Ed) 2012;65(7):627–33. PMID: 22609214. [PubMed: 22609214]
  57. Kaba RA, Ahmed O and Cannie D. ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation. Global Cardiology Science and Practice 2013;(4). [PMC free article: PMC3991206] [PubMed: 24749107]
  58. Kamae I, Hashimoto Y, Koretsune Y, et al. Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan. Clin Ther 2015;37(12):2837–51. PMID: 26608819. [PubMed: 26608819]
  59. Kamel H, Easton JD, Johnston SC, et al. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology 2012;79(14):1428–34. PMID: 22993279. [PMC free article: PMC3525294] [PubMed: 22993279]
  60. Kansal AR, Sharma M, Bradley-Kennedy C, et al. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Thromb Haemost 2012;108(4):672–82. PMID: 22898892. [PubMed: 22898892]
  61. Khan F, Huang H and Datta YH. Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation. J Thromb Thrombolysis 2016;42(4):573–8. PMID: 27520093. [PMC free article: PMC5042846] [PubMed: 27520093]
  62. Kirchhof P, Blank BF, Calvert M, et al. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial. American Heart Journal 2017;190:12–18. [PMC free article: PMC5546174] [PubMed: 28760205]
  63. Knecht S, Petsch S and Studer B. Atrial fibrillation in high-risk patients with ischaemic stroke. The Lancet Neurology 2017;16(7):498. [PubMed: 28653643]
  64. Konigsbrugge O, Simon A, Domanovits H, et al. Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry. BMC Cardiovasc Disord 2016;16(1):254. PMID: 27938343. [PMC free article: PMC5148877] [PubMed: 27938343]
  65. Kopecky S. New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence. Am J Cardiovasc Drugs 2012;12(5):287–94. PMID: 22946769. [PubMed: 22946769]
  66. Korenstra J, Wijtvliet EP, Veeger NJ, et al. Effectiveness and safety of dabigatran versus acenocoumarol in ‘real-world’ patients with atrial fibrillation. Europace 2016;18(9):1319–27. PMID: 26843571. [PMC free article: PMC5006960] [PubMed: 26843571]
  67. Kumana CR, Cheung BM, Siu DC, et al. Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights. Cardiovasc Ther 2016;34(2):100–6. PMID: 26727005. [PubMed: 26727005]
  68. Labbé V, Ederhy S, Fartoukh M, et al. Erratum: Should we administrate anticoagulants to critically ill patients with new onset supraventricular arrhythmias? (Archives of Cardiovascular Diseases (2015) 108(4) (217–219) (S1875213615000091) (10.1016/j.acvd.2015.01.001)). Archives of Cardiovascular Diseases 2016;109(12):656–658. [PubMed: 27938691]
  69. Lasek-Bal A, Urbanek T and Gierek D. Analysis of the efficacy and safety of new oral anticoagulant drugs in the secondary stroke prevention in patients with AF: single center experience based on 311 patients. Int Angiol 2015;34(6):552–61. PMID: 25410296. [PubMed: 25410296]
  70. Li X, Tse VC, Lau WC, et al. Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses. PLoS One 2016;11(6):e0157129. PMID: 27362421. [PMC free article: PMC4928891] [PubMed: 27362421]
  71. Li X, Wen SN, Li SN, et al. Over 1-year efficacy and safety of left atrial appendage occlusion versus novel oral anticoagulants for stroke prevention in atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials and observational studies. Heart Rhythm 2016;13(6):1203–14. PMID: 26724488. [PubMed: 26724488]
  72. Lip GY, Lanitis T, Kongnakorn T, et al. Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation. Clin Ther 2015;37(11):2476–2488.e27. PMID: 26477648. [PubMed: 26477648]
  73. Lip GY, Lanitis T, Mardekian J, et al. Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. Stroke 2015;46(10):2830–7. PMID: 26316345. [PubMed: 26316345]
  74. Loffredo L, Perri L and Violi F. Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials. Dig Liver Dis 2015;47(5):429–31. PMID: 25732432. [PubMed: 25732432]
  75. Lüscher TF. Atrial fibrillation and thrombo- embolism: Anticoagulants or devices?. European Heart Journal 2017;38(12):839–842. [PubMed: 28375429]
  76. Masbah N and Macleod MJ. The cost savings of Newer oral anticoagulants in atrial fbrillation-related stroke prevention. International Journal of Clinical Pharmacology and Therapeutics 2017;55(3):220–230. [PubMed: 28025962]
  77. Masotti L, Di Napoli M, Ageno W, et al. Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation. Italian Journal of Medicine 2013;7(SUPPL. 8):8–21.
  78. Molnar AO and Sood MM. Predicting in a predicament: Stroke and hemorrhage risk prediction in dialysis patients with atrial fibrillation. Semin Dial 2018;31(1):37–47. Digital Object Identifier: 10.1111/sdi.12637. PMID: 28699181. [PubMed: 28699181] [CrossRef]
  79. Nielsen PB and Lip GYH. Adding Rigor to Stroke Rate Investigations in Patients with Atrial Fibrillation. Circulation 2017;135(3):220–223. [PubMed: 28093493]
  80. Nishimura M and Hsu JC. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. Am J Cardiol 2018;121(1):131–140. Digital Object Identifier: 10.1016/j.amjcard.2017.09.030. PMID: 29132650. [PubMed: 29132650] [CrossRef]
  81. Noseworthy PA, Yao X, Gersh BJ, et al. Baseline characteristics and event rates among anticoagulated patients with atrial fibrillation in practice and pivotal NOAC trials. Data Brief 2017;14:563–565. Digital Object Identifier: 10.1016/j.dib.2017.08.010. PMID: 28861455. [PMC free article: PMC5568872] [PubMed: 28861455] [CrossRef]
  82. Otto CM. Heartbeat: Left atrial appendage occlusion for stroke prevention. Heart 2017;103(2):89–90. [PubMed: 28057808]
  83. Ottosen TP, Svendsen ML, Hansen ML, et al. Preadmission oral anticoagulant therapy and clinical outcome in patients hospitalised with acute stroke and atrial fibrillation. Dan Med J 2014;61(9):A4904. PMID: 25186543. [PubMed: 25186543]
  84. Padjen V, Jovanovic DR, Leys D, et al. Predicting the outcomes of acute ischaemic stroke in atrial fibrillation: the role of baseline CHADS2, CHA2DS2-VASC and HAS-BLED score values. Acta Cardiol 2013;68(6):590–6. PMID: 24579437. [PubMed: 24579437]
  85. Pandya E, Masood N, Wang Y, et al. Impact of a Computerized Antithrombotic Risk Assessment Tool on the Prescription of Thromboprophylaxis in Atrial Fibrillation. Clin Appl Thromb Hemost 2016;1076029616670031. PMID: 27671272. [PMC free article: PMC6714633] [PubMed: 27671272]
  86. Panikker S, Lord J, Jarman JW, et al. Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation. Eur Heart J 2016;37(46):3470–3482. PMID: 26935273. [PMC free article: PMC5841215] [PubMed: 26935273]
  87. Parks AL and Fang MC. Scoring Systems for Estimating the Risk of Anticoagulant-Associated Bleeding. Seminars in Thrombosis and Hemostasis 2017 [PubMed: 28359135]
  88. Pelliccia F, Rosanio S, Marazzi G, et al. Efficacy and safety of novel anticoagulants versus vitamin K antagonists in patients with mild and moderate to severe renal insufficiency: Focus on apixaban. International Journal of Cardiology 2016;225:77–81. [PubMed: 27716554]
  89. Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013;127(2):224–32. PMID: 23212720. [PubMed: 23212720]
  90. Pilote L, Eisenberg MJ, Essebag V, et al. Temporal trends in medication use and outcomes in atrial fibrillation. Can J Cardiol 2013;29(10):1241–8. PMID: 23313007. [PubMed: 23313007]
  91. Potpara TS and Blomstrom-Lundqvist C. Sex-related differences in atrial fibrillation: Can we discern true disparities from biases?. Heart 2017;103(13):979–981. Digital Object Identifier: 10.1136/heartjnl-2016-311085. [PubMed: 28456754] [CrossRef]
  92. Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation focus on non-vitamin k antagonist oral anticoagulants. Thrombosis and Haemostasis 2017;117(2):209–218. [PubMed: 27831592]
  93. Riario Sforza GG, Gentile F, Stock F, et al. Safety and timing of resuming dabigatran after major gastrointestinal bleeding reversed by idarucizumab. SAGE Open Med Case Rep 2018;6:2050313x17753336. Digital Object Identifier: 10.1177/2050313x17753336. PMID: 29348918. [PMC free article: PMC5768245] [PubMed: 29348918] [CrossRef]
  94. Russo-Alvarez G, Martinez KA, Valente M, et al. Thromboembolic and Major Bleeding Events With Rivaroxaban Versus Warfarin Use in a Real-World Setting. Ann Pharmacother 2018;52(1):19–25. Digital Object Identifier: 10.1177/1060028017727290. PMID: 28831812. [PubMed: 28831812] [CrossRef]
  95. Pisters R, Nieuwlaat R, Lane DA, et al. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost 2013;109(2):328–36. PMID: 23179181. [PubMed: 23179181]
  96. Piyaskulkaew C, Singh T, Szpunar S, et al. CHA(2)DS(2)-VASc versus CHADS(2) for stroke risk assessment in low-risk patients with atrial fibrillation: a pilot study from a single center of the NCDR-PINNACLE registry. J Thromb Thrombolysis 2014;37(4):400–3. PMID: 23943340. [PubMed: 23943340]
  97. Polymeris AA, Traenka C, Hert L, et al. Frequency and Determinants of Adherence to Oral Anticoagulants in Stroke Patients with Atrial Fibrillation in Clinical Practice. Eur Neurol 2016;76(3-4):187–193. PMID: 27705975. [PubMed: 27705975]
  98. Price MJ, Reddy VY, Valderrabano M, et al. Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience. JACC Cardiovasc Interv 2015;8(15):1925–32. PMID: 26627989. [PubMed: 26627989]
  99. Proietti M, Laroche C, Opolski G, et al. ‘Real-world’ atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. Europace 2017;19(5):722–733. PMID: 27194538. [PubMed: 27194538]
  100. Reddy VY, Akehurst RL, Armstrong SO, et al. Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF: Warfarin Versus NOACs Versus LAA Closure. J Am Coll Cardiol 2015;66(24):2728–39. PMID: 26616031. [PubMed: 26616031]
  101. Renda G, Ricci F, Giugliano RP, et al. Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. Journal of the American College of Cardiology 2017;69(11):1363–1371. [PubMed: 28302287]
  102. Roldan V, Marin F, Fernandez H, et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real-world” population with atrial fibrillation receiving anticoagulant therapy. Chest 2013;143(1):179–184. PMID: 22722228. [PubMed: 22722228]
  103. Roldan V, Marin F, Fernandez H, et al. Renal impairment in a “real-life” cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 2013;111(8):1159–64. PMID: 23337836. [PubMed: 23337836]
  104. Roldan V, Marin F, Manzano-Fernandez S, et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?. Thromb Haemost 2013;109(5):956–60. PMID: 23572113. [PubMed: 23572113]
  105. Ronco F, Mazzone P, Hosseinian L, et al. Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease. CardioRenal Medicine 2017:207–217. [PMC free article: PMC5511995] [PubMed: 28736561]
  106. Salata BM, Hutton DW, Levine DA, et al. Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients >/= 65 Years With Nonvalvular Atrial Fibrillation. Am J Cardiol 2016;117(1):54–60. PMID: 26552509. [PMC free article: PMC4780215] [PubMed: 26552509]
  107. Sambola A, Montoro JB, Del Blanco BG, et al. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial. Am Heart J 2013;166(4):669–75. PMID: 24093846. [PubMed: 24093846]
  108. Sani M, Ayubi E, Mansori K, et al. Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation: Methodological issues of prediction models. International Journal of Cardiology 2016;222:949. [PubMed: 27526365]
  109. Santarpia G, De Rosa S, Sabatino J, et al. Should We Maintain Anticoagulation after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation? The Need for a Randomized Study. Front Cardiovasc Med 2017;4:85. Digital Object Identifier: 10.3389/fcvm.2017.00085. PMID: 29312960. [PMC free article: PMC5742595] [PubMed: 29312960] [CrossRef]
  110. Saposnik G and Joundi RA. Visual Aid Tool to Improve Decision Making in Anticoagulation for Stroke Prevention. J Stroke Cerebrovasc Dis 2016;25(10):2380–5. PMID: 27318647. [PubMed: 27318647]
  111. Schiavoni M, Margaglione M and Coluccia A. Use of dabigatran and rivaroxaban in non-valvular atrial fibrillation: one-year follow-up experience in an Italian centre. Blood Transfus 2017:1–6. PMID: 28287377. [PMC free article: PMC5839619] [PubMed: 28287377]
  112. Seiffge DJ, Traenka C, Polymeris A, et al. Early start of DOAC after ischemic stroke: Risk of intracranial hemorrhage and recurrent events. Neurology 2016;87(18):1856–1862. PMID: 27694266. [PubMed: 27694266]
  113. Senoo K, Lane D and Lip GY. Stroke and bleeding risk in atrial fibrillation. Korean Circ J 2014;44(5):281–90. PMID: 25278980. [PMC free article: PMC4180604] [PubMed: 25278980]
  114. Shiffman D, Perez MV, Bare LA, et al. Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis. BMC Cardiovasc Disord 2015;15:104. PMID: 26419225. [PMC free article: PMC4587718] [PubMed: 26419225]
  115. Sholzberg M, Pavenski K, Shehata N, et al. Bleeding complications from the direct oral anticoagulants. BMC Hematology 2015;15(1). [PMC free article: PMC4690423] [PubMed: 26705474]
  116. Skjoth F, Larsen TB, Rasmussen LH, et al. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2014;111(5):981–8. PMID: 24577485. [PubMed: 24577485]
  117. Smythe MA, Forman MJ, Bertran EA, et al. Dabigatran versus warfarin major bleeding in practice: an observational comparison of patient characteristics, management and outcomes in atrial fibrillation patients. J Thromb Thrombolysis 2015;40(3):280–7. PMID: 25851800. [PubMed: 25851800]
  118. Spencer RJ and Amerena JV. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses. Am J Cardiovasc Drugs 2015;15(6):395–401. PMID: 26062914. [PubMed: 26062914]
  119. Stanton BE, Barasch NS and Tellor KB. Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment. Pharmacotherapy 2017;37(4):412–419 [PubMed: 28117916]
  120. Stevens RE. How the clot factors. 2013;79.
  121. Strunets A, Mirza M, Sra J, et al. Novel anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly. Expert Rev Clin Pharmacol 2013;6(6):677–89. PMID: 24164615. [PubMed: 24164615]
  122. Sun MT, Wood MK, Chan W, et al. Risk of Intraocular Bleeding With Novel Oral Anticoagulants Compared With Warfarin: A Systematic Review and Meta-analysis. JAMA Ophthalmol 2017;135(8):864–870. Digital Object Identifier: 10.1001/jamaophthalmol.2017.2199. PMID: 28687831. [PMC free article: PMC5710315] [PubMed: 28687831] [CrossRef]
  123. Takizawa S, Tanaka F, Nishiyama K, et al. Protocol for Cerebral Microbleeds during the Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin Therapy in Stroke Patients with Nonvalvular Atrial Fibrillation (CMB-NOW) Study: Multisite Pilot Trial. J Stroke Cerebrovasc Dis 2015;24(9):2143–8. PMID: 26153510. [PubMed: 26153510]
  124. Tervonen T, Ustyugova A, Sri Bhashyam S, et al. Comparison of Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Multicriteria Decision Analysis. Value Health 2017;20(10):1394–1402. Digital Object Identifier: 10.1016/j.jval.2017.06.006. PMID: 29241899. [PubMed: 29241899] [CrossRef]
  125. Van Mieghem W and Lancellotti P. CHADS2 risk score and rate of stroke or systemic embolism and major bleeding in patients with non-valvular atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants. Acta Cardiol 2017;72(4):390–396. Digital Object Identifier: 10.1080/00015385.2017.1327248. PMID: 28681678. [PubMed: 28681678] [CrossRef]
  126. Vestergaard AS and Ehlers LH. A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark. Pharmacoeconomics 2015;33(9):967–79. PMID: 25943684. [PubMed: 25943684]
  127. Wang KL, Lip GY, Lin SJ, et al. Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis. Stroke 2015;46(9):2555–61. PMID: 26304863. [PMC free article: PMC4542566] [PubMed: 26304863]
  128. Wang Y and Bajorek B. Clinical pre-test of a computerised antithrombotic risk assessment tool for stroke prevention in atrial fibrillation patients: giving consideration to NOACs. J Eval Clin Pract 2016;22(6):892–898. PMID: 27273715. [PubMed: 27273715]
  129. Wong CW. Anticoagulation for stroke prevention in elderly patients with non-valvular atrial fibrillation: What are the obstacles?. Hong Kong Medical Journal 2016;22(6):608–615. [PubMed: 27920399]
  130. Xu WW, Hu SJ and Wu T. Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis. J Zhejiang Univ Sci B 2017;18(7):567–576. Digital Object Identifier: 10.1631/jzus.B1600143. PMID: 28681581. [PMC free article: PMC5498837] [PubMed: 28681581] [CrossRef]
  131. Yang LT, Tsai WC and Su HM. Echocardiographic parameters versus CHA2DS2-VASc score in prediction of overall cardiac events, heart failure, and stroke in non-valvular atrial fibrillation. Cardiol J 2017. Digital Object Identifier: 10.5603/CJ.a2017.0086. PMID: 28714523. [PubMed: 28714523] [CrossRef]
  132. Zeng WT, Sun XT, Tang K, et al. Risk of thromboembolic events in atrial fibrillation with chronic kidney disease. Stroke 2015;46(1):157–63. PMID: 25424480. [PubMed: 25424480]

Does not meet study population requirements-2017

  1. Aachi RV, Birnbaum LA, Topel CH, et al. Laboratory characteristics of ischemic stroke patients with atrial fibrillation on or off therapeutic warfarin. Clin Cardiol 2017. Digital Object Identifier: 10.1002/clc.22838. PMID: 29251360. [PMC free article: PMC6490348] [PubMed: 29251360] [CrossRef]
  2. Abdul-Jawad Altisent O, Durand E, Munoz-Garcia AJ, et al. Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv 2016;9(16):1706–17. PMID: 27539691. [PubMed: 27539691]
  3. Abe M, Ogawa H, Ishii M, et al. Relation of Stroke and Major Bleeding to Creatinine Clearance in Patients With Atrial Fibrillation (from the Fushimi AF Registry). Am J Cardiol 2017;119(8):1229–1237. PMID: 28219663. [PubMed: 28219663]
  4. Acciarresi M, Paciaroni M, Agnelli G, et al. Prestroke CHA2DS2-VASc Score and Severity of Acute Stroke in Patients with Atrial Fibrillation: Findings from RAF Study. J Stroke Cerebrovasc Dis 2017;26(6):1363–1368. PMID: 28236595. [PubMed: 28236595]
  5. Ad N, Holmes SD and Friehling T. Minimally Invasive Stand-Alone Cox Maze Procedure for Persistent and Long-Standing Persistent Atrial Fibrillation: Perioperative Safety and 5-Year Outcomes. Circ Arrhythm Electrophysiol 2017;10(11). Digital Object Identifier: 10.1161/circep.117.005352. PMID: 29138143. [PubMed: 29138143] [CrossRef]
  6. Ad N, Holmes SD, Ali R, et al. A single center’s experience with pacemaker implantation after the Cox maze procedure for atrial fibrillation. Journal of Thoracic and Cardiovascular Surgery 2017;154(1):139–146.e1. Digital Object Identifier: 10.1016/j.jtcvs.2016.12.047. [PubMed: 28262289] [CrossRef]
  7. Admassie E, Chalmers L and Bereznicki LR. Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study. Eur J Clin Pharmacol 2017;73(12):1681–1689. Digital Object Identifier: 10.1007/s00228-017-2337-9. PMID: 28939954. [PubMed: 28939954] [CrossRef]
  8. Airy M, Chang TI, Ding VY, et al. Risk profiles for acute health events after incident atrial fibrillation in patients with end-stage renal disease on hemodialysis. Nephrol Dial Transplant 2017. Digital Object Identifier: 10.1093/ndt/gfx301. PMID: 29145634. [PMC free article: PMC6113645] [PubMed: 29145634] [CrossRef]
  9. Al Suwaidi J. Diabetes and silent atrial fibrillation: A dangerous liaison?. Glob Cardiol Sci Pract 2014;2014(4):367–70. PMID: 25780790. [PMC free article: PMC4355510] [PubMed: 25780790]
  10. Albage A, Sartipy U, Kenneback G, et al. Long-Term Risk of Ischemic Stroke After the Cox-Maze III Procedure for Atrial Fibrillation. Ann Thorac Surg 2017. PMID: 28242081. [PubMed: 28242081]
  11. Allende NG, Rodríguez Pagani C, Carrasco E, et al. Correlation between CHA2DS2-VASc score and atrial thrombus in patients with atrial fibrillation undergoing cardioversion. Revista Argentina de Cardiologia 2013;81(2):144–150.
  12. Almasi M, Hodjati Firoozabadi N, Ghasemi F, et al. The Value of ABCD2F Scoring System (ABCD2 Combined with Atrial Fibrillation) to Predict 90-Day Recurrent Brain Stroke. Neurology Research International 2016;2016. [PMC free article: PMC5011522] [PubMed: 27642521]
  13. Alonso A, Bengtson LG, MacLehose RF, et al. Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. Stroke 2014;45(8):2286–91. PMID: 24994722. [PMC free article: PMC4116615] [PubMed: 24994722]
  14. Alonso-Coello P, Montori VM, Diaz MG, et al. Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives. Health Expect 2015;18(6):2318–27. PMID: 24813058. [PMC free article: PMC5810657] [PubMed: 24813058]
  15. Altay S, Yıldırımtürk Ö, Çakmak HA, et al. New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study. Anatolian Journal of Cardiology 2017;17(5):353–361. [PMC free article: PMC5469081] [PubMed: 28100898]
  16. Altintas O, Niftaliyev E, Tasal A, et al. Paf-related ischemic stroke: Clinical, radiological and echocardiographic findings. Journal of Neurological Sciences 2015;32(4):617–627
  17. Al-Turaiki AM, Al-Ammari MA, Al-Harbi SA, et al. Assessment and comparison of CHADS2, CHA2DS2-VASc, and HAS-BLED scores in patients with atrial fibrillation in Saudi Arabia. Annals of Thoracic Medicine 2016;11(2):146–150. [PMC free article: PMC4854062] [PubMed: 27168864]
  18. Amano H, Saito D, Yabe T, et al. Efficacy and Safety of Triple Therapy and Dual Therapy With Direct Oral Anticoagulants Compared to Warfarin. Int Heart J 2017;58(4):570–576. Digital Object Identifier: 10.1536/ihj.16-381. PMID: 28701676. [PubMed: 28701676] [CrossRef]
  19. Amara W, Larsen TB, Sciaraffia E, et al. Patients’ attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. Europace 2016;18(1):151–5. PMID: 26462697. [PubMed: 26462697]
  20. Amaral CH, Amaral AR, Nagel V, et al. Incidence and functional outcome of atrial fibrillation and non-atrial fibrillation-related cardioembolic stroke in Joinville, Brazil: A population-based study. Arquivos de Neuro-Psiquiatria 2017;75(5):288–294. [PubMed: 28591388]
  21. Amerena J, Chen SA, Sriratanasathavorn C, et al. An international observational prospective survey assessing the control of atrial fibrillation in Asia-Pacific: Results of the record-AFAP registry. Clinical Medicine Insights: Cardiology 2015;9:77–83. [PMC free article: PMC4517830] [PubMed: 26279634]
  22. Andersson P and Londahl M. Treatment with oral anticoagulant drugs restrained from patients with atrial fibrillation: An assessment in a geographically well-defined catchment area. Eur J Prev Cardiol 2016;23(13):1437–43. PMID: 26976847. [PubMed: 26976847]
  23. Andersson T, Magnuson A, Bryngelsson IL, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J 2013;34(14):1061–7. PMID: 23321349. [PMC free article: PMC3618889] [PubMed: 23321349]
  24. Andersson T, Magnuson A, Bryngelsson IL, et al. Patients with atrial fibrillation and outcomes of cerebral infarction in those with treatment of warfarin versus no warfarin with references to CHA2DS2-VASc score, age and sex - A Swedish nationwide observational study with 48 433 patients. PLoS One 2017;12(5):e0176846. PMID: 28472091. [PMC free article: PMC5417522] [PubMed: 28472091]
  25. Apostolakis S, Haeusler KG, Oeff M, et al. Low stroke risk after elective cardioversion of atrial fibrillation: an analysis of the Flec-SL trial. Int J Cardiol 2013;168(4):3977–81. PMID: 23871349. [PubMed: 23871349]
  26. Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 2013;144(5):1555–1563. PMID: 23669885. [PubMed: 23669885]
  27. Appelros P, Farahmand B, Terent A, et al. To Treat or Not to Treat: Anticoagulants as Secondary Preventives to the Oldest Old With Atrial Fibrillation. Stroke 2017;48(6):1617–1623. PMID: 28487335. [PubMed: 28487335]
  28. Arbring K, Uppugunduri S and Lindahl TL. Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics. BMC Health Serv Res 2013;13:85. PMID: 23497203. [PMC free article: PMC3599319] [PubMed: 23497203]
  29. Arihiro S, Todo K, Koga M, et al. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. Int J Stroke 2016;11(5):565–74. PMID: 26927811. [PubMed: 26927811]
  30. Asberg S, Eriksson M, Henriksson KM, et al. Reduced risk of death with warfarin - results of an observational nationwide study of 20 442 patients with atrial fibrillation and ischaemic stroke. Int J Stroke 2013;8(8):689–95. PMID: 22928583. [PubMed: 22928583]
  31. Aslan O, Yaylali YT, Yildirim S, et al. Dabigatran Versus Warfarin in Atrial Fibrillation: Multicenter Experience in Turkey. Clin Appl Thromb Hemost 2016;22(2):147–52. PMID: 25115764. [PubMed: 25115764]
  32. Aspberg S, Chang Y, Atterman A, et al. Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. Eur Heart J 2016;37(42):3203–3210. PMID: 26941204. [PubMed: 26941204]
  33. Atas H, Sahin AA, Barutcu Atas D, et al. Potential Causes and Implications of Low Target Therapeutic Ratio in Warfarin-Treated Patients for Thrombosis Prophylaxis. Clin Appl Thromb Hemost 2017:1076029617695484. PMID: 28301912. [PMC free article: PMC6714662] [PubMed: 28301912]
  34. Avgil-Tsadok M, Jackevicius CA, Essebag V, et al. Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost 2016;115(1):152–60. PMID: 26354766. [PubMed: 26354766]
  35. Awker AL, Bell MA, McGraw M, et al. Impact of educational intervention on management of periprocedural anticoagulation. Am J Health Syst Pharm 2017;74(23 Supplement 4):S95–s101. Digital Object Identifier: 10.2146/ajhp160726. PMID: 29167146. [PubMed: 29167146] [CrossRef]
  36. Badal M, Aryal MR, Mege J, et al. Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants. Heart Lung Circ 2015;24(1):94–7. PMID: 25108758. [PubMed: 25108758]
  37. Badhwar V, Rankin JS, Ad N, et al. Surgical Ablation of Atrial Fibrillation in the United States: Trends and Propensity Matched Outcomes. Ann Thorac Surg 2017;104(2):493–500. Digital Object Identifier: 10.1016/j.athoracsur.2017.05.016. PMID: 28669501. [PubMed: 28669501] [CrossRef]
  38. Baek YS, Kim TH, Uhm JS, et al. Prevalence and the clinical outcome of atrial fibrillation in patients with Autoimmune Rheumatic Disease. Int J Cardiol 2016;214:4–9. PMID: 27055157. [PubMed: 27055157]
  39. Bahit MC, Lopes RD, Wojdyla DM, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol 2013;170(2):215–20. PMID: 24192334. [PubMed: 24192334]
  40. Bai Y, Zhu J, Yang YM, et al. Clinical characteristics and one year outcomes in Chinese atrial fibrillation patients with stable coronary artery disease: a population-based study. J Geriatr Cardiol 2016;13(8):665–671. PMID: 27781056. [PMC free article: PMC5067427] [PubMed: 27781056]
  41. Bajorek BV, Magin PJ, Hilmer SN, et al. Optimizing Stroke Prevention in Patients With Atrial Fibrillation: A Cluster-Randomized Controlled Trial of a Computerized Antithrombotic Risk Assessment Tool in Australian General Practice, 2012-2013. Prev Chronic Dis 2016;13:E90. PMID: 27418212. [PMC free article: PMC4951074] [PubMed: 27418212]
  42. Bakhai A, Darius H, De Caterina R, et al. Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: Results from the PREFER in AF registry. European Heart Journal - Quality of Care and Clinical Outcomes 2016;2(4):299–305. Digital Object Identifier: 10.1093/ehjqcco/qcw031. [PubMed: 29474715] [CrossRef]
  43. Balcı KG, Balcı MM, Canpolat U, et al. Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation. Anatolian Journal of Cardiology 2016;16(7):474–481 [PMC free article: PMC5331393] [PubMed: 26680544]
  44. Bando S, Nishikado A, Hiura N, et al. Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: Analysis of the Shikoku Rivaroxaban Registry Trial (SRRT). J Cardiol 2018;71(2):197–201. Digital Object Identifier: 10.1016/j.jjcc.2017.08.005. PMID: 28969968. [PubMed: 28969968] [CrossRef]
  45. Barbieri LR, Sobral ML, Geronimo GM, et al. Incidence of stroke and acute renal failure in patients of postoperative atrial fibrillation after myocardial revascularization. Rev Bras Cir Cardiovasc 2013;28(4):442–8. PMID: 24598947. [PMC free article: PMC4389434] [PubMed: 24598947]
  46. Barnett AS, Kim S, Fonarow GC, et al. Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation). Circ Arrhythm Electrophysiol 2017;10(11). Digital Object Identifier: 10.1161/circep.117.005051. PMID: 29141842. [PubMed: 29141842] [CrossRef]
  47. Barra ME, Fanikos J, Connors JM, et al. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. Am J Med 2016;129(11):1198–1204. PMID: 27341955. [PubMed: 27341955]
  48. Barra S, Almeida I, Caetano F, et al. Stroke prediction with an adjusted R-CHA2DS2VASc score in a cohort of patients with a Myocardial Infarction. Thromb Res 2013;132(2):293–9. PMID: 23928474. [PubMed: 23928474]
  49. Barra S, Providencia R, Paiva L, et al. Mid-term Risk Stratification of Patients with a Myocardial Infarction and Atrial Fibrillation: Beyond GRACE and CHADS. J Atr Fibrillation 2013;6(4):17–24. PMID: 28496907. [PMC free article: PMC5153131] [PubMed: 28496907]
  50. Barysiene J, Zebrauskaite A, Petrikonyte D, et al. Findings of transoesophageal echocardiogram in appropriately anticoagulated patients with persistent atrial fibrillation prior to planned cardioversion. BMC Cardiovasc Disord 2017;17(1):67. PMID: 28228120. [PMC free article: PMC5322653] [PubMed: 28228120]
  51. Batra G, Friberg L, Erlinge D, et al. Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention. Eur Heart J Cardiovasc Pharmacother 2018;4(1):36–45. Digital Object Identifier: 10.1093/ehjcvp/pvx033. PMID: 29126156. [PubMed: 29126156] [CrossRef]
  52. Batra G, Svennblad B, Held C, et al. All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart 2016;102(12):926–33. PMID: 26928408. [PubMed: 26928408]
  53. Baturova MA, Lindgren A, Carlson J, et al. Non-permanent atrial fibrillation and oral anticoagulant therapy are related to survival during 10 years after first-ever ischemic stroke. International Journal of Cardiology 2017;232:134–139. [PubMed: 28132778]
  54. Baturova MA, Lindgren A, Shubik YV, et al. Documentation of atrial fibrillation prior to first-ever ischemic stroke. Acta Neurol Scand 2014;129(6):412–9. PMID: 24299072. [PubMed: 24299072]
  55. Baturova MA, Sheldon SH, Carlson J, et al. Electrocardiographic and Echocardiographic predictors of paroxysmal atrial fibrillation detected after ischemic stroke. BMC Cardiovasc Disord 2016;16(1):209. PMID: 27809773. [PMC free article: PMC5093933] [PubMed: 27809773]
  56. Bayar N, Ureyen CM, Erkal Z, et al. Evaluation of the association between stroke/transient ischemic attack and atrial electromechanical delay in patients with paroxysmal atrial fibrillation. Anatol J Cardiol 2016;16(8):572–578. PMID: 27004705. [PMC free article: PMC5368512] [PubMed: 27004705]
  57. Becattini C, Franco L, Beyer-Westendorf J, et al. Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. International Journal of Cardiology 2017;227:261–266 [PubMed: 27843050]
  58. Bekwelem W, Jensen PN, Norby FL, et al. Carotid Atherosclerosis and Stroke in Atrial Fibrillation: The Atherosclerosis Risk in Communities Study. Stroke 2016;47(6):1643–6. PMID: 27217511. [PMC free article: PMC4880451] [PubMed: 27217511]
  59. Belen E, Ozal E and Pusuroglu H. Association of the CHA2DS2-VASc score with left atrial spontaneous echo contrast: a cross-sectional study of patients with rheumatic mitral stenosis in sinus rhythm. Heart Vessels 2016;31(9):1537–43. PMID: 26475711. [PubMed: 26475711]
  60. Bellmann B, Fiebach JB, Guttmann S, et al. Incidence of MRI-detected brain lesions and neurocognitive function after electrical cardioversion in anticoagulated patients with persistent atrial fibrillation. Int J Cardiol 2017. PMID: 28592382. [PubMed: 28592382]
  61. Bellomo A, De Benedetto G, Fossati C, et al. Atrial fibrillation (AF) and cognitive impairment in the elderly: a case-control study. Arch Gerontol Geriatr 2012;55(2):247–50. PMID: 21940057. [PubMed: 21940057]
  62. Bembenek JP, Karlinski M, Kobayashi A, et al. The prestroke use of vitamin K antagonists for atrial fibrillation - trends over 15 years. Int J Clin Pract 2015;69(2):180–5. PMID: 25358816. [PubMed: 25358816]
  63. Benamer S, Lusty D and Everington T. Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial Fibrillation. Cardiol Ther 2016;5(2):215–221. PMID: 27457612. [PMC free article: PMC5125109] [PubMed: 27457612]
  64. Berger R, Salhanick SD, Chase M, et al. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. Ann Emerg Med 2013;61(4):475–9. PMID: 23522810. [PubMed: 23522810]
  65. Bernard A, Fauchier L, Pellegrin C, et al. Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. Thromb Haemost 2013;110(3):560–8. PMID: 23846210. [PubMed: 23846210]
  66. Berti S, Santoro G, Brscic E, et al. Left atrial appendage closure using AMPLATZER devices: A large, multicenter, Italian registry. Int J Cardiol 2017;248:103–107. Digital Object Identifier: 10.1016/j.ijcard.2017.07.052. PMID: 28797952. [PubMed: 28797952] [CrossRef]
  67. Beshir SA, Aziz Z, Yap LB, et al. Evaluation of the predictive performance of bleeding risk scores in patients with non-valvular atrial fibrillation on oral anticoagulants. J Clin Pharm Ther 2017. Digital Object Identifier: 10.1111/jcpt.12634. PMID: 29030869. [PubMed: 29030869] [CrossRef]
  68. Beyer-Westendorf J, Gelbricht V, Forster K, et al. Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care-results from the Dresden NOAC registry. Br J Clin Pharmacol 2014;78(4):908–17. PMID: 24697922. [PMC free article: PMC4239984] [PubMed: 24697922]
  69. Biedermann JS, van Rein N, van den Besselaar AM, et al. Impact of point-of-care international normalized ratio monitoring on quality of treatment with vitamin K antagonists in non-self-monitoring patients: a cohort study. J Thromb Haemost 2016;14(4):695–703. PMID: 26806724. [PubMed: 26806724]
  70. Bisson A, Bodin A, Clementy N, et al. Prediction of Incident Atrial Fibrillation According to Gender in Patients With Ischemic Stroke From a Nationwide Cohort. Am J Cardiol 2017. Digital Object Identifier: 10.1016/j.amjcard.2017.11.016. PMID: 29307458. [PubMed: 29307458] [CrossRef]
  71. Bista D, Chalmers L, Peterson GM, et al. Anticoagulant Use in Patients With Nonvalvular Atrial Fibrillation. Clin Appl Thromb Hemost 2016:1076029616642511. PMID: 27071408. [PubMed: 27071408]
  72. Bista D, Chalmers L, Peterson GM, et al. Patient Characteristics and Antithrombotic Prescribing Patterns in Patients With Atrial Fibrillation in Tasmania. Clin Appl Thromb Hemost 2017;23(5):438–444. PMID: 26699867. [PubMed: 26699867]
  73. Black-Maier E, Kim S, Steinberg BA, et al. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. Clin Cardiol 2017. PMID: 28543401. [PMC free article: PMC5638096] [PubMed: 28543401]
  74. Blissit KT, Mullenix ML and Brittain KG. Evaluation of Time in Therapeutic Range on Warfarin Therapy between Face-to-Face and Telephone Follow-Up in a VA Medical Center. Journal of Pharmacy Technology 2015;31(2):78–83.
  75. Bo M, Li Puma F, Badinella Martini M, et al. Effects of oral anticoagulant therapy in older medical in-patients with atrial fibrillation: a prospective cohort observational study. Aging Clin Exp Res 2017;29(3):491–497. PMID: 27100358. [PubMed: 27100358]
  76. Bo M, Sciarrillo I, Li Puma F, et al. Effects of Oral Anticoagulant Therapy in Medical Inpatients >/=65 Years With Atrial Fibrillation. Am J Cardiol 2016;117(4):590–5. PMID: 26718230. [PubMed: 26718230]
  77. Boriani G, Laroche C, Diemberger I, et al. Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. Sci Rep 2016;6:30271. PMID: 27466080. [PMC free article: PMC4964613] [PubMed: 27466080]
  78. Boriani G, Laroche C, Diemberger I, et al. Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry. J Cardiovasc Electrophysiol 2018. Digital Object Identifier: 10.1111/jce.13428. PMID: 29345382. [PubMed: 29345382] [CrossRef]
  79. Boriani G, Laroche C, Diemberger I, et al. ‘Real-world’ management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry. Europace 2016;18(5):648–57. PMID: 26826133. [PubMed: 26826133]
  80. Bramlage P, Cuneo A, Zeymer U, et al. Prognosis of patients with atrial fibrillation undergoing percutaneous coronary intervention receiving drug eluting stents. Clin Res Cardiol 2013;102(4):289–97. PMID: 23291664. [PubMed: 23291664]
  81. Brancaccio D, Neri L, Bellocchio F, et al. Patients’ Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study. Am J Nephrol 2016;44(4):258–267. PMID: 27598317. [PubMed: 27598317]
  82. Brodie MM, Newman JC, Smith T, et al. Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants. Am J Med 2017. Digital Object Identifier: 10.1016/j.amjmed.2017.11.007. PMID: 29175237. [PubMed: 29175237] [CrossRef]
  83. Brunner Frandsen NS, Andersen AD, Ashournia H, et al. Anticoagulant treatment in patients with atrial fibrillation and ischemic stroke. J Stroke Cerebrovasc Dis 2015;24(6):1120–5. PMID: 25881779. [PubMed: 25881779]
  84. Bryk AH, Plens K and Undas A. Prediction of unstable anticoagulation with acenocoumarol versus warfarin in atrial fibrillation. Cardiology Journal 2017;24(5):477–483. Digital Object Identifier: 10.5603/CJ.a2017.0038. [PubMed: 28353307] [CrossRef]
  85. Buchwald F, Norrving B and Petersson J. Atrial Fibrillation in Transient Ischemic Attack Versus Ischemic Stroke: A Swedish Stroke Register (Riksstroke) Study. Stroke 2016;47(10):2456–61. PMID: 27561674. [PubMed: 27561674]
  86. Budera P, Osmancik P, Herman D, et al. Midterm outcomes of two-staged hybrid ablation of persistent and long-standing persistent atrial fibrillation using the versapolar epicardial surgical device and subsequent catheter ablation. Journal of Interventional Cardiac Electrophysiology 2017;50(2):187–194. Digital Object Identifier: 10.1007/s10840-017-0286-y. [PubMed: 28921386] [CrossRef]
  87. Bunch TJ, May HT, Bair TL, et al. Five-year impact of catheter ablation for atrial fibrillation in patients with a prior history of stroke. J Cardiovasc Electrophysiol 2017. Digital Object Identifier: 10.1111/jce.13390. PMID: 29131434. [PubMed: 29131434] [CrossRef]
  88. Caballero L, Ruiz-Nodar JM, Marin F, et al. Oral anticoagulation improves the prognosis of octogenarian patients with atrial fibrillation undergoing percutaneous coronary intervention and stenting. Age Ageing 2013;42(1):70–5. PMID: 22983982. [PubMed: 22983982]
  89. Canavero I, Cavallini A, Sacchi L, et al. Safely Addressing Patients with Atrial Fibrillation to Early Anticoagulation after Acute Stroke. J Stroke Cerebrovasc Dis 2017;26(1):7–18. PMID: 27614403. [PubMed: 27614403]
  90. Cangemi DJ, Krill T, Weideman R, et al. A Comparison of the Rate of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin. Am J Gastroenterol 2017;112(5):734–739. Digital Object Identifier: 10.1038/ajg.2017.39. PMID: 28244496. [PubMed: 28244496] [CrossRef]
  91. Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017;377(16):1513–1524. Digital Object Identifier: 10.1056/NEJMoa1708454. PMID: 28844193. [PubMed: 28844193] [CrossRef]
  92. Cao C, Martinelli A, Spoelhof B, et al. In Potential Stroke Patients on Warfarin, the International Normalized Ratio Predicts Ischemia. Cerebrovasc Dis Extra 2017;7(2):111–119. Digital Object Identifier: 10.1159/000478793. PMID: 28803231. [PMC free article: PMC5618398] [PubMed: 28803231] [CrossRef]
  93. Capodanno D, Rossini R, Musumeci G, et al. Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy. Int J Cardiol 2015;199:319–25. PMID: 26241637. [PubMed: 26241637]
  94. Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014;35(47):3346–55. PMID: 25182247. [PubMed: 25182247]
  95. Carlsson AC, Wandell P, Gasevic D, et al. Neighborhood deprivation and warfarin, aspirin and statin prescription - A cohort study of men and women treated for atrial fibrillation in Swedish primary care. Int J Cardiol 2015;187:547–52. PMID: 25863300. [PMC free article: PMC4442047] [PubMed: 25863300]
  96. Castellucci LA, Shaw J, van der Salm K, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thromb Res 2015;136(4):727–31. PMID: 26272305. [PubMed: 26272305]
  97. Cavallari I, Ruff CT, Nordio F, et al. Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. Int J Cardiol 2018. Digital Object Identifier: 10.1016/j.ijcard.2018.01.065. PMID: 29395361. [PubMed: 29395361] [CrossRef]
  98. Cha MJ, Choi EK, Han KD, et al. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation. Stroke 2017;48(11):3040–3048. Digital Object Identifier: 10.1161/strokeaha.117.018773. PMID: 28974629. [PubMed: 28974629] [CrossRef]
  99. Chamberlain AM, Alonso A, Gersh BJ, et al. Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study. Am Heart J 2017;185:74–84. PMID: 28267478. [PMC free article: PMC5343767] [PubMed: 28267478]
  100. Chamberlain AM, Brown RD, Jr., Alonso A, et al. No Decline in the Risk of Stroke Following Incident Atrial Fibrillation Since 2000 in the Community: A Concerning Trend. J Am Heart Assoc 2016;5(6). PMID: 27412902. [PMC free article: PMC4937280] [PubMed: 27412902]
  101. Champion S, Lefort Y, Gauzere BA, et al. CHADS2 and CHA2DS2-VASc scores can predict thromboembolic events after supraventricular arrhythmia in the critically ill patients. J Crit Care 2014;29(5):854–8. PMID: 24970692. [PubMed: 24970692]
  102. Chan EW, Lau WC, Siu CW, et al. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study. Heart Rhythm 2016;13(8):1581–8. PMID: 27033342. [PubMed: 27033342]
  103. Chan KE, Edelman ER, Wenger JB, et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 2015;131(11):972–9. PMID: 25595139. [PMC free article: PMC4363265] [PubMed: 25595139]
  104. Chan PH, Huang D, Hai JJ, et al. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation. Heart Rhythm 2016;13(2):366–73. PMID: 26392326. [PubMed: 26392326]
  105. Chan PH, Huang D, Lau CP, et al. Net Clinical Benefit of Dabigatran Over Warfarin in Patients With Atrial Fibrillation Stratified by CHA2DS2-VASc and Time in Therapeutic Range. Can J Cardiol 2016;32(10):1247.e15–1247.e21. PMID: 27118057. [PubMed: 27118057]
  106. Chan PH, Huang D, Yip PS, et al. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. Europace 2016;18(5):665–71. PMID: 26504109. [PubMed: 26504109]
  107. Chan PH, Lau CP, Tse HF, et al. CHA2DS2-VASc Recalibration With an Additional Age Category (50-64 Years) Enhances Stroke Risk Stratification in Chinese Patients With Atrial Fibrillation. Can J Cardiol 2016;32(12):1381–1387. PMID: 27523274. [PubMed: 27523274]
  108. Chan PH, Li WH, Hai JJ, et al. Impact of Antithrombotic Therapy in Atrial Fibrillation on the Presentation of Coronary Artery Disease. PLoS One 2015;10(6):e0131479. PMID: 26098876. [PMC free article: PMC4476741] [PubMed: 26098876]
  109. Chan YH, Kuo CT, Yeh YH, et al. Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation. J Am Coll Cardiol 2016;68(13):1389–1401. PMID: 27659460. [PubMed: 27659460]
  110. Chan YH, Wu LS, Chang SH, et al. Young Male Patients with Atrial Fibrillation and CHA2DS2-VASc Score of 1 May Not Need Anticoagulants: A Nationwide Population-Based Study. PLoS One 2016;11(3):e0151485. PMID: 26986069. [PMC free article: PMC4795759] [PubMed: 26986069]
  111. Chan YH, Yeh YH, See LC, et al. Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin. J Am Coll Cardiol 2016;68(21):2272–2283. PMID: 27884245. [PubMed: 27884245]
  112. Chan YH, Yeh YH, Tu HT, et al. Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation. Oncotarget 2017;8(58):98898–98917. Digital Object Identifier: 10.18632/oncotarget.22026. PMID: 29228736. [PMC free article: PMC5716776] [PubMed: 29228736] [CrossRef]
  113. Chan YH, Yen KC, See LC, et al. Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation. Stroke 2016;47(2):441–9. PMID: 26732563. [PubMed: 26732563]
  114. Chandriah H, Kumolosasi E, Islahudin F, et al. Effectiveness and safety of a 10mg warfarin initiation nomogram in Asian population. Pak J Pharm Sci 2015;28(3):927–32. PMID: 26004726. [PubMed: 26004726]
  115. Chang HY, Zhou M, Tang W, et al. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. Bmj 2015;350:h1585. PMID: 25911526. [PMC free article: PMC4413867] [PubMed: 25911526]
  116. Chang SH, Chou IJ, Yeh YH, et al. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. Jama 2017;318(13):1250–1259. Digital Object Identifier: 10.1001/jama.2017.13883. PMID: 28973247. [PMC free article: PMC5818856] [PubMed: 28973247] [CrossRef]
  117. Chang YT, Hu YF, Liao JN, et al. The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate. Blood Coagul Fibrinolysis 2016;27(4):389–95. PMID: 26991859. [PubMed: 26991859]
  118. Chao TF, Lin YJ, Chang SL, et al. R2CHADS2 score and thromboembolic events after catheter ablation of atrial fibrillation in comparison with the CHA2DS2-VASc score. Can J Cardiol 2014;30(4):405–12. PMID: 24582725. [PubMed: 24582725]
  119. Chao TF, Lin YJ, Tsao HM, et al. CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. J Am Coll Cardiol 2011;58(23):2380–5. PMID: 22115643. [PubMed: 22115643]
  120. Chao TF, Lip GYH, Lin YJ, et al. Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: Attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study. Int J Cardiol 2018;254:157–161. Digital Object Identifier: 10.1016/j.ijcard.2017.11.025. PMID: 29407081. [PubMed: 29407081] [CrossRef]
  121. Chao TF, Lip GYH, Liu CJ, et al. Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation. J Am Coll Cardiol 2018;71(2):122–132. Digital Object Identifier: 10.1016/j.jacc.2017.10.085. PMID: 29325634. [PubMed: 29325634] [CrossRef]
  122. Chao TF, Lip GY, Liu CJ, et al. Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study. Stroke 2016;47(10):2462–9. PMID: 27625386. [PubMed: 27625386]
  123. Chao TF, Liu CJ, Liao JN, et al. Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage. Circulation 2016;133(16):1540–7. PMID: 26969761. [PubMed: 26969761]
  124. Chao TF, Liu CJ, Tuan TC, et al. Comparisons of CHADS2 and CHA2DS2-VASc scores for stroke risk stratification in atrial fibrillation: Which scoring system should be used for Asians?. Heart Rhythm 2016;13(1):46–53. PMID: 26277496. [PubMed: 26277496]
  125. Chao TF, Liu CJ, Tuan TC, et al. Impact on Outcomes of Changing Treatment Guideline Recommendations for Stroke Prevention in Atrial Fibrillation: A Nationwide Cohort Study. Mayo Clin Proc 2016;91(5):567–74. PMID: 27068667. [PubMed: 27068667]
  126. Chao TF, Liu CJ, Tuan TC, et al. Risk and Prediction of Sudden Cardiac Death and Ventricular Arrhythmias for Patients with Atrial Fibrillation - A Nationwide Cohort Study. Sci Rep 2017;7:46445. PMID: 28422144. [PMC free article: PMC5396069] [PubMed: 28422144]
  127. Chao TF, Liu CJ, Wang KL, et al. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm 2014;11(10):1752–9. PMID: 24952148. [PubMed: 24952148]
  128. Chao TF, Liu CJ, Wang KL, et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in ‘low-risk’ Asian patients with atrial fibrillation. J Am Coll Cardiol 2014;64(16):1658–65. PMID: 25323252. [PubMed: 25323252]
  129. Chen KP, Huang CX, Huang DJ, et al. Anticoagulation therapy in Chinese patients with non-valvular atrial fibrillation: a prospective, multi-center, randomized, controlled study. Chin Med J (Engl) 2012;125(24):4355–60. PMID: 23253701. [PubMed: 23253701]
  130. Chen LY, Lopez FL, Gottesman RF, et al. Atrial fibrillation and cognitive decline-the role of subclinical cerebral infarcts: the atherosclerosis risk in communities study. Stroke 2014;45(9):2568–74. PMID: 25052319. [PMC free article: PMC4146651] [PubMed: 25052319]
  131. Chen PC, Lip GY, Yeh G, et al. Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study. PLoS One 2015;10(4):e0125257. PMID: 25923742. [PMC free article: PMC4414564] [PubMed: 25923742]
  132. Chen YL, Cheng CL, Huang JL, et al. Mortality prediction using CHADS2/CHA2DS2-VASc/R2CHADS2 scores in systolic heart failure patients with or without atrial fibrillation. Medicine (Baltimore) 2017;96(43):e8338. Digital Object Identifier: 10.1097/md.0000000000008338. PMID: 29069008. [PMC free article: PMC5671841] [PubMed: 29069008] [CrossRef]
  133. Chen Z, Bai W, Li C, et al. Left Atrial Appendage Parameters Assessed by Real-Time Three-Dimensional Transesophageal Echocardiography Predict Thromboembolic Risk in Patients With Nonvalvular Atrial Fibrillation. J Ultrasound Med 2017;36(6):1119–1128. PMID: 28233335. [PubMed: 28233335]
  134. Chia PL, Teoh X, Hua CM, et al. Anticoagulation use and predictors of stroke, bleeding and mortality in multi-ethnic Asian patients with atrial fibrillation: A single centre experience. Med J Malaysia 2016;71(5):256–258. PMID: 28064291. [PubMed: 28064291]
  135. Chiang CE, Naditch-Brule L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012;5(4):632–9. PMID: 22787011. [PubMed: 22787011]
  136. Chiu PF, Huang CH, Liou HH, et al. Lower-dose warfarin delays renal progression and prolongs patient survival in patients with stage 3 - 5 chronic kidney disease and nonvalvular atrial fibrillation: a 12-year follow-up study. Int J Clin Pharmacol Ther 2014;52(6):504–8. PMID: 24755133. [PubMed: 24755133]
  137. Cho SW, Hwang JK, Chun KJ, et al. Impact of moderate to severe renal impairment on long-term clinical outcomes in patients with atrial fibrillation. J Cardiol 2017;69(3):577–583. PMID: 27236240. [PubMed: 27236240]
  138. Choi HI, Ahn JM, Kang SH, et al. Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents. JACC Cardiovasc Interv 2017;10(11):1075–1085. PMID: 28527773. [PubMed: 28527773]
  139. Choi J, Kim J, Shim JH, et al. Risks Versus Benefits of Anticoagulation for Atrial Fibrillation in Cirrhotic Patients. J Cardiovasc Pharmacol 2017;70(4):255–262. Digital Object Identifier: 10.1097/fjc.0000000000000513. PMID: 28991879. [PubMed: 28991879] [CrossRef]
  140. Chou PS, Ho BL, Chan YH, et al. Delayed diagnosis of atrial fibrillation after first-ever stroke increases recurrent stroke risk: A 5-year nationwide follow-up study. Intern Med J 2017. Digital Object Identifier: 10.1111/imj.13686. PMID: 29193638. [PubMed: 29193638] [CrossRef]
  141. Chou RH, Chiu CC, Huang CC, et al. Prediction of vascular dementia and Alzheimer’s disease in patients with atrial fibrillation or atrial flutter using CHADS2 score. J Chin Med Assoc 2016;79(9):470–6. PMID: 27234974. [PubMed: 27234974]
  142. Chow DH, Bieliauskas G, Sawaya FJ, et al. A comparative study of different imaging modalities for successful percutaneous left atrial appendage closure. Open Heart 2017;4(2):e000627. Digital Object Identifier: 10.1136/openhrt-2017-000627. PMID: 28761682. [PMC free article: PMC5515183] [PubMed: 28761682] [CrossRef]
  143. Christiansen CB, Gerds TA, Olesen JB, et al. Atrial fibrillation and risk of stroke: a nationwide cohort study. Europace 2016;18(11):1689–1697. PMID: 26838693. [PubMed: 26838693]
  144. Christophersen IE, Yin X, Larson MG, et al. A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study. Am Heart J 2016;178:45–54. PMID: 27502851. [PMC free article: PMC5344697] [PubMed: 27502851]
  145. Chu CH, Weng WC, Su FC, et al. Association between Atrial Fibrillation and Three-Year Mortality in Nondiabetic Patients with Acute First-Ever Ischemic Stroke. J Stroke Cerebrovasc Dis 2016;25(11):2660–2667. PMID: 27480821. [PubMed: 27480821]
  146. Chu CY, Lee WH, Hsu PC, et al. Association of Increased Epicardial Adipose Tissue Thickness With Adverse Cardiovascular Outcomes in Patients With Atrial Fibrillation. Medicine (Baltimore) 2016;95(11):e2874. PMID: 26986099. [PMC free article: PMC4839880] [PubMed: 26986099]
  147. Chung JE, Choi YR, Seong JM, et al. INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation. Int J Clin Pharm 2015;37(6):1038–46. PMID: 26068570. [PubMed: 26068570]
  148. Chyou JY, Hunter TD, Mollenkopf SA, et al. Individual and Combined Risk Factors for Incident Atrial Fibrillation and Incident Stroke: An Analysis of 3 Million At-Risk US Patients. J Am Heart Assoc 2015;4(7). PMID: 26206736. [PMC free article: PMC4608064] [PubMed: 26206736]
  149. Clark NP, Douketis JD, Hasselblad V, et al. Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial. Am Heart J 2018;195:108–114. Digital Object Identifier: 10.1016/j.ahj.2017.09.015. PMID: 29224638. [PMC free article: PMC5730345] [PubMed: 29224638] [CrossRef]
  150. Clavel-Ruiperez FG, Consuegra-Sanchez L, Felix Redondo FJ, et al. Mortality and Atrial Fibrillation in the FIACA Study: Evidence of a Differential Effect According to Admission Diagnosis. Rev Esp Cardiol (Engl Ed) 2017. PMID: 28528882. [PubMed: 28528882]
  151. Coma M, Gonzalez-Moneo MJ, Enjuanes C, et al. Effect of Permanent Atrial Fibrillation on Cognitive Function in Patients With Chronic Heart Failure. Am J Cardiol 2016;117(2):233–9. PMID: 26686573. [PubMed: 26686573]
  152. Conti A, Alesi A, Trausi F, et al. Hypertension and atrial fibrillation: prognostic aspects of troponin elevations in clinical practice. Crit Pathw Cardiol 2014;13(4):141–6. PMID: 25396290. [PubMed: 25396290]
  153. Costa C, González-Alujas T, Valente F, et al. Left atrial strain: A new predictor of thrombotic risk and successful electrical cardioversion. Echo Research and Practice 2016;3(2):45–52. [PMC free article: PMC4989095] [PubMed: 27249551]
  154. Crivera C, Nelson WW, Bookhart B, et al. Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. Curr Med Res Opin 2015;31(10):1889–95. Digital Object Identifier: 10.1185/03007995.2015.1077213. PMID: 26211815. [PubMed: 26211815] [CrossRef]
  155. Cutting S, Regan E, Lee VH, et al. High ABCD2 Scores and In-Hospital Interventions following Transient Ischemic Attack. Cerebrovascular Diseases Extra 2016:76–83 [PMC free article: PMC5091225] [PubMed: 27721312]
  156. Damluji AA, Al-Damluji MS, Marzouka GR, et al. New-onset versus prior history of atrial fibrillation: Outcomes from the AFFIRM trial. Am Heart J 2015;170(1):156–63, 163.e1. PMID: 26093877. [PubMed: 26093877]
  157. Dan GA, Badila E, Weiss E, et al. Arterial hypertension in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme pilot survey on atrial fibrillation. Int J Cardiol 2018;254:136–141. Digital Object Identifier: 10.1016/j.ijcard.2017.10.092. PMID: 29407080. [PubMed: 29407080] [CrossRef]
  158. De Regibus V, Iacopino S, Abugattas JP, et al. Single freeze strategy with the second- generation cryballoon for atrial fibrillation: a multicenter international retrospective analysis in a large cohort of patients. Journal of Interventional Cardiac Electrophysiology 2017;49(2):173–180. Digital Object Identifier: 10.1007/s10840-017-0254-6. [PubMed: 28573498] [CrossRef]
  159. De Vecchis R, Cantatrione C and Mazzei D. Clinical Relevance of Anticoagulation and Dual Antiplatelet Therapy to the Outcomes of Patients With Atrial Fibrillation and Recent Percutaneous Coronary Intervention With Stent. J Clin Med Res 2016;8(2):153–61. PMID: 26767085. [PMC free article: PMC4701072] [PubMed: 26767085]
  160. Desteghe L, Raymaekers Z, Lutin M, et al. Performance of handheld electrocardiogram devices to detect atrial fibrillation in a cardiology and geriatric ward setting. Europace 2017;19(1):29–39. PMID: 26893496. [PubMed: 26893496]
  161. Diaconu CC and Balaceanu A. Atrial fibrillation and comorbidities in very elderly patients. Archives of the Balkan Medical Union 2015;50(2):190–193.
  162. Dinh T, Baur LH, Pisters R, et al. Aspirin versus vitamin K antagonist treatment guided by transoesophageal echocardiography in patients with atrial fibrillation: a pilot study. Heart 2014;100(7):563–8. PMID: 24488608. [PubMed: 24488608]
  163. Disertori M, Franzosi MG, Barlera S, et al. Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial. BMC Cardiovasc Disord 2013;13:28. PMID: 23586654. [PMC free article: PMC3639147] [PubMed: 23586654]
  164. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med 2015;373(9):823–33. PMID: 26095867. [PMC free article: PMC4931686] [PubMed: 26095867]
  165. Dublin S, Anderson ML, Haneuse SJ, et al. Atrial fibrillation and risk of dementia: a prospective cohort study. J Am Geriatr Soc 2011;59(8):1369–75. PMID: 21806558. [PMC free article: PMC3289545] [PubMed: 21806558]
  166. Duraes AR, de Souza Roriz P, de Almeida Nunes B, et al. Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study. Drugs R D 2016;16(2):149–54. PMID: 26892845. [PMC free article: PMC4875919] [PubMed: 26892845]
  167. Eapen ZJ, Mi X, Fonarow GC, et al. Anticoagulation and Clinical Outcomes in Heart Failure Patients With Atrial Fibrillation: Findings From the ADHERE Registry. J Atr Fibrillation 2013;6(4):953. PMID: 28496911. [PMC free article: PMC5153135] [PubMed: 28496911]
  168. Elbadawi A, Olorunfemi O, Ogunbayo GO, et al. Cardiovascular Outcomes With Surgical Left Atrial Appendage Exclusion in Patients With Atrial Fibrillation Who Underwent Valvular Heart Surgery (from the National Inpatient Sample Database). Am J Cardiol 2017;119(12):2056–2060. Digital Object Identifier: 10.1016/j.amjcard.2017.03.037. PMID: 28438308. [PubMed: 28438308] [CrossRef]
  169. Ellis MH, Neuman T, Bitterman H, et al. Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study. Eur J Intern Med 2016;33:55–9. PMID: 27296588. [PubMed: 27296588]
  170. Emdin CA, Anderson SG, Salimi-Khorshidi G, et al. Usual blood pressure, atrial fibrillation and vascular risk: evidence from 4.3 million adults. Int J Epidemiol 2017;46(1):162–172. PMID: 27143136. [PMC free article: PMC5407172] [PubMed: 27143136]
  171. Enomoto Y, Iijima R, Tokue M, et al. Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents. Cardiovasc Interv Ther 2014;29(3):193–9. PMID: 24366503. [PubMed: 24366503]
  172. Erkuner O, Claessen R, Pisters R, et al. Poor anticoagulation relates to extended access times for cardioversion and is associated with long-term major cardiac and cerebrovascular events. Int J Cardiol 2016;225:337–341. PMID: 27756038. [PubMed: 27756038]
  173. Ertas F, Eren NK, Kaya H, et al. The atrial fibrillation in Turkey: Epidemiologic Registry (AFTER). Cardiol J 2013;20(4):447–52. PMID: 23677730. [PubMed: 23677730]
  174. Esato M, Chun YH, An Y, et al. Clinical Impact of Asymptomatic Presentation Status in Patients With Paroxysmal and Sustained Atrial Fibrillation: The Fushimi AF Registry. Chest 2017;152(6):1266–1275. Digital Object Identifier: 10.1016/j.chest.2017.08.004. PMID: 28823813. [PubMed: 28823813] [CrossRef]
  175. Fahmy P, Spencer R, Tsang M, et al. Left Atrial Appendage Closure for Atrial Fibrillation Is Safe and Effective After Intracranial or Intraocular Hemorrhage. Can J Cardiol 2016;32(3):349–54. PMID: 26831513. [PubMed: 26831513]
  176. Fan X and Zhang Y. Comparison of triple antithrombotic therapy and dual antiplatelet therapy for patients with atrial fibrillation after percutaneous coronary stenting. Pak J Pharm Sci 2016;29:(5 Suppl):1769–1773. PMID: 28476700. [PubMed: 28476700]
  177. Fauchier L, Chaize G, Gaudin AF, et al. Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study. Int J Cardiol 2016;217:85–91. PMID: 27179213. [PubMed: 27179213]
  178. Fauchier L, Clementy N, Bisson A, et al. Prognosis in patients with atrial fibrillation and a presumed “temporary cause” in a community-based cohort study. Clin Res Cardiol 2017;106(3):202–210. PMID: 27695988. [PubMed: 27695988]
  179. Fauchier L, Clementy N, Pelade C, et al. Patients With Ischemic Stroke and Incident Atrial Fibrillation: A Nationwide Cohort Study. Stroke 2015;46(9):2432–7. PMID: 26251249. [PubMed: 26251249]
  180. Fauchier L, Lecoq C, Ancedy Y, et al. Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting. Am J Cardiol 2016;118(5):700–7. PMID: 27453515. [PubMed: 27453515]
  181. Fauchier L, Samson A, Chaize G, et al. Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study. Open Heart 2015;2(1):e000290. PMID: 26688739. [PMC free article: PMC4680587] [PubMed: 26688739]
  182. Fauchier L, Villejoubert O, Clementy N, et al. Causes of Death and Influencing Factors in Patients with Atrial Fibrillation. Am J Med 2016;129(12):1278–1287. PMID: 27476087. [PubMed: 27476087]
  183. Ferreira J, Ezekowitz MD, Connolly SJ, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail 2013;15(9):1053–61. PMID: 23843099. [PubMed: 23843099]
  184. Fiedler KA, Maeng M, Mehilli J, et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol 2015;65(16):1619–29. PMID: 25908066. [PubMed: 25908066]
  185. Flaker G, Lopes RD, Al-Khatib SM, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol 2014;63(11):1082–7. PMID: 24211508. [PubMed: 24211508]
  186. Fontaine GV, Mathews KD, Woller SC, et al. Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. Clin Appl Thromb Hemost 2014;20(7):665–72. PMID: 24875781. [PubMed: 24875781]
  187. Forbes HL and Polasek TM. Potential drug–drug interactions with direct oral anticoagulants in elderly hospitalized patients. Therapeutic Advances in Drug Safety 2017;8(10):319–328. Digital Object Identifier: 10.1177/2042098617719815. [PMC free article: PMC5865464] [PubMed: 29593860] [CrossRef]
  188. Formiga F, Ferrer A, Mestre D, et al. High rate of mortality in Spanish community-dwelling population aged 85 with atrial fibrillation after three years of follow-up: The Octabaix study. Australas J Ageing 2016;35(3):216–9. PMID: 26991145. [PubMed: 26991145]
  189. Fosbol EL, Wang TY, Li S, et al. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. Am Heart J 2013;166(5):864–70. PMID: 24176442. [PubMed: 24176442]
  190. Frain BE, Castelino R and Bereznicki L. The Utilization of Antithrombotic Therapy in Older Australians With Atrial Fibrillation. Clin Appl Thromb Hemost 2016:1076029616637184. PMID: 26994296. [PubMed: 26994296]
  191. Freeman JV, Simon DN, Go AS, et al. Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes 2015;8(4):393–402. PMID: 26058720. [PubMed: 26058720]
  192. Friberg L and Oldgren J. Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. Open Heart 2017;4(2):e000682. Digital Object Identifier: 10.1136/openhrt-2017-000682. PMID: 29018536. [PMC free article: PMC5623334] [PubMed: 29018536] [CrossRef]
  193. Friedman DJ, Piccini JP, Wang T, et al. Association Between Left Atrial Appendage Occlusion and Readmission for Thromboembolism Among Patients With Atrial Fibrillation Undergoing Concomitant Cardiac Surgery. Jama 2018;319(4):365–374. Digital Object Identifier: 10.1001/jama.2017.20125. PMID: 29362794. [PMC free article: PMC5833567] [PubMed: 29362794] [CrossRef]
  194. Gao WQ, Guo YT, Ma JL, et al. Analysis of antithrombotic therapy in elderly patients with atrial fibrillation. Genet Mol Res 2014;13(1):736–43. PMID: 24615038. [PubMed: 24615038]
  195. Garcia Callejo FJ, Becares Martinez C, Calvo Gonzalez J, et al. Epistaxis and dabigatran, a new non-vitamin K antagonist oral anticoagulant. Acta Otorrinolaringol Esp 2014;65(6):346–54. PMID: 24958185. [PubMed: 24958185]
  196. Garcia DA, Wallentin L, Lopes RD, et al. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J 2013;166(3):549–58. PMID: 24016506. [PubMed: 24016506]
  197. Garcia-Fernandez A, Marin F, Roldan V, et al. The HAS-BLED score predicts long-term major bleeding and death in anticoagulated non-valvular atrial fibrillation patients undergoing electrical cardioversion. Int J Cardiol 2016;217:42–8. PMID: 27179207. [PubMed: 27179207]
  198. Garg PK, O’Neal WT, Ogunsua A, et al. Usefulness of the American Heart Association’s Life Simple 7 to Predict the Risk of Atrial Fibrillation (from the REasons for Geographic And Racial Differences in Stroke [REGARDS] Study). Am J Cardiol 2018;121(2):199–204. Digital Object Identifier: 10.1016/j.amjcard.2017.09.033. PMID: 29153246. [PMC free article: PMC6080623] [PubMed: 29153246] [CrossRef]
  199. Gaubert M, Resseguier N, Laine M, et al. Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. J Thromb Haemost 2017. Digital Object Identifier: 10.1111/jth.13931. PMID: 29274198. [PubMed: 29274198] [CrossRef]
  200. Gawałko M, KapłonCieślicka A, Budnik M, et al. Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion. Polish Archives of Internal Medicine 2017;127(12):823–831. Digital Object Identifier: 10.20452/pamw.4117. [PubMed: 28972957] [CrossRef]
  201. Ge Y, Ha ACT, Atzema CL, et al. Association of Atrial Fibrillation and Oral Anticoagulant Use With Perioperative Outcomes After Major Noncardiac Surgery. J Am Heart Assoc 2017;6(12). Digital Object Identifier: 10.1161/jaha.117.006022. PMID: 29233826. [PMC free article: PMC5778996] [PubMed: 29233826] [CrossRef]
  202. Geis NA, Kiriakou C, Chorianopoulos E, et al. Feasibility and safety of Vitamin K antagonist monotherapy in atrial fibrillation patients undergoing transcatheter aortic valve implantation. EuroIntervention 2017;12(17):2058–2066. Digital Object Identifier: 10.4244/EIJ-D-15-00259. [PubMed: 28433958] [CrossRef]
  203. Geng J, Zhang Y, Wang Y, et al. Catheter ablation versus rate control in patients with atrial fibrillation and heart failure: A multicenter study. Medicine (Baltimore) 2017;96(49):e9179. Digital Object Identifier: 10.1097/md.0000000000009179. PMID: 29245366. [PMC free article: PMC5728981] [PubMed: 29245366] [CrossRef]
  204. Genovesi S, Rebora P, Gallieni M, et al. Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study. J Nephrol 2016. PMID: 27834042. [PubMed: 27834042]
  205. Genovesi S, Rossi E, Gallieni M, et al. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. Nephrol Dial Transplant 2015;30(3):491–8. PMID: 25352571. [PubMed: 25352571]
  206. Ghazali H, Essid J, Yahmadi A, et al. Evaluation of anticoagulation therapy in non-valvular Atrial Fibrillation in the emergency department. Tunisie Medicale 2016;94(11):469–474. [PubMed: 28994871]
  207. Gieling EM, van den Ham HA, van Onzenoort H, et al. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. Br J Clin Pharmacol 2017. PMID: 28205318. [PMC free article: PMC5510083] [PubMed: 28205318]
  208. Giugliano RP, Ruff CT, Wiviott SD, et al. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. Am J Med 2016;129(8):850–857.e2. PMID: 26994510. [PubMed: 26994510]
  209. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014;370(26):2467–77. PMID: 24963566. [PubMed: 24963566]
  210. Goda T, Sugiyama Y, Ohara N, et al. P-Wave Terminal Force in Lead V1 Predicts Paroxysmal Atrial Fibrillation in Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases 2017;26(9):1912–1915. Digital Object Identifier: 10.1016/j.jstrokecerebrovasdis.2017.06.031. [PubMed: 28716584] [CrossRef]
  211. Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016;388(10055):1995–2003. PMID: 27590218. [PubMed: 27590218]
  212. Goldstein BA, Arce CM, Hlatky MA, et al. Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. Circulation 2012;126(19):2293–301. PMID: 23032326. [PMC free article: PMC3640842] [PubMed: 23032326]
  213. Golive A, May HT, Bair TL, et al. The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial Fibrillation. Am J Cardiol 2017;120(1):75–82. PMID: 28483209. [PubMed: 28483209]
  214. Golwala H, Jackson LR, 2nd, Simon DN, et al. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. Am Heart J 2016;174:29–36. PMID: 26995367. [PubMed: 26995367]
  215. Gomes GG, Gali WL, Sarabanda AVL, et al. Late Results of Cox Maze III Procedure in Patients with Atrial Fibrillation Associated with Structural Heart Disease. Arq Bras Cardiol 2017;109(1):14–22. Digital Object Identifier: 10.5935/abc.20170082. PMID: 28678926. [PMC free article: PMC5524471] [PubMed: 28678926] [CrossRef]
  216. Gonzalez-Perez A, Saez ME, Johansson S, et al. Incidence and Predictors of Hemorrhagic Stroke in Users of Low-Dose Acetylsalicylic Acid. J Stroke Cerebrovasc Dis 2015;24(10):2321–8. PMID: 26189158. [PubMed: 26189158]
  217. Gorman EW, Perkel D, Dennis D, et al. Validation Of The HAS-BLED Tool In Atrial Fibrillation Patients Receiving Rivaroxaban. J Atr Fibrillation 2016;9(2):16–18. PMID: 27909541. [PMC free article: PMC5129694] [PubMed: 27909541]
  218. Gorzelak-Pabis P, Zyzak S, Krewko L, et al. Assessment of the mean time in the therapeutic INR range and the SAME-TT2R2 score in patients with atrial fibrillation and cognitive impairment. Pol Arch Med Wewn 2016;126(7-8):494–501. PMID: 27511466. [PubMed: 27511466]
  219. Goto S, Ikeda Y, Shimada K, et al. One-year cardiovascular event rates in Japanese outpatients with myocardial infarction, stroke, and atrial fibrillation. -Results From the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE). Circ J 2011;75(11):2598–604. PMID: 21857143. [PubMed: 21857143]
  220. Goto S, Merrill P, Wallentin L, et al. Antithrombotic Therapy Use and Clinical Outcomes Following Thromboembolic Events in Patients with Atrial Fibrillation: Insights from ARISTOTLE. Eur Heart J Cardiovasc Pharmacother 2018. Digital Object Identifier: 10.1093/ehjcvp/pvy002. PMID: 29385429. [PubMed: 29385429] [CrossRef]
  221. Goto S, Zhu J, Liu L, et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J 2014;168(3):303–9. PMID: 25173541. [PubMed: 25173541]
  222. Graves KG, May HT, Jacobs V, et al. Atrial fibrillation incrementally increases dementia risk across all CHADS2 and CHA2DS2VASc strata in patients receiving long-term warfarin. Am Heart J 2017;188:93–98. PMID: 28577686. [PubMed: 28577686]
  223. Gray MP, Saba S, Zhang Y, et al. Outcomes of Patients With Atrial Fibrillation Newly Recommended for Oral Anticoagulation Under the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline. J Am Heart Assoc 2018;7(1). Digital Object Identifier: 10.1161/jaha.117.007881. PMID: 29301756. [PMC free article: PMC5778974] [PubMed: 29301756] [CrossRef]
  224. Green L, Tan J, Morris JK, et al. A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study). Haematologica 2018. Digital Object Identifier: 10.3324/haematol.2017.182220. PMID: 29371325. [PMC free article: PMC5865412] [PubMed: 29371325] [CrossRef]
  225. Greenblatt DJ, Patel M, Harmatz JS, et al. Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection. J Clin Pharmacol 2017. Digital Object Identifier: 10.1002/jcph.1040. PMID: 29194698. [PubMed: 29194698] [CrossRef]
  226. Greve AM, Gerdts E, Boman K, et al. Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. Int J Cardiol 2013;166(1):72–6. PMID: 21996417. [PubMed: 21996417]
  227. Gronberg T, Hartikainen JE, Nuotio I, et al. Anticoagulation, CHA2DS2VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study). Am J Cardiol 2016;117(8):1294–8. PMID: 26892448. [PubMed: 26892448]
  228. Gunawardene MA, Dickow J, Schaeffer BN, et al. Risk stratification of patients with left atrial appendage thrombus prior to catheter ablation of atrial fibrillation: An approach towards an individualized use of transesophageal echocardiography. Journal of Cardiovascular Electrophysiology 2017;28(10):1127–1136. Digital Object Identifier: 10.1111/jce.13279. [PubMed: 28635023] [CrossRef]
  229. Günaydin S, Baştan B, Acar H, et al. Holter monitorisation results in early period of acute ischemic stroke. Noropsikiyatri Arsivi 2017;54(4):339–342. Digital Object Identifier: 10.5152/npa.2016.17012. [PMC free article: PMC5758078] [PubMed: 29321708] [CrossRef]
  230. Guo Y, Apostolakis S, Blann AD, et al. Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation. Int J Cardiol 2013;168(2):904–9. PMID: 23167998. [PubMed: 23167998]
  231. Guo Y, Wang H, Tian Y, et al. Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. Chest 2015;148(1):62–72. PMID: 25501045. [PMC free article: PMC4493879] [PubMed: 25501045]
  232. Guo Y, Wang H, Zhao X, et al. Relation of renal dysfunction to the increased risk of stroke and death in female patients with atrial fibrillation. Int J Cardiol 2013;168(2):1502–8. PMID: 23375056. [PubMed: 23375056]
  233. Guo Y, Zhu H, Chen Y, et al. Comparing Bleeding Risk Assessment Focused on Modifiable Risk Factors Only Versus Validated Bleeding Risk Scores in Atrial Fibrillation. Am J Med 2017. Digital Object Identifier: 10.1016/j.amjmed.2017.09.009. PMID: 28943382. [PubMed: 28943382] [CrossRef]
  234. Guo YT, Zhang Y, Shi XM, et al. Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: The Beijing PLA Hospital Atrial Fibrillation Project. Sci Rep 2016;6:31755. PMID: 27557876. [PMC free article: PMC4997334] [PubMed: 27557876]
  235. Guttmann OP, Pavlou M, O’Mahony C, et al. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). Eur J Heart Fail 2015;17(8):837–45. PMID: 26183688. [PMC free article: PMC4737264] [PubMed: 26183688]
  236. Hamatani Y, Ogawa H, Takabayashi K, et al. Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Sci Rep 2016;6:31042. PMID: 27485817. [PMC free article: PMC4971566] [PubMed: 27485817]
  237. Han TS, Fry CH, Fluck D, et al. Evaluation of anticoagulation status for atrial fibrillation on early ischaemic stroke outcomes: a registry-based, prospective cohort study of acute stroke care in Surrey, UK. BMJ Open 2017;7(12):e019122. Digital Object Identifier: 10.1136/bmjopen-2017-019122. PMID: 29247109. [PMC free article: PMC5736041] [PubMed: 29247109] [CrossRef]
  238. Hanon O, Vidal JS, Le Heuzey JY, et al. Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. International Journal of Cardiology 2017;232:98–104. [PubMed: 28111055]
  239. Hao L, Zhong JQ, Zhang W, et al. Uninterrupted dabigatran versus warfarin in the treatment of intracardiac thrombus in patients with non-valvular atrial fibrillation. International Journal of Cardiology 2015;190(1):63–66. [PubMed: 25912125]
  240. Harel Z, Mamdani M, Juurlink DN, et al. Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study. Canadian Journal of Cardiology 2016;32(8):986.e17–986.e22. [PubMed: 26992571]
  241. Hasegawa J, Bieber B, Larkina M, et al. Cardiovascular and Stroke Risk in Japanese Hemodialysis Patients With Atrial Fibrillation. Therapeutic Apheresis and Dialysis 2016;20(6):608–614. [PubMed: 27897386]
  242. Hatala R, Hlivák P, Urban L, et al. Thromboembolic risk profile in patients with atrial fibrillation in internal and cardiologic outpatient clinics in slovakia: Data from registry of atrial FIBrillation in real life practice (REALFIB*). Cardiology Letters 2012;21(3):98–110.
  243. He H, Guo J and Zhang A. The value of urine albumin in predicting thromboembolic events for patients with non-valvular atrial fibrillation. Int J Cardiol 2016;221:827–30. PMID: 27434352. [PubMed: 27434352]
  244. Hecker J, Marten S, Keller L, et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2016;115(5):939–49. PMID: 26791999. [PubMed: 26791999]
  245. Hegenbart U, Bochtler T, Benner A, et al. Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: Results of a prospective phase 2 study with long-term follow up. Haematologica 2017;102(8):1424–1431. Digital Object Identifier: 10.3324/haematol.2016.163246. [PMC free article: PMC5541875] [PubMed: 28522573] [CrossRef]
  246. Hellman T, Kiviniemi T, Nuotio I, et al. Intensity of anticoagulation and risk of thromboembolism after elective cardioversion of atrial fibrillation. Thromb Res 2017;156:163–167. Digital Object Identifier: 10.1016/j.thromres.2017.06.026. PMID: 28662483. [PubMed: 28662483] [CrossRef]
  247. Hernandez I and Zhang Y. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. Am J Cardiovasc Drugs 2017;17(1):37–47. PMID: 27637493. [PMC free article: PMC6572759] [PubMed: 27637493]
  248. Hernandez I, Baik SH, Pinera A, et al. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2015;175(1):18–24. PMID: 25365537. [PMC free article: PMC6608584] [PubMed: 25365537]
  249. Hernandez I, Zhang Y, Brooks MM, et al. Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation. Stroke 2017;48(1):159–166. PMID: 27909200. [PMC free article: PMC5183492] [PubMed: 27909200]
  250. Hess CN, Broderick S, Piccini JP, et al. Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. Am Heart J 2012;164(4):607–15. PMID: 23067921. [PMC free article: PMC3777661] [PubMed: 23067921]
  251. Hess PL, Kim S, Fonarow GC, et al. Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. Am J Med 2017;130(4):449–456. PMID: 27888051. [PubMed: 27888051]
  252. Hippisley-Cox J, Coupland C and Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. Bmj 2013;346:f2573. PMID: 23641033. [PMC free article: PMC3641809] [PubMed: 23641033]
  253. Hirata Y, Kusunose K, Yamada H, et al. Age-related changes in morphology of left atrial appendage in patients with atrial fibrillation. International Journal of Cardiovascular Imaging 2017;1–8. Digital Object Identifier: 10.1007/s10554-017-1232-x. [PubMed: 28808846] [CrossRef]
  254. Ho CW, Ho MH, Chan PH, et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke 2015;46(1):23–30. PMID: 25406148. [PubMed: 25406148]
  255. Ho JC, Chang AM, Yan BP, et al. Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. Clin Cardiol 2012;35(12):E40–5. PMID: 23108916. [PMC free article: PMC6652425] [PubMed: 23108916]
  256. Hohnloser SH, Cappato R, Ezekowitz MD, et al. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial. Europace 2016;18(2):184–90. PMID: 26487668. [PMC free article: PMC4767121] [PubMed: 26487668]
  257. Hołda MK, Koziej M, Wszołek K, et al. Left atrial accessory appendages, diverticula, and left-sided septal pouch in multi-slice computed tomography. Association with atrial fibrillation and cerebrovascular accidents. International Journal of Cardiology 2017;244:163–168. Digital Object Identifier: 10.1016/j.ijcard.2017.06.042. [PubMed: 28629626] [CrossRef]
  258. Homsi R, Nath B, Luetkens JA, et al. Can Contrast-Enhanced Multi-Detector Computed Tomography Replace Transesophageal Echocardiography for the Detection of Thrombogenic Milieu and Thrombi in the Left Atrial Appendage: A Prospective Study with 124 Patients. Rofo 2016;188(1):45–52. PMID: 26422416. [PubMed: 26422416]
  259. Hong KS, Kim YK, Bae HJ, et al. Quality of Anticoagulation with Warfarin in Korean Patients with Atrial Fibrillation and Prior Stroke: A Multicenter Retrospective Observational Study. J Clin Neurol 2017;13(3):273–280. Digital Object Identifier: 10.3988/jcn.2017.13.3.273. PMID: 28748679. [PMC free article: PMC5532324] [PubMed: 28748679] [CrossRef]
  260. Hori M, Connolly SJ, Zhu J, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013;44(7):1891–6. PMID: 23743976. [PubMed: 23743976]
  261. Hori M, Matsumoto M, Tanahashi N, et al. Predictive factors for bleeding during treatment with rivaroxaban and warfarin in Japanese patients with atrial fibrillation - Subgroup analysis of J-ROCKET AF. J Cardiol 2016;68(6):523–528. PMID: 26796348. [PubMed: 26796348]
  262. Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial. J Stroke Cerebrovasc Dis 2014;23(2):379–83. PMID: 23954611. [PubMed: 23954611]
  263. Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study. Circ J 2012;76(9):2104–11. PMID: 22664783. [PubMed: 22664783]
  264. Hori M, Matsumoto M, Tanahashi N, et al. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J 2013;77(3):632–8. PMID: 23229461. [PubMed: 23229461]
  265. Hoshino T, Ishizuka K, Shimizu S, et al. CHADS2 score predicts functional outcome of stroke in patients with a history of coronary artery disease. J Neurol Sci 2013;331(1-2):57–60. PMID: 23714421. [PubMed: 23714421]
  266. Hsu CC, Hsu PF, Sung SH, et al. Is There a Preferred Stroke Prevention Strategy for Diabetic Patients with Non-Valvular Atrial Fibrillation? Comparing Warfarin, Dabigatran and Rivaroxaban. Thromb Haemost 2018;118(1):72–81. Digital Object Identifier: 10.1160/th17-02-0095. PMID: 29304527. [PubMed: 29304527] [CrossRef]
  267. Hsu JC, Maddox TM, Kennedy K, et al. Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. J Am Coll Cardiol 2016;67(25):2913–23. PMID: 27339487. [PubMed: 27339487]
  268. Hu WS and Lin CL. CHA2DS2-VASc score for ischaemic stroke risk stratification in patients with chronic obstructive pulmonary disease with and without atrial fibrillation: a nationwide cohort study. Europace 2017. PMID: 28407109. [PubMed: 28407109]
  269. Hu WS and Lin CL. Impact of atrial fibrillation on the development of ischemic stroke among cancer patients classified by CHA2DS2-VASc score-a nationwide cohort study. Oncotarget 2018;9(7):7623–7630. Digital Object Identifier: 10.18632/oncotarget.24143. [PMC free article: PMC5800930] [PubMed: 29484138] [CrossRef]
  270. Huang CS, Chen CI, Liu YT, et al. CHA2DS2-VASc score and heart rate predict ischemic stroke outcomes in patients with atrial fibrillation. Acta Cardiologica Sinica 2014;30(1):16–21. [PMC free article: PMC4804816] [PubMed: 27122763]
  271. Huang H, Liu Y, Xu Y, et al. Percutaneous Left Atrial Appendage Closure With the LAmbre Device for Stroke Prevention in Atrial Fibrillation: A Prospective, Multicenter Clinical Study. JACC Cardiovasc Interv 2017;10(21):2188–2194. Digital Object Identifier: 10.1016/j.jcin.2017.06.072. PMID: 29122133. [PubMed: 29122133] [CrossRef]
  272. Hudzik B, Szkodzinski J, Hawranek M, et al. CHA2DS2-VASc score is useful in predicting poor 12-month outcomes following myocardial infarction in diabetic patients without atrial fibrillation. Acta Diabetol 2016;53(5):807–15. PMID: 27339195. [PMC free article: PMC5014889] [PubMed: 27339195]
  273. Hung Y, Chao TF, Liu CJ, et al. Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2-VASc Score of 1 (Men) or 2 (Women)?. J Am Heart Assoc 2016;5(10). PMID: 27702803. [PMC free article: PMC5121486] [PubMed: 27702803]
  274. Hwang HS, Park MW, Yoon HE, et al. Clinical significance of chronic kidney disease and atrial fibrillation on morbidity and mortality in patients with acute myocardial infarction. Am J Nephrol 2014;40(4):345–52. PMID: 25358406. [PubMed: 25358406]
  275. Ikeda T, Yasaka M, Kida M, et al. A survey of reasons for continuing warfarin therapy in the era of direct oral anticoagulants in Japanese patients with atrial fibrillation: The SELECT study. Patient Preference and Adherence 2018;12:135–143. Digital Object Identifier: 10.2147/PPA.S152584. [PMC free article: PMC5775732] [PubMed: 29398909] [CrossRef]
  276. Ikegami Y, Tanimoto K, Inagawa K, et al. Identification of left atrial appendage thrombi in patients with persistent and long-standing persistent atrial fibrillation using intra-cardiac echocardiography and cardiac computed tomography. Circulation Journal 2018;82(1):46–52. Digital Object Identifier: 10.1253/circj.CJ-17-0077. [PubMed: 28740038] [CrossRef]
  277. Inoue H, Atarashi H, Kodani E, et al. Regional Differences in Frequency of Warfarin Therapy and Thromboembolism in Japanese Patients With Non-Valvular Atrial Fibrillation- Analysis of the J-RHYTHM Registry. Circ J 2016;80(7):1548–55. PMID: 27251064. [PubMed: 27251064]
  278. Inoue H, Okumura K, Atarashi H, et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. Circ J 2013;77(9):2264–70. PMID: 23708863. [PubMed: 23708863]
  279. Inoue K, Suna S, Iwakura K, et al. Outcomes for Atrial Fibrillation Patients with Silent Left Atrial Thrombi Detected by Transesophageal Echocardiography. Am J Cardiol 2017;120(6):940–946. Digital Object Identifier: 10.1016/j.amjcard.2017.06.022. PMID: 28750827. [PubMed: 28750827] [CrossRef]
  280. Inoue T and Suematsu Y. Left atrial appendage resection can be performed minimally invasively with good clinical and echocardiographic outcomes without any severe risk. Eur J Cardiothorac Surg 2018. Digital Object Identifier: 10.1093/ejcts/ezx506. PMID: 29370349. [PubMed: 29370349] [CrossRef]
  281. Ishikawa S, Sugioka K, Sakamoto S, et al. Relationship between tissue Doppler measurements of left ventricular diastolic function and silent brain infarction in patients with non-valvular atrial fibrillation. European Heart Journal Cardiovascular Imaging 2017;18(11):1245–1252. Digital Object Identifier: 10.1093/ehjci/jew220. [PubMed: 28039210] [CrossRef]
  282. Islam MS, Ammour N, Alajlan N, et al. Rhythm-based heartbeat duration normalization for atrial fibrillation detection. Comput Biol Med 2016;72:160–9. PMID: 27043858. [PubMed: 27043858]
  283. Jaakkola S, Nuotio I, Kiviniemi TO, et al. Clinical manifestations and outcomes of severe warfarin overanticoagulation: from the EWA study. Annals of Medicine 2017;1–8. Digital Object Identifier: 10.1080/07853890.2017.1407494. [PubMed: 29156997] [CrossRef]
  284. Jackevicius CA, Tsadok MA, Essebag V, et al. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation. Heart 2017. PMID: 28286333. [PubMed: 28286333]
  285. Jackson LR, 2nd, Piccini JP, Cyr DD, et al. Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. Clin Cardiol 2016;39(9):497–506. PMID: 27468086. [PMC free article: PMC6490848] [PubMed: 27468086]
  286. Jacobs A, Decloedt EH and Bassa F. A preliminary review of warfarin toxicity in a tertiary hospital in Cape Town, South Africa. Cardiovascular Journal of Africa 2017;28(6):346–349. Digital Object Identifier: 10.5830/CVJA-2017-029. [PMC free article: PMC5885058] [PubMed: 28656193] [CrossRef]
  287. Jacobs V, May HT, Bair TL, et al. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation. Am J Cardiol 2016;118(2):210–4. PMID: 27236255. [PubMed: 27236255]
  288. Jacobs V, Woller SC, Stevens S, et al. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm 2014;11(12):2206–13. PMID: 25111326. [PubMed: 25111326]
  289. Jacobs V, Woller SC, Stevens SM, et al. Percent time with a supratherapeutic INR in atrial fibrillation patients also using an antiplatelet agent is associated with long-term risk of dementia. Journal of Cardiovascular Electrophysiology 2015;26(11):1180–1186. [PubMed: 26268931]
  290. Jain V, Marshall IJ, Crichton SL, et al. Trends in the prevalence and management of pre-stroke atrial fibrillation, the South London Stroke Register, 1995-2014. PLoS One 2017;12(4):e0175980. PMID: 28410424. [PMC free article: PMC5391932] [PubMed: 28410424]
  291. Jang SJ, Kim MS, Park HJ, et al. Impact of heart failure with normal ejection fraction on the occurrence of ischaemic stroke in patients with atrial fibrillation. Heart 2013;99(1):17–21. PMID: 22942291. [PubMed: 22942291]
  292. Johansson C, Dahlqvist E, Andersson J, et al. Incidence, type of atrial fibrillation and risk factors for stroke: a population-based cohort study. Clin Epidemiol 2017;9:53–62. PMID: 28182159. [PMC free article: PMC5283072] [PubMed: 28182159]
  293. Jones WS, Mi X, Patel MR, et al. Combined use of warfarin and oral P2Y12 inhibitors in patients with atrial fibrillation and acute coronary syndrome. Clin Cardiol 2014;37(3):152–9. PMID: 24338960. [PMC free article: PMC6649619] [PubMed: 24338960]
  294. Kaasenbrood F, Hollander M, Rutten FH, et al. Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination. Europace 2016;18(10):1514–1520. PMID: 26851813. [PMC free article: PMC5072135] [PubMed: 26851813]
  295. Kabra R, Girotra S and Vaughan Sarrazin M. Refining Stroke Prediction in Atrial Fibrillation Patients by Addition of African-American Ethnicity to CHA2DS2-VASc Score. J Am Coll Cardiol 2016;68(5):461–70. PMID: 27470453. [PMC free article: PMC5394427] [PubMed: 27470453]
  296. Kai B, Bogorad Y, Nguyen LN, et al. Warfarin use and the risk of mortality, stroke, and bleeding in hemodialysis patients with atrial fibrillation. Heart Rhythm 2017;14(5):645–651. PMID: 28185918. [PubMed: 28185918]
  297. Kamel H, Hunter M, Moon YP, et al. Electrocardiographic Left Atrial Abnormality and Risk of Stroke: Northern Manhattan Study. Stroke 2015;46(11):3208–12. PMID: 26396031. [PMC free article: PMC4624510] [PubMed: 26396031]
  298. Kanai Y, Oguro H, Tahara N, et al. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants’ Administration for Secondary Prevention of Stroke. J Stroke Cerebrovasc Dis 2018;27(2):338–345. Digital Object Identifier: 10.1016/j.jstrokecerebrovasdis.2017.09.007. PMID: 29033229. [PubMed: 29033229] [CrossRef]
  299. Kaneko H, Neuss M, Weissenborn J, et al. Predictors of thrombus formation after percutaneous left atrial appendage closure using the WATCHMAN device. Heart and Vessels 2017:1–7. [PubMed: 28477098]
  300. Kang HG, Suk SH, Cheong JS, et al. Vascular risk factors for stroke among urban community dwelling adults in Ansan city, Korea. Neurology Asia 2016;21(4):317–324.
  301. Kang MK, Han C, Chun KJ, et al. Factors associated with stroke in patients with paroxysmal atrial fibrillation beyond CHADS2 score. Cardiol J 2016;23(4):429–36. PMID: 27296157. [PubMed: 27296157]
  302. Kang SH, Choi EK, Han KD, et al. Risk of Ischemic Stroke in Patients With Non-Valvular Atrial Fibrillation Not Receiving Oral Anticoagulants- Korean Nationwide Population-Based Study. Circ J 2017. PMID: 28413184. [PubMed: 28413184]
  303. Kang SH, Kim J, Park JJ, et al. Risk of stroke in congestive heart failure with and without atrial fibrillation. Int J Cardiol 2017;248:182–187. Digital Object Identifier: 10.1016/j.ijcard.2017.07.056. PMID: 28826798. [PubMed: 28826798] [CrossRef]
  304. Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc 2016;5(5). PMID: 27207971. [PMC free article: PMC4889207] [PubMed: 27207971]
  305. Katoh H, Nozue T and Michishita I. Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation. Heart and Vessels 2017;32(9):1130–1136. Digital Object Identifier: 10.1007/s00380-017-0962-y. [PubMed: 28283738] [CrossRef]
  306. Kefer J, Aminian A, Vermeersch P, et al. Transcatheter Left Atrial Appendage Occlusion for Stroke Prevention in Patients with Atrial Fibrillation: Results from the Belgian Registry. EuroIntervention 2017. Digital Object Identifier: 10.4244/eij-d-17-00076. PMID: 28966159. [PubMed: 28966159] [CrossRef]
  307. Kefer J, Tzikas A, Freixa X, et al. Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Int J Cardiol 2016;207:335–40. PMID: 26820363. [PubMed: 26820363]
  308. Kelly FR, Hull RA, Arrey-Mbi TB, et al. Left atrial appendage morphology and risk of stroke following pulmonary vein isolation for drug-refractory atrial fibrillation in low CHA2DS2Vasc risk patients. BMC Cardiovasc Disord 2017;17(1):70. PMID: 28245798. [PMC free article: PMC5331636] [PubMed: 28245798]
  309. Keskar V, McArthur E, Wald R, et al. The association of anticoagulation, ischemic stroke, and hemorrhage in elderly adults with chronic kidney disease and atrial fibrillation. Kidney Int 2017;91(4):928–936. PMID: 28017326. [PubMed: 28017326]
  310. Kilickiran Avci B, Vatan B, Ozden Tok O, et al. The Trends in Utilizing Nonvitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A Real-Life Experience. Clin Appl Thromb Hemost 2016;22(8):785–791. PMID: 25878174. [PubMed: 25878174]
  311. Kim D, Chung JW, Kim CK, et al. Impact of CHADS(2) Score on Neurological Severity and Long-Term Outcome in Atrial Fibrillation-Related Ischemic Stroke. J Clin Neurol 2012;8(4):251–8. PMID: 23323132. [PMC free article: PMC3540283] [PubMed: 23323132]
  312. Kim EJ, Yin X, Fontes JD, et al. Atrial fibrillation without comorbidities: Prevalence, incidence and prognosis (from the Framingham Heart Study). Am Heart J 2016;177:138–44. PMID: 27297859. [PMC free article: PMC4908973] [PubMed: 27297859]
  313. Kim H, Kim TH, Cha MJ, et al. A Prospective Survey of Atrial Fibrillation Management for Real-world Guideline Adherence: COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) Registry. Korean Circ J 2017;47(6):877–887. Digital Object Identifier: 10.4070/kcj.2017.0146. PMID: 29171211. [PMC free article: PMC5711680] [PubMed: 29171211] [CrossRef]
  314. Kim JB, Chong BK, Jung SH, et al. Maze procedure in patients with left ventricular dysfunction. Int J Cardiol 2014;170(3):331–7. PMID: 24268862. [PubMed: 24268862]
  315. Kim JJ, Hill HL, Groce JB, et al. Pharmacy Student Monitoring of Direct Oral Anticoagulants. Journal of Pharmacy Practice 2018. Digital Object Identifier: 10.1177/0897190017752713. [PubMed: 29366379] [CrossRef]
  316. Kim JS, Lee H, Suh Y, et al. Left Atrial Appendage Occlusion in Non-Valvular Atrial Fibrillation in a Korean Multi-Center Registry. Circ J 2016;80(5):1123–30. PMID: 26984716. [PubMed: 26984716]
  317. Kim TH, Yang PS, Kim D, et al. CHA2DS2-VASc Score for Identifying Truly Low-Risk Atrial Fibrillation for Stroke: A Korean Nationwide Cohort Study. Stroke 2017;48(11):2984–2990. Digital Object Identifier: 10.1161/strokeaha.117.018551. PMID: 28939672. [PubMed: 28939672] [CrossRef]
  318. Kim TH, Yang PS, Uhm JS, et al. CHA2DS2-VASc Score (Congestive Heart Failure, Hypertension, Age >/=75 [Doubled], Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack [Doubled], Vascular Disease, Age 65-74, Female) for Stroke in Asian Patients With Atrial Fibrillation: A Korean Nationwide Sample Cohort Study. Stroke 2017;48(6):1524–1530. PMID: 28455320. [PubMed: 28455320]
  319. Kim Y and Lee SH. Embolic stroke and after-admission atrial fibrillation. Int J Cardiol 2016;222:576–80. PMID: 27513654. [PubMed: 27513654]
  320. Kim Y, Kim TJ, Park JB, et al. Novel echocardiographic indicator for potential cardioembolic stroke. Eur J Neurol 2016;23(3):613–20. PMID: 26601639. [PubMed: 26601639]
  321. Kim YD, Lee KY, Nam HS, et al. Factors associated with ischemic stroke on therapeutic anticoagulation in patients with nonvalvular atrial fibrillation. Yonsei Med J 2015;56(2):410–7. PMID: 25683989. [PMC free article: PMC4329352] [PubMed: 25683989]
  322. Kim YG, Choi JI, Kim MN, et al. Non-Vitamin K antagonist oral anticoagulants versus warfarin for the prevention of spontaneous echo-contrast and thrombus in patients with atrial fibrillation or flutter undergoing cardioversion: A trans-esophageal echocardiography study. PLoS ONE 2018;13(1). Digital Object Identifier: 10.1371/journal.pone.0191648. [PMC free article: PMC5779688] [PubMed: 29360845] [CrossRef]
  323. King JB, Azadani PN, Suksaranjit P, et al. Left Atrial Fibrosis and Risk of Cerebrovascular and Cardiovascular Events in Patients With Atrial Fibrillation. J Am Coll Cardiol 2017;70(11):1311–1321. Digital Object Identifier: 10.1016/j.jacc.2017.07.758. PMID: 28882227. [PubMed: 28882227] [CrossRef]
  324. Kiviniemi T, Karjalainen P, Rubboli A, et al. Thrombocytopenia in patients with atrial fibrillation on oral anticoagulation undergoing percutaneous coronary intervention. Am J Cardiol 2013;112(4):493–8. PMID: 23672991. [PubMed: 23672991]
  325. Kis Z, Theuns DA, Bhagwandien R, et al. Type and rate of atrial fibrillation termination due to rotational activity ablation combined with pulmonary vein isolation. Journal of Cardiovascular Electrophysiology 2017;28(8):862–869. Digital Object Identifier: 10.1111/jce.13240. [PubMed: 28471019] [CrossRef]
  326. Ko SH, Park YM, Yun JS, et al. Severe hypoglycemia is a risk factor for atrial fibrillation in type 2 diabetes mellitus: Nationwide population-based cohort study. Journal of Diabetes and its Complications 2018;32(2):157–163. Digital Object Identifier: 10.1016/j.jdiacomp.2017.09.009. [PMC free article: PMC6278599] [PubMed: 29196120] [CrossRef]
  327. Kobayashi N, Yamawaki M, Nakano M, et al. A new scoring system (DAIGA) for predicting bleeding complications in atrial fibrillation patients after drug-eluting stent implantation with triple antithrombotic therapy. Int J Cardiol 2016;223:985–991. PMID: 27591697. [PubMed: 27591697]
  328. Kodani E, Atarashi H, Inoue H, et al. Beneficial Effect of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation- Results of the J-RHYTHM Registry 2. Circ J 2016;80(4):843–51. PMID: 27001190. [PubMed: 27001190]
  329. Kodani E, Atarashi H, Inoue H, et al. Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Nonvalvular Atrial Fibrillation: A Subanalysis of the J-RHYTHM Registry. J Am Heart Assoc 2016;5(9). PMID: 27620886. [PMC free article: PMC5079049] [PubMed: 27620886]
  330. Kodani E, Atarashi H, Inoue H, et al. Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry. Eur Heart J Qual Care Clin Outcomes 2018;4(1):59–68. Digital Object Identifier: 10.1093/ehjqcco/qcx032. PMID: 28950373. [PMC free article: PMC5862022] [PubMed: 28950373] [CrossRef]
  331. Kodani E, Atarashi H, Inoue H, et al. Secondary Prevention of Stroke with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry. J Stroke Cerebrovasc Dis 2016;25(3):585–99. PMID: 26725259. [PubMed: 26725259]
  332. Koga M, Yoshimura S, Hasegawa Y, et al. Higher Risk of Ischemic Events in Secondary Prevention for Patients With Persistent Than Those With Paroxysmal Atrial Fibrillation. Stroke 2016;47(10):2582–8. PMID: 27531346. [PubMed: 27531346]
  333. Komatsu T, Sato Y, Ozawa M, et al. Comparison between CHADS2 and CHA2DS2-VASc score for risk stratification of ischemic stroke in Japanese patients with non-valvular paroxysmal atrial fibrillation not receiving anticoagulant therapy. Int Heart J 2014;55(2):119–25. PMID: 24632957. [PubMed: 24632957]
  334. Komatsu T, Tachibana H, Satoh Y, et al. Relationship between CHA(2)DS(2)-VASc scores and ischemic stroke/cardiovascular events in Japanese patients with paroxysmal atrial fibrillation not receiving anticoagulant therapy. J Cardiol 2012;59(3):321–8. PMID: 22386575. [PubMed: 22386575]
  335. Kondo T, Yamada T, Morita T, et al. The CHADS2 score predicts ischemic stroke in chronic heart failure patients without atrial fibrillation: comparison to other stroke risk scores. Heart Vessels 2017;32(2):193–200. PMID: 27325225. [PubMed: 27325225]
  336. Kongbunkiat K, Kasemsap N, Travanichakul S, et al. Hospital mortality from atrial fibrillation associated with ischemic stroke: a national data report. Int J Neurosci 2015;125(12):924–8. PMID: 25387068. [PubMed: 25387068]
  337. Kooiman J, van Hagen N, Iglesias Del Sol A, et al. The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. PLoS One 2015;10(4):e0122520. PMID: 25905638. [PMC free article: PMC4407886] [PubMed: 25905638]
  338. Kooiman J, van Rein N, Spaans B, et al. Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease. PLoS One 2014;9(5):e94420. PMID: 24817475. [PMC free article: PMC4015895] [PubMed: 24817475]
  339. Kopin D, Jones WS, Sherwood MW, et al. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. American Heart Journal 2018;197:133–141. Digital Object Identifier: 10.1016/j.ahj.2017.11.005. [PubMed: 29447773] [CrossRef]
  340. Koretsune Y, Yamashita T, Kimura T, et al. Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment. Circ J 2015;79(7):1486–95. PMID: 25925842. [PubMed: 25925842]
  341. Körmendy D, Pilgrim T, Pulver C, et al. Outcome after simultaneous PCI and left atrial appendage occlusion. Kardiovaskulare Medizin 2015;18(3):96–102.
  342. Kornej J, Hindricks G, Kosiuk J, et al. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry. Circ Arrhythm Electrophysiol 2013;6(5):868–74. PMID: 24047706. [PubMed: 24047706]
  343. Kundu A, O’Day K, Shaikh AY, et al. Relation of Atrial Fibrillation in Acute Myocardial Infarction to In-Hospital Complications and Early Hospital Readmission. Am J Cardiol 2016;117(8):1213–8. PMID: 26874548. [PMC free article: PMC5075423] [PubMed: 26874548]
  344. Kupczyńska K, Kasprzak JD, Michalski B, et al. Prognostic significance of spontaneous echocardiographic contrast detected by transthoracic and transesophageal echocardiography in the era of harmonic imaging. Archives of Medical Science 2013;9(5):808–814. [PMC free article: PMC3832826] [PubMed: 24273561]
  345. Kuwata S, Taramasso M, Zuber M, et al. Feasibility of concomitant MitraClip and left atrial appendage occlusion. EuroIntervention 2017;12(16):1940–1945. PMID: 28044988. [PubMed: 28044988]
  346. Kwon CH, Kim M, Kim J, et al. Real-world comparison of non-vitamin K antagonist oral anticoagulants and warfarin in Asian octogenarian patients with atrial fibrillation. J Geriatr Cardiol 2016;13(7):566–72. PMID: 27605936. [PMC free article: PMC4996830] [PubMed: 27605936]
  347. Kwon Y, Norby FL, Jensen PN, et al. Association of Smoking, Alcohol, and Obesity with Cardiovascular Death and Ischemic Stroke in Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study and Cardiovascular Health Study (CHS). PLoS One 2016;11(1):e0147065. PMID: 26756465. [PMC free article: PMC4710457] [PubMed: 26756465]
  348. Labaf A, Carlwe M and Svensson PJ. Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden. Thromb J 2014;12(1):29. PMID: 25506268. [PMC free article: PMC4265344] [PubMed: 25506268]
  349. Labin JE, Haque N, Sinn LA, et al. The Cox-Maze IV procedure for atrial fibrillation is equally efficacious in patients with rheumatic and degenerative mitral valve disease. Journal of Thoracic and Cardiovascular Surgery 2017;154(3):835–844. Digital Object Identifier: 10.1016/j.jtcvs.2017.03.152. [PubMed: 28583297] [CrossRef]
  350. Lahtela HM, Bah A, Kiviniemi T, et al. Outcome of octogenarians with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. Clin Cardiol 2017. Digital Object Identifier: 10.1002/clc.22821. PMID: 29243834. [PMC free article: PMC6490386] [PubMed: 29243834] [CrossRef]
  351. Lai CL, Chen HM, Liao MT, et al. Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients. J Am Heart Assoc 2017;6(4). PMID: 28438735. [PMC free article: PMC5533025] [PubMed: 28438735]
  352. Lai HC, Chien WC, Chung CH, et al. Atrial fibrillation, liver disease, antithrombotics and risk of cerebrovascular events: A population-based cohort study. Int J Cardiol 2016;223:829–837. PMID: 27580216. [PubMed: 27580216]
  353. Lai YH, Hsieh TC, Chou CL, et al. Hazards of antithrombotic therapy on hemodialysis patients with atrial fibrillation and high thromboembolic risk: A Taiwanese population-based cohort study. International Journal of Clinical and Experimental Medicine 2017;10(9):13982–13991.
  354. Laliberte F, Moore Y, Dea K, et al. Gastrointestinal comorbidities associated with atrial fibrillation. Springerplus 2014;3:603. PMID: 25392776. [PMC free article: PMC4210454] [PubMed: 25392776]
  355. Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013;62(11):981–9. PMID: 23747760. [PubMed: 23747760]
  356. Lamberts M, Lip GY, Ruwald MH, et al. Antithrombotic treatment in patients with heart failure and associated atrial fibrillation and vascular disease: a nationwide cohort study. J Am Coll Cardiol 2014;63(24):2689–98. PMID: 24794118. [PubMed: 24794118]
  357. Lang C, Seyfang L, Ferrari J, et al. Do Women With Atrial Fibrillation Experience More Severe Strokes? Results From the Austrian Stroke Unit Registry. Stroke 2017;48(3):778–780. PMID: 28151397. [PubMed: 28151397]
  358. Larsen TB, Rasmussen LH, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013;61(22):2264–73. PMID: 23562920. [PubMed: 23562920]
  359. Lasek-Bal A, Kowalewska-Twardela T, Warsz-Wianecka A, et al. The importance of atrial fibrillation and selected echocardiographic parameters for the effectiveness and safety of thrombolytic therapy in patients with stroke. Neurol Neurochir Pol 2017. Digital Object Identifier: 10.1016/j.pjnns.2017.09.001. PMID: 28985990. [PubMed: 28985990] [CrossRef]
  360. Lau CP, Gbadebo TD, Connolly SJ, et al. Ethnic differences in atrial fibrillation identified using implanted cardiac devices. J Cardiovasc Electrophysiol 2013;24(4):381–7. PMID: 23356818. [PubMed: 23356818]
  361. Lau WCY, Li X, Wong ICK, et al. Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin. J Thromb Haemost 2017;15(10):1923–1933. Digital Object Identifier: 10.1111/jth.13780. PMID: 28748652. [PubMed: 28748652] [CrossRef]
  362. Lee JH, Kim J, Kim M, et al. Extremely low-frame-rate digital fluoroscopy in catheter ablation of atrial fibrillation: A comparison of 2 versus 4 frame rate. Medicine (United States) 2017;96(24). Digital Object Identifier: 10.1097/MD.0000000000007200. [PMC free article: PMC5478349] [PubMed: 28614264] [CrossRef]
  363. Lee JM, Kim JB, Uhm JS, et al. Additional value of left atrial appendage geometry and hemodynamics when considering anticoagulation strategy in patients with atrial fibrillation with low CHA2DS2-VASc scores. Heart Rhythm 2017. PMID: 28559088. [PubMed: 28559088]
  364. Lee KH, Li SY, Liu JS, et al. Association of warfarin with congestive heart failure and peripheral artery occlusive disease in hemodialysis patients with atrial fibrillation. J Chin Med Assoc 2017;80(5):277–282. PMID: 28214287. [PubMed: 28214287]
  365. Lee KH, Park HW, Cho JG, et al. Comparison of non-vitamin K antagonist oral anticoagulants and warfarin on clinical outcomes in atrial fibrillation patients with renal dysfunction. Europace 2015;17: Suppl 2:ii69–75. PMID: 26842118. [PubMed: 26842118]
  366. Lee SJ, Sung JH, Kim JB, et al. The safety and efficacy of vitamin K antagonist in atrial fibrillation patients with previous ulcer bleeding: Long-term results from a multicenter study. Medicine (Baltimore) 2016;95(47):e5467. PMID: 27893694. [PMC free article: PMC5134887] [PubMed: 27893694]
  367. Lee Y, Park HC, Lee Y, et al. Comparison of Morphologic Features and Flow Velocity of the Left Atrial Appendage Among Patients With Atrial Fibrillation Alone, Transient Ischemic Attack, and Cardioembolic Stroke. Am J Cardiol 2017;119(10):1596–1604. PMID: 28364953. [PubMed: 28364953]
  368. Lee YJ, Park JK, Uhm JS, et al. Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy. Int J Cardiol 2016;203:372–8. PMID: 26539960. [PubMed: 26539960]
  369. Leef GC, Hellkamp AS, Patel MR, et al. Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. J Am Heart Assoc 2017;6(6). PMID: 28615214. [PMC free article: PMC5669143] [PubMed: 28615214]
  370. Lehto M, Niiranen J, Korhonen P, et al. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry. Pharmacoepidemiol Drug Saf 2017;26(6):657–665. PMID: 28317274. [PubMed: 28317274]
  371. Lemesle G, Ducrocq G, Elbez Y, et al. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. Clin Cardiol 2017;40(10):932–939. Digital Object Identifier: 10.1002/clc.22750. PMID: 28692742. [PMC free article: PMC6490437] [PubMed: 28692742] [CrossRef]
  372. Lerario MP, Gialdini G, Lapidus DM, et al. Risk of Ischemic Stroke after Intracranial Hemorrhage in Patients with Atrial Fibrillation. PLoS One 2015;10(12):e0145579. PMID: 26701759. [PMC free article: PMC4689346] [PubMed: 26701759]
  373. Leung M, van Rosendael PJ, Abou R, et al. Left atrial function to identify patients with atrial fibrillation at high risk of stroke: new insights from a large registry. Eur Heart J 2017. Digital Object Identifier: 10.1093/eurheartj/ehx736. PMID: 29300883. [PubMed: 29300883] [CrossRef]
  374. Li B, Wang T, Lou Y, et al. Sex Differences in Outcomes and Associated Risk Factors After Acute Ischemic Stroke in Elderly Patients: A Prospective Follow-up Study. J Stroke Cerebrovasc Dis 2015;24(10):2277–84. PMID: 26169546. [PubMed: 26169546]
  375. Li CH, Liu CJ, Chou AY, et al. European Society of Cardiology Guideline-Adherent Antithrombotic Treatment and Risk of Mortality in Asian Patients with Atrial Fibrillation. Sci Rep 2016;6:30734. PMID: 27498702. [PMC free article: PMC4976390] [PubMed: 27498702]
  376. Li G, Thabane L, Delate T, et al. Can We Predict Individual Combined Benefit and Harm of Therapy? Warfarin Therapy for Atrial Fibrillation as a Test Case. PLoS One 2016;11(8):e0160713. PMID: 27513986. [PMC free article: PMC4981352] [PubMed: 27513986]
  377. Li LH, Sheng CS, Hu BC, et al. The prevalence, incidence, management and risks of atrial fibrillation in an elderly Chinese population: a prospective study. BMC Cardiovasc Disord 2015;15:31. PMID: 25953603. [PMC free article: PMC4427946] [PubMed: 25953603]
  378. Li Q, Zhang Y, Kang H, et al. Mining association rules between stroke risk factors based on the Apriori algorithm. Technology and Health Care 2017;25(S1):S197–S205. Digital Object Identifier: 10.3233/THC-171322. [PubMed: 28582907] [CrossRef]
  379. Li SY, Zhao XQ, Wang CX, et al. One-year clinical prediction in Chinese ischemic stroke patients using the CHADS2 and CHA2DS2-VASc scores: the China National Stroke Registry. CNS Neurosci Ther 2012;18(12):988–93. PMID: 23121837. [PMC free article: PMC6493534] [PubMed: 23121837]
  380. Li WH, Huang D, Chiang CE, et al. Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project. Clin Cardiol 2017;40(4):222–229. PMID: 27893153. [PMC free article: PMC6490525] [PubMed: 27893153]
  381. Li X, Liu H, Du X, et al. Integrated Machine Learning Approaches for Predicting Ischemic Stroke and Thromboembolism in Atrial Fibrillation. AMIA Annu Symp Proc 2016;2016:799–807. PMID: 28269876. [PMC free article: PMC5333223] [PubMed: 28269876]
  382. Li X, Liu H, Du X, et al. Using Frequent Item Set Mining and Feature Selection Methods to Identify Interacted Risk Factors - The Atrial Fibrillation Case Study. Stud Health Technol Inform 2016;228:562–6. PMID: 27577446. [PubMed: 27577446]
  383. Liantinioti C, Tympas K, Katsanos AH, et al. Duration of paroxysmal atrial fibrillation in cryptogenic stroke is not associated with stroke severity and early outcomes. J Neurol Sci 2017;376:191–195. PMID: 28431610. [PubMed: 28431610]
  384. Liao KM and Chen CY. Incidence and risk factors of atrial fibrillation in Asian COPD patients. International Journal of COPD 2017;12:2523–2530. Digital Object Identifier: 10.2147/COPD.S143691. [PMC free article: PMC5574688] [PubMed: 28883719] [CrossRef]
  385. Liao MT, Lin LY, Yang YH, et al. ACEI and ARB did not Reduce the Incidence of Dementia in Patients with Atrial Fibrillation: A Nationwide Cohort Study. Acta Cardiol Sin 2013;29(4):323–7. PMID: 27122725. [PMC free article: PMC4804898] [PubMed: 27122725]
  386. Lin WY, Lin YJ, Chung FP, et al. Impact of renal dysfunction on clinical outcome in patients with low risk of atrial fibrillation. Circ J 2014;78(4):853–8. PMID: 24521763. [PubMed: 24521763]
  387. Lin YS, Tung TH, Wang J, et al. Peripheral arterial disease and atrial fibrillation and risk of stroke, heart failure hospitalization and cardiovascular death: A nationwide cohort study. Int J Cardiol 2016;203:204–11. PMID: 26512838. [PubMed: 26512838]
  388. Ling TY, Jin Q, Pan WQ, et al. Cryoballoon ablation in Chinese patients with paroxysmal atrial fibrillation: 1-year follow-up. PACE - Pacing and Clinical Electrophysiology 2017;40(10):1067–1072. Digital Object Identifier: 10.1111/pace.13157. [PubMed: 28703873] [CrossRef]
  389. Lip GY, Hunter TD, Quiroz ME, et al. Atrial Fibrillation Diagnosis Timing, Ambulatory ECG Monitoring Utilization, and Risk of Recurrent Stroke. Circ Cardiovasc Qual Outcomes 2017;10(1). PMID: 28096204. [PubMed: 28096204]
  390. Lip GY, Laroche C, Boriani G, et al. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace 2015;17(1):24–31. PMID: 24957921. [PubMed: 24957921]
  391. Lip GYH, Merino JL, Dan GA, et al. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study). Am J Cardiol 2018;121(2):193–198. Digital Object Identifier: 10.1016/j.amjcard.2017.10.008. PMID: 29169605. [PubMed: 29169605] [CrossRef]
  392. Lipworth L, Okafor H, Mumma MT, et al. Race-specific impact of atrial fibrillation risk factors in blacks and whites in the southern community cohort study. Am J Cardiol 2012;110(11):1637–42. PMID: 22922000. [PMC free article: PMC3496834] [PubMed: 22922000]
  393. Liu R, Yang X, Li S, et al. Novel composite scoring system to predict unknown atrial fibrillation in acute ischemic stroke patients. Brain Research 2017;1674:36–41. Digital Object Identifier: 10.1016/j.brainres.2017.08.005. [PubMed: 28823956] [CrossRef]
  394. Liu X, Huang H, Yu J, et al. Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications. Int J Clin Pharmacol Ther 2014;52(6):454–9. PMID: 24755126. [PubMed: 24755126]
  395. Lopatowska P, Tomaszuk-Kazberuk A, Mlodawska E, et al. Management of patients with valvular and non-valvular atrial fibrillation in Poland: Results from Reference Cardiology University Center. Cardiol J 2015;22(3):296–305. PMID: 25428729. [PubMed: 25428729]
  396. Lopes RD, Rao M, Simon DN, et al. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Am J Med 2016;129(6):592–599.e1. PMID: 26797080. [PubMed: 26797080]
  397. Loukianov MM, Boytsov SA, Yakushin SS, et al. Outpatient registry of cardiovascular diseases (recvasa): Prospective follow-up data, estimation of risks and outcomes in patients with atrial fibrillation. Rational Pharmacotherapy in Cardiology 2014;10(5):470–480.
  398. Lu R, Mei J, Zhao D, et al. Concomitant thoracoscopic surgery for solitary pulmonary nodule and atrial fibrillation. Interact Cardiovasc Thorac Surg 2017. Digital Object Identifier: 10.1093/icvts/ivx346. PMID: 29136152. [PubMed: 29136152] [CrossRef]
  399. Luger S, Hohmann C, Niemann D, et al. Adherence to oral anticoagulant therapy in secondary stroke prevention - impact of the novel oral anticoagulants. Patient Prefer Adherence 2015;9:1695–705. PMID: 26648702. [PMC free article: PMC4664488] [PubMed: 26648702]
  400. Luong C, Thompson DJ, Bennett M, et al. Right atrial volume is superior to left atrial volume for prediction of atrial fibrillation recurrence after direct current cardioversion. Can J Cardiol 2015;31(1):29–35. PMID: 25547547. [PubMed: 25547547]
  401. Macha K, Volbers B, Bobinger T, et al. Early Initiation of Anticoagulation with Direct Oral Anticoagulants in Patients after Transient Ischemic Attack or Ischemic Stroke. J Stroke Cerebrovasc Dis 2016;25(9):2317–21. PMID: 27449113. [PubMed: 27449113]
  402. Magnani JW, Norby FL, Agarwal SK, et al. Racial Differences in Atrial Fibrillation-Related Cardiovascular Disease and Mortality: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA Cardiol 2016;1(4):433–41. PMID: 27438320. [PMC free article: PMC5347977] [PubMed: 27438320]
  403. Maheshwari A, Norby FL, Soliman EZ, et al. Abnormal P-Wave Axis and Ischemic Stroke: The ARIC Study (Atherosclerosis Risk In Communities). Stroke 2017. PMID: 28626057. [PMC free article: PMC5534350] [PubMed: 28626057]
  404. Manzano-Fernandez S, Sanchez-Martinez M, Flores-Blanco PJ, et al. Comparison of the Global Registry of Acute Coronary Events Risk Score Versus the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse outcomes With Early Implementation of the ACC/AHA Guidelines Risk Score to Predict In-Hospital Mortality and Major Bleeding in Acute Coronary Syndromes. Am J Cardiol 2016;117(7):1047–54. PMID: 26857164. [PubMed: 26857164]
  405. Mao L, Li C, Li T, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation. Vascular 2014;22(4):252–8. PMID: 23929423. [PubMed: 23929423]
  406. Marfella R, Sasso FC, Siniscalchi M, et al. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol 2013;62(6):525–30. PMID: 23684685. [PubMed: 23684685]
  407. Martínez-Sellés M, Datino T, Figueiras-Graillet LM, et al. New-onset atrial fibrillation and prognosis in nonagenarians after acute myocardial infarction. Netherlands Heart Journal 2013;21(11):499–503. [PMC free article: PMC3824740] [PubMed: 23821493]
  408. Masotti L, Innocenti R, Spolveri S, et al. Stroke prevention in atrial fibrillation: Findings from Tuscan FADOI Stroke Registry. Italian Journal of Medicine 2015;9(2):134–140.
  409. Masoud A, Bartoletti S, Fairbairn T, et al. Outcome of left atrial appendage occlusion in high-risk patients. Heart 2017. Digital Object Identifier: 10.1136/heartjnl-2017-312383. PMID: 29122931. [PubMed: 29122931] [CrossRef]
  410. Massera D, Wang D, Vorchheimer DA, et al. Increased risk of stroke and mortality following new-onset atrial fibrillation during hospitalization. Europace 2016. PMID: 27207814. [PubMed: 27207814]
  411. Mathur R, Pollara E, Hull S, et al. Ethnicity and stroke risk in patients with atrial fibrillation. Heart 2013;99(15):1087–92. PMID: 23720487. [PubMed: 23720487]
  412. Mattsson N, Nielsen OW, Johnson L, et al. Prognostic Impact of Mild Hypokalemia in Terms of Death and Stroke in the General Population-A Prospective Population Study. Am J Med 2017. Digital Object Identifier: 10.1016/j.amjmed.2017.09.026. PMID: 29024624. [PubMed: 29024624] [CrossRef]
  413. McAlister FA, Jacka M, Graham M, et al. The prediction of postoperative stroke or death in patients with preoperative atrial fibrillation undergoing non-cardiac surgery: a VISION sub-study. J Thromb Haemost 2015;13(10):1768–75. PMID: 26270168. [PubMed: 26270168]
  414. McGrath ER, Go AS, Chang Y, et al. Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke. J Am Geriatr Soc 2017;65(2):241–248. PMID: 28039855. [PMC free article: PMC5310977] [PubMed: 28039855]
  415. McGrath ER, Kapral MK, Fang J, et al. Antithrombotic therapy after acute ischemic stroke in patients with atrial fibrillation. Stroke 2014;45(12):3637–42. PMID: 25378422. [PubMed: 25378422]
  416. Mega JL, Walker JR, Ruff CT, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015;385(9984):2280–7. PMID: 25769357. [PubMed: 25769357]
  417. Meirhaeghe A, Cottel D, Cousin B, et al. Sex Differences in Stroke Attack, Incidence, and Mortality Rates in Northern France. J Stroke Cerebrovasc Dis 2018. Digital Object Identifier: 10.1016/j.jstrokecerebrovasdis.2017.12.023. PMID: 29429886. [PubMed: 29429886] [CrossRef]
  418. Melgaard L, Gorst-Rasmussen A, Rasmussen LH, et al. Vascular Disease and Risk Stratification for Ischemic Stroke and All-Cause Death in Heart Failure Patients without Diagnosed Atrial Fibrillation: A Nationwide Cohort Study. PLoS One 2016;11(3):e0152269. PMID: 27015524. [PMC free article: PMC4807813] [PubMed: 27015524]
  419. Melloni C, Shrader P, Carver J, et al. Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes 2017;3(3):192–197. Digital Object Identifier: 10.1093/ehjqcco/qcx004. PMID: 28838088. [PubMed: 28838088] [CrossRef]
  420. Melmed KR, Lyden P, Gellada N, et al. Intracerebral Hemorrhagic Expansion Occurs in Patients Using Non–Vitamin K Antagonist Oral Anticoagulants Comparable with Patients Using Warfarin. Journal of Stroke and Cerebrovascular Diseases 2017;26(8):1874–1882. Digital Object Identifier: 10.1016/j.jstrokecerebrovasdis.2017.04.025. [PubMed: 28647419] [CrossRef]
  421. Merlino G, Rana M, Naliato S, et al. CHA2DS2-VASc score predicts short- and long-term outcomes in patients with acute ischemic stroke treated with intravenous thrombolysis. J Thromb Thrombolysis 2018;45(1):122–129. Digital Object Identifier: 10.1007/s11239-017-1575-0. PMID: 29064076. [PubMed: 29064076] [CrossRef]
  422. Michalski F, Tittl L, Werth S, et al. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. Thromb Haemost 2015;114(5):1076–84. PMID: 25994496. [PubMed: 25994496]
  423. Miura S, Arita T, Domei T, et al. Impact of preprocedural atrial fibrillation on immediate and long-term outcomes after successful percutaneous mitral valvuloplasty of significant mitral stenosis. Cardiovascular Intervention and Therapeutics 2018;33(1):46–54. Digital Object Identifier: 10.1007/s12928-016-0434-9. [PMC free article: PMC5754370] [PubMed: 27709537] [CrossRef]
  424. Mizrahi EH, Waitzman A, Arad M, et al. Atrial fibrillation predicts cognitive impairment in patients with ischemic stroke. Am J Alzheimers Dis Other Demen 2011;26(8):623–6. PMID: 22218734. [PubMed: 22218734]
  425. Mogensen UM, Jhund PS, Abraham WT, et al. Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol 2017;70(20):2490–2500. Digital Object Identifier: 10.1016/j.jacc.2017.09.027. PMID: 29145948. [PubMed: 29145948] [CrossRef]
  426. Morillas P, Pallares V, Facila L, et al. The CHADS2 Score to Predict Stroke Risk in the Absence of Atrial Fibrillation in Hypertensive Patients Aged 65 Years or Older. Rev Esp Cardiol (Engl Ed) 2015;68(6):485–91. PMID: 25487320. [PubMed: 25487320]
  427. Musharbash FN, Schill MR, Sinn LA, et al. Performance of the Cox-maze IV procedure is associated with improved long-term survival in patients with atrial fibrillation undergoing cardiac surgery. Journal of Thoracic and Cardiovascular Surgery 2018;155(1):159–170. Digital Object Identifier: 10.1016/j.jtcvs.2017.09.095. [PMC free article: PMC5732870] [PubMed: 29056264] [CrossRef]
  428. Naganuma M, Shiga T, Nagao T, et al. Clinical outcomes and anticoagulant intensity in Japanese nonvalvular atrial fibrillation patients ≥ 65 years of age with a CHADS<inf>2</inf> score 0-1 and taking warfarin. Japanese Journal of Clinical Pharmacology and Therapeutics 2015;46(4):191–197.
  429. Naganuma M, Shiga T, Nagao T, et al. Effectiveness and safety of dabigatran versus warfarin in “real-world” Japanese patients with atrial fibrillation: A single-center observational study. J Arrhythm 2017;33(2):107–110. PMID: 28416975. [PMC free article: PMC5388055] [PubMed: 28416975]
  430. Naser N, Kulic M, Dilic M, et al. The Cumulative Incidence of Stroke, Myocardial infarction, Heart Failure and Sudden Cardiac Death in Patients with Atrial Fibrillation. Med Arch 2017;71(5):316–319. Digital Object Identifier: 10.5455/medarh.2017.71.316-319. PMID: 29284897. [PMC free article: PMC5723164] [PubMed: 29284897] [CrossRef]
  431. Nelson JA, Vavalle JP, May CH, et al. Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation. J Thromb Thrombolysis 2014;37(3):331–7. PMID: 23733104. [PubMed: 23733104]
  432. Nielsen PB, Larsen TB, Skjoth F, et al. Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation. JAMA Intern Med 2017;177(4):563–570. PMID: 28241151. [PMC free article: PMC5470390] [PubMed: 28241151]
  433. Nielsen-Kudsk JE, Johnsen SP, Wester P, et al. Left atrial appendage occlusion versus standard medical care in patients with atrial fibrillation and intracerebral hemorrhage: A propensity score matched follow-up study. EuroIntervention 2017. PMID: 28485276. [PubMed: 28485276]
  434. Ning W, Li Y, Ma C, et al. The Refinement of Risk Stratification for Atrial Thrombus or Spontaneous Echo Contrast in Nonvalvular Atrial Fibrillation. Int Heart J 2017;58(6):885–893. Digital Object Identifier: 10.1536/ihj.16-444. PMID: 29151480. [PubMed: 29151480] [CrossRef]
  435. Nishikii-Tachibana M, Murakoshi N, Seo Y, et al. Prevalence and Clinical Determinants of Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation Before Pulmonary Vein Isolation. Am J Cardiol 2015;116(9):1368–73. PMID: 26358509. [PubMed: 26358509]
  436. Nishino M, Okamoto N, Tanaka A, et al. Different risk factors for bleeding and discontinuation between dabigatran and rivaroxaban. J Cardiol 2016;68(2):156–60. PMID: 26443373. [PubMed: 26443373]
  437. Nishtala PS, Gnjidic D, Jamieson HA, et al. ‘Real-world’ haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand. Int J Cardiol 2016;203:746–52. PMID: 26590888. [PubMed: 26590888]
  438. Noheria A, Shrader P, Piccini JP, et al. Rhythm Control Versus Rate Control and Clinical Outcomes in Patients with Atrial Fibrillation: Results from the ORBIT-AF Registry. JACC: Clinical Electrophysiology 2016;2(2):221–229. [PubMed: 29766874]
  439. Nomura E, Ohshita T, Imamura E, et al. Early administration of non-vitamin K antagonist oral anticoagulants for acute ischemic stroke patients with atrial fibrillation in comparison with warfarin mostly combined with heparin. Circ J 2015;79(4):862–6. PMID: 25736910. [PubMed: 25736910]
  440. Noseworthy PA, Yao X, Gersh BJ, et al. Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making. Int J Cardiol 2017;245:174–177. Digital Object Identifier: 10.1016/j.ijcard.2017.07.043. PMID: 28733071. [PubMed: 28733071] [CrossRef]
  441. Ntaios G, Lip GY, Makaritsis K, et al. CHADS(2), CHA(2)S(2)DS(2)-VASc, and long-term stroke outcome in patients without atrial fibrillation. Neurology 2013;80(11):1009–17. PMID: 23408865. [PubMed: 23408865]
  442. Obokata M, Negishi K, Kurosawa K, et al. Left atrial strain provides incremental value for embolism risk stratification over CHA(2)DS(2)-VASc score and indicates prognostic impact in patients with atrial fibrillation. J Am Soc Echocardiogr 2014;27(7):709–716.e4. PMID: 24767972. [PubMed: 24767972]
  443. O’Brien EC, Kim S, Thomas L, et al. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry. J Am Heart Assoc 2016;5(5). PMID: 27146448. [PMC free article: PMC4889165] [PubMed: 27146448]
  444. O’Caoimh R, Igras E, Ramesh A, et al. Assessing the Appropriateness of Oral Anticoagulation for Atrial Fibrillation in Advanced Frailty: Use of Stroke and Bleeding Risk-Prediction Models. J Frailty Aging 2017;6(1):46–52. PMID: 28244558. [PubMed: 28244558]
  445. Ogata T, Matsuo R, Kiyuna F, et al. Left Atrial Size and Long-Term Risk of Recurrent Stroke After Acute Ischemic Stroke in Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc 2017;6(8). Digital Object Identifier: 10.1161/jaha.117.006402. PMID: 28862939. [PMC free article: PMC5586470] [PubMed: 28862939] [CrossRef]
  446. Ogawa H, Senoo K, An Y, et al. Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries. EBioMedicine 2017;18:199–203. PMID: 28330631. [PMC free article: PMC5405156] [PubMed: 28330631]
  447. Ohara T, Uehara T, Toyoda K, et al. Early Stroke Risk after Transient Ischemic Attack in Patients without Large-Artery Disease or Atrial Fibrillation. J Stroke Cerebrovasc Dis 2015;24(7):1656–61. PMID: 25922155. [PubMed: 25922155]
  448. Ohsawa M, Okamura T, Tanno K, et al. Risk of stroke and heart failure attributable to atrial fibrillation in middle-aged and elderly people: Results from a five-year prospective cohort study of Japanese community dwellers. J Epidemiol 2017. PMID: 28390793. [PMC free article: PMC5549250] [PubMed: 28390793]
  449. Okin PM, Bang CN, Wachtell K, et al. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Circ Arrhythm Electrophysiol 2013;6(2):243–51. PMID: 23403268. [PubMed: 23403268]
  450. Okumura K, Inoue H, Atarashi H, et al. Validation of CHA(2)DS(2)-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry. Circ J 2014;78(7):1593–9. PMID: 24759791. [PubMed: 24759791]
  451. Okumura Y, Yokoyama K, Matsumoto N, et al. Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry. J Arrhythm 2017;33(4):289–296. Digital Object Identifier: 10.1016/j.joa.2016.11.003. PMID: 28765759. [PMC free article: PMC5529323] [PubMed: 28765759] [CrossRef]
  452. Ondrakova M, Motovska Z, Waldauf P, et al. Antithrombotic therapy of patients with atrial fibrillation discharged after major non-cardiac surgery. 1-year follow-up. Sub-analysis of PRAGUE 14 study. PLoS One 2017;12(5):e0177519. PMID: 28542316. [PMC free article: PMC5443499] [PubMed: 28542316]
  453. O’Neal WT, Efird JT, Judd SE, et al. Impact of Awareness and Patterns of Nonhospitalized Atrial Fibrillation on the Risk of Mortality: The Reasons for Geographic And Racial Differences in Stroke (REGARDS) Study. Clin Cardiol 2016;39(2):103–10. PMID: 26880475. [PMC free article: PMC4769105] [PubMed: 26880475]
  454. O’Neal WT, Salahuddin T, Broughton ST, et al. Atrial Fibrillation and Cardiovascular Outcomes in the Elderly. Pacing Clin Electrophysiol 2016;39(9):907–13. PMID: 27333877. [PubMed: 27333877]
  455. O’Neal WT, Sandesara P, Hammadah M, et al. Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction. Am J Cardiol 2017;119(11):1785–1790. PMID: 28395886. [PMC free article: PMC5423833] [PubMed: 28395886]
  456. Ono F, Tanaka S, Nakao YM, et al. Utilization of Anticoagulant and Antiplatelet Agents Among Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention- Retrospective Cohort Study Using a Nationwide Claims Database in Japan. Circ J 2017. Digital Object Identifier: 10.1253/circj.CJ-17-0547. PMID: 28883227. [PubMed: 28883227] [CrossRef]
  457. Opolski G, Kosior DA, Kurzelewski M, et al. Oneyear followup of the Polish subset of the RecordAF registry of patients with newly diagnosed atrial fibrillation. Pol Arch Med Wewn 2013;123(5):238–45. PMID: 23673794. [PubMed: 23673794]
  458. Ording AG, Horvath-Puho E, Adelborg K, et al. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. Cancer Med 2017;6(6):1165–1172. PMID: 28544489. [PMC free article: PMC5463075] [PubMed: 28544489]
  459. Overvad TF, Rasmussen LH, Skjoth F, et al. Body mass index and adverse events in patients with incident atrial fibrillation. Am J Med 2013;126(7):640.e9–17. PMID: 23601271. [PubMed: 23601271]
  460. Paciaroni M and Agnelli G. Solutions to Reduce Cardiovascular Events in Patients with Atrial Fibrillation. J Atr Fibrillation 2012;5(3):45–53. PMID: 28496778. [PMC free article: PMC5153218] [PubMed: 28496778]
  461. Palamaner Subash Shantha G, Bhave PD, Girotra S, et al. Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation. Circ Cardiovasc Qual Outcomes 2017;10(4). PMID: 28408716. [PMC free article: PMC5412710] [PubMed: 28408716]
  462. Palareti G, Salomone L, Cavazza M, et al. Stroke/thromboembolism and intracranial hemorrhage in a real-world atrial fibrillation population: the Complications of Atrial Fibrillation in the Bologna Area (CAFBO) study. Chest 2014;146(4):1073–1080. PMID: 24810397. [PubMed: 24810397]
  463. Pallisgaard JL, Schjerning AM, Lindhardt TB, et al. Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study. Eur J Prev Cardiol 2016;23(6):621–7. PMID: 26254188. [PubMed: 26254188]
  464. Palomaki A, Kiviniemi T, Mustonen P, et al. Mortality after stroke in patients with paroxysmal and chronic atrial fibrillation - The FibStroke study. Int J Cardiol 2017;227:869–874. PMID: 27639597. [PubMed: 27639597]
  465. Pandey A, Gersh BJ, McGuire DK, et al. Association of Body Mass Index With Care and Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry. JACC: Clinical Electrophysiology 2016;2(3):355–363. [PubMed: 29766895]
  466. Park YA, Uhm JS, Pak HN, et al. Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage. Heart Rhythm 2016;13(9):1794–802. PMID: 27554947. [PubMed: 27554947]
  467. Patel PA, Zhao X, Fonarow GC, et al. Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. Circ Cardiovasc Qual Outcomes 2015;8(4):383–92. PMID: 26058721. [PMC free article: PMC4512906] [PubMed: 26058721]
  468. Patell R, Gutierrez A, Rybicki L, et al. Usefulness of CHADS2 and CHA2DS2-VASc Scores for Stroke Prediction in Patients With Cancer and Atrial Fibrillation. Am J Cardiol 2017;120(12):2182–2186. Digital Object Identifier: 10.1016/j.amjcard.2017.08.038. PMID: 29033049. [PubMed: 29033049] [CrossRef]
  469. Pathan F, Sivaraj E, Negishi K, et al. Use of Atrial Strain to Predict Atrial Fibrillation After Cerebral Ischemia. JACC Cardiovasc Imaging 2017. Digital Object Identifier: 10.1016/j.jcmg.2017.07.027. PMID: 29153561. [PubMed: 29153561] [CrossRef]
  470. Patti G, Lucerna M, Cavallari I, et al. Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF. J Am Coll Cardiol 2017;69(4):409–419. PMID: 28126158. [PubMed: 28126158]
  471. Patti G, Lucerna M, Pecen L, et al. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation). J Am Heart Assoc 2017;6(7). Digital Object Identifier: 10.1161/jaha.117.005657. PMID: 28736385. [PMC free article: PMC5586290] [PubMed: 28736385] [CrossRef]
  472. Pennlert J, Overholser R, Asplund K, et al. Optimal Timing of Anticoagulant Treatment After Intracerebral Hemorrhage in Patients With Atrial Fibrillation. Stroke 2017;48(2):314–320. PMID: 27999135. [PubMed: 27999135]
  473. Piccini JP, Simon DN, Steinberg BA, et al. Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men: Two-Year Results From the ORBIT-AF Registry. JAMA Cardiol 2016;1(3):282–91. PMID: 27438106. [PubMed: 27438106]
  474. Pilgrim T, Kalesan B, Zanchin T, et al. Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents. EuroIntervention 2013;8(9):1061–71. PMID: 23339812. [PubMed: 23339812]
  475. Pipilis A, Farmakis D, Kaliambakos S, et al. Anticoagulation therapy in elderly patients with atrial fibrillation: results from the Registry of Atrial Fibrillation To Investigate the Implementation of New Guidelines (RAFTING). J Cardiovasc Med (Hagerstown) 2017;18(7):545–549. PMID: 26825445. [PubMed: 26825445]
  476. Podolecki T, Lenarczyk R, Kowalczyk J, et al. Stroke and death prediction with CHA2DS2-vasc score after myocardial infarction in patients without atrial fibrillation. J Cardiovasc Med (Hagerstown) 2015;16(7):497–502. PMID: 25829193. [PubMed: 25829193]
  477. Pokorney SD, Simon DN, Thomas L, et al. Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J 2015;170(1):141–8, 148.e1. PMID: 26093875. [PubMed: 26093875]
  478. Pol T, Held C, Westerbergh J, et al. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. J Am Heart Assoc 2018;7(3). Digital Object Identifier: 10.1161/jaha.117.007444. PMID: 29419390. [PMC free article: PMC5850246] [PubMed: 29419390] [CrossRef]
  479. Poli D, Antonucci E, Pengo V, et al. Comparison of HAS-BLED and HAS-BED Versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation. Am J Cardiol 2017;119(7):1012–1016. PMID: 28237286. [PubMed: 28237286]
  480. Poli D, Antonucci E, Testa S, et al. The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. J Thromb Haemost 2013;11(6):1053–8. PMID: 23578305. [PubMed: 23578305]
  481. Poli S, Diedler J, Hartig F, et al. Insertable cardiac monitors after cryptogenic stroke-a risk factor based approach to enhance the detection rate for paroxysmal atrial fibrillation. Eur J Neurol 2016;23(2):375–81. PMID: 26470854. [PubMed: 26470854]
  482. Potpara TS, Dan GA, Trendafilova E, et al. Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the Balkan Region: The BALKAN-AF Survey. Sci Rep 2016;6:20432. PMID: 26869284. [PMC free article: PMC4751531] [PubMed: 26869284]
  483. Prats-Sanchez L, Guisado-Alonso D, Painous C, et al. Insular damage, new-onset atrial fibrillation and outcome after acute intracerebral hemorrhage. Eur J Neurol 2017. Digital Object Identifier: 10.1111/ene.13522. PMID: 29171121. [PubMed: 29171121] [CrossRef]
  484. Proietti M, Mairesse GH, Goethals P, et al. A population screening programme for atrial fibrillation: A report from the Belgian Heart Rhythm Week screening programme. Europace 2016;18(12):1779–1786. [PubMed: 27170000]
  485. Proietti M, Raparelli V, Basili S, et al. Relation of female sex to left atrial diameter and cardiovascular death in atrial fibrillation: The AFFIRM Trial. Int J Cardiol 2016;207:258–63. PMID: 26808988. [PubMed: 26808988]
  486. Providencia R, Fernandes A, Paiva L, et al. Decreased glomerular filtration rate and markers of left atrial stasis in patients with nonvalvular atrial fibrillation. Cardiology 2013;124(1):3–10. PMID: 23257736. [PubMed: 23257736]
  487. Puurunen MK, Kiviniemi T, Schlitt A, et al. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. Thromb Res 2014;133(4):560–6. PMID: 24461143. [PubMed: 24461143]
  488. Quinn GR, Singer DE, Chang Y, et al. How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation?. Am J Cardiol 2016;118(5):697–9. PMID: 27394408. [PMC free article: PMC5131634] [PubMed: 27394408]
  489. Qvist JF, Sorensen PH and Dixen U. Hospitalisation patterns change over time in patients with atrial fibrillation. Dan Med J 2014;61(1):A4765. PMID: 24393590. [PubMed: 24393590]
  490. Rabadi MH and Aston CE. Predictors of mortality over a 5-year period in veterans with atrial fibrillation. Experimental and Clinical Cardiology 2014;20(1):2993–3010.
  491. Rahmadina A, Gofir A and Nugroho AE. The role of anticoagulation control on the mortality rate in warfarin treated ischemic stroke patients with atrial fibrillation. International Journal of Pharmaceutical and Clinical Research 2015;7(4):311–316.
  492. Reinier K, Marijon E, Uy-Evanado A, et al. The association between atrial fibrillation and sudden cardiac death: the relevance of heart failure. JACC Heart Fail 2014;2(3):221–7. PMID: 24952687. [PubMed: 24952687]
  493. Ribeiro HB, Urena M, Le Ven F, et al. Long-term prognostic value and serial changes of plasma N-terminal prohormone B-type natriuretic peptide in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2014;113(5):851–9. PMID: 24528616. [PubMed: 24528616]
  494. Riley TR, Gauthier-Lewis ML, Sanchez CK, et al. Evaluation of Bleeding Events Requiring Hospitalization in Patients With Atrial Fibrillation Receiving Dabigatran, Warfarin, or Antiplatelet Therapy. J Pharm Pract 2017;30(2):214–218. PMID: 26951615. [PubMed: 26951615]
  495. Ritzenthaler T, Derex L, Davenas C, et al. Safety of early initiation of rivaroxaban or dabigatran after thrombolysis in acute ischemic stroke. Rev Neurol (Paris) 2015;171(8-9):613–5. PMID: 25857461. [PubMed: 25857461]
  496. Rivera-Caravaca JM, Marin F, Esteve-Pastor MA, et al. Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality. Int J Clin Pract 2018. Digital Object Identifier: 10.1111/ijcp.13069. PMID: 29436121. [PubMed: 29436121] [CrossRef]
  497. Rizos T, Horstmann S, Dittgen F, et al. Preexisting Heart Disease Underlies Newly Diagnosed Atrial Fibrillation After Acute Ischemic Stroke. Stroke 2016;47(2):336–41. PMID: 26742800. [PubMed: 26742800]
  498. Rodriguez-Bernal CL, Hurtado I, Garcia-Sempere A, et al. Oral Anticoagulants Initiation in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort. Front Pharmacol 2017;8:63. PMID: 28261098. [PMC free article: PMC5314137] [PubMed: 28261098]
  499. Rodriguez-Manero M, Lopez-Pardo E, Cordero A, et al. Clinical profile and outcomes in octogenarians with atrial fibrillation: A community-based study in a specific European health care area. Int J Cardiol 2017;243:211–215. Digital Object Identifier: 10.1016/j.ijcard.2017.03.149. PMID: 28747024. [PubMed: 28747024] [CrossRef]
  500. Rowin EJ, Orfanos A, Estes NAM, et al. Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. American Journal of Cardiology 2017;119(11):1862–1865. [PubMed: 28395893]
  501. Rozenbaum Z, Elis A, Shuvy M, et al. CHA2DS2-VASc score and clinical outcomes of patients with acute coronary syndrome. Eur J Intern Med 2016;36:57–61. PMID: 27707608. [PubMed: 27707608]
  502. Ruff CT, Bhatt DL, Steg PG, et al. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. Int J Cardiol 2014;170(3):413–8. PMID: 24321327. [PubMed: 24321327]
  503. Russo V, Rago A, Papa AA, et al. Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study. J Thromb Thrombolysis 2017. Digital Object Identifier: 10.1007/s11239-017-1599-5. PMID: 29260427. [PubMed: 29260427] [CrossRef]
  504. Ryu WS, Bae EK, Park SH, et al. Increased Left Ventricular Filling Pressure and Arterial Occlusion in Stroke Related to Atrial Fibrillation. Journal of Stroke and Cerebrovascular Diseases 2018. Digital Object Identifier: 10.1016/j.jstrokecerebrovasdis.2017.12.009. [PubMed: 29310958] [CrossRef]
  505. Sa T, Sargento-Freitas J, Pinheiro V, et al. CHADS(2) and CHA(2)DS(2)VASc scores as predictors of cardioembolic sources in secondary stroke prevention. Rev Port Cardiol 2013;32(5):373–8. PMID: 23566635. [PubMed: 23566635]
  506. Sacchi L, Rubrichi S, Rognoni C, et al. From decision to shared-decision: Introducing patients’ preferences into clinical decision analysis. Artif Intell Med 2015;65(1):19–28. PMID: 25455562. [PubMed: 25455562]
  507. Sadeghi R, Parsa Mahjoob M, Asadollahi M, et al. Prevalence, main determinants, and early outcome of patients with atrial fibrillation hospitalized with ischemic stroke: evaluation of the value of risk assessment scores for predicting risk of stroke or major bleeding following anticoagulation therapy. Acta Biomed 2015;86(2):162–9. PMID: 26422431. [PubMed: 26422431]
  508. Saito T, Kawamura Y, Tanabe Y, et al. Cerebral microbleeds and asymptomatic cerebral infarctions in patients with atrial fibrillation. J Stroke Cerebrovasc Dis 2014;23(6):1616–22. PMID: 24680089. [PubMed: 24680089]
  509. Saji N, Kimura K, Aoki J, et al. Intracranial Hemorrhage Caused by Non-Vitamin K Antagonist Oral Anticoagulants (NOACs)- Multicenter Retrospective Cohort Study in Japan. Circ J 2015;79(5):1018–23. PMID: 25739470. [PubMed: 25739470]
  510. Saji N, Kimura K, Tateishi Y, et al. Safety and efficacy of non-vitamin K oral anticoagulant treatment compared with warfarin in patients with non-valvular atrial fibrillation who develop acute ischemic stroke or transient ischemic attack: a multicenter prospective cohort study (daVinci study). J Thromb Thrombolysis 2016;42(4):453–62. PMID: 27207691. [PubMed: 27207691]
  511. Sakr SA, El-Rasheedy WA, Ramadan MM, et al. Association between left atrial appendage morphology evaluated by trans-esophageal echocardiography and ischemic cerebral stroke in patients with atrial fibrillation. Int Heart J 2015;56(3):329–34. PMID: 25912903. [PubMed: 25912903]
  512. Salam AM, AlBinali HA, Al-Sulaiti EM, et al. Effect of age on treatment, trends and outcome of patients hospitalized with atrial fibrillation: insights from a 20-years registry in a Middle-Eastern country (1991-2010). Aging Clin Exp Res 2012;24(6):682–90. PMID: 23211770. [PubMed: 23211770]
  513. Salam AM, AlBinali HA, Al-Mulla AW, et al. Women hospitalized with atrial fibrillation: gender differences, trends and outcome from a 20-year registry in a Middle Eastern country (1991-2010). Int J Cardiol 2013;168(2):975–80. PMID: 23159409. [PubMed: 23159409]
  514. Salehi R, Enamzadeh E and Goldust M. Study of cognitive disorders in stroke-free patients with a history of atrial fibrillation. Pak J Biol Sci 2013;16(1):44–7. PMID: 24199485. [PubMed: 24199485]
  515. Saliba W, Barnett-Griness O, Elias M, et al. The association between red cell distribution width and stroke in patients with atrial fibrillation. Am J Med 2015;128(2):192.e11–8. PMID: 25447618. [PubMed: 25447618]
  516. Saliba W, Gronich N, Barnett-Griness O, et al. The role of CHADS2 and CHA2 DS2 -VASc scores in the prediction of stroke in individuals without atrial fibrillation: a population-based study. J Thromb Haemost 2016;14(6):1155–62. PMID: 27037960. [PubMed: 27037960]
  517. Saliba W, Gronich N, Barnett-Griness O, et al. Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study. Am J Med 2016;129(8):843–9. PMID: 27012854. [PubMed: 27012854]
  518. Salim I, Al Suwaidi J, AlBinali HA, et al. Impact of Chronic Kidney Disease on the Presentation and Outcome of Patients Hospitalized With Atrial Fibrillation: Insights From Qatar. Angiology 2018;69(3):212–219. Digital Object Identifier: 10.1177/0003319717717849. PMID: 28691505. [PubMed: 28691505] [CrossRef]
  519. Sambola A, Mutuberria M, Garcia Del Blanco B, et al. Effects of Triple Therapy in Patients With Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Regarding Thromboembolic Risk Stratification. Circ J 2016;80(2):354–62. PMID: 26725763. [PubMed: 26725763]
  520. Sambola A, Mutuberria M, Garcia Del Blanco B, et al. Impact of Triple Therapy in Elderly Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. PLoS One 2016;11(1):e0147245. PMID: 26808678. [PMC free article: PMC4726489] [PubMed: 26808678]
  521. Sasahara E, Nakagawa K, Hirai T, et al. Clinical and transesophageal echocardiographic variables for prediction of thromboembolic events in patients with nonvalvular atrial fibrillation at low-intermediate risk. J Cardiol 2012;60(6):484–8. PMID: 23063013. [PubMed: 23063013]
  522. Sauer EM, Sauer R, Kallmunzer B, et al. Impaired renal function in stroke patients with atrial fibrillation. J Stroke Cerebrovasc Dis 2014;23(5):1225–8. PMID: 24280266. [PubMed: 24280266]
  523. Schlitt A, Rubboli A, Lip GY, et al. The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study. Catheter Cardiovasc Interv 2013;82(7):E864–70. PMID: 23765437. [PubMed: 23765437]
  524. Schmidt M, Ulrichsen SP, Pedersen L, et al. 30-year nationwide trends in incidence of atrial fibrillation in Denmark and associated 5-year risk of heart failure, stroke, and death. Int J Cardiol 2016;225:30–36. PMID: 27705839. [PubMed: 27705839]
  525. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 2015;386(9989):154–62. PMID: 25960110. [PMC free article: PMC4553037] [PubMed: 25960110]
  526. Scowcroft AC, Lee S and Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart 2013;99(2):127–32. PMID: 23086966. [PMC free article: PMC3551210] [PubMed: 23086966]
  527. Seivani Y, Abdel-Wahab M, Geist V, et al. Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. Clin Res Cardiol 2013;102(11):799–806. PMID: 23771774. [PubMed: 23771774]
  528. Senoo K and Lip GY. Female Sex, Time in Therapeutic Range, and Clinical Outcomes in Atrial Fibrillation Patients Taking Warfarin. Stroke 2016;47(6):1665–8. PMID: 27125527. [PubMed: 27125527]
  529. Senoo K, An Y, Ogawa H, et al. Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom. Heart 2016;102(23):1878–1882. PMID: 27312001. [PubMed: 27312001]
  530. Seo WK, Kang SH, Jung JM, et al. Novel composite score to predict atrial Fibrillation in acute stroke patients: AF predicting score in acute stroke. Int J Cardiol 2016;209:184–9. PMID: 26896619. [PubMed: 26896619]
  531. Shah R, Li S, Stamplecoski M, et al. Low Use of Oral Anticoagulant Prescribing for Secondary Stroke Prevention: Results From the Ontario Stroke Registry. Med Care 2016;54(10):907–12. PMID: 27367867. [PubMed: 27367867]
  532. Shao XH, Yang YM, Zhu J, et al. Comparison of the clinical features and outcomes in two age-groups of elderly patients with atrial fibrillation. Clin Interv Aging 2014;9:1335–42. PMID: 25143720. [PMC free article: PMC4136954] [PubMed: 25143720]
  533. Sharif Z, Srinivas B, Tiedt I, et al. Evaluating cardioversion outcomes for atrial fibrillation on novel oral anticoagulants versus warfarin: experience at a tertiary referral centre. Ir J Med Sci 2017. PMID: 28233168. [PubMed: 28233168]
  534. Sherid M, Sifuentes H, Sulaiman S, et al. Gastrointestinal bleeding with dabigatran, a comparative study with warfarin: a multicenter experience. Korean J Gastroenterol 2015;65(4):205–14. PMID: 25896154. [PubMed: 25896154]
  535. Shih CJ, Ou SM, Chao PW, et al. Risks of Death and Stroke in Patients Undergoing Hemodialysis With New-Onset Atrial Fibrillation: A Competing-Risk Analysis of a Nationwide Cohort. Circulation 2016;133(3):265–72. PMID: 26680239. [PubMed: 26680239]
  536. Shimada YJ, Yamashita T, Koretsune Y, et al. Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin-Insights From the ENGAGE AF-TIMI 48 Trial. Circ J 2015;79(12):2560–7. PMID: 26460886. [PubMed: 26460886]
  537. Shosha RI, Ibrahim OM, Setiha ME, et al. The efficacy and safety of rivaroxaban as an alternative to warfarin for the prevention of thromboembolism in patients with atrial fibrillation. International Journal of Pharmaceutical Sciences Review and Research 2017;43(2):38–48.
  538. Sibolt G, Curtze S, Melkas S, et al. Poststroke dementia is associated with recurrent ischaemic stroke. J Neurol Neurosurg Psychiatry 2013;84(7):722–6. PMID: 23418214. [PubMed: 23418214]
  539. Silva R, Silva PAE, Lima MC, et al. Thromboembolism and bleeding risk scores and predictors of cardiac death in a population with atrial fibrillation. Arq Bras Cardiol 2017:0. PMID: 28562832. [PMC free article: PMC5524470] [PubMed: 28562832]
  540. Siontis KC, Gersh BJ, Killian JM, et al. Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: Characteristics and prognostic implications. Heart Rhythm 2016;13(7):1418–24. PMID: 26961300. [PMC free article: PMC4802367] [PubMed: 26961300]
  541. Siu CW, Lip GY, Lam KF, et al. Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong. Heart Rhythm 2014;11(8):1401–8. PMID: 24747420. [PubMed: 24747420]
  542. Sjalander S, Svensson PJ and Friberg L. Atrial fibrillation patients with CHA2DS2-VASc >1 benefit from oral anticoagulation prior to cardioversion. Int J Cardiol 2016;215:360–3. PMID: 27128562. [PubMed: 27128562]
  543. Skaarup KG, Christensen H, Host N, et al. Diagnosing Paroxysmal Atrial Fibrillation in Patients With Ischemic Strokes and Transient Ischemic Attacks Using Echocardiographic Measurements of Left Atrium Function. Am J Cardiol 2016;117(1):91–9. PMID: 26525212. [PubMed: 26525212]
  544. Sluggett JK, Caughey GE, Ward MB, et al. Antithrombotic use following transient ischaemic attack or ischaemic stroke among older Australians with atrial fibrillation. Intern Med J 2014;44(11):1134–7. PMID: 25367727. [PubMed: 25367727]
  545. Son MK, Lim NK, Kim HW, et al. Risk of ischemic stroke after atrial fibrillation diagnosis: A national sample cohort. PLoS One 2017;12(6):e0179687. PMID: 28636620. [PMC free article: PMC5479557] [PubMed: 28636620]
  546. Špinar J, Vítovec J, Soucek M, et al. He First Registry. Comparison of anticoagulant treatment in patients with atrial fibrillation. Experimental and Clinical Cardiology 2014;20(1):662–673.
  547. Stadnik SN. Cognitive symptoms of chronic disorders of cerebral circulation in patients with atrial fibrillation. New Armenian Medical Journal 2015;9(1):36–44.
  548. Staerk L, Lip GY, Olesen JB, et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. Bmj 2015;351:h5876. PMID: 26572685. [PMC free article: PMC4646074] [PubMed: 26572685]
  549. Staszewsky L, Cortesi L, Baviera M, et al. Diabetes mellitus as risk factor for atrial fibrillation hospitalization: Incidence and outcomes over nine years in a region of Northern Italy. Diabetes Res Clin Pract 2015;109(3):476–84. PMID: 26220013. [PubMed: 26220013]
  550. Stefansdottir H, Arnar DO, Aspelund T, et al. Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts. Stroke 2013;44(4):1020–5. PMID: 23444303. [PMC free article: PMC3632359] [PubMed: 23444303]
  551. Steinberg BA, Kim S, Piccini JP, et al. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation 2013;128(7):721–8. PMID: 23861512. [PMC free article: PMC3908483] [PubMed: 23861512]
  552. Steinberg BA, Shrader P, Thomas L, et al. Factors associated with non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). American Heart Journal 2017;189:40–47. [PubMed: 28625380]
  553. Steinberg BA, Simon DN, Thomas L, et al. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). Am J Cardiol 2017;119(10):1590–1595. PMID: 28363354. [PubMed: 28363354]
  554. Stepina EV, Loukianov MM, Bichurina MA, et al. Oral anticoagulants in ambulatory and in-hospital treatment of patients with atrial fibrillation associated with hypertension, ischemic heart disease and chronic heart failure: Data from hospital registry RECVASA-CLINIC. Rational Pharmacotherapy in Cardiology 2017;13(2):146–154.
  555. Stolk LM, de Vries F, Ebbelaar C, et al. Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. Br J Clin Pharmacol 2017. PMID: 28326589. [PMC free article: PMC6495191] [PubMed: 28326589]
  556. Subic A, Cermakova P, Religa D, et al. Treatment of Atrial Fibrillation in Patients with Dementia: A Cohort Study from the Swedish Dementia Registry. J Alzheimers Dis 2017. Digital Object Identifier: 10.3233/jad-170575. PMID: 29286925. [PMC free article: PMC5798527] [PubMed: 29286925] [CrossRef]
  557. Sudarshana DM, Konstantinou EK, Arepalli S, et al. The prevalence of adverse ocular hemorrhagic events in patients utilizing oral anticoagulant and antiplatelet therapy in routine clinical practice. Ophthalmic Surgery Lasers and Imaging Retina 2018;49(1):27–34. Digital Object Identifier: 10.3928/23258160-20171215-04. [PubMed: 29304263] [CrossRef]
  558. Suh SY, Kang WC, Oh PC, et al. Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation. Heart Vessels 2014;29(5):578–83. PMID: 23974943. [PubMed: 23974943]
  559. Sullivan RM, Zhang J, Zamba G, et al. Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM). Am J Cardiol 2012;110(12):1799–802. PMID: 22995971. [PubMed: 22995971]
  560. Sun Y, Hu D, Stevens S, et al. Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. Thromb Res 2017. PMID: 28433206. [PubMed: 28433206]
  561. Sunbul M, Oguz M, Dogan Z, et al. Heart Failure and Mortality in Patients With Nonvalvular Atrial Fibrillation Started on Novel Oral Anticoagulant Therapy: A Single-Center Experience. Clin Appl Thromb Hemost 2017;23(5):454–459. PMID: 26566667. [PubMed: 26566667]
  562. Suzuki M, Matsue Y, Nakamura R, et al. Improvement of HAS-BLED bleeding score predictive capability by changing the definition of renal dysfunction in Japanese atrial fibrillation patients on anticoagulation therapy. J Cardiol 2014;64(6):482–7. PMID: 24836929. [PubMed: 24836929]
  563. Suzuki S, Otsuka T, Sagara K, et al. Nine-Year Trend of Anticoagulation Use, Thromboembolic Events, and Major Bleeding in Patients With Non-Valvular Atrial Fibrillation- Shinken Database Analysis. Circ J 2016;80(3):639–49. PMID: 26794283. [PubMed: 26794283]
  564. Suzuki S, Yamashita T, Okumura K, et al. Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy-pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. Circ J 2015;79(2):432–8. PMID: 25501800. [PubMed: 25501800]
  565. Sylaja PN, Pandian JD, Kaul S, et al. Ischemic Stroke Profile, Risk Factors, and Outcomes in India: The Indo-US Collaborative Stroke Project. Stroke 2018;49(1):219–222. Digital Object Identifier: 10.1161/strokeaha.117.018700. PMID: 29167386. [PMC free article: PMC5742046] [PubMed: 29167386] [CrossRef]
  566. Szummer K, Gasparini A, Eliasson S, et al. Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction. J Am Heart Assoc 2017;6(3). PMID: 28249846. [PMC free article: PMC5524023] [PubMed: 28249846]
  567. Szymanski FM, Filipiak KJ, Platek AE, et al. Assessment of CHADS2 and CHA 2DS 2-VASc scores in obstructive sleep apnea patients with atrial fibrillation. Sleep Breath 2015;19(2):531–7. PMID: 25084983. [PMC free article: PMC4428805] [PubMed: 25084983]
  568. Taillandier S, Brunet Bernard A, Lallemand B, et al. Prognosis in patients hospitalized with permanent and nonpermanent atrial fibrillation in heart failure. Am J Cardiol 2014;113(7):1189–95. PMID: 24507167. [PubMed: 24507167]
  569. Takashima S, Nakagawa K, Hirai T, et al. Transesophageal echocardiographic findings are independent and relevant predictors of ischemic stroke in patients with nonvalvular atrial fibrillation. J Clin Neurol 2012;8(3):170–6. PMID: 23091525. [PMC free article: PMC3469796] [PubMed: 23091525]
  570. Tanahashi N, Hori M, Matsumoto M, et al. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF. J Stroke Cerebrovasc Dis 2013;22(8):1317–25. PMID: 23352688. [PubMed: 23352688]
  571. Tanaka K, Yamada T, Torii T, et al. Pre-admission CHADS2, CHA2DS2-VASc, and R2CHADS2 Scores on Severity and Functional Outcome in Acute Ischemic Stroke with Atrial Fibrillation. J Stroke Cerebrovasc Dis 2015;24(7):1629–35. PMID: 25906940. [PubMed: 25906940]
  572. Tanislav C, Milde S, Schwartzkopff S, et al. Secondary stroke prevention in atrial fibrillation: a challenge in the clinical practice. BMC Neurol 2014;14:195. PMID: 25265943. [PMC free article: PMC4189749] [PubMed: 25265943]
  573. Tateishi Y, Tsujino A, Hamabe J, et al. Cardiac diastolic dysfunction predicts in-hospital mortality in acute ischemic stroke with atrial fibrillation. J Neurol Sci 2014;345(1-2):83–6. PMID: 25052726. [PubMed: 25052726]
  574. Thomas KL, Piccini JP, Liang L, et al. Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure. Journal of the American Heart Association 2013;2(5). [PMC free article: PMC3835220] [PubMed: 24072530]
  575. Tischer T, Schneider R, Lauschke J, et al. Prevalence of atrial fibrillation in patients with high CHADS2- and CHA2DS2VASc-scores: anticoagulate or monitor high-risk patients?. Pacing Clin Electrophysiol 2014;37(12):1651–7. PMID: 25621351. [PMC free article: PMC4282384] [PubMed: 25621351]
  576. Tiwari S, Lochen ML, Jacobsen BK, et al. CHA2DS2-VASc score, left atrial size and atrial fibrillation as stroke risk factors in the Tromso Study. Open Heart 2016;3(2):e000439. PMID: 27621829. [PMC free article: PMC5013428] [PubMed: 27621829]
  577. Tomita H, Okumura K, Inoue H, et al. Validation of Risk Scoring System Excluding Female Sex From CHA2DS2-VASc in Japanese Patients With Nonvalvular Atrial Fibrillation - Subanalysis of the J-RHYTHM Registry. Circ J 2015;79(8):1719–26. PMID: 25971525. [PubMed: 25971525]
  578. Toyoda K, Yasaka M, Uchiyama S, et al. CHADS2 and CHA2DS2-VASc scores as bleeding risk indices for patients with atrial fibrillation: the Bleeding with Antithrombotic Therapy Study. Hypertens Res 2014;37(5):463–6. PMID: 24196199. [PubMed: 24196199]
  579. Tsao HM, Hu WC, Tsai PH, et al. Functional Remodeling of Both Atria is Associated with Occurrence of Stroke in Patients with Paroxysmal and Persistent Atrial Fibrillation. Acta Cardiol Sin 2017;33(1):50–57. PMID: 28115807. [PMC free article: PMC5241436] [PubMed: 28115807]
  580. Tsao HM, Hu WC, Tsai PH, et al. The Abundance of Epicardial Adipose Tissue Surrounding Left Atrium Is Associated With the Occurrence of Stroke in Patients With Atrial Fibrillation. Medicine (Baltimore) 2016;95(14):e3260. PMID: 27057876. [PMC free article: PMC4998792] [PubMed: 27057876]
  581. Tseng AS, William Schleifer J, Shen WK, et al. Real-world incidence of efficacy and safety outcomes in patients on direct oral anticoagulants with left ventricular systolic dysfunction at a tertiary referral center. Clin Cardiol 2017. Digital Object Identifier: 10.1002/clc.22833. PMID: 29247519. [PMC free article: PMC6490385] [PubMed: 29247519] [CrossRef]
  582. Tu HT, Campbell BC, Meretoja A, et al. Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation. Cerebrovasc Dis 2013;36(4):273–80. PMID: 24135809. [PubMed: 24135809]
  583. Tung MK, Ramkumar S, Cameron JD, et al. Retrospective Cohort Study Examining Reduced Intensity and Duration of Anticoagulant and Antiplatelet Therapy Following Left Atrial Appendage Occlusion with the WATCHMAN Device. Heart Lung Circ 2017;26(5):477–485. PMID: 27916590. [PubMed: 27916590]
  584. Turagam MK, Parikh V, Afzal MR, et al. Replacing warfarin with a novel oral anticoagulant: Risk of recurrent bleeding and stroke in patients with warfarin ineligible or failure in patients with atrial fibrillation (The ROAR study). Journal of Cardiovascular Electrophysiology 2017. [PubMed: 28497899]
  585. Turk UO, Tuncer E, Alioglu E, et al. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry. Cardiol J 2015;22(5):567–75. PMID: 26100825. [PubMed: 26100825]
  586. Tzikas A, Freixa X, Llull L, et al. Patients with intracranial bleeding and atrial fibrillation treated with left atrial appendage occlusion: Results from the Amplatzer Cardiac Plug registry. Int J Cardiol 2017;236:232–236. PMID: 28215464. [PubMed: 28215464]
  587. Tziomalos K, Giampatzis V, Bouziana SD, et al. Acenocoumarol vs. low-dose dabigatran in real-world patients discharged after ischemic stroke. Blood Coagul Fibrinolysis 2016;27(2):185–9. PMID: 26366831. [PubMed: 26366831]
  588. Uchiyama S, Hori M, Matsumoto M, et al. Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF. J Stroke Cerebrovasc Dis 2014;23(5):1142–7. PMID: 24189454. [PubMed: 24189454]
  589. Valent F. New oral anticoagulant prescription rate and risk of bleeding in an Italian region. Pharmacoepidemiology and Drug Safety 2017;26(10):1205–1212. Digital Object Identifier: 10.1002/pds.4279. [PubMed: 28758284] [CrossRef]
  590. van Diepen S, Youngson E, Ezekowitz JA, et al. Which risk score best predicts perioperative outcomes in nonvalvular atrial fibrillation patients undergoing noncardiac surgery?. Am Heart J 2014;168(1):60–7.e5. PMID: 24952861. [PubMed: 24952861]
  591. Vanbeselaere V, Truyers C, Elli S, et al. Association between atrial fibrillation, anticoagulation, risk of cerebrovascular events and multimorbidity in general practice: a registry-based study. BMC Cardiovasc Disord 2016;16:61. PMID: 27021333. [PMC free article: PMC4810573] [PubMed: 27021333]
  592. Velu JF, Kortlandt FA, Hendriks T, et al. Comparison of Outcome After Percutaneous Mitral Valve Repair With the MitraClip in Patients With Versus Without Atrial Fibrillation. Am J Cardiol 2017;120(11):2035–2040. Digital Object Identifier: 10.1016/j.amjcard.2017.08.022. PMID: 29033048. [PubMed: 29033048] [CrossRef]
  593. Vestergaard AS, Skjoth F, Lip GY, et al. Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation: A Registry Study. Stroke 2016;47(4):979–85. PMID: 26883499. [PubMed: 26883499]
  594. Viliani D, Vivas D, Chung M, et al. Prognosis of different types of atrial fibrillation in the primary angioplasty era. Coron Artery Dis 2012;23(8):511–6. PMID: 22990415. [PubMed: 22990415]
  595. Vinereanu D, Wang A, Mulder H, et al. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. Heart 2018. Digital Object Identifier: 10.1136/heartjnl-2017-312272. PMID: 29352007. [PubMed: 29352007] [CrossRef]
  596. Vora A, Kapoor A, Nair M, et al. Clinical presentation, management, and outcomes in the Indian Heart Rhythm Society-Atrial Fibrillation (IHRS-AF) registry. Indian Heart Journal 2017;69(1):43–47. [PMC free article: PMC5319007] [PubMed: 28228305]
  597. Vorselaars VM, Velthuis S, Swaans MJ, et al. Percutaneous left atrial appendage closure-An alternative strategy for anticoagulation in atrial fibrillation and hereditary hemorrhagic telangiectasia?. Cardiovasc Diagn Ther 2015;5(1):49–53. PMID: 25774347. [PMC free article: PMC4329160] [PubMed: 25774347]
  598. Wan H, Wu S, Wang J, et al. Body mass index and the risk of all-cause mortality among patients with nonvalvular atrial fibrillation: a multicenter prospective observational study in China. Eur J Clin Nutr 2017;71(4):494–499. PMID: 27782115. [PubMed: 27782115]
  599. Wandell P, Carlsson AC, Holzmann M, et al. Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation-a cohort study in primary care. Eur J Clin Pharmacol 2017;73(2):215–221. PMID: 27826643. [PMC free article: PMC5226983] [PubMed: 27826643]
  600. Wandell P, Carlsson AC, Holzmann MJ, et al. Warfarin treatment and risk of stroke among primary care patients with atrial fibrillation. Scand Cardiovasc J 2016;50(5-6):311–316. PMID: 27460750. [PMC free article: PMC5152680] [PubMed: 27460750]
  601. Wandell P, Carlsson AC, Sundquist K, et al. Effect of cardiovascular drug classes on all-cause mortality among atrial fibrillation patients treated in primary care in Sweden: a cohort study. Eur J Clin Pharmacol 2013;69(2):279–87. PMID: 22990327. [PubMed: 22990327]
  602. Wandell PE, Carlsson AC, Sundquist J, et al. Pharmacotherapy and mortality in atrial fibrillation-a cohort of men and women 75 years or older in Sweden. Age Ageing 2015;44(2):232–8. PMID: 25324331. [PubMed: 25324331]
  603. Wang D, Liu M, Hao Z, et al. Association between reduced kidney function and clinical outcomes after ischaemic stroke with atrial fibrillation. Eur J Neurol 2014;21(1):160–6. PMID: 24237478. [PubMed: 24237478]
  604. Wang SV, Franklin JM, Glynn RJ, et al. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. Bmj 2016;353:i2607. PMID: 27221664. [PMC free article: PMC4878389] [PubMed: 27221664]
  605. Wang T, Li B, Gu H, et al. Effect of age on long-term outcomes after stroke with atrial fibrillation: a hospital-based follow-up study in China. Oncotarget 2017. PMID: 28427162. [PMC free article: PMC5581141] [PubMed: 28881842]
  606. Wang TK, Sathananthan J, Marshall M, et al. Relationships between Anticoagulation, Risk Scores and Adverse Outcomes in Dialysis Patients with Atrial Fibrillation. Heart Lung Circ 2016;25(3):243–9. PMID: 26481398. [PubMed: 26481398]
  607. Washam JB, Hellkamp AS, Lokhnygina Y, et al. Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). Am J Cardiol 2017;120(4):588–594. Digital Object Identifier: 10.1016/j.amjcard.2017.05.026. PMID: 28645473. [PubMed: 28645473] [CrossRef]
  608. Washida K, Kowa H, Hamaguchi H, et al. Validation of the R2CHADS2 and CHADS2 Scores for Predicting Post-stroke Cognitive Impairment. Intern Med 2017;56(20):2719–2725. Digital Object Identifier: 10.2169/internalmedicine.6651-15. PMID: 28924104. [PMC free article: PMC5675932] [PubMed: 28924104] [CrossRef]
  609. Wasmer K, Kobe J, Dechering D, et al. CHADS(2) and CHA(2)DS (2)-VASc score of patients with atrial fibrillation or flutter and newly detected left atrial thrombus. Clin Res Cardiol 2013;102(2):139–44. PMID: 22983022. [PubMed: 22983022]
  610. Watanabe E, Yamamoto M, Kodama I, et al. Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry. Int J Cardiol 2016;212:311–7. PMID: 27057949. [PubMed: 27057949]
  611. Wee XT, Ho LM, Ho HK, et al. Incidence of thromboembolic and bleeding events in patients with newly diagnosed nonvalvular atrial fibrillation: An Asian multicenter retrospective cohort study in Singapore. Clin Cardiol 2017. Digital Object Identifier: 10.1002/clc.22811. PMID: 29251769. [PMC free article: PMC6490354] [PubMed: 29251769] [CrossRef]
  612. Weijs B, de Vos CB, Tieleman RG, et al. The occurrence of cardiovascular disease during 5-year follow-up in patients with idiopathic atrial fibrillation. Europace 2013;15(1):18–23. PMID: 22782972. [PubMed: 22782972]
  613. Wetmore JB, Ellerbeck EF, Mahnken JD, et al. Atrial fibrillation and risk of stroke in dialysis patients. Ann Epidemiol 2013;23(3):112–8. PMID: 23332588. [PMC free article: PMC3570646] [PubMed: 23332588]
  614. Whitlock RP, Vincent J, Blackall MH, et al. Left Atrial Appendage Occlusion Study II (LAAOS II). Can J Cardiol 2013;29(11):1443–7. PMID: 24054920. [PubMed: 24054920]
  615. Winkle RA, Mead RH, Engel G, et al. Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients. Europace 2014;16(2):195–201. PMID: 24036378. [PMC free article: PMC3905705] [PubMed: 24036378]
  616. Wojtaszczyk A, Buchta P, Myrda K, et al. Hybrid dual stage closed chest ablation of persistent atrial fibrillation. Cor et Vasa 2017;59(4):e337–e344. Digital Object Identifier: 10.1016/j.crvasa.2017.06.008. [CrossRef]
  617. Wong KS, Hu DY, Oomman A, et al. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke 2014;45(6):1739–47. PMID: 24763930. [PubMed: 24763930]
  618. Xian Y, O’Brien EC, Liang L, et al. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. Jama 2017;317(10):1057–1067. PMID: 28291892. [PubMed: 28291892]
  619. Xiang E, Ahuja T, Raco V, et al. Anticoagulation prescribing patterns in patients with cancer. J Thromb Thrombolysis 2018;45(1):89–98. Digital Object Identifier: 10.1007/s11239-017-1558-1. PMID: 29052104. [PubMed: 29052104] [CrossRef]
  620. Xing Y, Ma Q, Ma X, et al. CHADS2 score has a better predictive value than CHA2DS2-VASc score in elderly patients with atrial fibrillation. Clin Interv Aging 2016;11:941–6. PMID: 27478371. [PMC free article: PMC4951063] [PubMed: 27478371]
  621. Xing YL, Ma Q, Ma XY, et al. Characteristics of non-valvular atrial fibrillation patients who benefit most from anticoagulation treatment. Int J Clin Exp Med 2015;8(10):18721–8. PMID: 26770487. [PMC free article: PMC4694387] [PubMed: 26770487]
  622. Yadlapati A, Groh C and Passman R. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. Am J Cardiol 2014;113(8):1362–3. PMID: 24576547. [PubMed: 24576547]
  623. Yamashita Y, Hamatani Y, Esato M, et al. Clinical Characteristics and Outcomes in Extreme Elderly (Age >/= 85 Years) Japanese Patients With Atrial Fibrillation: The Fushimi AF Registry. Chest 2016;149(2):401–12. PMID: 26181726. [PubMed: 26181726]
  624. Yamashita Y, Takagi D, Hamatani Y, et al. Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry. Heart Vessels 2016;31(12):2025–2034. PMID: 26973346. [PubMed: 26973346]
  625. Yamashita Y, Uozumi R, Hamatani Y, et al. Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients ― fushimi AF registry ―. Circulation Journal 2017;81(9):1278–1285. Digital Object Identifier: 10.1253/circj.CJ-16-1337. [PubMed: 28428449] [CrossRef]
  626. Yanagisawa S, Inden Y, Fujii A, et al. Renal function and risk of stroke and bleeding in patients undergoing catheter ablation for atrial fibrillation: Comparison between uninterrupted direct oral anticoagulants and warfarin administration. Heart Rhythm 2017. Digital Object Identifier: 10.1016/j.hrthm.2017.10.033. PMID: 29107192. [PubMed: 29107192] [CrossRef]
  627. Yang H, Bouma BJ, Mulder BJM, et al. Is Initiating NOACs for Atrial Arrhythmias Safe in Adults with Congenital Heart Disease?. Cardiovascular Drugs and Therapy 2017;31(4):413–417. Digital Object Identifier: 10.1007/s10557-017-6745-y. [PMC free article: PMC5591797] [PubMed: 28785894] [CrossRef]
  628. Yang YM, Shao XH, Zhu J, et al. Risk factors and incidence of stroke and MACE in Chinese atrial fibrillation patients presenting to emergency departments: a national wide database analysis. Int J Cardiol 2014;173(2):242–7. PMID: 24630382. [PubMed: 24630382]
  629. Yao X, Abraham NS, Alexander GC, et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc 2016;5(2). PMID: 26908412. [PMC free article: PMC4802483] [PubMed: 26908412]
  630. Yap LB, Eng DT, Sivalingam L, et al. A Comparison of Dabigatran With Warfarin for Stroke Prevention in Atrial Fibrillation in an Asian Population. Clin Appl Thromb Hemost 2016;22(8):792–797. PMID: 25962393. [PubMed: 25962393]
  631. Yap SH, Ng YP, Roslan A, et al. A comparison of dabigatran and warfarin for stroke prevention in elderly Asian population with nonvalvular atrial fibrillation: An audit of current practice in Malaysia. Med J Malaysia 2017;72(6):360–364. PMID: 29308774. [PubMed: 29308774]
  632. Yavuz B, Ayturk M, Ozkan S, et al. A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation. J Thromb Thrombolysis 2016;42(3):399–404. PMID: 27085540. [PubMed: 27085540]
  633. Yiginer O, Tezcan M, Erdal E, et al. A real-world, retrospective, observational study of dabigatran and rivaroxaban in turkey: Elderly patients receive inappropriately low dose of rivaroxaban. International Journal of Clinical and Experimental Medicine 2017;10(7):10634–10642.
  634. Yiin GS, Howard DP, Paul NL, et al. Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study. Circulation 2014;130(15):1236–44. PMID: 25208551. [PMC free article: PMC5384634] [PubMed: 25208551]
  635. Yin L, Ling X, Zhang Y, et al. CHADS2 and CHA2DS2-VASc scoring systems for predicting atrial fibrillation following cardiac valve surgery. PLoS One 2015;10(4):e0123858. PMID: 25849563. [PMC free article: PMC4388656] [PubMed: 25849563]
  636. Yoshida K, Obokata M, Kurosawa K, et al. Effect of Sex Differences on the Association Between Stroke Risk and Left Atrial Anatomy or Mechanics in Patients With Atrial Fibrillation. Circ Cardiovasc Imaging 2016;9(10). PMID: 27729360. [PubMed: 27729360]
  637. Yoshizawa R, Komatsu T, Kunugita F, et al. Comparison of the CHADS2, CHA2DS2-VASc and R2CHADS2 Scores in Japanese Patients with Non-valvular Paroxysmal Atrial Fibrillation Not Receiving Anticoagulation Therapy. Intern Med 2017;56(21):2827–2836. Digital Object Identifier: 10.2169/internalmedicine.8914-17. PMID: 28943575. [PMC free article: PMC5709623] [PubMed: 28943575] [CrossRef]
  638. Yuan Z, Makadia R, Ryan P, et al. Incidence of ischemic stroke or transient ischemic attack in patients with multiple risk factors with or without atrial fibrillation: a retrospective cohort study. Curr Med Res Opin 2015;31(7):1257–66. PMID: 25877807. [PubMed: 25877807]
  639. Zhai HB, Liu J, Dong ZC, et al. Current Use of Oral Anticoagulants and Prognostic Analysis in Patients with Atrial Fibrillation Undergoing Coronary Stenting. Chin Med J (Engl) 2017;130(12):1418–1423. PMID: 28584203. [PMC free article: PMC5463470] [PubMed: 28584203]
  640. Zhang J, Liu X, Liu X, et al. Stroke risks and patterns of warfarin therapy among atrial fibrillation patients post radiofrequency ablation. Medicine (United States) 2017;96(47). Digital Object Identifier: 10.1097/MD.0000000000008762. [PMC free article: PMC5708973] [PubMed: 29381974] [CrossRef]
  641. Zhao Y, Ji L, Liu J, et al. Intensity of Left Atrial Spontaneous Echo Contrast as a Correlate for Stroke Risk Stratification in Patients with Nonvalvular Atrial Fibrillation. Sci Rep 2016;6:27650. PMID: 27277939. [PMC free article: PMC4899705] [PubMed: 27277939]
  642. Zhao Y, Zou C, Wang C, et al. Long-Term Outcomes after Stroke in Elderly Patients with Atrial Fibrillation: A Hospital-Based Follow-Up Study in China. Front Aging Neurosci 2016;8:56. PMID: 27065856. [PMC free article: PMC4809894] [PubMed: 27065856]
  643. Zhou Q, Song H, Zhang L, et al. Roles of real-time three-dimensional transesophageal echocardiography in peri-operation of transcatheter left atrial appendage closure. Medicine (Baltimore) 2017;96(4):e5637. PMID: 28121919. [PMC free article: PMC5287943] [PubMed: 28121919]
  644. Zhu J, Gao RJ, Liu Q, et al. Metabolic benefits of rivaroxaban in non-valvular atrial fibrillation patients after radiofrequency catheter ablation. J Zhejiang Univ Sci B 2017;18(11):946–954. Digital Object Identifier: 10.1631/jzus.B1600492. PMID: 29119732. [PMC free article: PMC5696313] [PubMed: 29119732] [CrossRef]
  645. Zuo ML, Liu S, Chan KH, et al. The CHADS2 and CHA 2DS 2-VASc scores predict new occurrence of atrial fibrillation and ischemic stroke. J Interv Card Electrophysiol 2013;37(1):47–54. PMID: 23389054. [PubMed: 23389054]

Does not meet tool/intervention or comparator requirements-2017

  1. Abdul-Rahim AH, Wong J, McAlpine C, et al. Associations with anticoagulation: a cross-sectional registry-based analysis of stroke survivors with atrial fibrillation. Heart 2014;100(7):557–62. PMID: 24459290. [PubMed: 24459290]
  2. Abumuaileq RRY, Abu-Assi E, López-López A, et al. Renal function assessment in atrial fibrillation: Usefulness of chronic kidney disease epidemiology collaboration vs reexpressed 4 variable modification of diet in renal disease. World Journal of Cardiology 2015;7(10):685–694. [PMC free article: PMC4620080] [PubMed: 26516423]
  3. Ahlehoff O, Gislason G, Lamberts M, et al. Risk of thromboembolism and fatal stroke in patients with psoriasis and nonvalvular atrial fibrillation: a Danish nationwide cohort study. J Intern Med 2015;277(4):447–55. PMID: 24860914. [PubMed: 24860914]
  4. Akao M, Chun YH, Wada H, et al. Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol 2013;61(4):260–6. PMID: 23403369. [PubMed: 23403369]
  5. Albertsen IE, Rasmussen LH, Lane DA, et al. The impact of smoking on thromboembolism and mortality in patients with incident atrial fibrillation: insights from the Danish Diet, Cancer, and Health study. Chest 2014;145(3):559–66. PMID: 24091709. [PubMed: 24091709]
  6. Almeida ED, Guimaraes RB, Stephan LS, et al. Clinical Differences between Subtypes of Atrial Fibrillation and Flutter: Cross-Sectional Registry of 407 Patients. Arq Bras Cardiol 2015;105(1):3–10. PMID: 26016782. [PMC free article: PMC4523282] [PubMed: 26016782]
  7. Amin A, Stokes M, Wu N, et al. Application of randomized clinical trial data to actual practice: apixaban therapy for reduction of stroke risk in non-valvular atrial fibrillation patients. Curr Med Res Opin 2013;29(10):1253–61. PMID: 23796193. [PubMed: 23796193]
  8. Amit G, Nyong J and Morillo CA. Efficacy of catheter ablation for nonparoxysmal atrial fibrillation. JAMA Cardiology 2017;2(7):812–813. Digital Object Identifier: 10.1001/jamacardio.2017.0901. [PubMed: 28423144] [CrossRef]
  9. An J, Niu F, Lang DT, et al. Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice. J Am Heart Assoc 2015;4(7). PMID: 26187996. [PMC free article: PMC4608075] [PubMed: 26187996]
  10. Andersson T, Magnuson A, Bryngelsson IL, et al. Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: a nationwide cohort study of 9519 patients. Int J Cardiol 2014;177(1):91–9. PMID: 25499348. [PubMed: 25499348]
  11. Andrade AA, Li J, Radford MJ, et al. Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation. J Gen Intern Med 2015;30(6):777–82. PMID: 25666214. [PMC free article: PMC4441681] [PubMed: 25666214]
  12. Angoulvant D, Villejoubert O, Bejan-Angoulvant T, et al. Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project. Chest 2015;148(2):491–498. PMID: 25812113. [PubMed: 25812113]
  13. Antonucci E, Poli D, Tosetto A, et al. The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. PLoS One 2015;10(5):e0124719. PMID: 26001109. [PMC free article: PMC4441383] [PubMed: 26001109]
  14. Apostolakis S, Sullivan RM, Olshansky B, et al. Hormone replacement therapy and adverse outcomes in women with atrial fibrillation: an analysis from the atrial fibrillation follow-up investigation of rhythm management trial. Stroke 2014;45(10):3076–9. PMID: 25190441. [PubMed: 25190441]
  15. Apostolakis S, Sullivan RM, Olshansky B, et al. Left ventricular geometry and outcomes in patients with atrial fibrillation: the AFFIRM Trial. Int J Cardiol 2014;170(3):303–8. PMID: 24315343. [PubMed: 24315343]
  16. Ashburner JM, Go AS, Chang Y, et al. Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. J Am Geriatr Soc 2017;65(1):35–41. PMID: 27861698. [PMC free article: PMC5258686] [PubMed: 27861698]
  17. Ashburner JM, Go AS, Reynolds K, et al. Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts). Am J Cardiol 2015;115(1):40–6. PMID: 25456871. [PubMed: 25456871]
  18. Aulin J, Siegbahn A, Hijazi Z, et al. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J 2015;170(6):1151–60. PMID: 26678637. [PubMed: 26678637]
  19. Azizy O, Rammos C, Lehmann N, et al. Percutaneous closure of the left atrial appendage in patients with diabetes mellitus. Diab Vasc Dis Res 2017:1479164117712176. PMID: 28595459. [PubMed: 28595459]
  20. Azoulay L, Dell’Aniello S, Simon TA, et al. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J 2014;35(28):1881–7. PMID: 24353282. [PubMed: 24353282]
  21. Balla SR, Cyr DD, Lokhnygina Y, et al. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). Am J Cardiol 2017;119(12):1989–1996. PMID: 28477860. [PubMed: 28477860]
  22. Banerjee A, Clementy N, Haguenoer K, et al. Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Am J Med 2014;127(10):972–8. PMID: 24929021. [PubMed: 24929021]
  23. Banerjee A, Fauchier L, Vourc’h P, et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2014;145(6):1370–1382. PMID: 24356875. [PubMed: 24356875]
  24. Barrios V, Escobar C, Prieto L, et al. Anticoagulation Control in Patients With Nonvalvular Atrial Fibrillation Attended at Primary Care Centers in Spain: The PAULA Study. Rev Esp Cardiol (Engl Ed) 2015;68(9):769–76. PMID: 26169326. [PubMed: 26169326]
  25. Bernier M, Abdelmoneim SS, Stuart Moir W, et al. CUTE-CV: a prospective study of enhanced left atrial appendage visualization with microbubble contrast agent use during transesophageal echocardiography guided cardioversion. Echocardiography 2013;30(9):1091–7. PMID: 23662846. [PubMed: 23662846]
  26. Berte B, Jost CA, Maurer D, et al. Long-term follow-up after left atrial appendage occlusion with comparison of transesophageal echocardiography versus computed tomography to guide medical therapy and data about postclosure cardioversion. J Cardiovasc Electrophysiol 2017;28(10):1140–1150. Digital Object Identifier: 10.1111/jce.13289. PMID: 28675629. [PubMed: 28675629] [CrossRef]
  27. Bertomeu-Gonzalez V, Anguita M, Moreno-Arribas J, et al. Quality of Anticoagulation With Vitamin K Antagonists. Clin Cardiol 2015;38(6):357–64. PMID: 25962838. [PMC free article: PMC6711074] [PubMed: 25962838]
  28. Bertozzo G, Zoppellaro G, Granziera S, et al. Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non-valvular atrial fibrillation. J Thromb Haemost 2016;14(11):2124–2131. PMID: 27471198. [PubMed: 27471198]
  29. Betts TR, Leo M, Panikker S, et al. Percutaneous left atrial appendage occlusion using different technologies in the United Kingdom: A multicenter registry. Catheter Cardiovasc Interv 2017;89(3):484–492. PMID: 27651124. [PubMed: 27651124]
  30. Bhardwaj R, Sharma P, Finkel MS, et al. Gender and geographic differences in CAD risk factors and CHADS2 scores in atrial fibrillation patients. W V Med J 2012;108(1):18–21. PMID: 25134188. [PubMed: 25134188]
  31. Blin P, Dureau-Pournin C, Lassalle R, et al. A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC. Br J Clin Pharmacol 2016;81(3):569–78. PMID: 26493768. [PMC free article: PMC4767200] [PubMed: 26493768]
  32. Boersma LV, Ince H, Kische S, et al. Efficacy and Safety of Left Atrial Appendage Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial. Heart Rhythm 2017. PMID: 28577840. [PubMed: 28577840]
  33. Bosch RF, Pittrow D, Beltzer A, et al. Gender differences in patients with atrial fibrillation. Herzschrittmacherther Elektrophysiol 2013;24(3):176–83. PMID: 23979564. [PubMed: 23979564]
  34. Bouillon K, Bertrand M, Boudali L, et al. Short-Term Risk of Bleeding During Heparin Bridging at Initiation of Vitamin K Antagonist Therapy in More Than 90 000 Patients With Nonvalvular Atrial Fibrillation Managed in Outpatient Care. J Am Heart Assoc 2016;5(11). PMID: 27799233. [PMC free article: PMC5210354] [PubMed: 27799233]
  35. Bronnum Nielsen P, Larsen TB, Gorst-Rasmussen A, et al. Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study. Chest 2015;147(6):1651–1658. PMID: 25412369. [PubMed: 25412369]
  36. Brunner KJ, Bunch TJ, Mullin CM, et al. Clinical predictors of risk for atrial fibrillation: implications for diagnosis and monitoring. Mayo Clin Proc 2014;89(11):1498–505. PMID: 25444486. [PubMed: 25444486]
  37. Bryk AH, Lukaszuk R, Donicz P, et al. Efficacy and safety of apixaban in real‑life patients at high bleeding risk. Polish Archives of Internal Medicine 2017;127(12):889–891. Digital Object Identifier: 10.20452/pamw.4169. [PubMed: 29272262] [CrossRef]
  38. Budts W, Laenens D, Van Calenbergh F, et al. Left atrial appendage occlusion with the Amplatzer Cardiac Plug could improve survival and prevent thrombo-embolic and major bleeding events in atrial fibrillation patients with increased bleeding risk. Acta Cardiol 2016;71(2):135–43. PMID: 27090034. [PubMed: 27090034]
  39. Burrell LD, Horne BD, Anderson JL, et al. Usefulness of left atrial appendage volume as a predictor of embolic stroke in patients with atrial fibrillation. Am J Cardiol 2013;112(8):1148–52. PMID: 23827402. [PubMed: 23827402]
  40. Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37(14):1145–53. PMID: 26330425. [PMC free article: PMC4823634] [PubMed: 26330425]
  41. Cappellari M, Carletti M, Danese A, et al. Early introduction of direct oral anticoagulants in cardioembolic stroke patients with non-valvular atrial fibrillation. J Thromb Thrombolysis 2016;42(3):393–8. PMID: 27329483. [PubMed: 27329483]
  42. Carrero JJ, Evans M, Szummer K, et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. Jama 2014;311(9):919–28. PMID: 24595776. [PubMed: 24595776]
  43. Casciano JP, Dotiwala ZJ, Martin BC, et al. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. J Manag Care Pharm 2013;19(4):302–16. PMID: 23627576. [PMC free article: PMC10437466] [PubMed: 23627576]
  44. Chan PH, Hai JJ, Chan EW, et al. Use of the SAMe-TT2R2 Score to Predict Good Anticoagulation Control with Warfarin in Chinese Patients with Atrial Fibrillation: Relationship to Ischemic Stroke Incidence. PLoS One 2016;11(3):e0150674. PMID: 27010633. [PMC free article: PMC4807017] [PubMed: 27010633]
  45. Chan PH, Li WH, Hai JJ, et al. Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation. Can J Cardiol 2016;32(10):1247.e23–1247.e28. PMID: 26927855. [PubMed: 26927855]
  46. Chang KC, Wang YC, Ko PY, et al. Increased risk of first-ever stroke in younger patients with atrial fibrillation not recommended for antithrombotic therapy by current guidelines: a population-based study in an East Asian cohort of 22 million people. Mayo Clin Proc 2014;89(11):1487–97. PMID: 25444485. [PubMed: 25444485]
  47. Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?. J Am Coll Cardiol 2015;65(7):635–42. PMID: 25677422. [PubMed: 25677422]
  48. Chao TF, Wang KL, Liu CJ, et al. Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan. J Am Coll Cardiol 2015;66(12):1339–47. PMID: 26383720. [PubMed: 26383720]
  49. Chau KH, Scherzer R, Grunfeld C, et al. CHA2DS2-VASc Score, Warfarin Use, and Risk for Thromboembolic Events Among HIV-Infected Persons With Atrial Fibrillation. J Acquir Immune Defic Syndr 2017;76(1):90–97. Digital Object Identifier: 10.1097/qai.0000000000001470. PMID: 28797024. [PMC free article: PMC5646359] [PubMed: 28797024] [CrossRef]
  50. Chaussade E, Hanon O, Boully C, et al. Real-life peak and trough dabigatran plasma measurements over time in hospitalized geriatric patients with atrial fibrillation. Journal of Nutrition, Health and Aging 2017;1–9. Digital Object Identifier: 10.1007/s12603-017-0982-4. [PubMed: 29300437] [CrossRef]
  51. Chen JJ, Lin LY, Yang YH, et al. Anti-platelet or anti-coagulant agent for the prevention of ischemic stroke in patients with end-stage renal disease and atrial fibrillation-a nation-wide database analyses. Int J Cardiol 2014;177(3):1008–11. PMID: 25449515. [PubMed: 25449515]
  52. Chen ST, Hellkamp AS, Becker RC, et al. Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Am J Cardiol 2017;120(10):1837–1840. Digital Object Identifier: 10.1016/j.amjcard.2017.07.095. PMID: 28886856. [PubMed: 28886856] [CrossRef]
  53. Chen T, Yang YM, Tan HQ, et al. Baseline characteristics and 1-year follow-up of Chinese atrial fibrillation patients according to age: a registry study. Pacing Clin Electrophysiol 2014;37(10):1392–403. PMID: 25039463. [PubMed: 25039463]
  54. Chen WC, Chen WC, Chen CY, et al. Amiodarone use is associated with increased risk of stroke in patients with nonvalvular atrial fibrillation: a nationwide population-based cohort study. Medicine (Baltimore) 2015;94(19):e849. PMID: 25984674. [PMC free article: PMC4602574] [PubMed: 25984674]
  55. Chen X, Wan R, Jiang W, et al. Evidence-based study on antithrombotic therapy in patients at risk of a stroke with paroxysmal atrial fibrillation. Exp Ther Med 2013;6(2):413–418. PMID: 24137200. [PMC free article: PMC3787006] [PubMed: 24137200]
  56. Cherian TS, Shrader P, Fonarow GC, et al. Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]). Am J Cardiol 2017;119(11):1763–1769. PMID: 28416199. [PubMed: 28416199]
  57. Chirino Navarta DA, Palacios R, Leonardi MS, et al. Presence of thrombus and spontaneous contrast in the left atrium of patients with atrial fibrillation anticoagulated with Dabigatran and Acenocoumarol. Revista Argentina de Cardiologia 2015;83(6):525–530.
  58. Chishaki A, Kumagai N, Takahashi N, et al. Non-valvular atrial fibrillation patients with low CHADS2 scores benefit from warfarin therapy according to propensity score matching subanalysis using the J-RHYTHM Registry. Thromb Res 2015;136(2):267–73. PMID: 26092429. [PubMed: 26092429]
  59. Choi JC, Dibonaventura MD, Kopenhafer L, et al. Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation. Patient Prefer Adherence 2014;8:167–77. PMID: 24532967. [PMC free article: PMC3923612] [PubMed: 24532967]
  60. Cinza-Sanjurjo S, Rey-Aldana D, Gestal-Pereira E, et al. Assessment of Degree of Anticoagulation Control in Patients With Atrial Fibrillation in Primary Health Care in Galicia, Spain: ANFAGAL Study. Rev Esp Cardiol (Engl Ed) 2015;68(9):753–60. PMID: 25440046. [PubMed: 25440046]
  61. Clua-Espuny JL, Panisello-Tafalla A, Lopez-Pablo C, et al. Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study. Cardiol Res 2014;5(1):12–22. PMID: 28392870. [PMC free article: PMC5358274] [PubMed: 28392870]
  62. Cohn BG, Keim SM and Yealy DM. Is emergency department cardioversion of recent-onset atrial fibrillation safe and effective?. J Emerg Med 2013;45(1):117–27. PMID: 23643237. [PubMed: 23643237]
  63. Cohoon KP, Mazur M, McBane RD, et al. The impact of gender and left atrial blood stasis on adiponectin levels in non-valvular atrial fibrillation. Int J Cardiol 2015;181:207–12. PMID: 25528313. [PMC free article: PMC4385434] [PubMed: 25528313]
  64. Cohoon KP, McBane RD, Ammash N, et al. Relationship between body mass index and left atrial appendage thrombus in nonvalvular atrial fibrillation. J Thromb Thrombolysis 2016;41(4):613–8. PMID: 26282111. [PubMed: 26282111]
  65. Coleman CI, Vaitsiakhovich T, Nguyen E, et al. Agreement between coding schemas used to identify bleeding-related hospitalizations in claims analyses of nonvalvular atrial fibrillation patients. Clinical Cardiology 2018. Digital Object Identifier: 10.1002/clc.22861. [PMC free article: PMC6489698] [PubMed: 29360144] [CrossRef]
  66. Connolly SJ, Wallentin L, Ezekowitz MD, et al. The long term multi-center observational study of dabigatran treatment in patients with atrial fibrillation: (RELY-ABLE) Study. Circulation 2013. [PubMed: 23770747]
  67. Cowan C, Healicon R, Robson I, et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart 2013;99(16):1166–72. PMID: 23393083. [PMC free article: PMC3717828] [PubMed: 23393083]
  68. Cressman AM, Macdonald EM, Yao Z, et al. Socioeconomic status and risk of hemorrhage during warfarin therapy for atrial fibrillation: A population-based study. Am Heart J 2015;170(1):133–40, 140.e1–3. PMID: 26093874. [PubMed: 26093874]
  69. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013;127(5):634–40. PMID: 23271794. [PubMed: 23271794]
  70. de Andres-Nogales F, Oyaguez I, Betegon-Nicolas L, et al. Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF Study. Rev Clin Esp 2015;215(2):73–82. PMID: 25288530. [PubMed: 25288530]
  71. De Caterina R, Bruggenjurgen B, Darius H, et al. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. Arch Cardiovasc Dis 2017. Digital Object Identifier: 10.1016/j.acvd.2017.04.007. PMID: 28942115. [PubMed: 28942115] [CrossRef]
  72. Deguchi I, Fukuoka T, Hayashi T, et al. Clinical outcomes of persistent and paroxysmal atrial fibrillation in patients with stroke. J Stroke Cerebrovasc Dis 2014;23(10):2840–4. PMID: 25294056. [PubMed: 25294056]
  73. Deguchi I, Ogawa H, Ohe Y, et al. Rate of antithrombotic drug use and clinical outcomes according to CHADS2 scores in patients with an initial cardioembolic stroke who had nonvalvular atrial fibrillation. J Stroke Cerebrovasc Dis 2013;22(6):846–50. PMID: 22819543. [PubMed: 22819543]
  74. Deitelzweig SB, Buysman E, Pinsky B, et al. Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Ther 2013;35(8):1201–10. PMID: 23867114. [PubMed: 23867114]
  75. Deitelzweig SB, Jing Y, Swindle JP, et al. Reviewing a clinical decision aid for the selection of anticoagulation treatment in patients with nonvalvular atrial fibrillation: applications in a US managed care health plan database. Clin Ther 2014;36(11):1566–1573.e3. PMID: 25438725. [PubMed: 25438725]
  76. Deitelzweig SB, Pinsky B, Buysman E, et al. Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Ther 2013;35(10):1536–45.e1. PMID: 24075151. [PubMed: 24075151]
  77. Demircelik MB, Cetin M, Cicekcioglu H, et al. Effect of left ventricular diastolic dysfunction on left atrial appendage function and thrombotic potential in nonvalvular atrial fibrillation. Anadolu Kardiyol Derg 2014;14(3):256–60. PMID: 24566551. [PubMed: 24566551]
  78. Denas G, Zoppellaro G, Padayattil Jose S, et al. Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA2 DS2 VASc 1 or 2): A treatment dilemma. Cardiovasc Ther 2017. Digital Object Identifier: 10.1111/1755-5922.12310. PMID: 29078033. [PubMed: 29078033] [CrossRef]
  79. Dodson JA, Petrone A, Gagnon DR, et al. Incidence and Determinants of Traumatic Intracranial Bleeding Among Older Veterans Receiving Warfarin for Atrial Fibrillation. JAMA Cardiol 2016;1(1):65–72. PMID: 27437657. [PMC free article: PMC5600874] [PubMed: 27437657]
  80. Dogan V, Basaran O, Beton O, et al. Coronary artery disease in outpatients with nonvalvular atrial fibrillation: results from the multicenter RAMSES study. Coron Artery Dis 2016;27(6):497–503. PMID: 27182772. [PubMed: 27182772]
  81. Dogan V, Basaran Ö, Beton O, et al. Gender-related differences in presentation and treatment of patients with non-valvular atrial fibrillation: Results from RAMSES study. Turk Kardiyoloji Dernegi Arsivi 2017;45(1):16–25. [PubMed: 28106016]
  82. Ebrahimi R, Han JK, Goe SH, et al. Patient Characteristics and Clinical Outcomes with Low-Dose Dabigatran. Front Cardiovasc Med 2017;4:42. Digital Object Identifier: 10.3389/fcvm.2017.00042. PMID: 28740848. [PMC free article: PMC5502329] [PubMed: 28740848] [CrossRef]
  83. Echouffo-Tcheugui JB, Shrader P, Thomas L, et al. Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. J Am Coll Cardiol 2017;70(11):1325–1335. Digital Object Identifier: 10.1016/j.jacc.2017.07.755. PMID: 28882229. [PubMed: 28882229] [CrossRef]
  84. Eckman MH, Wise RE, Speer B, et al. Integrating real-time clinical information to provide estimates of net clinical benefit of antithrombotic therapy for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2014;7(5):680–6. PMID: 25205788. [PubMed: 25205788]
  85. Ehrlich JR, Kaluzny M, Baumann S, et al. Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation. Clin Res Cardiol 2011;100(11):1029–36. PMID: 21725858. [PubMed: 21725858]
  86. Eisen A, Ruff CT, Braunwald E, et al. Digoxin use and subsequent clinical outcomes in patients with atrial fibrillation with or without heart failure in the ENGAGE AF-TIMI 48 trial. Journal of the American Heart Association 2017;6(7). Digital Object Identifier: 10.1161/JAHA.117.006035. [PMC free article: PMC5586309] [PubMed: 28666993] [CrossRef]
  87. Emren SV, Ada F, Aldemir M, et al. Is CHA2DS2-VASc Score Different in Patients with Non-valvular Atrial Fibrillation Suffering from Cerebral and Non-cerebral Thromboembolism?CHA2DS2-VASc Score in Thromboembolism. J Atr Fibrillation 2017;10(2):1575. Digital Object Identifier: 10.4022/jafib.1575. PMID: 29250228. [PMC free article: PMC5673287] [PubMed: 29250228] [CrossRef]
  88. Emren SV, Zoghi M, Berilgen R, et al. Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study. Bosn J Basic Med Sci 2017. Digital Object Identifier: 10.17305/bjbms.2017.2279. PMID: 28968197. [PMC free article: PMC5988538] [PubMed: 28968197] [CrossRef]
  89. Engelberger RP, Noll G, Schmidt D, et al. Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study. Eur J Intern Med 2015;26(7):508–14. PMID: 25935131. [PubMed: 25935131]
  90. Esteve-Pastor MA, Rivera-Caravaca JM, Shantsila A, et al. Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial. Thromb Haemost 2017;117(12):2261–2266. Digital Object Identifier: 10.1160/th17-10-0710. PMID: 29212113. [PubMed: 29212113] [CrossRef]
  91. Ezekowitz MD, Eikelboom J, Oldgren J, et al. Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. Europace 2016;18(7):973–8. PMID: 26944733. [PMC free article: PMC4927062] [PubMed: 26944733]
  92. Fastner C, Behnes M, Sartorius B, et al. Left atrial appendage morphology, echocardiographic characterization, procedural data and in-hospital outcome of patients receiving left atrial appendage occlusion device implantation: a prospective observational study. BMC Cardiovasc Disord 2016;16:25. PMID: 26822890. [PMC free article: PMC4730589] [PubMed: 26822890]
  93. Fastner C, Behnes M, Sartorius B, et al. Procedural success and intra-hospital outcome related to left atrial appendage morphology in patients that receive an interventional left atrial appendage closure. Clin Cardiol 2017. PMID: 28409845. [PMC free article: PMC6490384] [PubMed: 28409845]
  94. Fauchier L, Lecoq C, Clementy N, et al. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project. Chest 2016;149(4):960–8. PMID: 26425935. [PubMed: 26425935]
  95. Faustino A, Paiva L, Providencia R, et al. Percutaneous closure of the left atrial appendage for prevention of thromboembolism in atrial fibrillation for patients with contraindication to or failure of oral anticoagulation: a single-center experience. Rev Port Cardiol 2013;32(6):461–71. PMID: 23639325. [PubMed: 23639325]
  96. Faustino A, Providencia R, Barra S, et al. Which method of left atrium size quantification is the most accurate to recognize thromboembolic risk in patients with non-valvular atrial fibrillation?. Cardiovasc Ultrasound 2014;12:28. PMID: 25052699. [PMC free article: PMC4121510] [PubMed: 25052699]
  97. Ferret L, Beuscart JB, Ficheur G, et al. Evaluation of compliance with recommendations of prevention of thromboembolism in atrial fibrillation in the elderly, by data reuse of electronic health records. Stud Health Technol Inform 2015;210:394–8. PMID: 25991173. [PubMed: 25991173]
  98. Fox KAA, Lucas JE, Pieper KS, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open 2017;7(12):e017157. Digital Object Identifier: 10.1136/bmjopen-2017-017157. PMID: 29273652. [PMC free article: PMC5778339] [PubMed: 29273652] [CrossRef]
  99. Fu Y, Li K and Yang X. ABO blood groups: A risk factor for left atrial and left atrial appendage thrombogenic milieu in patients with non-valvular atrial fibrillation. Thromb Res 2017;156:45–50. PMID: 28582641. [PubMed: 28582641]
  100. Gafoor S, Franke J, Bertog S, et al. Left atrial appendage occlusion in octogenarians: short-term and 1-year follow-up. Catheter Cardiovasc Interv 2014;83(5):805–10. PMID: 24259397. [PubMed: 24259397]
  101. Gallagher AM, van Staa TP, Murray-Thomas T, et al. Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes. BMJ Open 2014;4(1):e003839. PMID: 24468720. [PMC free article: PMC3913087] [PubMed: 24468720]
  102. Gallego P, Roldan V, Marin F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013;110(6):1189–98. PMID: 24096615. [PubMed: 24096615]
  103. Gallego P, Roldan V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014;127(11):1083–8. PMID: 24858062. [PubMed: 24858062]
  104. Gamst J, Christiansen CF, Rasmussen BS, et al. Pre-existing atrial fibrillation and risk of arterial thromboembolism and death in intensive care unit patients: a population-based cohort study. Crit Care 2015;19:299. PMID: 26286550. [PMC free article: PMC4543470] [PubMed: 26286550]
  105. Gangireddy SR, Halperin JL, Fuster V, et al. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit. Eur Heart J 2012;33(21):2700–8. PMID: 23008509. [PubMed: 23008509]
  106. Ghenzi RA, Obeid S, Maisano F, et al. The evolving role of left atrial appendage occlusion. Kardiovaskulare Medizin 2016;19(11):288–295.
  107. Granger CB, Lopes RD, Hanna M, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 2015;169(1):25–30. PMID: 25497244. [PubMed: 25497244]
  108. Guerios EE, Chamie F, Montenegro M, et al. First results of the Brazilian Registry of Percutaneous Left Atrial Appendage Closure. Arq Bras Cardiol 2017;109(5):440–447. Digital Object Identifier: 10.5935/abc.20170150. PMID: 29069203. [PMC free article: PMC5729780] [PubMed: 29069203] [CrossRef]
  109. Gullón A, Suárez C, Díez-Manglano J, et al. Antithrombotic treatment and characteristics of elderly patients with non-valvular atrial fibrillation hospitalized at Internal Medicine departments. NONAVASC registry. Medicina Clinica 2017;148(5):204–210. [PubMed: 27993408]
  110. Guo Y, Wang H, Tian Y, et al. Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial fibrillation. An analysis of 425,600 Chinese individuals without prior stroke. Thromb Haemost 2016;115(1):184–92. PMID: 26322338. [PubMed: 26322338]
  111. Guo Y, Wang H, Zhao X, et al. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int J Cardiol 2013;168(5):4678–84. PMID: 23972369. [PubMed: 23972369]
  112. Gupta DK, Shah AM, Giugliano RP, et al. Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. Eur Heart J 2014;35(22):1457–65. PMID: 24302269. [PMC free article: PMC4048534] [PubMed: 24302269]
  113. Gupta N, Haft JI, Bajaj S, et al. Role of the combined CHADS2 score and echocardiographic abnormalities in predicting stroke in patients with paroxysmal atrial fibrillation. J Clin Neurosci 2012;19(9):1242–5. PMID: 22721894. [PubMed: 22721894]
  114. Hald EM, Rinde LB, Lochen ML, et al. Atrial Fibrillation and Cause-Specific Risks of Pulmonary Embolism and Ischemic Stroke. J Am Heart Assoc 2018;7(3). Digital Object Identifier: 10.1161/jaha.117.006502. PMID: 29378729. [PMC free article: PMC5850231] [PubMed: 29378729] [CrossRef]
  115. Han SY, Palmeri ST, Broderick SH, et al. Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting. J Electrocardiol 2013;46(1):45–50. PMID: 23063241. [PubMed: 23063241]
  116. Hayashi T, Kato Y, Fukuoka T, et al. Clinical Features of Ischemic Stroke during Treatment with Dabigatran: An Association between Decreased Severity and a Favorable Prognosis. Intern Med 2015;54(19):2433–7. PMID: 26424298. [PubMed: 26424298]
  117. Hayden DT, Hannon N, Callaly E, et al. Rates and Determinants of 5-Year Outcomes After Atrial Fibrillation-Related Stroke: A Population Study. Stroke 2015;46(12):3488–93. PMID: 26470776. [PubMed: 26470776]
  118. Hell MM, Achenbach S, Yoo IS, et al. 3D printing for sizing left atrial appendage closure device: Head-to-head comparison with computed tomography and transoesophageal echocardiography. EuroIntervention 2017;13(10):1234–1241. Digital Object Identifier: 10.4244/EIJ-D-17-00359. [PubMed: 28671551] [CrossRef]
  119. Hellfritzsch M, Grove EL, Husted SE, et al. Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation. Europace 2017;19(7):1091–1095. Digital Object Identifier: 10.1093/europace/euw241. [PMC free article: PMC5834049] [PubMed: 28641379] [CrossRef]
  120. Helmert S, Marten S, Mizera H, et al. Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry. J Thromb Thrombolysis 2017;44(2):169–178. Digital Object Identifier: 10.1007/s11239-017-1519-8. PMID: 28643004. [PubMed: 28643004] [CrossRef]
  121. Helsen F, Nuyens D, De Meester P, et al. Left atrial appendage occlusion: single center experience with PLAATO LAA Occlusion System((R)) and AMPLATZER Cardiac Plug. J Cardiol 2013;62(1):44–9. PMID: 23668912. [PubMed: 23668912]
  122. Hernandez AF, Liang L, Fonarow GC, et al. Associations between anticoagulation therapy and risks of mortality and readmission among patients with heart failure and atrial fibrillation. Circ Cardiovasc Qual Outcomes 2014;7(5):670–9. PMID: 25205789. [PubMed: 25205789]
  123. Hess PL, Greiner MA, Fonarow GC, et al. Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims. Clin Cardiol 2012;35(11):649–57. PMID: 23070696. [PMC free article: PMC4076954] [PubMed: 23070696]
  124. Hijazi Z, Aulin J, Andersson U, et al. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart 2016;102(7):508–17. PMID: 26839066. [PubMed: 26839066]
  125. Hijazi Z, Siegbahn A, Andersson U, et al. Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. Clin Chem 2015;61(2):368–78. PMID: 25451868. [PubMed: 25451868]
  126. Hijazi Z, Wallentin L, Siegbahn A, et al. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol 2014;63(1):52–61. PMID: 24055845. [PubMed: 24055845]
  127. Horstmann S, Rizos T, Rauch G, et al. Atrial fibrillation and prestroke cognitive impairment in stroke. J Neurol 2014;261(3):546–53. PMID: 24413641. [PubMed: 24413641]
  128. Horstmann S, Zugck C, Krumsdorf U, et al. Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage. Neurology 2014;82(2):135–8. PMID: 24319042. [PMC free article: PMC3897438] [PubMed: 24319042]
  129. Hoshi Y, Nozawa Y, Ogasawara M, et al. Atrial electromechanical interval may predict cardioembolic stroke in apparently low risk elderly patients with paroxysmal atrial fibrillation. Echocardiography 2014;31(2):140–8. PMID: 23906195. [PubMed: 23906195]
  130. Hrynkiewicz-Szymanska A, Dluzniewski M, Platek AE, et al. Association of the CHADS2 and CHA 2DS 2-VASc scores with left atrial enlargement: a prospective cohort study of unselected atrial fibrillation patients. J Thromb Thrombolysis 2015;40(2):240–7. PMID: 25490871. [PMC free article: PMC4477077] [PubMed: 25490871]
  131. Hsu PC, Lee WH, Chu CY, et al. Prognostic role of left atrial strain and its combination index with transmitral E-wave velocity in patients with atrial fibrillation. Sci Rep 2016;6:17318. PMID: 26833057. [PMC free article: PMC4735288] [PubMed: 26833057]
  132. Hu H, Cui K, Jiang J, et al. Safety and efficacy analysis of one-stop intervention for treating nonvalvular atrial fibrillation. Pacing Clin Electrophysiol 2017. Digital Object Identifier: 10.1111/pace.13250. PMID: 29194654. [PubMed: 29194654] [CrossRef]
  133. Huang B, Yang Y, Zhu J, et al. Clinical characteristics and impact of diabetes mellitus on outcomes in patients with nonvalvular atrial fibrillation. Yonsei Med J 2015;56(1):62–71. PMID: 25510748. [PMC free article: PMC4276779] [PubMed: 25510748]
  134. Huang D, Anguo L, Yue WS, et al. Refinement of ischemic stroke risk in patients with atrial fibrillation and CHA2 DS2 -VASc score of 1. Pacing Clin Electrophysiol 2014;37(11):1442–7. PMID: 25039724. [PubMed: 25039724]
  135. Huisman MV, Rothman KJ, Paquette M, et al. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry. American Heart Journal 2018;198:55–63. Digital Object Identifier: 10.1016/j.ahj.2017.08.018. [PubMed: 29653649] [CrossRef]
  136. Induruwa I, Amis E, Hannon N, et al. The increasing burden of atrial fibrillation in acute medical admissions, an opportunity to optimise stroke prevention. Journal of the Royal College of Physicians of Edinburgh 2017;47(4):331–335. Digital Object Identifier: 10.4997/JRCPE.2017.405. [PubMed: 29537402] [CrossRef]
  137. Inoue H, Atarashi H, Okumura K, et al. Impact of gender on the prognosis of patients with nonvalvular atrial fibrillation. Am J Cardiol 2014;113(6):957–62. PMID: 24461771. [PubMed: 24461771]
  138. Inoue H, Atarashi H, Okumura K, et al. Thromboembolic events in paroxysmal vs. permanent non-valvular atrial fibrillation. Subanalysis of the J-RHYTHM Registry. Circ J 2014;78(10):2388–93. PMID: 25099606. [PubMed: 25099606]
  139. Islas F, Olmos C, Vieira C, et al. Thromboembolic risk in atrial fibrillation: association between left atrium mechanics and risk scores. A study based on 3D wall-motion tracking technology. Echocardiography 2015;32(4):644–53. PMID: 25091933. [PubMed: 25091933]
  140. Jakobsen M, Kolodziejczyk C, Klausen Fredslund E, et al. Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation - a nationwide cohort study. BMC Health Serv Res 2017;17(1):398. PMID: 28606079. [PMC free article: PMC5469002] [PubMed: 28606079]
  141. Johnsen SP, Svendsen ML, Hansen ML, et al. Preadmission oral anticoagulant treatment and clinical outcome among patients hospitalized with acute stroke and atrial fibrillation: a nationwide study. Stroke 2014;45(1):168–75. PMID: 24281225. [PubMed: 24281225]
  142. Kabra R, Cram P, Girotra S, et al. Effect of race on outcomes (stroke and death) in patients >65 years with atrial fibrillation. Am J Cardiol 2015;116(2):230–5. PMID: 26004053. [PMC free article: PMC4780330] [PubMed: 26004053]
  143. Kakkar AK, Mueller I, Bassand JP, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One 2013;8(5):e63479. PMID: 23704912. [PMC free article: PMC3660389] [PubMed: 23704912]
  144. Karayiannides S, Lundman P, Friberg L, et al. High overall cardiovascular risk and mortality in patients with atrial fibrillation and diabetes: A nationwide report. Diab Vasc Dis Res 2018;15(1):31–38. Digital Object Identifier: 10.1177/1479164117735013. PMID: 29052435. [PubMed: 29052435] [CrossRef]
  145. Kautzner J, Peichl P, Sramko M, et al. Catheter ablation of atrial fibrillation in elderly population. J Geriatr Cardiol 2017;14(9):563–568. Digital Object Identifier: 10.11909/j.issn.1671-5411.2017.09.008. PMID: 29144514. [PMC free article: PMC5641643] [PubMed: 29144514] [CrossRef]
  146. Kawabata M, Yokoyama Y, Sasano T, et al. Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice. J Cardiol 2013;62(2):121–6. PMID: 23680005. [PubMed: 23680005]
  147. Khalid F, Qureshi W, Qureshi S, et al. Impact of restarting warfarin therapy in renal disease anticoagulated patients with gastrointestinal hemorrhage. Ren Fail 2013;35(9):1228–35. PMID: 23902367. [PubMed: 23902367]
  148. Kim BJ, Kim HJ, Do Y, et al. The impact of prior antithrombotic status on cerebral infarction in patients with atrial fibrillation. J Stroke Cerebrovasc Dis 2014;23(8):2054–9. PMID: 25113085. [PubMed: 25113085]
  149. Kim MH, Bell KF, Makenbaeva D, et al. Health care burden of dyspepsia among nonvalvular atrial fibrillation patients. J Manag Care Spec Pharm 2014;20(4):391–9. PMID: 24684644. [PMC free article: PMC10437634] [PubMed: 24684644]
  150. Kim TH, Kim JY, Mun HS, et al. Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis. J Thromb Haemost 2015;13(2):182–90. PMID: 25472735. [PubMed: 25472735]
  151. Kimmons LA, Kabra R, Davis M, et al. Dabigatran Use in the Real World: A Multihospital System Experience. J Pharm Pract 2014;27(4):384–8. PMID: 24319080. [PubMed: 24319080]
  152. Kirchhof P, Schmalowsky J, Pittrow D, et al. Management of patients with atrial fibrillation by primary-care physicians in Germany: 1-year results of the ATRIUM registry. Clin Cardiol 2014;37(5):277–84. PMID: 24652779. [PMC free article: PMC6649363] [PubMed: 24652779]
  153. Kodani E, Atarashi H, Inoue H, et al. Use of warfarin in elderly patients with non-valvular atrial fibrillation - subanalysis of the J-RHYTHM Registry. Circ J 2015;79(11):2345–52. PMID: 26329097. [PubMed: 26329097]
  154. Kooistra HAM, Piersma-Wichers M, Kluin-Nelemans HC, et al. Impact of Vitamin K antagonists on quality of life in a prospective cohort of 807 atrial fibrillation patients. Circulation: Cardiovascular Quality and Outcomes 2016;9(4):388–394. [PubMed: 27329860]
  155. Kurfirst V, Mokráček A, Čanádyová J, et al. Effectivity of left atrial appendage occlusion with AtriClip in 155 consecutive patients – Single center study. Cor et Vasa 2017;59(4):e376–e380. Digital Object Identifier: 10.1016/j.crvasa.2017.05.015. [CrossRef]
  156. Lahewala S, Arora S, Patel P, et al. Atrial fibrillation: Utility of CHADS2 and CHA2DS2-VASc scores as predictors of readmission, mortality and resource utilization. Int J Cardiol 2017;245:162–167. Digital Object Identifier: 10.1016/j.ijcard.2017.06.090. PMID: 28874288. [PubMed: 28874288] [CrossRef]
  157. Lahtela HM, Kiviniemi TO, Puurunen MK, et al. Renal Impairment and Prognosis of Patients with Atrial Fibrillation Undergoing Coronary Intervention - The AFCAS Trial. PLoS One 2015;10(6):e0128492. PMID: 26030623. [PMC free article: PMC4451758] [PubMed: 26030623]
  158. Lamberts M, Gislason GH, Lip GY, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 2014;129(15):1577–85. PMID: 24470482. [PubMed: 24470482]
  159. Lau DH, Hendriks J, Kalman JM, et al. Blood pressure control in atrial fibrillation. Circulation 2017;135(19):1799–1801. [PubMed: 28483830]
  160. Lauffenburger JC, Rhoney DH, Farley JF, et al. Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy. Pharmacotherapy 2015;35(6):560–8. PMID: 26044889. [PMC free article: PMC4750642] [PubMed: 26044889]
  161. Lee JM, Shim J, Uhm JS, et al. Impact of increased orifice size and decreased flow velocity of left atrial appendage on stroke in nonvalvular atrial fibrillation. Am J Cardiol 2014;113(6):963–9. PMID: 24462064. [PubMed: 24462064]
  162. Lee SJ, Uhm JS, Kim JY, et al. The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis. Int J Cardiol 2015;180:185–91. PMID: 25463361. [PubMed: 25463361]
  163. Lempereur M, Aminian A, Freixa X, et al. Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Previous Major Gastrointestinal Bleeding (from the Amplatzer Cardiac Plug Multicenter Registry). Am J Cardiol 2017. PMID: 28595859. [PubMed: 28595859]
  164. Li S, Zhao X, Wang C, et al. Risk factors for poor outcome and mortality at 3 months after the ischemic stroke in patients with atrial fibrillation. J Stroke Cerebrovasc Dis 2013;22(8):e419–25. PMID: 23721617. [PubMed: 23721617]
  165. Li X, Lu Y, Yin J, et al. Genotype-based anticoagulant therapy with warfarin for atrial fibrillation. International Journal of Clinical and Experimental Medicine 2017;10(9):14056–14062.
  166. Li Y, Ding W, Wang H, et al. Relationship of CHA2DS2-VASc and CHADS2 score to left atrial remodeling detected by velocity vector imaging in patients with atrial fibrillation. PLoS One 2013;8(10):e77653. PMID: 24147047. [PMC free article: PMC3798687] [PubMed: 24147047]
  167. Liesenfeld KH, Clemens A, Kreuzer J, et al. Dabigatran treatment simulation in patients undergoing maintenance haemodialysis. Thromb Haemost 2016;115(3):562–9. PMID: 26467062. [PubMed: 26467062]
  168. Lin AH, Oakley LS, Phan HL, et al. Prevalence of stroke and the need for thromboprophylaxis in young patients with atrial fibrillation: a cohort study. J Cardiovasc Med (Hagerstown) 2014;15(3):189–93. PMID: 24625564. [PubMed: 24625564]
  169. Lin YP and Tan TY. Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?. Medicine (Baltimore) 2015;94(38):e1627. PMID: 26402834. [PMC free article: PMC4635774] [PubMed: 26402834]
  170. Lip GY, Clementy N, Pericart L, et al. Stroke and major bleeding risk in elderly patients aged >/=75 years with atrial fibrillation: the Loire Valley atrial fibrillation project. Stroke 2015;46(1):143–50. PMID: 25424474. [PubMed: 25424474]
  171. Lip GY, Halperin JL, Petersen P, et al. A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2). J Thromb Haemost 2015;13(8):1405–13. PMID: 26052866. [PubMed: 26052866]
  172. Lip GY, Nielsen PB, Skjoth F, et al. Atrial fibrillation patients categorized as “not for anticoagulation” according to the 2014 Canadian Cardiovascular Society algorithm are not “low risk”. Can J Cardiol 2015;31(1):24–8. PMID: 25547546. [PubMed: 25547546]
  173. Lip GYH, Clementy N, Pierre B, et al. The impact of associated diabetic retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrillation: the loire valley atrial fibrillation project. Chest 2015;147(4):1103–1110. PMID: 25412290. [PubMed: 25412290]
  174. Lip GYH, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014;146(3):719–726. PMID: 24722973. [PubMed: 24722973]
  175. Lip GYH, Nielsen PB, Skjoth F, et al. The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide cohort study. Chest 2014;146(5):1337–1346. PMID: 25086251. [PubMed: 25086251]
  176. Lobos-Bejarano JM, Castellanos Rodriguez A, Barrios V, et al. Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists. Int J Clin Pract 2017;71(9). Digital Object Identifier: 10.1111/ijcp.12974. PMID: 28722795. [PubMed: 28722795] [CrossRef]
  177. Lopatowska P, Tomaszuk-Kazberuk A, Mlodawska E, et al. Do CHA2 DS2 VASc and HAS-BLED scores influence ‘real-world’ anticoagulation management in atrial fibrillation? 1556 patient registry from the reference cardiology centre. Pharmacoepidemiol Drug Saf 2015;24(12):1297–303. PMID: 26419506. [PubMed: 26419506]
  178. Lowe BS, Kusunose K, Motoki H, et al. Prognostic significance of left atrial appendage “sludge” in patients with atrial fibrillation: a new transesophageal echocardiographic thromboembolic risk factor. J Am Soc Echocardiogr 2014;27(11):1176–83. PMID: 25262162. [PubMed: 25262162]
  179. Lubitz SA, Moser C, Sullivan L, et al. Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community. J Am Heart Assoc 2013;2(5):e000126. PMID: 24002369. [PMC free article: PMC3835216] [PubMed: 24002369]
  180. Macedo AF, Bell J, McCarron C, et al. Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink. Thromb Res 2015;136(2):250–60. PMID: 26073321. [PubMed: 26073321]
  181. Maksym J, Mazurek T, Kochman J, et al. Dual antiplatelet therapy is safe and efficient after left atrial appendage closure. Kardiol Pol 2018. Digital Object Identifier: 10.5603/KP.a2017.0245. PMID: 29350390. [PubMed: 29350390] [CrossRef]
  182. Manzano-Fernandez S, Andreu-Cayuelas JM, Marin F, et al. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Rev Esp Cardiol (Engl Ed) 2015;68(6):497–504. PMID: 25457087. [PubMed: 25457087]
  183. Marcucci M, Nobili A, Tettamanti M, et al. Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. Eur J Intern Med 2013;24(8):800–6. PMID: 24035703. [PubMed: 24035703]
  184. Marcucci M, Skjoth F, Lip GY, et al. A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation. Int J Cardiol 2016;203:785–90. PMID: 26595784. [PubMed: 26595784]
  185. Marzona I, O’Donnell M, Teo K, et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. Cmaj 2012;184(6):E329–36. PMID: 22371515. [PMC free article: PMC3314061] [PubMed: 22371515]
  186. Maura G, Billionnet C, Alla F, et al. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases. Pharmacotherapy 2017. Digital Object Identifier: 10.1002/phar.2046. PMID: 29028119. [PubMed: 29028119] [CrossRef]
  187. Mazurek M, Shantsila E, Lane DA, et al. Secondary Versus Primary Stroke Prevention in Atrial Fibrillation: Insights From the Darlington Atrial Fibrillation Registry. Stroke 2017;48(8):2198–2205. Digital Object Identifier: 10.1161/strokeaha.116.016146. PMID: 28679859. [PubMed: 28679859] [CrossRef]
  188. Melgaard L, Gorst-Rasmussen A, Lane DA, et al. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. Jama 2015;314(10):1030–8. PMID: 26318604. [PubMed: 26318604]
  189. Melgaard L, Rasmussen LH, Skjoth F, et al. Age dependence of risk factors for stroke and death in young patients with atrial fibrillation: a nationwide study. Stroke 2014;45(5):1331–7. PMID: 24676780. [PubMed: 24676780]
  190. Mert KU, Mert GO, Basaran O, et al. Real-world stroke prevention strategies in nonvalvular atrial fibrillation in patients with renal impairment. Eur J Clin Invest 2017;47(6):428–438. PMID: 28407216. [PubMed: 28407216]
  191. Michel J, Mundell D, Boga T, et al. Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data. Heart Lung Circ 2013;22(1):50–5. PMID: 23058974. [PubMed: 23058974]
  192. Miyamoto K, Aiba T, Arihiro S, et al. Impact of renal function deterioration on adverse events during anticoagulation therapy using non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Heart Vessels 2016;31(8):1327–36. PMID: 26276272. [PubMed: 26276272]
  193. Moon J, Lee HJ, Kim YJ, et al. Short stature and ischemic stroke in nonvalvular atrial fibrillation: new insight into the old observation. Int J Cardiol 2014;174(3):541–4. PMID: 24814538. [PubMed: 24814538]
  194. Moroni F, Masotti L, Vannucchi V, et al. Confidence in the Use of Direct Oral Anticoagulants in the Acute Phase of Nonvalvular Atrial Fibrillation-Related Ischemic Stroke Over the Years: A Real-World Single-Center Study. J Stroke Cerebrovasc Dis 2018;27(1):76–82. Digital Object Identifier: 10.1016/j.jstrokecerebrovasdis.2017.08.001. PMID: 28918086. [PubMed: 28918086] [CrossRef]
  195. Murarka S, Lazkani M, Moualla S, et al. Left atrial anatomy and patient-related factors associated with adverse outcomes with the watchman device-a real world experience. J Interv Cardiol 2017;30(2):163–169. PMID: 28256020. [PubMed: 28256020]
  196. Naderi S, Wang Y, Miller AL, et al. The impact of age on the epidemiology of atrial fibrillation hospitalizations. Am J Med 2014;127(2):158.e1–7. PMID: 24332722. [PMC free article: PMC4436031] [PubMed: 24332722]
  197. Nagarakanti R, Wallentin L, Noack H, et al. Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). Am J Cardiol 2015;116(8):1204–9. PMID: 26282726. [PubMed: 26282726]
  198. Nakagawa K, Hirai T, Ohara K, et al. Impact of persistent smoking on long-term outcomes in patients with nonvalvular atrial fibrillation. J Cardiol 2015;65(5):429–33. PMID: 25129639. [PubMed: 25129639]
  199. Nar G, Inci S, Aksan G, et al. The Relationships between Atrial Electromechanical Delay and CHA2DS2-VASc Score in Patients Diagnosed with Paroxysmal AF. Echocardiography 2015;32(9):1359–66. PMID: 25470534. [PubMed: 25470534]
  200. Naruse Y, Sato A, Hoshi T, et al. Triple antithrombotic therapy is the independent predictor for the occurrence of major bleeding complications: analysis of percent time in therapeutic range. Circ Cardiovasc Interv 2013;6(4):444–51. PMID: 23941857. [PubMed: 23941857]
  201. Navar-Boggan AM, Rymer JA, Piccini JP, et al. Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke. Am Heart J 2015;169(1):39–44.e2. PMID: 25497246. [PubMed: 25497246]
  202. Nelson WW, Laliberté F, Patel AA, et al. Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk. Current Medical Research and Opinion 2017;33(4):631–638. [PubMed: 28008771]
  203. Nelson WW, Wang L, Baser O, et al. Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. Int J Clin Pharm 2015;37(1):53–9. PMID: 25428444. [PMC free article: PMC4312387] [PubMed: 25428444]
  204. Nielsen PB, Larsen TB and Lip GY. Recalibration of the HAS-BLED Score: Should Hemorrhagic Stroke Account for One or Two Points?. Chest 2016;149(2):311–4. PMID: 26356508. [PubMed: 26356508]
  205. Nielsen PB, Larsen TB, Skjoth F, et al. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. Circulation 2015;132(6):517–25. PMID: 26059010. [PubMed: 26059010]
  206. Ntaios G, Vemmou A, Koroboki E, et al. The type of atrial fibrillation is associated with long-term outcome in patients with acute ischemic stroke. Int J Cardiol 2013;167(4):1519–23. PMID: 22609009. [PubMed: 22609009]
  207. Numa S, Hirai T, Nakagawa K, et al. Hyperuricemia and transesophageal echocardiographic thromboembolic risk in patients with atrial fibrillation at clinically low-intermediate risk. Circ J 2014;78(7):1600–5. PMID: 24805815. [PubMed: 24805815]
  208. Ogawa S, Ikeda T, Kitazono T, et al. Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation: insights from the Rivaroxaban Postmarketing Surveillance Registry. J Stroke Cerebrovasc Dis 2014;23(10):2520–6. PMID: 25245483. [PubMed: 25245483]
  209. Ogino Y, Ishikawa T, Ishigami T, et al. Characteristics and prognosis of pacemaker-identified new-onset atrial fibrillation in Japanese people. Circulation Journal 2017;81(6):794–798. [PubMed: 28250283]
  210. Ohgushi A, Ohtani T, Nakayama N, et al. Risk of major bleeding at different PT-INR ranges in elderly Japanese patients with non-valvular atrial fibrillation receiving warfarin: a nested case-control study. J Pharm Health Care Sci 2016;2:2. PMID: 26819747. [PMC free article: PMC4729034] [PubMed: 26819747]
  211. Okura H, Kataoka T, Yoshiyama M, et al. Aortic atherosclerotic plaque and long-term prognosis in patients with atrial fibrillation-a transesophageal echocardiography study. Circ J 2013;77(1):68–72. PMID: 23047295. [PubMed: 23047295]
  212. Olesen JB, Sorensen R, Hansen ML, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace 2015;17(2):187–93. PMID: 25236181. [PubMed: 25236181]
  213. Overvad TF, Rasmussen LH, Skjoth F, et al. Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation. The prospective Danish Diet, Cancer and Health study. Thromb Haemost 2014;112(4):789–95. PMID: 25055988. [PubMed: 25055988]
  214. Overvad TF, Skjoth F, Lip GY, et al. Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide Cohort Study. Stroke 2015;46(8):2168–74. PMID: 26152296. [PubMed: 26152296]
  215. Owada S, Tomita H, Kinjo T, et al. CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough. Thromb Res 2015;135(1):62–7. PMID: 25466835. [PubMed: 25466835]
  216. Pang H, Han B, Fu Q, et al. Severity of Hypertension Correlates with Risk of Thromboembolic Stroke. J Cardiovasc Transl Res 2017. PMID: 28567670. [PubMed: 28567670]
  217. Park YK, Lee MJ, Kim JH, et al. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation. J Stroke Cerebrovasc Dis 2017;26(6):1383–1390. PMID: 28412319. [PubMed: 28412319]
  218. Pastori D, Farcomeni A, Poli D, et al. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. Intern Emerg Med 2016;11(2):199–204. PMID: 26471883. [PubMed: 26471883]
  219. Pastori D, Pignatelli P, Angelico F, et al. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors. Chest 2015;147(6):1644–1650. PMID: 25429521. [PubMed: 25429521]
  220. Patel AA, Lennert B, Macomson B, et al. Anticoagulant use for prevention of stroke in a commercial population with atrial fibrillation. Am Health Drug Benefits 2012;5(5):291–8. PMID: 24991327. [PMC free article: PMC4046452] [PubMed: 24991327]
  221. Perino AC, Fan J, Schmitt SK, et al. Treating Specialty and Outcomes in Newly Diagnosed Atrial Fibrillation: From the TREAT-AF Study. J Am Coll Cardiol 2017;70(1):78–86. Digital Object Identifier: 10.1016/j.jacc.2017.04.054. PMID: 28662810. [PMC free article: PMC5830104] [PubMed: 28662810] [CrossRef]
  222. Philippart R, Brunet-Bernard A, Clementy N, et al. Prognostic value of CHA2DS2-VASc score in patients with ‘non-valvular atrial fibrillation’ and valvular heart disease: the Loire Valley Atrial Fibrillation Project. Eur Heart J 2015;36(28):1822–30. PMID: 25994754. [PubMed: 25994754]
  223. Piccini JP, Hammill BG, Sinner MF, et al. Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. Eur Heart J 2014;35(4):250–6. PMID: 24282186. [PMC free article: PMC3896863] [PubMed: 24282186]
  224. Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation 2016;133(4):352–60. PMID: 26673560. [PubMed: 26673560]
  225. Pisters R, van Vugt SPG, Brouwer MA, et al. Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. Neth Heart J 2017;25(10):551–558. Digital Object Identifier: 10.1007/s12471-017-1009-9. PMID: 28674871. [PMC free article: PMC5612862] [PubMed: 28674871] [CrossRef]
  226. Plicht B, Konorza TF, Kahlert P, et al. Risk factors for thrombus formation on the Amplatzer Cardiac Plug after left atrial appendage occlusion. JACC Cardiovasc Interv 2013;6(6):606–13. PMID: 23787233. [PubMed: 23787233]
  227. Poli L, Grassi M, Zedde M, et al. Anticoagulants Resumption after Warfarin-Related Intracerebral Haemorrhage: The Multicenter Study on Cerebral Hemorrhage in Italy (MUCH-Italy). Thromb Haemost 2018. Digital Object Identifier: 10.1055/s-0038-1627454. PMID: 29433151. [PubMed: 29433151] [CrossRef]
  228. Polovina M, Dikic D, Vlajkovic A, et al. Adverse cardiovascular outcomes in atrial fibrillation: Validation of the new 2MACE risk score. Int J Cardiol 2017;249:191–197. Digital Object Identifier: 10.1016/j.ijcard.2017.09.154. PMID: 28986061. [PubMed: 28986061] [CrossRef]
  229. Potpara TS, Stankovic GR, Beleslin BD, et al. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study. Chest 2012;141(2):339–347. PMID: 21622553. [PubMed: 21622553]
  230. Procter NE, Ball J, Heresztyn T, et al. Subtle renal dysfunction and bleeding risk in atrial fibrillation: symmetric dimethylarginine predicts HAS-BLED score. Am J Cardiovasc Dis 2015;5(2):101–9. PMID: 26309773. [PMC free article: PMC4539096] [PubMed: 26309773]
  231. Proietti M and Lip GY. Geographical differences in thromboembolic and bleeding risks in patients with non-valvular atrial fibrillation: An ancillary analysis from the SPORTIF trials. Int J Cardiol 2017;236:244–248. PMID: 28284508. [PubMed: 28284508]
  232. Proietti M, Lane DA and Lip GY. Relation of the SAMe-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials. Int J Cardiol 2016;216:168–72. PMID: 27156060. [PubMed: 27156060]
  233. Proietti M, Romiti GF, Olshansky B, et al. Systolic Blood Pressure Visit-to-Visit Variability and Major Adverse Outcomes in Atrial Fibrillation: The AFFIRM Study (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). Hypertension 2017;70(5):949–958. Digital Object Identifier: 10.1161/hypertensionaha.117.10106. PMID: 28974568. [PubMed: 28974568] [CrossRef]
  234. Qin D, Leef G, Alam MB, et al. Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation. J Cardiol 2016;67(5):471–6. PMID: 26233885. [PubMed: 26233885]
  235. Qureshi W, Mittal C, Patsias I, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol 2014;113(4):662–8. PMID: 24355310. [PubMed: 24355310]
  236. Radwan HI. Relation between left atrial measurements and thromboembolic risk markers assessed by echocardiography in patients with nonvalvular atrial fibrillation: A cross-sectional study. Egyptian Heart Journal 2017;69(1):1–11. [PMC free article: PMC5839420] [PubMed: 29622949]
  237. Rao MP, Halvorsen S, Wojdyla D, et al. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. J Am Heart Assoc 2015;4(12). PMID: 26627878. [PMC free article: PMC4845276] [PubMed: 26627878]
  238. Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014;63(4):321–8. PMID: 24076487. [PubMed: 24076487]
  239. Reinecke H, Nabauer M, Gerth A, et al. Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. Kidney Int 2015;87(1):200–9. PMID: 24897032. [PubMed: 24897032]
  240. Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, et al. Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA2DS2-VASc and HAS-BLED. American Heart Journal 2018;197:27–34. Digital Object Identifier: 10.1016/j.ahj.2017.11.004. [PubMed: 29447781] [CrossRef]
  241. Rizos T, Wagner A, Jenetzky E, et al. Paroxysmal atrial fibrillation is more prevalent than persistent atrial fibrillation in acute stroke and transient ischemic attack patients. Cerebrovasc Dis 2011;32(3):276–82. PMID: 21893980. [PubMed: 21893980]
  242. Roldan V, Rivera-Caravaca JM, Shantsila A, et al. Enhancing the ‘real world’ prediction of cardiovascular events and major bleeding with the CHA2DS2-VASc and HAS-BLED scores using multiple biomarkers. Ann Med 2017;1–9. Digital Object Identifier: 10.1080/07853890.2017.1378429. PMID: 28892413. [PubMed: 28892413] [CrossRef]
  243. Roldan V, Vilchez JA, Manzano-Fernandez S, et al. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation. Stroke 2014;45(3):696–701. PMID: 24519407. [PubMed: 24519407]
  244. Sandhu RK, Bakal JA, Ezekowitz JA, et al. Risk stratification schemes, anticoagulation use and outcomes: the risk-treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. Heart 2011;97(24):2046–50. PMID: 22076011. [PubMed: 22076011]
  245. Santoro G, Meucci F, Stolcova M, et al. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. EuroIntervention 2016;11(10):1188–94. PMID: 25354761. [PubMed: 25354761]
  246. Saw J, Fahmy P, DeJong P, et al. Cardiac CT angiography for device surveillance after endovascular left atrial appendage closure. Eur Heart J Cardiovasc Imaging 2015;16(11):1198–206. PMID: 25851318. [PMC free article: PMC4609159] [PubMed: 25851318]
  247. Schill MR, Sinn LA, Greenberg JW, et al. A Minimally Invasive Stand-alone Cox-Maze Procedure Is as Effective as Median Sternotomy Approach. Innovations (Phila) 2017;12(3):186–191. PMID: 28549027. [PMC free article: PMC5546149] [PubMed: 28549027]
  248. Schnabel RB, Pecen L, Ojeda FM, et al. Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart 2017;103(13):1024–1030. PMID: 28228467. [PMC free article: PMC5529986] [PubMed: 28228467]
  249. Seeger J, Bothner C, Dahme T, et al. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk. Clin Res Cardiol 2016;105(3):225–9. PMID: 26318322. [PubMed: 26318322]
  250. Seidel A, Parwani AS, Krackhardt F, et al. Safety and efficacy of catheter-based left atrial appendage closure in patients with contraindications for long-term anticoagulation. Minerva Cardioangiol 2017. PMID: 28565887. [PubMed: 28565887]
  251. Senoo K and Lip GY. Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation: The AMADEUS Trial. Stroke 2016;47(2):523–6. PMID: 26628383. [PubMed: 26628383]
  252. Senoo K and Lip GY. Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial. Int J Cardiol 2016;221:379–82. PMID: 27409565. [PubMed: 27409565]
  253. Senoo K and Lip GY. Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: AMADEUS Trial. Stroke 2015;46(11):3202–7. PMID: 26463692. [PubMed: 26463692]
  254. Senoo K, Lip GY, Lane DA, et al. Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation: AMADEUS Trial. Stroke 2015;46(9):2523–8. PMID: 26205373. [PubMed: 26205373]
  255. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014;129(11):1196–203. PMID: 24452752. [PubMed: 24452752]
  256. Shantha GPS, Mentias A, Bhise V, et al. Gender Differences in the Trends of Hospitalizations for Acute Stroke Among Patients With Atrial Fibrillation in the United States: 2005 to 2014. Am J Cardiol 2017;120(9):1541–1548. Digital Object Identifier: 10.1016/j.amjcard.2017.07.044. PMID: 28842143. [PubMed: 28842143] [CrossRef]
  257. Shen JI, Montez-Rath ME, Lenihan CR, et al. Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. Am J Kidney Dis 2015;66(4):677–88. PMID: 26162653. [PMC free article: PMC4584203] [PubMed: 26162653]
  258. Shibazaki K, Kimura K, Aoki J, et al. Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci 2013;331(1-2):90–3. PMID: 23743245. [PubMed: 23743245]
  259. Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J 2014;167(6):810–7. PMID: 24890529. [PMC free article: PMC5381802] [PubMed: 24890529]
  260. Shrestha S, Baser O and Kwong WJ. Effect of Renal Function on Dosing of Non–Vitamin K Antagonist Direct Oral Anticoagulants Among Patients With Nonvalvular Atrial Fibrillation. Annals of Pharmacotherapy 2018;52(2):147–153. Digital Object Identifier: 10.1177/1060028017728295. [PubMed: 28856898] [CrossRef]
  261. Shroff GR, Solid CA and Herzog CA. Atrial fibrillation, stroke, and anticoagulation in Medicare beneficiaries: trends by age, sex, and race, 1992-2010. J Am Heart Assoc 2014;3(3):e000756. PMID: 24895161. [PMC free article: PMC4309061] [PubMed: 24895161]
  262. Shroff GR, Solid CA, Bloomgarden Z, et al. Temporal trends in ischemic stroke and anticoagulation therapy for non-valvular atrial fibrillation: effect of diabetes. J Diabetes 2017;9(2):115–122. PMID: 26929264. [PubMed: 26929264]
  263. Sievert H, Rasekh A, Bartus K, et al. Left Atrial Appendage Ligation in Nonvalvular Atrial Fibrillation Patients at High Risk for Embolic Events with Ineligibility for Oral Anticoagulation Initial Report of Clinical Outcomes. JACC: Clinical Electrophysiology 2015;1(6):465–474. [PubMed: 29759399]
  264. Silberberg A, Tan MK, Yan AT, et al. Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation: From the Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation (FREEDOM AF) and Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation (CONNECT AF). Am J Cardiol 2017;120(4):582–587. Digital Object Identifier: 10.1016/j.amjcard.2017.05.027. PMID: 28666577. [PubMed: 28666577] [CrossRef]
  265. Singer AJ, Quinn A, Dasgupta N, et al. Management and Outcomes of Bleeding Events in Patients in the Emergency Department Taking Warfarin or a Non–Vitamin K Antagonist Oral Anticoagulant. Journal of Emergency Medicine 2017;52(1):1–7.e1. [PubMed: 27793500]
  266. Sinigoj P, Malmstrom RE, Vene N, et al. Dabigatran Concentration: Variability and Potential Bleeding Prediction In “Real-Life” Patients With Atrial Fibrillation. Basic Clin Pharmacol Toxicol 2015;117(5):323–9. PMID: 25981948. [PubMed: 25981948]
  267. Sjalander S, Sjalander A, Svensson PJ, et al. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace 2014;16(5):631–8. PMID: 24158253. [PubMed: 24158253]
  268. Skov J, Sidelmann JJ, Bladbjerg EM, et al. Lysability of fibrin clots is a potential new determinant of stroke risk in atrial fibrillation. Thromb Res 2014;134(3):717–22. PMID: 25042725. [PubMed: 25042725]
  269. Sogaard M, Skjoth F, Kjaeldgaard JN, et al. Atrial fibrillation in patients with severe mental disorders and the risk of stroke, fatal thromboembolic events and bleeding: a nationwide cohort study. BMJ Open 2017;7(12):e018209. Digital Object Identifier: 10.1136/bmjopen-2017-018209. PMID: 29217725. [PMC free article: PMC5728273] [PubMed: 29217725] [CrossRef]
  270. Song TJ, Kim J, Lee HS, et al. The frequency of cerebral microbleeds increases with CHADS(2) scores in stroke patients with non-valvular atrial fibrillation. Eur J Neurol 2013;20(3):502–8. PMID: 23057579. [PubMed: 23057579]
  271. Soo Y, Chan N, Leung KT, et al. Age-specific trends of atrial fibrillation-related ischaemic stroke and transient ischaemic attack, anticoagulant use and risk factor profile in Chinese population: a 15-year study. J Neurol Neurosurg Psychiatry 2017. PMID: 28550068. [PubMed: 28550068]
  272. Sorescu AM, Enache T and Guberna S. The prevalence of long-term oral anticoagulation therapy in a cardiology center in Bucharest, Romania. Clujul Medical 2018;91(1):37–41. Digital Object Identifier: 10.15386/cjmed-837. [PMC free article: PMC5808264] [PubMed: 29440949] [CrossRef]
  273. Spivey CA, Liu X, Qiao Y, et al. Economic outcomes of warfarin discontinuation among patients with atrial fibrillation. American Journal of Pharmacy Benefits 2016;8(4):141–148.
  274. Stavrakis S, Stoner JA, Kardokus J, et al. Intermittent vs. Continuous Anticoagulation theRapy in patiEnts with Atrial Fibrillation (iCARE-AF): a randomized pilot study. J Interv Card Electrophysiol 2017;48(1):51–60. PMID: 27696012. [PMC free article: PMC5458416] [PubMed: 27696012]
  275. Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J 2015;36(33):2239–45. PMID: 25971288. [PubMed: 25971288]
  276. Steinberg BA, Hellkamp AS, Lokhnygina Y, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J 2015;36(5):288–96. PMID: 25209598. [PMC free article: PMC4313363] [PubMed: 25209598]
  277. Steinberg BA, Kim S, Fonarow GC, et al. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J 2014;167(5):735–42.e2. PMID: 24766985. [PMC free article: PMC4006943] [PubMed: 24766985]
  278. Steinberg BA, Kim S, Thomas L, et al. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation 2014;129(20):2005–12. PMID: 24682387. [PMC free article: PMC4050636] [PubMed: 24682387]
  279. Stepinska J, Kremis E, Konopka A, et al. Stroke prevention in atrial fibrillation patients in Poland and other European countries: insights from the GARFIELD-AF registry. Kardiol Pol 2016;74(4):362–71. PMID: 26365937. [PubMed: 26365937]
  280. Su HM, Lin TH, Hsu PC, et al. Global left ventricular longitudinal systolic strain as a major predictor of cardiovascular events in patients with atrial fibrillation. Heart 2013;99(21):1588–96. PMID: 24014280. [PubMed: 24014280]
  281. Suarez-Kurtz G and Botton MR. Pharmacogenetics of coumarin anticoagulants in Brazilians. Expert Opin Drug Metab Toxicol 2015;11(1):67–79. PMID: 25345887. [PubMed: 25345887]
  282. Suh DC, Choi JC, Schein J, et al. Factors associated with warfarin discontinuation, including bleeding patterns, in atrial fibrillation patients. Curr Med Res Opin 2013;29(7):761–71. PMID: 23581534. [PubMed: 23581534]
  283. Szczepañska-Szerej A, Wojtan M and Szajnoga B. The international normalized ratio (INR) as seen in a population of patients with atrial fibrillation and cerebral infarction undergoing long-term treatment with vitamin K antagonists. Current Issues in Pharmacy and Medical Sciences 2015;28(4):269–272.
  284. Szymala M, Streb W, Mitrega K, et al. Percutaneous left atrial appendage occlusion procedures in patients with heart failure. Kardiol Pol 2017. PMID: 28612910. [PubMed: 28612910]
  285. Takabayashi K, Hamatani Y, Yamashita Y, et al. Incidence of Stroke or Systemic Embolism in Paroxysmal Versus Sustained Atrial Fibrillation: The Fushimi Atrial Fibrillation Registry. Stroke 2015;46(12):3354–61. PMID: 26514188. [PubMed: 26514188]
  286. Tanaka K, Yamada T, Torii T, et al. Clinical characteristics of atrial fibrillation-related cardioembolic stroke in patients aged 80 years or older. Geriatrics and Gerontology International 2017;17(5):708–713. [PubMed: 27255203]
  287. Tang RB, Xu ZY, Avula UMR, et al. Risk Stratification for Acute Pulmonary Embolism in Patients with Atrial Fibrillation: Role of CHADS 2 Score. Seminars in Thrombosis and Hemostasis 2017;43(8):864–870. Digital Object Identifier: 10.1055/s-0037-1604112. [PubMed: 28750426] [CrossRef]
  288. Tarantini G, D’Amico G, Latib A, et al. Percutaneous left atrial appendage occlusion in patients with atrial fibrillation and left appendage thrombus: feasibility, safety and clinical efficacy. EuroIntervention 2017. Digital Object Identifier: 10.4244/eij-d-17-00777. PMID: 29086706. [PubMed: 29086706] [CrossRef]
  289. Tellor KB, Patel S, Armbruster AL, et al. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital. J Clin Pharm Ther 2015;40(4):447–51. PMID: 26010016. [PubMed: 26010016]
  290. Tellor KB, Wang M, Green MS, et al. Evaluation of Apixaban for the Treatment of Nonvalvular Atrial Fibrillation with Regard to Dosing and Safety in a Community Hospital. Journal of Pharmacy Technology 2017;33(4):140–145. Digital Object Identifier: 10.1177/8755122517706423. [CrossRef]
  291. Tepper PG, Liu X, Hamilton M, et al. Ischemic Stroke in Nonvalvular Atrial Fibrillation at Warfarin Initiation: Assessment via a Large Insurance Database. Stroke 2017;48(6):1487–1494. PMID: 28446621. [PubMed: 28446621]
  292. Teunissen C, Clappers N, Hassink RJ, et al. A decade of atrial fibrillation ablation shifts in patient characteristics and procedural outcomes. Netherlands Heart Journal 2017;25(10):559–566. Digital Object Identifier: 10.1007/s12471-017-1019-7. [PMC free article: PMC5612867] [PubMed: 28718039] [CrossRef]
  293. Tiwari S, Lochen ML, Jacobsen BK, et al. Atrial fibrillation is associated with cognitive decline in stroke-free subjects: the Tromso Study. Eur J Neurol 2017;24(12):1485–1492. Digital Object Identifier: 10.1111/ene.13445. PMID: 28901674. [PubMed: 28901674] [CrossRef]
  294. Tran TH, Nguyen C, Lam T, et al. Bleeding incidence and real-life prescribing practices with dabigatran use in an acute care setting. Consult Pharm 2014;29(11):735–40. PMID: 25369188. [PubMed: 25369188]
  295. Tsivgoulis G, Lioutas VA, Varelas P, et al. Direct oral anticoagulant- vs vitamin K antagonist-related nontraumatic intracerebral hemorrhage. Neurology 2017;89(11):1142–1151. Digital Object Identifier: 10.1212/wnl.0000000000004362. PMID: 28814457. [PubMed: 28814457] [CrossRef]
  296. Uehara M, Funabashi N, Takaoka H, et al. The CHADS2 score is a useful predictor of coronary arteriosclerosis on 320 slice CT and may correlate with prognosis in subjects with atrial fibrillation. Int J Cardiol 2015;179:84–9. PMID: 25464421. [PubMed: 25464421]
  297. Urena M, Rodes-Cabau J, Freixa X, et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol 2013;62(2):96–102. PMID: 23665098. [PubMed: 23665098]
  298. Vanassche T, Lauw MN, Eikelboom JW, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 2015;36(5):281–7a. PMID: 25187524. [PubMed: 25187524]
  299. Vanerio G. International Normalized Ratio Variability: A Measure of Anticoagulation Quality or a Powerful Mortality Predictor. J Stroke Cerebrovasc Dis 2015;24(10):2223–8. PMID: 26232891. [PubMed: 26232891]
  300. Vatan MB, Yilmaz S, Agac MT, et al. Relationship between CHA2DS2-VASc score and atrial electromechanical function in patients with paroxysmal atrial fibrillation: A pilot study. J Cardiol 2015;66(5):382–7. PMID: 25818642. [PubMed: 25818642]
  301. Vene N, Mavri A, Gubensek M, et al. Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation - Data from the Ljubljana Registry. PLoS One 2016;11(6):e0156943. PMID: 27280704. [PMC free article: PMC4900606] [PubMed: 27280704]
  302. Ventrella F, Mastroianni F, Cappello S, et al. Effects of the availability of new oral anticoagulants in patients with non-valvular atrial fibrillation in the real world: The NAIF study. Italian Journal of Medicine 2017;11(2):176–183.
  303. Verdecchia P, Molini G, Bartolini C, et al. Safety of dabigatran in an elderly population: single center experience in Italy. Curr Drug Saf 2015;10(2):165–9. PMID: 25387822. [PubMed: 25387822]
  304. Verdecchia P, Reboldi G, Di Pasquale G, et al. Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). Am J Cardiol 2014;113(4):669–75. PMID: 24359765. [PubMed: 24359765]
  305. Violi F, Davi G, Proietti M, et al. Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study. Thromb Haemost 2016;115(4):856–63. PMID: 26740316. [PubMed: 26740316]
  306. Vora AN, Wang TY, Li S, et al. Selection of Stent Type in Patients With Atrial Fibrillation Presenting With Acute Myocardial Infarction: An Analysis From the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry-Get With the Guidelines. J Am Heart Assoc 2017;6(8). Digital Object Identifier: 10.1161/jaha.116.005280. PMID: 28862960. [PMC free article: PMC5586409] [PubMed: 28862960] [CrossRef]
  307. Wakasugi M, Kazama JJ, Tokumoto A, et al. Association between warfarin use and incidence of ischemic stroke in Japanese hemodialysis patients with chronic sustained atrial fibrillation: a prospective cohort study. Clin Exp Nephrol 2014;18(4):662–9. PMID: 24113782. [PubMed: 24113782]
  308. Wang HJ, Si QJ, Shan ZL, et al. Effects of body mass index on risks for ischemic stroke, thromboembolism, and mortality in Chinese atrial fibrillation patients: a single-center experience. PLoS One 2015;10(4):e0123516. PMID: 25848965. [PMC free article: PMC4388788] [PubMed: 25848965]
  309. Westenbrink BD, Alings M, Connolly SJ, et al. Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial. J Thromb Haemost 2015;13(5):699–707. PMID: 25683276. [PubMed: 25683276]
  310. Wiebe J, Bertog S, Franke J, et al. Safety of percutaneous left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation. Catheter Cardiovasc Interv 2014;83(5):796–802. PMID: 24327462. [PubMed: 24327462]
  311. Williams BA, Evans MA, Honushefsky AM, et al. Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation. J Am Heart Assoc 2017;6(10). Digital Object Identifier: 10.1161/jaha.117.006669. PMID: 29025746. [PMC free article: PMC5721868] [PubMed: 29025746] [CrossRef]
  312. Wolff A, Shantsila E, Lip GY, et al. Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. Age Ageing 2015;44(5):874–8. PMID: 26082176. [PubMed: 26082176]
  313. Wu D, Mansoor G, Kempf C, et al. Renal function, attributes and coagulation treatment in atrial fibrillation (R-FACT Study): retrospective, observational, longitudinal cohort study of renal function and antithrombotic treatment patterns in atrial fibrillation patients with documented eGFR in real-world clinical practices in Germany. Int J Clin Pract 2014;68(6):714–24. PMID: 24499317. [PubMed: 24499317]
  314. Wu S, Yang YM, Zhu J, et al. Impact of age on the association between body mass index and all-cause mortality in patients with atrial fibrillation. Journal of Nutrition, Health and Aging 2016:1–8. [PubMed: 29188871]
  315. Xiong Q, Shantsila A, Lane DA, et al. Sex differences in clinical characteristics and inpatient outcomes among 2442 hospitalized Chinese patients with nonvalvular atrial fibrillation: The Nanchang Atrial Fibrillation Project. Int J Cardiol 2015;201:195–9. PMID: 26298380. [PubMed: 26298380]
  316. Yaghi S, Sherzai A, Pilot M, et al. The CHADS2 Components Are Associated with Stroke-Related In-hospital Mortality in Patients with Atrial Fibrillation. J Stroke Cerebrovasc Dis 2015;24(10):2404–7. PMID: 26231476. [PubMed: 26231476]
  317. Yang Q, Churilov L, Fan D, et al. 1.4 times increase in atrial fibrillation-related ischemic stroke and TIA over 12 years in a stroke center. Journal of the Neurological Sciences 2017;379:1–6. [PubMed: 28716216]
  318. Yang YJ, Yuan JQ, Fan CM, et al. Incidence of ischemic stroke and systemic embolism in patients with hypertrophic cardiomyopathy, nonvalvular atrial fibrillation, CHA2DS2-VASc score of </=1 and without anticoagulant therapy. Heart Vessels 2016;31(7):1148–53. PMID: 26231425. [PubMed: 26231425]
  319. Yap LB, Rusani BI, Umadevan D, et al. A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation. J Thromb Thrombolysis 2014;38(1):39–44. PMID: 24197653. [PubMed: 24197653]
  320. Yaranov DM, Smyrlis A, Usatii N, et al. Effect of obstructive sleep apnea on frequency of stroke in patients with atrial fibrillation. Am J Cardiol 2015;115(4):461–5. PMID: 25529543. [PubMed: 25529543]
  321. Yodogawa K, Mii A, Fukui M, et al. Warfarin use and incidence of stroke in Japanese hemodialysis patients with atrial fibrillation. Heart Vessels 2016;31(10):1676–80. PMID: 26646256. [PubMed: 26646256]
  322. Yu AY, Malo S, Wilton S, et al. Anticoagulation and population risk of stroke and death in incident atrial fibrillation: a population-based cohort study. CMAJ Open 2016;4(1):E1–6. PMID: 27280108. [PMC free article: PMC4866920] [PubMed: 27280108]
  323. Yu GI, Cho KI, Kim HS, et al. Association between the N-terminal plasma brain natriuretic peptide levels or elevated left ventricular filling pressure and thromboembolic risk in patients with non-valvular atrial fibrillation. J Cardiol 2016;68(2):110–6. PMID: 26775889. [PubMed: 26775889]
  324. Zubaid M, Rashed WA, Alsheikh-Ali AA, et al. Management and 1-year outcomes of patients with atrial fibrillation in the Middle East: Gulf survey of atrial fibrillation events. Angiology 2015;66(5):464–71. PMID: 24904179. [PubMed: 24904179]

No outcomes of interest-2017

  1. Al-Kassou B and Omran H. Comparison of the Feasibility and Safety of First- versus Second-Generation AMPLATZER™ Occluders for Left Atrial Appendage Closure. BioMed Research International 2017;2017. Digital Object Identifier: 10.1155/2017/1519362. [PMC free article: PMC5632477] [PubMed: 29085833] [CrossRef]
  2. Akdag S, Simsek H, Sahin M, et al. Association of epicardial adipose tissue thickness and inflammation parameters with CHA2DS2-VASASc score in patients with nonvalvular atrial fibrillation. Therapeutics and Clinical Risk Management 2015;11:1675–1681. [PMC free article: PMC4644180] [PubMed: 26609234]
  3. Andrade JG, Krahn AD, Skanes AC, et al. Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. Can J Cardiol 2016;32(6):747–53. PMID: 26774235. [PubMed: 26774235]
  4. Antonenko K, Paciaroni M, Agnelli G, et al. Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: Results from the RAF-study (Early Recurrence and Cerebral Bleeding in Patients with Acute Ischemic Stroke and Atrial Fibrillation). European Stroke Journal 2017;2(1):46–53. [PMC free article: PMC6377059] [PubMed: 30886901]
  5. Azarbal F, Stefanick ML, Assimes TL, et al. Lean body mass and risk of incident atrial fibrillation in post-menopausal women. European Heart Journal 2016;37(20):1606–1613. [PMC free article: PMC4875559] [PubMed: 26371115]
  6. Basaran O, Beton O, Dogan V, et al. ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study). Anatol J Cardiol 2016;16(10):734–741. PMID: 27723665. [PMC free article: PMC5324932] [PubMed: 27723665]
  7. Bernaitis N, Ching CK, Badrick T, et al. Identifying Warfarin Control With Stroke and Bleed Risk Scores. Heart Lung Circ 2017. Digital Object Identifier: 10.1016/j.hlc.2017.11.009. PMID: 29233496. [PubMed: 29233496] [CrossRef]
  8. Bernaitis N, Ching CK, Chen L, et al. The Sex, Age, Medical History, Treatment, Tobacco Use, Race Risk (SAMe TT2R2) Score Predicts Warfarin Control in a Singaporean Population. J Stroke Cerebrovasc Dis 2017;26(1):64–69. PMID: 27671097. [PubMed: 27671097]
  9. Bertaglia E, Anselmino M, Zorzi A, et al. NOACs and atrial fibrillation: Incidence and predictors of left atrial thrombus in the real world. International Journal of Cardiology 2017;249:179–183. Digital Object Identifier: 10.1016/j.ijcard.2017.07.048. [PubMed: 29121724] [CrossRef]
  10. Biteker M, Basaran O, Dogan V, et al. Real-World Clinical Characteristics and Treatment Patterns of Individuals Aged 80 and Older with Nonvalvular Atrial Fibrillation: Results from the ReAl-life Multicenter Survey Evaluating Stroke Study. J Am Geriatr Soc 2017. PMID: 28394435. [PubMed: 28394435]
  11. Bohm M, Ezekowitz MD, Connolly SJ, et al. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol 2015;65(23):2481–93. Digital Object Identifier: 10.1016/j.jacc.2015.03.577. PMID: 26065986. [PubMed: 26065986] [CrossRef]
  12. Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart 2017;103(4):307–314. PMID: 27647168. [PMC free article: PMC5293840] [PubMed: 27647168]
  13. Cha MJ, Kim YD, Nam HS, et al. Stroke mechanism in patients with non-valvular atrial fibrillation according to the CHADS2 and CHA2 DS2 -VASc scores. Eur J Neurol 2012;19(3):473–9. PMID: 21972975. [PubMed: 21972975]
  14. Chapa DW, Akintade B, Schron E, et al. Is health-related quality of life a predictor of hospitalization or mortality among women or men with atrial fibrillation?. J Cardiovasc Nurs 2014;29(6):555–64. PMID: 24165699. [PubMed: 24165699]
  15. Chen YY, Liu Q, Liu L, et al. Effect of Metabolic Syndrome on Risk Stratification for Left Atrial or Left Atrial Appendage Thrombus Formation in Patients with Nonvalvular Atrial Fibrillation. Chin Med J (Engl) 2016;129(20):2395–2402. PMID: 27748329. [PMC free article: PMC5072249] [PubMed: 27748329]
  16. Clemens A, Peng S, Brand S, et al. Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups. Am J Cardiol 2014;114(6):849–55. PMID: 25103918. [PubMed: 25103918]
  17. Collings SL, Lefevre C, Johnson ME, et al. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany. PLoS One 2017;12(10):e0185642. Digital Object Identifier: 10.1371/journal.pone.0185642. PMID: 29016695. [PMC free article: PMC5634552] [PubMed: 29016695] [CrossRef]
  18. Daoud EG, Glotzer TV, Wyse DG, et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm 2011;8(9):1416–23. PMID: 21699833. [PubMed: 21699833]
  19. Deguchi I, Tanahashi N and Takao M. Timing of Treatment Initiation With Oral Anticoagulants for Acute Ischemic Stroke in Patients With Nonvalvular Atrial Fibrillation. Circ J 2017;81(2):180–184. PMID: 27980235. [PubMed: 27980235]
  20. Demir S, Ozdag MF, Kendirli MT, et al. What Do Anticoagulants Say about Microemboli?. J Stroke Cerebrovasc Dis 2015;24(11):2474–7. PMID: 26381781. [PubMed: 26381781]
  21. Disertori M, Lombardi F, Barlera S, et al. Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. Am Heart J 2011;162(2):382–9. PMID: 21835301. [PubMed: 21835301]
  22. Dublin S, Anderson ML, Heckbert SR, et al. Neuropathologic changes associated with atrial fibrillation in a population-based autopsy cohort. J Gerontol A Biol Sci Med Sci 2014;69(5):609–15. PMID: 24077599. [PMC free article: PMC3991149] [PubMed: 24077599]
  23. Dukanovic A, Staerk L, Fosbol EL, et al. Predicted risk of stroke and bleeding and use of oral anticoagulants in atrial fibrillation: Danish nationwide temporal trends 2011-2016. Thromb Res 2017;160:19–26. Digital Object Identifier: 10.1016/j.thromres.2017.10.010. PMID: 29080549. [PubMed: 29080549] [CrossRef]
  24. Durham TA, Hassmiller Lich K, Viera AJ, et al. Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial Fibrillation. Am J Cardiol 2017;120(10):1820–1829. Digital Object Identifier: 10.1016/j.amjcard.2017.07.091. PMID: 28867127. [PubMed: 28867127] [CrossRef]
  25. Eckman MH, Costea A, Attari M, et al. Atrial fibrillation decision support tool: Population perspective. Am Heart J 2017;194:49–60. Digital Object Identifier: 10.1016/j.ahj.2017.08.016. PMID: 29223435. [PMC free article: PMC5726779] [PubMed: 29223435] [CrossRef]
  26. Elbadawi A, Elgendy IY, Ha LD, et al. In-Hospital Cerebrovascular Outcomes of Patients With Atrial Fibrillation and Cancer (from the National Inpatient Sample Database). Am J Cardiol 2018;121(5):590–595. Digital Object Identifier: 10.1016/j.amjcard.2017.11.027. PMID: 29352566. [PubMed: 29352566] [CrossRef]
  27. Fairman KA, Davis LE, Kruse CR, et al. Financial Impact of Direct-Acting Oral Anticoagulants in Medicaid: Budgetary Assessment Based on Number Needed to Treat. Appl Health Econ Health Policy 2017;15(2):203–214. PMID: 27896681. [PubMed: 27896681]
  28. Fauchier L, Bisson A, Clementy N, et al. Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation. American Heart Journal 2018;198:39–45. Digital Object Identifier: 10.1016/j.ahj.2017.12.017. [PubMed: 29653646] [CrossRef]
  29. Fong MK, Sheng B, Chu YP, et al. Atrial fibrillation patients who sustained warfarin-associated intracerebral haemorrhage have poor neurological outcomes: Results from a matched case series. Hong Kong Medical Journal 2017;23(2):117–121. [PubMed: 28232641]
  30. Fumagalli S, Nieuwlaat R, Tarantini F, et al. Characteristics, management and prognosis of elderly patients in the Euro Heart Survey on atrial fibrillation. Aging Clin Exp Res 2012;24(5):517–23. PMID: 22572627. [PubMed: 22572627]
  31. Gilligan AM, Gandhi P, Song X, et al. All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin. American Journal of Cardiovascular Drugs 2017;17(6):481–492. Digital Object Identifier: 10.1007/s40256-017-0244-1. [PMC free article: PMC5701952] [PubMed: 28795348] [CrossRef]
  32. Giustozzi M, Vedovati MC, Verdecchia P, et al. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life. Eur J Intern Med 2016;33:42–6. PMID: 27394924. [PubMed: 27394924]
  33. Gorczyca-Michta I and Wozakowska-Kaplon B. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience. Kardiol Pol 2015;73(2):85–93. PMID: 25179482. [PubMed: 25179482]
  34. Gorczyca-Michta I, Wozakowska-Kaplon B, Starzyk K, et al. The evaluation of the recommended prevention of thrombosis in hospitalized patients with atrial fibrillation and high thromboembolism risk. Kardiol Pol 2018. Digital Object Identifier: 10.5603/KP.a2017.0241. PMID: 29297187. [PubMed: 29297187] [CrossRef]
  35. Guertin JR, Dorais M, Khairy P, et al. Atrial fibrillation: a real-life observational study in the Quebec population. Can J Cardiol 2011;27(6):794–9. PMID: 21745721. [PubMed: 21745721]
  36. Hanon O, Chaussade E, Gueranger P, et al. Patient-reported treatment satisfaction with rivaroxaban for stroke prevention in atrial fibrillation. A French observational study, the SAFARI study. PLoS ONE 2016;11(12). [PMC free article: PMC5147833] [PubMed: 27935987]
  37. Hong HJ, Kim YD, Cha MJ, et al. Early neurological outcomes according to CHADS2 score in stroke patients with non-valvular atrial fibrillation. Eur J Neurol 2012;19(2):284–90. PMID: 21914056. [PubMed: 21914056]
  38. Hong Y, Yang X, Zhao W, et al. Sex differences in outcomes among stroke survivors with non-valvular atrial fibrillation in China. Frontiers in Neurology 2017;8(APR). [PMC free article: PMC5406396] [PubMed: 28496431]
  39. Huang J, Wu SL, Xue YM, et al. Association of CHADS2 and CHA2DS2-VASc Scores with Left Atrial Thrombus with Nonvalvular Atrial Fibrillation: A Single Center Based Retrospective Study in a Cohort of 2695 Chinese Subjects. Biomed Res Int 2017;2017:6839589. PMID: 28373985. [PMC free article: PMC5360946] [PubMed: 28373985]
  40. Hugo GS, Figueiras-Graillet LM, Anguita M, et al. Oral anticoagulation in octogenarians with atrial fibrillation. Int J Cardiol 2016;223:87–90. PMID: 27532238. [PubMed: 27532238]
  41. Hwang J, Chung JW, Lee MJ, et al. Implications of CHA2DS2-VASc Score in Stroke Patients with Atrial Fibrillation: An Analysis of 938 Korean Patients. European Neurology 2017:307–315. [PubMed: 28456792]
  42. Induruwa I, Evans NR, Aziz A, et al. Clinical frailty is independently associated with non-prescription of anticoagulants in older patients with atrial fibrillation. Geriatr Gerontol Int 2017. PMID: 28418196. [PubMed: 28418196]
  43. Ioannou A, Metaxa S, Kassianos G, et al. Anticoagulation for the prevention of stroke in non-valvular AF in general practice: room for improvement. Drugs Context 2016;5:212295. PMID: 27403193. [PMC free article: PMC4924976] [PubMed: 27403193]
  44. Jeong WK, Choi JH, Son JP, et al. Volume and morphology of left atrial appendage as determinants of stroke subtype in patients with atrial fibrillation. Heart Rhythm 2016;13(4):820–7. PMID: 26707792. [PubMed: 26707792]
  45. Kamel H, Johnson DR, Hegde M, et al. Detection of atrial fibrillation after stroke and the risk of recurrent stroke. J Stroke Cerebrovasc Dis 2012;21(8):726–31. PMID: 21546265. [PubMed: 21546265]
  46. Katz DF, Maddox TM, Turakhia M, et al. Analysis from the national cardiovascular data registry’s outpatient practice innovation and clinical excellence atrial fibrillation registry. Circulation: Cardiovascular Quality and Outcomes 2017;10(5). [PubMed: 28506981]
  47. Katz DF, Maddox TM, Turakhia M, et al. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS2 to the CHA2DS2-VASc Score for Thromboembolic Risk Assessment: Analysis From the National Cardiovascular Data Registry’s Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry. Circ Cardiovasc Qual Outcomes 2017;10(5). PMID: 28506981. [PubMed: 28506981]
  48. Kawabata M, Goya M, Sasaki T, et al. Left Atrial Appendage Thrombi Formation in Japanese Non-Valvular Atrial Fibrillation Patients During Anticoagulation Therapy- Warfarin vs. Direct Oral Anticoagulants. Circ J 2017;81(5):645–651. PMID: 28179613. [PubMed: 28179613]
  49. Kim MN, Kim SA, Choi JI, et al. Improvement of Predictive Value for Thromboembolic Risk by Incorporating Left Atrial Functional Parameters in the CHADS2 and CHA2DS2-VASc Scores. Int Heart J 2015;56(3):286–92. PMID: 25912904. [PubMed: 25912904]
  50. Kocis PT, Liu G, Makenbaeva D, et al. Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation. Drugs - Real World Outcomes 2016;3(2):165–173. [PMC free article: PMC4914537] [PubMed: 27398295]
  51. Komen J, Forslund T, Hjemdahl P, et al. Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs. Eur J Clin Pharmacol 2017;73(10):1315–1322. Digital Object Identifier: 10.1007/s00228-017-2289-0. PMID: 28664360. [PMC free article: PMC5612279] [PubMed: 28664360] [CrossRef]
  52. Kongnakorn T, Lanitis T, Lieven A, et al. Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium. Clin Drug Investig 2014;34(10):709–21. PMID: 25164005. [PubMed: 25164005]
  53. Laliberte F, Cloutier M, Crivera C, et al. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users. Adv Ther 2015;32(3):216–27. PMID: 25784509. [PMC free article: PMC4376962] [PubMed: 25784509]
  54. Laliberte F, Pilon D, Raut MK, et al. Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?. Curr Med Res Opin 2014;30(4):645–53. PMID: 24256067. [PubMed: 24256067]
  55. Laliberte F, Pilon D, Raut MK, et al. Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies. Hosp Pract (1995) 2014;42(3):17–25. PMID: 25255403. [PubMed: 25255403]
  56. Lane DA, Skjøth F, Lip GYH, et al. Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. Journal of the American Heart Association 2017;6(5). [PMC free article: PMC5524079] [PubMed: 28455344]
  57. Lee JM, Seo J, Uhm JS, et al. Why is left atrial appendage morphology related to strokes? an analysis of the flow velocity and orifice size of the left atrial appendage. Journal of Cardiovascular Electrophysiology 2015;26(9):922–927. [PubMed: 25959871]
  58. Lip GYH, Al-Saady N, Ezekowitz MD, et al. The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. Am Heart J 2017;193:16–22. Digital Object Identifier: 10.1016/j.ahj.2017.07.010. PMID: 29129251. [PubMed: 29129251] [CrossRef]
  59. Lip GYH, Lane DA, Buller H, et al. Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study. Chest 2013;144(6):1839–1847. PMID: 24009027. [PubMed: 24009027]
  60. Liu FD, Zhao R, Wang XM, et al. Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai. Chronic Diseases and Translational Medicine 2015;1(4):203–209. [PMC free article: PMC5643732] [PubMed: 29063008]
  61. Lum CJ and Azuma S. A comparison of methods for estimating glomerular filtration rate for a population in Hawai’i with non-valvular atrial fibrillation. Hawaii J Med Public Health 2013;72(9 Suppl 4):27–9. PMID: 24052915. [PMC free article: PMC3764554] [PubMed: 24052915]
  62. Macario E, Schneider YT, Campbell SM, et al. Quality of Life Experiences among Women with Atrial Fibrillation: Findings from an Online Survey. Women’s Health Issues 2016;26(3):288–297. [PubMed: 27094912]
  63. Majeed A, Hwang HG, Connolly SJ, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013;128(21):2325–32. PMID: 24081972. [PubMed: 24081972]
  64. Markl M, Lee DC, Ng J, et al. Left Atrial 4-Dimensional Flow Magnetic Resonance Imaging: Stasis and Velocity Mapping in Patients With Atrial Fibrillation. Invest Radiol 2016;51(3):147–54. PMID: 26488375. [PMC free article: PMC4742429] [PubMed: 26488375]
  65. Maruyama K, Uchiyama S, Shiga T, et al. Brain Natriuretic Peptide Is a Powerful Predictor of Outcome in Stroke Patients with Atrial Fibrillation. Cerebrovasc Dis Extra 2017;7(1):35–43. PMID: 28253498. [PMC free article: PMC5465753] [PubMed: 28253498]
  66. Mascioli G, Lucca E, Michelotti F, et al. Severe Spontaneous Echo Contrast/Auricolar Thrombosis in “Nonvalvular” AF: Value of Thromboembolic Risk Scores. Pacing Clin Electrophysiol 2017;40(1):57–62. PMID: 27730663. [PubMed: 27730663]
  67. Micieli A, Wijeysundera HC, Qiu F, et al. A Decision Analysis of Percutaneous Left Atrial Appendage Occlusion Relative to Novel and Traditional Oral Anticoagulation for Stroke Prevention in Patients with New-Onset Atrial Fibrillation. Med Decis Making 2016;36(3):366–74. PMID: 26139448. [PubMed: 26139448]
  68. Mochalina N, Joud A, Carlsson M, et al. Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: A population-based cohort study. Thromb Res 2016;140:94–9. PMID: 26938155. [PubMed: 26938155]
  69. Mohammed S, Aljundi AH, Kasem M, et al. Anticoagulation control among patients with nonvalvular atrial fibrillation: A single tertiary cardiac center experience. J Adv Pharm Technol Res 2017;8(1):14–18. PMID: 28217549. [PMC free article: PMC5288964] [PubMed: 28217549]
  70. Moreno-Arribas J, Bertomeu-Gonzalez V, Anguita-Sanchez M, et al. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study. J Cardiovasc Pharmacol Ther 2016;21(2):150–6. PMID: 26229096. [PubMed: 26229096]
  71. Murin J, Naditch-Brule L, Brette S, et al. Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey. PLoS One 2014;9(1):e86443. PMID: 24497948. [PMC free article: PMC3908888] [PubMed: 24497948]
  72. Nelson WW, Desai S, Damaraju CV, et al. International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation. Am J Cardiovasc Drugs 2015;15(3):205–11. PMID: 25944648. [PMC free article: PMC4451756] [PubMed: 25944648]
  73. Nieuwlaat R, Connolly BJ, Hubers LM, et al. Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study. Thromb Res 2012;129(6):715–9. PMID: 21924760. [PubMed: 21924760]
  74. Olesen JB, SØrensen R, Hansen ML, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace 2014;17(2):187–193. [PubMed: 25236181]
  75. Ono K, Iwama M, Kawasaki M, et al. Motion of left atrial appendage as a determinant of thrombus formation in patients with a low CHADS2 score receiving warfarin for persistent nonvalvular atrial fibrillation. Cardiovasc Ultrasound 2012;10:50. PMID: 23270370. [PMC free article: PMC3538692] [PubMed: 23270370]
  76. Pandya EY, Anderson E, Chow C, et al. Contemporary utilization of antithrombotic therapy for stroke prevention in patients with atrial fibrillation: an audit in an Australian hospital setting. Ther Adv Drug Saf 2018;9(2):97–111. Digital Object Identifier: 10.1177/2042098617744926. PMID: 29387335. [PMC free article: PMC5772521] [PubMed: 29387335] [CrossRef]
  77. Pasca S, Venturelli U, Bertone A, et al. Direct Oral Anticoagulants for Very Elderly People With Atrial Fibrillation: Efficacy and Safe Enough?. Clin Appl Thromb Hemost 2017;23(1):58–63. PMID: 26620417. [PubMed: 26620417]
  78. Politi C, Ciarambino T, Riva L, et al. Sex-gender and atrial fibrillation treatment in the AntiThrombotic Agents in Atrial Fibrillation (ATA-AF) study. Italian Journal of Medicine 2016;10(3):207–212.
  79. Poppe KK, Doughty RN, Harwood M, et al. Identification, risk assessment, and management of patients with atrial fibrillation in a large primary care cohort. Int J Cardiol 2018;254:119–124. Digital Object Identifier: 10.1016/j.ijcard.2017.11.045. PMID: 29407079. [PubMed: 29407079] [CrossRef]
  80. Potpara TS, Polovina MM, Licina MM, et al. Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade Atrial Fibrillation Study. Eur J Heart Fail 2013;15(4):415–24. PMID: 23302606. [PubMed: 23302606]
  81. Ricci RP, Vaccari D, Morichelli L, et al. Stroke incidence in patients with cardiac implantable electronic devices remotely controlled with automatic alerts of atrial fibrillation. A sub-Analysis of the HomeGuide study. International Journal of Cardiology 2016;219:251–256. [PubMed: 27340918]
  82. Rivera-Caravaca JM, Marin F, Esteve-Pastor MA, et al. Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. Am J Cardiol 2017;120(12):2176–2181. Digital Object Identifier: 10.1016/j.amjcard.2017.09.003. PMID: 29111209. [PubMed: 29111209] [CrossRef]
  83. Roldan V, Marin F, Manzano-Fernandez S, et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 2013;62(23):2199–204. PMID: 24055744. [PubMed: 24055744]
  84. Saito T, Kawamura Y, Sato N, et al. Non-vitamin k antagonist oral anticoagulants do not increase cerebral microbleeds. J Stroke Cerebrovasc Dis 2015;24(6):1373–7. PMID: 25847305. [PubMed: 25847305]
  85. Saliba W and Rennert G. CHA2DS2-VASc score is directly associated with the risk of pulmonary embolism in patients with atrial fibrillation. Am J Med 2014;127(1):45–52. PMID: 24384101. [PubMed: 24384101]
  86. Saw J, Bennell MC, Singh SM, et al. Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Patients With Contraindications to Anticoagulation. Canadian Journal of Cardiology 2016;32(11):1355. [PubMed: 27432692]
  87. Simons LA, Ortiz M, Freedman B, et al. Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience. Current Medical Research and Opinion 2017;33(7):1337–1341. [PubMed: 28425296]
  88. Soliman EZ, Lopez F, O’Neal WT, et al. Atrial fibrillation and risk of ST-segment-elevation versus non-ST-segment-elevation myocardial infarction the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2015;131(21):1843–1850. [PMC free article: PMC4447576] [PubMed: 25918127]
  89. Steinberg BA, Shrader P, Thomas L, et al. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J 2017;189:40–47. PMID: 28625380. [PubMed: 28625380]
  90. Stevanovic J, Pompen M, Le HH, et al. Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands. PLoS One 2014;9(8):e103974. PMID: 25093723. [PMC free article: PMC4122386] [PubMed: 25093723]
  91. Stortecky S, Buellesfeld L, Wenaweser P, et al. Atrial fibrillation and aortic stenosis: impact on clinical outcomes among patients undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv 2013;6(1):77–84. PMID: 23386662. [PubMed: 23386662]
  92. Thompson LE, Maddox TM, Lei L, et al. Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR((R))) PINNACLE Registry. J Am Heart Assoc 2017;6(7). Digital Object Identifier: 10.1161/jaha.117.005801. PMID: 28724655. [PMC free article: PMC5586299] [PubMed: 28724655] [CrossRef]
  93. Uz O, Atalay M, Doʇan M, et al. The CHA<inf>2</inf>DS<inf>2</inf>-VASc score as a predictor of left atrial thrombus in patients with non-valvular atrial fibrillation. Medical Principles and Practice 2014;23(3):234–238. [PMC free article: PMC5586880] [PubMed: 24751402]
  94. Vedovati MC, Verdecchia P, Giustozzi M, et al. Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation. Int J Cardiol 2017;236:363–369. PMID: 28131705. [PubMed: 28131705]
  95. Verheugt FWA, Gao H, Al Mahmeed W, et al. Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. Eur Heart J 2017. Digital Object Identifier: 10.1093/eurheartj/ehx730. PMID: 29281086. [PubMed: 29281086] [CrossRef]
  96. Vidal-Perez R, Otero-Ravina F, Lado-Lopez M, et al. The change in the atrial fibrillation type as a prognosis marker in a community study: long-term data from AFBAR (Atrial Fibrillation in the BARbanza) study. Int J Cardiol 2013;168(3):2146–52. PMID: 23452888. [PubMed: 23452888]
  97. Vlacho B, Giner-Soriano M, Zabaleta-del-Olmo E, et al. Dabigatran and vitamin K antagonists’ use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records. European Journal of Clinical Pharmacology 2017;73(10):1323–1330. Digital Object Identifier: 10.1007/s00228-017-2305-4. [PubMed: 28725983] [CrossRef]
  98. Wang SV, Rogers JR, Jin Y, et al. Use of electronic healthcare records to identify complex patients with atrial fibrillation for targeted intervention. Journal of the American Medical Informatics Association 2017;24(2):339–344. [PMC free article: PMC7651901] [PubMed: 27375290]
  99. Wang Z, Hua Q, Li Y, et al. CHA2DS2-VASc can better predict short-term prognosis in acute ischemic stroke patients with non-valvular atrial fibrillation. International Journal of Clinical and Experimental Medicine 2016;9(3):6758–6764.
  100. Weijs B, Pisters R, Nieuwlaat R, et al. Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort. Europace 2012;14(2):184–90. PMID: 22135317. [PubMed: 22135317]
  101. Wieczorek J, Mizia-Stec K, Lasek-Bal A, et al. CHA2DS2-Vasc score, age and body mass index as the main risk factors of hyperintense brain lesions in asymptomatic patients with paroxysmal non-valvular atrial fibrillation. International Journal of Cardiology 2016;215:476–481. [PubMed: 27131768]
  102. Willens HJ, Gomez-Marin O, Nelson K, et al. Correlation of CHADS2 and CHA2DS2-VASc scores with transesophageal echocardiography risk factors for thromboembolism in a multiethnic United States population with nonvalvular atrial fibrillation. J Am Soc Echocardiogr 2013;26(2):175–84. PMID: 23253435. [PubMed: 23253435]
  103. Yao X, Shah ND, Sangaralingham LR, et al. Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. Journal of the American College of Cardiology 2017;69(23):2779–2790. [PubMed: 28595692]
  104. Yao X, Tangri N, Gersh BJ, et al. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol 2017;70(21):2621–2632. Digital Object Identifier: 10.1016/j.jacc.2017.09.1087. PMID: 29169468. [PubMed: 29169468] [CrossRef]
  105. Yong C, Azarbal F, Abnousi F, et al. Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study). Am J Cardiol 2016;117(1):61–8. PMID: 26552504. [PubMed: 26552504]
  106. Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013;6(5):567–74. PMID: 23922182. [PubMed: 23922182]
  107. Zheng HJ, Ouyang SK, Zhao Y, et al. The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China. International Journal of General Medicine 2017;10:69–77. [PMC free article: PMC5345993] [PubMed: 28293117]

Not Available in English-2012

  1. Hu DY, Zhang HP, Sun YH, et al. [The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin]. Zhonghua Xin Xue Guan Bing Za Zhi. 2006;34(4):295–8. PMID: 16776915. [PubMed: 16776915]
  2. Perez-Ortega I, Moniche-Alvarez F, Dolores Jimenez-Hernandez M, et al. Cardioembolic stroke in atrial fibrillation and new anticoagulation criteria: A therapeutic dare ORIGINAL (NON-ENGLISH) TITLE Ictus cardioembolico por fibrilacion auricular y nuevos criterios de anticoagulacion: Un reto terapeutico. Rev Neurol. 2012;55(2):74–80. PMID: 22760766. [PubMed: 22760766]

Not a Clinical Study-2012

  1. Aalbers J. South Africa’s poor warfarin control raises questions of benefit above other anticoagulant therapies in atrial fibrillation. Cardiovasc J Afr. 2011;22(4):220. PMID: 21881695. [PubMed: 21881695]
  2. Anonymous. Bleeding risk with warfarin is high among elderly. J Fam Pract. 2007;56(9):709. PMID: 17802645. [PubMed: 17802645]
  3. Anonymous. Warfarin prevents more stroke than clopidogrel and aspirin in afib. J Fam Pract. 2006;55(9):753. PMID: 17009433. [PubMed: 17009433]
  4. Anonymous. Warfarin versus aspirin in stroke prevention. Med Today. 2002;3(2):10.
  5. Badar A, Richardson J, Scaife J, et al. Estimation of thromboembolic and bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention for acute coronary syndrome. EuroIntervention. 2010;6.
  6. Banerjee A, Lane DA, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107(3):584–9. PMID: 22186961. [PubMed: 22186961]
  7. Benditt DG, Adabag S, Chen LY. An earnest search for atrial fibrillation patients without thromboembolic risk. J Cardiovasc Electrophysiol. 2012;23(7):714–6. PMID: 22313332. [PubMed: 22313332]
  8. Bouzin M, Cavaco D, Adragao P, et al. Atrial fibrillation ablation with therapeutic INR: A safe strategy. Europace. 2010;12(Suppl.1):i113.
  9. Butler A, Tait RC. Restarting oral anticoagulation after intracranial hemorrhage. Stroke. 2004;35(1):e5–6; author reply e5-6. PMID: 14671234. [PubMed: 14671234]
  10. Ciudici MC, Paul DL, Sloane C, et al. Outpatient atrial Fibrillation ablation on therapeutic warfarin safety, efficacy, and cost savings. Europace. 2010;12:i113.
  11. Crosato M, Calzolari V, Grisolia EF, et al. Perioperative warfarin management in pacing surgery. Europace. 2010;12:i44.
  12. Darby-Stewart A, Dachs R, Graber MA. Rivaroxaban vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Am Fam Physician. 2012;85(6):577–86. PMID: 22534269. [PubMed: 22534269]
  13. DeSilvey DL. Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation: the ACTIVE W trial. Am J Geriatr Cardiol. 2006;15(5):326–7. PMID: 16957455. [PubMed: 16957455]
  14. Di Biase L, Burkhardt JD, Lakkireddy DJ, et al. Catheter ablation of atrial fibrillation under therapeutic coumadin: Prevalence of pericardial effusion comparing paroxysmal and non paroxysmal atrial fibrillation. Eur Heart J. 2011;32:804.
  15. Dufaitre G, Ederhy S, Lang S, et al. Tee-detected left atrial thrombogenic milieu is associated with increased cardiovascular events in patients with non valvular atrial fibrillation. Arch Cardiovasc Dis. 2011;104(4):288.
  16. Eikelboom JW, Quinlan DJ, Connolly SJ, et al. Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation. J Thromb Haemost. 2012;10(5):966–8. PMID: 22360879. [PubMed: 22360879]
  17. Engelbertz C and Reinecke H. Atrial fibrillation and oral anticoagulation in chronic kidney disease. J Atrial Fibrillation. 2012;4(6)74–85.
  18. Fang MC, Singer DE. Risk of intracranial hemorrhage in atrial fibrillation. Cardiol Rev. 2005;22(12):24–8.
  19. Gao F, Zhou YJ, Wang ZJ, et al. Comparison of different antithrombotic regime in patients with atrial fibrillation undergoing drug-eluting stent implantation. EuroIntervention. 2010;6(Supp H).
  20. Gloekler S, Schmid M, Saguner AA, et al. Transcatheter left atrial appendage occlusion in atrial fibrillation: Comparison of non-dedicated versus dedicated amplatzer devices. Eur Heart J. 2011;32:667.
  21. Granger CB, Hanna M and Wallentin L. The authors reply. N Engl J Med. 2012;366(1):89.
  22. Hart RG, Pearce LA, Koudstaal PJ. Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial. Stroke. 2004;35(4):948–51. PMID: 14988571. [PubMed: 14988571]
  23. Hohnloser S, Yusuf S, Eikelboom J, et al. Apixaban in patients with atrial fibrillation and their risk for cardiovascular hospitalization: Insights from the AVERROES trial. Eur Heart J. 2011;32(Suppl.1):671.
  24. Kakar P, Lane D, Lip GY. Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema. Chest. 2006;130(5):1296–9. PMID: 17099002. [PubMed: 17099002]
  25. Kita K, Lyn R, Cortes G, et al. The ARISTOTLE trial: Apixaban versus warfarin in patients with atrial fibrillation. Intervent Cardiol. 2011;3(6):637.
  26. Klein G, Hartung J, Tallone EM, et al. Left atrial appendage occlusion with the watchman-device in patients with atrial fibrillation and warfarin contraindications. Eur Heart J. 2011;32(Suppl.1):556–7.
  27. Lang S, Ederhy S, Dufaitre G, et al. Adding C-reactive protein to the CHADS2 and CHA2DS2-VASc scores improves prediction of cardiovascular events including heart failure in patients with non valvular atrial fibrillation. Eur Heart J. 2011;32(Suppl.1):461.
  28. Lee EH, Kwong WJ, Casciano J, et al. Improving bleeding risk assessment for anticoagulant use in atrial fibrillation. Value Health. 2011;14(3):A37.
  29. Leithauser B, Broemel T, Park JW. Left atrial appendage closure with Amplatzer Cardiac Plug for prevention of stroke in atrial fibrillation: in-vivo imaging. J Cardiovasc Med (Hagerstown). 2011;12(3):209–11. PMID: 20479656. [PubMed: 20479656]
  30. Limantoro I and Pisters R. Peri-procedural antithrombotic bridging and the assessment of the associated risk of major bleeding. Thromb Haemost. 2012;108(1):9–10. PMID: 22688666. [PubMed: 22688666]
  31. Lip GYH, Frison L, Halperin JL, et al. Comparative analysis of the HAS-BLED score with other bleeding risk scores, Using estimates of net reclassification improvement and integrated discrimination improvement. J Am Coll Cardiol. 2011;58(13):1398–9.
  32. Makosch GA, Griffiths A, Meredith T, et al. Catheter ablation of atrial fibrillation whilst taking therapeutic warfarin: A british experience. Heart. 2010;96(Suppl.1):A79–80.
  33. Malo M, Valle S, Izquierdo I, et al. Clinical experience in combined anti-platelet plus anticoagulant therapy in patients with valvular and non valvular atrial fibrillation. Haematologica. 2009;94(Suppl.2):668.
  34. Mant J, Hobbs R, Fletcher K, et al. Is warfarin a safe alternative to aspirin in elderly patients with atrial fibrillation?. Cardiol Rev. 2008;25(7):32–6.
  35. Meyer JP, Gillatt DA, Lush R, et al. Managing the warfarinized urological patient. BJU Int. 2003;92(4):351–4. PMID: 12930417. [PubMed: 12930417]
  36. Mohrs OK, Schraeder R, Petersen SE, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO): planning and follow-up using contrast-enhanced MRI. AJR Am J Roentgenol. 2006;186(2):361–4. PMID: 16423938. [PubMed: 16423938]
  37. Molina CA and Selim MH. The dilemma of resuming anticoagulation after intracranial hemorrhage little evidence facing big fears. Stroke. 2011;42(12):3665–6. PMID: 22052525. [PubMed: 22052525]
  38. Murray RD, Shah A, Jasper SE, et al. Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study. Am Heart J. 2000;139(6):E1–7. PMID: 10827367. [PubMed: 10827367]
  39. Nerella N. A 5-item score predicted risk for warfarin-associated major hemorrhage in patients with atrial fibrillation. Ann Intern Med. 2011;155(10):JC5–13. PMID: 22084360. [PubMed: 22084360]
  40. Nicola Tufano N, Attanasio S, Sessa G, et al. Prevention of thromboembolism in paroxysmal atrial fibrillation: from guidelines to daily practice in an emergency department. Eur J Cardiovasc Prev Rehabil. 2011;18(1):S114.
  41. Ohtsuka T, Ninomiya M, Nonaka T. Resection of fibrillated atrial appendage may mitigate a risk of stroke. Innov Technol Tech Cardiothorac Vasc Surg. 2010;5(3):229.
  42. Ostermayer S, Reschke M, Billinger K, et al. Percutaneous closure of the left atrial appendage. J Interv Cardiol. 2003;16(6):553–6. PMID: 14632953. [PubMed: 14632953]
  43. Park JW, Bethencour A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug for prevention of stroke in atrial fibrillation. EuroIntervention. 2010;6(Suppl.H). [PubMed: 20479656]
  44. Park JW, Bethencour A, Sievert H, et al. Left atrial appendage closure with amplatzer cardiac plug for prevention of stroke in atrial fibrillation. Initial european experience. Eur Heart J. 2010;31(Suppl.1):513.
  45. Park JW, Bethencour A, Sievert H, et al. Left atrial appendage closure with amplatzer cardiac plug for prevention of stroke in atrial fibrillation-initial European experience. Eur Heart J Suppl. 2010;12(Suppl.A):S14.
  46. Peters DC. Association of left atrial fibrosis detected by delayed enhancement magnetic resonance imaging and risk of stroke in patients with atrial fibrillation. J Atrial Fibrillation. 2011;2(6). [PMC free article: PMC5153052] [PubMed: 28496697]
  47. Petrie C. Clopidogrel in atrial fibrillation: Is there any justification now in the era of new anticoagulants?. Am J Cardiol. 2012;110(1):165. PMID: 22704302. [PubMed: 22704302]
  48. Pocnulli D, Hartford M, Karlsson T, et al. The role of the CHADS2 score in acute coronary syndromes very long-term risk of death in patients with and without atrial fibrillation. Europace. 2010;12(Suppl.1):i131.
  49. Poli D, Antonucci E, Di Gennaro L, et al. VKA treatment and bleeding rate of patients aged older than 80 years: Results from a prospective collaborative study. Eur Heart J. 2011;32(Suppl.1):671.
  50. Providencia R. Should we rely on risk assessment by the CHADS(2) score in patients with non-valvular atrial fibrillation undergoing direct current cardioversion?. Am J Cardiol. 2012;110(3):468–9. PMID: 22793001. [PubMed: 22793001]
  51. Romero-Ortuno R and O’Shea D. Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients’ choice. Age Ageing. 2012;41(2):250–4. PMID: 22156597. [PubMed: 22156597]
  52. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635–41. PMID: 20934556. [PubMed: 20934556]
  53. Rutten FH, Van Riet EES, Hollander M, et al. Longterm effects of aspirin and vitamin K antagonists on mortality in patients with atrial fibrillation and heart failure. An observational study. Eur J Heart Fail Suppl. 2011;10(Suppl.1):S120–1.
  54. Sakai T, Kujime S, Moriyama A, et al. Combination therapy with K channel blocker and warfarin in atrial fibrillation might be more effective for prevention of cerebral infarction than with warfarin alone. Europace. 2010;12(Suppl.1):i76.
  55. Salzberg SP, Emmert MY, Gruenenfelder J, et al. Excellent clinical outcome 1 year after left atrial appendage clip occlusion. Eur Heart J. 2010;31(Suppl.1):513.
  56. Sanna T, Di Lazzaro V. Thromboembolic risk management in paroxysmal atrial fibrillation after brain haemorrhage. Int J Stroke. 2011;6(1):92–3. PMID: 21205251. [PubMed: 21205251]
  57. Sawaya FJ, Musallam KM, Arnaout S, et al. Switching patients from warfarin to dabigatran therapy: To RE-LY or not to rely. Int J Cardiol. 2012;154(2):e27–8. PMID: 21624685. [PubMed: 21624685]
  58. Schulman S and Majeed A. The oral thrombin inhibitor dabigatran: Strengths and weaknesses. Semin Thromb Hemost. 2012;38(1):7–15. PMID: 22314598. [PubMed: 22314598]
  59. Schulman S. Resumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage no. Stroke. 2011;42(12):3663–4. PMID: 22052515. [PubMed: 22052515]
  60. Smit MD, Van Gelder IC. Risk-benefit ratio assessment for stroke prevention in intermediate risk atrial fibrillation patients: will TEE-based aspirin treatment fill the gap?. Neth Heart J. 2011;19(5):212–3. PMID: 21487742. [PMC free article: PMC3087023] [PubMed: 21487742]
  61. Smoyer-Tomic K, Sander S, Siu K, et al. Anticoagulant use, the prevalence of bridging and relation to length of stay among hospitalized patients with non-valvular atrial fibrillation. Value Health. 2011;14(3):A49. [PMC free article: PMC3713944] [PubMed: 23006024]
  62. Spyropoulos AC, Douketis J, Kaatz S, et al. Bridging anticoagulation in patients who require temporary interruption of warfarin for elective surger or procedure-the BRIDGE trial: Design, rationale and clinical implications. Blood. 2011;118(21):A4327.
  63. Steiner T. Resumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage yes. Stroke. 2011;42(12):3661–2. PMID: 22052514. [PubMed: 22052514]
  64. Testa L, Agnifili M, Latini RA, et al. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM. 2012;105(10):949–57. PMID: 22771555. [PubMed: 22771555]
  65. Vassiliou VS. Apixaban versus warfarin in Atrial Fibrillation [1]. N Engl J Med. 2012;366(1):88; author reply 89. PMID: 22216849. [PubMed: 22216849]
  66. Zed PJ, Anthony CJ, Ackroyd-Stolarz S, et al. INTENSITY of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department. Can J Emerg Med. 2010;12(3):272.

Not Original Peer-Reviewed Data/Abstract Only-2012

  1. Abraham JCMM, Wassertheil-Smoller S, Larson J, et al. Stroke risk in post-menopausal women with atrial fibrillation in the women’s health initiative: A validation and comparison of the CHADS2 and CHA2DS2-VASC risk scores. J Am Coll Cardiol. 2012;59(13Suppl.1):E569.
  2. Abu Assi E, Otero Ravina F, Lado A, et al. Validity of the HAS-BLED risk score in a community-based cohort of elderly patients with atrial fibrillation. the AFBAR (Atrial Fibrillation in the BARbanza area) study. Eur Heart J. 2011;32(Suppl.1):463.
  3. Adams C, Ross I, Bainbridge D, et al. The immediate and long term effectiveness of surgical ligation of the left atrial appendage in patients undergoing cardiac surgery. Can J Cardiol. 2010;26(Suppl.D):101D.
  4. Alexander JH, Lopes R, McMurray J, et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in atrial fibrillation in patients taking concomitant aspirin. J Am Coll Cardiol. 2012;59(13Suppl.1):E1697.
  5. Andersen SS, Raunso J, Schmiegelow M, et al. Combination therapy with warfarin and amiodarone increases risk of bleeding in patients with atrial fibrillation - A nationwide study. Eur Heart J. 2011;32(Suppl.1):672.
  6. Andrey A, Evgeny Z, Aleksey K, et al. Comparison of the catheter ablation vs. rate-control strategy in patients with long-lasting persistent atrial fibrillation: Results of 5 years of follow-up. J Interv Card Electrophysiol. 2012;33(3):345.
  7. Andrey A, Evgeny Z, Maksim R, et al. Long-term outcomes of extremely long-lasting persistent atrial fibrillation ablation. J Interv Card Electrophysiol. 2012;33(3):280–1.
  8. Anonymous. Apixaban superior to warfarin in preventing stroke or systemic embolism. Aust J Pharm. 2012;93(1104):93.
  9. Anonymous. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008;39(6):1901–10. PMID: 18420954. [PubMed: 18420954]
  10. Anonymous. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159(3):340–7e1. PMID: 20211293. [PubMed: 20211293]
  11. Atarashi H, Inoue H, Okumura K, et al. Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation-the J-RHYTHM Registry study design. J Cardiol. 2011;57(1):95–9. PMID: 20934857. [PubMed: 20934857]
  12. Azana Fernandez EH, Da vila Barboza YR and Ribera Casado JM. Acenocoumarol or aspirin for stroke prevention in an elderly population with atrial fibrillation: Complications of treatment. Eur Geriatr Med. 2011;2(Suppl. 1):S80–1.
  13. Baker WL and Phung O. Do differences exist between oral anticoagulants in patients with nonvalvular atrial fibrillation? an adjusted indirect comparison meta-analysis. J Am Coll Cardiol. 2012;59(13 Suppl.1):E597.
  14. Bassiouny M, Saliba W, Rickard J, et al. Use of dabigatran for peri-procedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation: A new paradigm in peri-procedural anticoagulation. Circulation. 2011;124(21):A13128.
  15. Berge E, Sandercock P. Anticoagulants versus antiplatelet agents for acute ischaemic stroke. Cochrane Database Syst Rev. 2002(4):CD003242. PMID: 12519590. [PubMed: 12519590]
  16. Biase LD, Santangeli P, Anselmino M, et al. Left atrial appendage morphology and risk of stroke in patients with AF and CHADS2 score 0-1: Is there an association. J Interv Card Electrophysiol. 2012;33(3):288–9.
  17. Blustin JM, McBane RD, Grill DE, et al. The association of thromboembolic complications and blood group in patients with atrial fibrillation. Circulation. 2011;124(21): A12072.
  18. Boersma LVA, Swaans M, Post M, et al. Ablation for atrial fibrillation in combination with left atrial appendage closure in patients with high CHADS2-score or incompatibility with oral anticoagulation. Europace. 2011;13(Suppl.3).
  19. Braut A, Neuzil P, Sick P, et al. LAA closure using a next-generation WATCHMAN LAA closure device. Eur Heart J. 2011;32(Suppl.1):467.
  20. Bunch TJ, Crandall BG, Weiss JP, et al. Pradaxa can be safely used as monotherapy or as a bridge to therapeutic warfarin after atrial fibrillation ablation. Circulation. 2011;124(21):A14708.
  21. Burgess S, Crown N, Louzada ML, et al. Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving oral anticoagulant therapy. Blood. 2011;118(21):2311. [PubMed: 23848301]
  22. Chang CH, Yang YHK and Lin LJ. Effectiveness of warfarin among atrial fibrillation patients in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20(Suppl.1):S21.
  23. Chang KC, Ko PY, Sung FC, et al. Atrial fibrillation is a strong predictor of stroke in young taiwanese adults. Circulation. 2011;124(21):A12835.
  24. Connolly S, Yusuf S, Budaj A, et al. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J. 2006;151(6):1187–93. PMID: 16781218. [PubMed: 16781218]
  25. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875–6. PMID: 21047252. [PubMed: 21047252]
  26. Coutts S, Frayne R, Sevick R, et al. Microbleeding on MRI as a marker for hemorrhage after stroke thrombolysis. Stroke. 2002;33(6):1457–8. PMID: 12052973. [PubMed: 12052973]
  27. Cove CL, Cowan AJ, Magnani JW, et al. Distribution of stroke risk factors among trial participants and urban black individuals with atrial fibrillation. Vasc Med. 2011;16(3):227.
  28. De Cuyper A, De Meester A, Descamps O, et al. Left atrial appendage thrombus detection in patients with persistent atrial fi brillation before cardioversion. Comparison between multidetector computed tomography and transesophageal echocardiography. Acta Cardiol. 2012;67(1):111–2.
  29. De Sutter J, Weytjens C, Willems AM, et al. CHA2DS2-VASc score as a complementary tool for the CHADS2 score in patients admitted with acute heart failure and atrial fi brillation. Practical implications and real-life use of warfarin at discharge: A report from the BIO-HF study. Acta Cardiol. 2012;67(1):112.
  30. Deneke T, Krug J, Schade A, et al. Silent cerebral lesions after left atrial ablation procedures. Heart Rhythm. 2012;9(5 Suppl.1):S422.
  31. Di Biase L, Gaita F, Anselmino M, et al. Does the left atrial appendage morphology correlates with the risk of stroke in patients with atrial fibrillation? Result from a multicenter study. Circulation. 2011;124:A10879. [PubMed: 22858289]
  32. Di Biase L, Gaita F, Anselmino M, et al. Does the left atrial appendage morphology correlates with the risk of stroke in patients with atrial fibrillation? Result from a multicenter study. PACE - Pacing Clin Electrophysiol. 2011;34(11):1317.
  33. Di Biase L, Gaita F, Anselmino M, et al. Does the left atrial appendage morphology correlates with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. G Ital Cardiol. 2011;12(12Suppl.3):e12. [PubMed: 22858289]
  34. Di Biase L, Santangeli P, Mohanty P, et al. Delayed cardiac tamponade following catheter ablation of atrial fibrillation with and without warfarin discontinuation: Single center experience. Circulation. 2011;124(21):A14189.
  35. Di Biase L, Tschopp D, Sanchez JE, et al. Catheter ablation of atrial fibrillation without dabigratan discontinuation: Preliminary safety and efficacy data. Circulation. 2011;124(21):A14277.
  36. Di Toro DC, Hadid C, Gallino S, et al. CHADS2 and CHA2DS2-VASC risk scores validation in an atrial fibrilation population. Heart Rhythm. 2012;9(5Suppl.1):S172.
  37. Donze J, Rodondi N, Monney P, et al. Prospective comparison of scores and clinical judgment to predict major bleeding in patients receiving oral anticoagulants. J Gen Intern Med. 2011;26(Suppl.1):S77–8.
  38. Eikelboom J, Synhorst D, Wright R, et al. Efficacy and safety of apixaban compared with aspirin in patients with atrial fibrillation who previously used and discontinued warfarin therapy: A secondary analysis of the AVERROES trial. Eur Heart J. 2011;32:465.
  39. Eikelboom JW, O’Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J. 2010;159(3):348–53.e1. PMID: 20211294. [PubMed: 20211294]
  40. Eitel C, Hindricks G, Sommer P, et al. Dabigatran in patients undergoing catheter ablation for atrial fibrillation. Europace. 2011;13(Suppl.3).
  41. Ellis CR, Streur MM and Nagarakanti R. Safety and efficacy of dabigatran versus warfarin in patients undergoing left atrial catheter ablation. Heart Rhythm. 2012;9(5Suppl.1):S421.
  42. Essebag V, Birnie D, Guerra P, et al. Anticoagulation management PRE and post atrial fibrillation ablation: A survey of Canadian centres. Can J Cardiol. 2010;26(Suppl.D):112D. [PubMed: 22840300]
  43. Fang MC, Go AS and Chang Y. A 5-item score predicted risk for warfarin-associated major hemorrhage in patients with atrial fibrillation. Ann Intern Med. 2011;155(10):JC5–13. PMID: 22084360. [PubMed: 22084360]
  44. Fauchier L, Olesen JB, Taillandier S, et al. Validation of the CHA2DS2-VASc score for stroke and thromboembolism risk stratification in patients with atrial fibrillation in a community based cohort study: The LVAF project. Eur Heart J. 2011;32(Suppl.1):466.
  45. Fauchier L, Taillandier S, Lagrenade I, et al. Prognosis in patients with atrial fibrillation and CHA2DS2VASc score=0 in a real world community based cohort study: The Loire Valley Atrial Fibrillation project. Eur Heart J. 2011;32(Suppl.1):7.
  46. Ferreira J, Ezekowitz MD, Connolly SJ, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: A subgroup analysis of the re-ly trial. Circulation. 2011;124(21):A10956.
  47. Figini F, Latib A, Chieffo A, et al. Managing patients with an indication for anticoagulant therapy after transcatheter aortic valve implantation. J Am Coll Cardiol. 2012;59(13Suppl.1):E1988.
  48. Flaker G, Ezekowitz M, Yusuf S, et al. Efficacy and Safety of Dabigatran Compared to Warfarin in Patients With Paroxysmal, Persistent, and Permanent Atrial Fibrillation: Results From the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Study. J Am Coll Cardiol. 2012;59(9):854–5. PMID: 22361407. [PubMed: 22361407]
  49. Flynn RWV, MacDonald TM, Choy AM, et al. When should an atrial fibrillation patient receive anticoagulants following intracerebral haemorrhage?. Pharmacoepidemiol Drug Saf. 2011;20(Suppl.1):S129.
  50. Fosbol EL, Wang T, Piccini J, et al. Comparative effectiveness and safety of antithrombotic therapy in older patients with atrial fibrillation and non-st elevation myocardial infarction (NSTEMI) treated with coronary stenting. J Am Coll Cardiol. 2012;59(13Suppl.1):E1866.
  51. Fountain RB, Holmes DR, Chandrasekaran K, et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. Am Heart J. 2006;151(5):956–61. PMID: 16644311. [PubMed: 16644311]
  52. Gallagher AM, Murray-Thomas T, Clemens A, et al. Incidence of vascular outcomes in patients with atrial fibrillation. Blood. 2011;118(21):4223.
  53. Gangireddy S, Coffey JO, Calenda BW, et al. The incidence of stroke after atrial fibrillation ablation in patients on dabigatran. Heart Rhythm. 2012;9(5Suppl.1):S472.
  54. Genovesi S, Santoro A, Fabbrini P, et al. Italian survey on hemorrhagic and thromboemolic risk and oral anticoagulant therapy in a large population of hemodalysis patients with atrial fibrillation. Nephrol Dial Transplant. 2012;27(Suppl.2):ii236.
  55. Goodman SG, Wojdyla DM, White HD, et al. Predictors of major bleeding risk: Insights from the rivaroxaban once-daily oral direct factor XA inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (Rocket AF). Circulation. 2011;124(21):A16903.
  56. Haines DE, Salazar M, Mead-Salley M, et al. Dabigatran versus warfarin for periprocedural anticoagulation at the time of catheter ablation of atrial fibrillation. Heart Rhythm. 2012;9(5Suppl. 1):S171–2.
  57. Han JH, Hwang HJ, Pak HN, et al. Preprocedural transesophageal echocardiography was not necessary for the stroke prevention evaluation in af patient on anticoagulation. Heart Rhythm. 2012;9(5Suppl.1):S347.
  58. Hart RG, Eikelboom J, Yusuf S, et al. Efficacy and safety of the novel oral factor Xa inhibitor apixaban in atrial fibrillation (AF) patients with chronic kidney disease (CKD): The AVERROES trial. Eur Heart J. 2011;32(Suppl.1):6.
  59. Healey JS, Eikelboom J, Wallentin L, et al. The risk of peri-operative bleeding with warfarin compared to two doses of dabigatran: Results from the RE-LY trial. Circulation. 2011;124(21):A12041.
  60. Heinzel FR, Forstner H, Lercher P, et al. Re-evaluating thromboembolic risk in cardiomyopathy patients using CHADS-VASc. Europace. 2011;13(Suppl.3).
  61. Hioki M, Matsuo SM, Narui F, et al. Does continuing warfarin therapy during catheter ablation reduce the thromboembolism in patients with atrial fibrillation?. Heart Rhythm. 2012;9(5Suppl.1):S132.
  62. Ho KW, Ivanov J, Seidelin P, et al. Should anticoagulation therapy be combined with dual antiplatelet therapy in patients with nonvalvular atrial fibrillation following percutaneous coronary intervention?. J Am Coll Cardiol. 2012;59(13Suppl.1):E264.
  63. Honig S, Steinwender C, Lambert T, et al. Significant reduction of bleeding complications after pulmonary vein isolation using different types of anticoagulant strategies. Journal fur Kardiologie. 2011;18(5-6):201–2.
  64. Hori M, Matsumoto M, Tanahashi N, et al. J-ROCKET AF: The safety and efficacy of rivaroxaban for prevention of stroke in Japanese patients with non-valvular atrial fibrillation. J Thromb Haemost. 2011;9(Suppl.2):20.
  65. Janse P, Theuns D, Bhagwandien R, et al. CHADS2 score does not predict left atrial thrombi before pulmonary vein isolation. Heart Rhythm. 2012;9(5Suppl.1):S221.
  66. Kaatz S, Douketis JD, White RH, et al. Can the CHADS2 score predict postoperative stroke risk in patients with chronic atrial fibrillation who are having elective non-cardiac surgery?. J Thromb Haemost. 2011;9(Suppl.2):635.
  67. Kazemimood R, Mirocha J and Shiota T. Clinical and echocardiograohic factors that are associated with left atrial or left atrial appendage thrombus or spontaneous echo contrast in patients with atrial fibrillation. J Am Coll Cardiol. 2012;59(13Suppl.1):E677.
  68. Kefer J, Vermeersch P, De Potter T, et al. Left atrial appendage closure with Amplatzer Cardiac Plug for stroke prevention in atrial fi brillation: Initial Belgian experience. Acta Cardiol. 2012;67(1):130–1.
  69. Konduru SV, Cheema A, Jones P, et al. Heparinization during catheter ablation for atrial fibrillation: A comparison of patients treated with dabigatran vs patients maintained on warfarin. Heart Rhythm. 2012;9(5Suppl.1):S200.
  70. Kosiuk J, Bode K, Kornej J, et al. Left ventricular diastolic dysfunction correlates with thromboembolic risk in atrial fibrillation. Heart Rhythm. 2012;9(5Suppl.1):S462.
  71. Krishnamoorthy S, Khoo C, Lim S, et al. Prognostic role of plasma von willebrand factor and soluble e-selectin levels for future cardiovascular events in a ‘real world’ community cohort of patients with atrial fibrillation. Heart Rhythm. 2012;9(5Suppl.1):S421-2. [PubMed: 23961715]
  72. Kuwahara T, Takahashi Y, Okubo K, et al. Prevention of periprocedural stroke and management of hemorrhagic complication in atrial fibrillation ablation under continuing warfarin administration. Heart Rhythm. 2012;9(5Suppl.1):S277.
  73. Lamberts M, Hansen M, Olesen J, et al. Risk of major bleeding after initiation of dual or triple antithrombotic drug therapy in atrial fibrillation patients following myocardial infarction and coronary stenting: A nationwide cohort study. J Am Coll Cardiol. 2012;59(13Suppl.1):E512.
  74. Lassila R, Munsterhjelm E, Joutsi-Korhonen L, et al. Laboratory follow-up and clinical management of a patient case with severe bleeding complication on dabigatran for atrial fibrillation. J Thromb Haemost. 2011;9(Suppl.2):840–1.
  75. Lee SJ, Hwang HJ, Pak HN, et al. The safety and efficacy of oral anticoagulation in patients with healed ulcer on vitamin K antagonist treatment. Heart Rhythm. 2012;9(5Suppl.1):S243.
  76. Lip GY, Yusuf S, Eikelboom J, et al. Impact of treatment with apixaban and aspirin in patients with atrial fibrillation in relation to the CHADS2 and CHA2DS2-vasc scores: The averroes study. Circulation. 2011;124(21):A15542.
  77. Lip GYH, Halperin JL, Petersen P, et al. Safety and tolerability of the oral factor Xa inhibitor, YM150 vs. warfarin in 1297 patients with nonvalvular atrial fibrillation: A dose confirmation study (OPAL-2). J Thromb Haemost. 2011;9(Suppl.2):748.
  78. Lip GYH, Larsen TB, Skjoth F, et al. Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol. 2012;60(8):738–46. PMID: 22575324 [PubMed: 22575324]
  79. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159(3):331–9. PMID: 20211292. [PubMed: 20211292]
  80. Lopes RD, Al-Khatib S, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin according to CHADS2 and hasbled risk scores for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012;59(13Suppl.1):E574.
  81. Maes F, Almpanis C, Scavee C, et al. Underuse of anticoagulation in older patients with atrial fbrillation. Acta Cardiol. 2011;66(1):95.
  82. Mahaffey KW, White HD, Nessel CC, et al. Ischemic cardiac outcomes in patients with af treated with vitamin k antagonism or factor XA inhibition: Results from the rocket AF Trial. Circulation. 2011;124(21):A13482. [PMC free article: PMC3896862] [PubMed: 24132190]
  83. Makino N, Nishino M, Tanaka A, et al. Left atrial appendage morphology determined by computed tomography can predict high risk patient for embolism with atrial fibrillation. Circulation. 2011;124(21):A11570.
  84. Mant JW, Richards SH, Hobbs FD, et al. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]. BMC Cardiovasc Disord. 2003;3:9. PMID: 12939169. [PMC free article: PMC201020] [PubMed: 12939169]
  85. Marazzi R, Ponti RD, Doni L, et al. Prevalence of left atrial appendage thrombi onmultidetector computed tomography as compared with transesophageal echocardiography and predisposing factors in candidates for pulmonary vein isolation. J Interv Card Electrophysiol. 2012;33(3):287.
  86. Martinek M, Sigmund E, Lemes C, et al. Asymptomatic cerebral lesions in pulmonary vein isolation under therapeutic anticoagulation. Heart Rhythm. 2012;9(5Suppl.1):S132-3.
  87. Mendoza I, Helguera M, Baez-Escudero J, et al. Atrial fibrillation ablation on uninterrupted anticoagulation with dabigatran versus warfarin. Heart Rhythm. 2012;9(5Suppl.1):S270-1.
  88. Muhammad MIA. Role of video-assisted thoracoscopy in the management of stroke. Heart Surgery Forum. 2012;15(Suppl. 1):S45.
  89. Murtaza G, Von Ballmoos MW and Masroor S. Cryomaze for sole-therapy atrial fibrillation. Circulation. 2011;124(21):A18025.
  90. Novakovic-Anucin SL, Gnip S, Povazan L, et al. Efficacy of combined antiplatelet therapy in preventing thromboembolism in patients with atrial fibrillation. J Thromb Haemost. 2011;9(Suppl.2):887.
  91. Oldgren J, Alings M and Darius H. Chads(2) score predicted bleeding and death in atrial fibrillation treated with anticoagulants. Ann Intern Med. 2012;156(8):JC4–13. PMID: 22508753 [PubMed: 22508753]
  92. Oldgren J, Hijazi Z, Andersson U, et al. Cystatin c is prognostic for stroke, death and bleeding in atrial fibrillation-a rely substudy. Circulation. 2011;124(21):A12492.
  93. Olesen JB, Lip GYH, Lane DA, et al. Rates of thromboembolism and bleeding with antithrombotic treatment in patients with atrial fibrillation: A nullreal worldnull nationwide cohort study. Eur Heart J. 2011;32(Suppl.1):465.
  94. Page S, Cantor E, Sporton S, et al. Lower heparin doses are required to achieve therapeutic anticoagulation in patients undergoing catheter ablation for atrial fibrillation on uninterrupted warfarin. J Interv Card Electrophysiol. 2012;33(3):339.
  95. Para O, Pieralli F, Lualdi C, et al. Management of oral anticoagulation at discharge in elderly patients with atrial fibrillation hospitalized in an Internal Medicine ward: An observational study. Ital J Med. 2012;6(1Suppl.1):105–6.
  96. Perros N and Schneck M. Resumption of antithrombotic therapy following hemorrhagic stroke in patients with atrial fibrillation. Neurology. 2012;78(1):P02.206.
  97. Piccini JP, Stevens SR, Patel MR, et al. Renal dysfunction is a potent predictor of stroke and systemic embolism among individuals with atrial fibrillation: Results from the Rocket AF trial. Circulation. 2011;124(21):A17137.
  98. Poli D, Antonucci E, Grifoni E, et al. Low bleeding risk of very old atrial fibrillation women on VKA treatment: Results from a prospective collaborative study. on behalf of the ad hoc study group of FCSA. J Thromb Haemost. 2011;9(Suppl.2):886.
  99. Providencia RA, Botelho A, Trigo J, et al. CHADSEcho: A new stroke risk classification for patients with atrial fibrillation. Europace. 2011;13(Suppl.3).
  100. Providencia RA, Botelho A, Trigo J, et al. Decreased left atrial appendage deformation: A new predictor of stroke risk in patients with atrial fibrillation?. Europace. 2011;13(Suppl.3).
  101. Providencia RA, Botelho A, Trigo J, et al. Importance of left ventricle dysfunction quantification for thromboembolic risk prediction in patients with atrial fibrillation. Eur J Heart Fail Suppl. 2011;10(Suppl.1):S15–6.
  102. Providencia RA, Botelho A, Trigo J, et al. Left atrial deformation in atrial fibrillation: Which parameter and segment are the best predictors of thromboembolic risk?. Europace. 2011;13(Suppl.3).
  103. Pump A, Szapary L, Komoly S, et al. Advantages of CHA2DS2-VASC scheme, a novel risk factors score to predict stroke in patients with atrial fibrillation. J Am Coll Cardiol. 2012;59(13Suppl.1):E1698.
  104. Rajdev A, Bradley J, Petrini J, et al. A community experience of the novel anticoagulant pradaxa. J Am Coll Cardiol. 2012;59(13Suppl.1):E601.
  105. Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest. 2004;126(6):1938–45. PMID: 15596696. [PubMed: 15596696]
  106. Roldan V, Gallego P, Marin F, et al. The HAS-BLED score also predicts cardiovascular events and mortality in atrial fibrillation. Eur Heart J. 2011;32(Suppl.1):322.
  107. Roldan V, Marin F, Gallego P, et al. Usefulness for CHA2DS2-VASc score for predicting adverse events in high risk anticoagulated patients with atrial fibrillation. Eur Heart J. 2011;32(Suppl.1):464.
  108. Romanov A, Pokushalov E, Corbucci G, et al. Ablation of paroxysmal and persistent atrial fibrillation: 1-year follow-up through continuous subcutaneous monitoring. Europace. 2011;13(Suppl.3). [PubMed: 20958836]
  109. Romanov A, Pokushalov E, Corbucci G, et al. Ablation of paroxysmal and persistent atrial fibrillation: 1-year follow-up through implantable ecg recorder. Pacing Clin Electrophysiol. 2011;34(11):1308.
  110. Roversi S, Malavasi V, D’Ascenzo F, et al. Picking the best novel oral anticoagulant for atrial fibrillation: Evidence from a warfarin-controlled network meta-analysis. J Am Coll Cardiol 2012;59(13Suppl.1):E598.
  111. Rowley CP, Bradford NS, Bernard ML, et al. Complications of atrial fibrillation ablation in patients anticoagulated with dabigatran compared to warfarin. Heart Rhythm. 2012;9(5Suppl. 1):S201.
  112. Saxena R and Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev. 2004;(4):CD000187. PMID: 15494992. [PubMed: 15494992]
  113. Saxena R and Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2004;(2):CD000185. PMID: 15106146. [PubMed: 15106146]
  114. Schade A, Krug J, Stahl C, et al. Left atrial appendage occlusion using the watchman device in a high risk population: Is there a significant risk of periprocedural cerebral stroke or microembolism?. Heart Rhythm. 2012;9(5Suppl.1):S317.
  115. Schlitt A, Rubboli A, Lathela H, et al. AFCAS, a prospective multicenter registry of patients with atrial fibrillation undergoing coronary artery stenting: Comparison of CHADS2-with CHA2DS2-VASc score. Circulation. 2011;124(21):A12001.
  116. Seet R, Rabinstein A, Christianson T, et al. Life-time bleeding events among stroke patients with atrial fibrillation during warfarin treatment: A population-based cohort study. Neurology. 78:PD2.010.
  117. Shim J, Uhm JS, Hwang HJ, et al. Larger left atrial appendage is an independent predictor of stroke in patients with atrial fibrillation. Circulation. 2011;124(21):A16425.
  118. Sick PB, Turi Z, Grube E, et al. Stroke prevention in non-valvular atrial fibrillation: Long-term results after 6 years of the WATCHMAN left atrial appendage occlusion pilot study. Eur Heart J. 2011;32(Suppl.1):468.
  119. Sigmund E, Lemes C, Derndorfer M, et al. Asymptomatic cerebral lesions in pulmonary vein isolation under therapeutic anticoagulation. J Interv Card Electrophysiol. 2012;33(3):286.
  120. Siu CW, Jim MH, Lau CP, et al. Low molecular weight heparin versus unfractionated heparin for thromboprophylaxis in patients with acute atrial fibrillation: a randomized control trial. Acute Card Care. 2011;13(3):196–8. PMID: 21517667. [PubMed: 21517667]
  121. Snipelisky D, Kauffman C and Kusumoto F. A comparison of bleeding complications post ablation between warfarin and dabigatran. Heart Rhythm. 2012;9(5Suppl.1):S203. [PubMed: 22869389]
  122. Sulke AN, Podd S, Sallomi DF, et al. MRI assessed brain abnormality in patients who have undergone pulmonary vein isolation: A randomised comparison of phased multi-electrode radiofrequency ablation (PVAC(trademark)) or conventional lasso guided irrigated radiofrequency ablation techniques. Heart Rhythm. 2012;9(5Suppl.1):S391.
  123. Tamura H, Watanabe T, Nishiyama S, et al. Left atrial appendage wall velocity measured by transthoracic echocardiography is a feasible marker for predicting poor prognosis in patients with cardioembolic stroke. Circulation. 2011;124(21):A12289.
  124. Tamura H, Watanabe T, Nishiyama S, et al. Left atrial appendage wall velocity obtained by transthoracic echocardiography may be a feasible parameter to detect high risk stroke patients despite low CHADS(;2); Score. Circulation. 2011;124(21):A11896.
  125. Timcenko M, Volceka D, Skorodumovs A, et al. Practical aspects of cardioembolic stroke prevention in patients eligible and uneligible for warfarin therapy. Pacing Clin Electrophysiol. 2011;34(11):1384–5.
  126. Toda E, Lip GYH, Uchiyama S, et al. Use of the CHADS2 and CHA2DS2-VASC score in Japanese patients with atrial fibrillation: A sub-analysis of the Japan thrombosis registry for atrial fibrillation, coronary or cerebrovascular events (J-trace). J Am Coll Cardiol. 2012;59(13Suppl.1):E674.
  127. Topinkova E, Novakova M, Chamradova MK, et al. Difficult choices: Antithrombotic treatment for atrial fibrillation in frail geriatric patients. Eur Geriatr Med. 2011;2(Suppl.1):S9–10.
  128. Tsadok MA, Jackevicius C, Rahme E, et al. Sex differences in risk factors, treatment patterns and clinical outcomes of stroke among patients with atrial fibrillation. Circulation. 2011;124(21):A13626.
  129. Underwood JM, Rogers KC, Pham M, et al. Evaluation of bleeding risk using HAS-BLED scoring in patients with atrial fibrillation receiving enoxaparin bridging therapy. Pharmacotherapy. 2011;31(10):409e.
  130. Van Der Zee SA, Reddy VY and Doshi SK. Peri-device flow after percutaneous closure of the left atrial appendage: One-year follow-up in 76 patients. Heart Rhythm. 2012;9(5Suppl.1):S127-8.
  131. van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke. 2009;40(4):1410–6. PMID: 19182090. [PubMed: 19182090]
  132. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288(19):2441–8. PMID: 12435257. [PubMed: 12435257]
  133. Ward MA and Biddle AK. Cost-effectiveness analysis of dabigatran compared to warfarin for stroke prevention in atrial fibrillation in a medicare population. Value Health. 2012;15(4):A121.
  134. Weimar T, Vosseler M, Czesla M, et al. Endoscopic approach for epicardial bipolar radiofrequency ablation in the surgical treatment of lone atrial fibrillation: Towards a revision of treatment strategies. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery. 2012;7(2):129.
  135. Wieloch M, Jonsson K and Svensson PJ. Correlations between estimated glomerular filtration rate, major bleeding and thromboembolic complications in patients on anticoagulation treatment with warfarin. Circulation. 2011;124(21):A15529.
  136. Willens HJ, Nelson K, De Nicco A, et al. A comparison of the correlation of CHADS(2) and CHA(2)DS(2)-VASc risk score and category with transesophageal echocardiography risk factors for thromboembolism. J Am Soc Echocardiogr. 2012;25(6):B63. [PubMed: 23253435]
  137. Wilson WW and Wilson W. Enoxaparin bridge therapy in patients with nonvalvular atrial fibrillation: A ten year retrospective analysis. J Am Coll Cardiol. 2012;59(13Suppl.1):E605.
  138. Yamaji H, Murakami T, Kawamura H, et al. Safety of dabigatran for atrial fibrillation ablation as a periprocedural anticoagulation strategy. Heart Rhythm. 2012;9(5Suppl.1):S170.
  139. Yamashita E, Sasaki T, Tsukada N, et al. CHA2DS2-VASc score for screening of thromboembolic risk prior to atrial fibrillation ablation: Comparison to CHADS2 scoring system. J Am Soc Echocardiogr. 2012;25(6):B64.
  140. Yamashita E, Sasaki T, Tsukada N, et al. Left atrial appendage dysfunction in female patients prior to catheter ablation for atrial fibrillation. J Am Soc Echocardiogr. 2012;25(6):B65.
  141. Yang F, Xu X, Winkelmayer W, et al. Warfarin use and bleeding risk in veterans with incident atrial fibrillation and severe chronic kidney disease: The treat-AF study. Heart Rhythm. 2012;9(5Suppl.1):S312.
  142. You JH, Tsui KK, Wong RS, et al. Improve warfarin therapy or use dabigatran for patients with atrial fibrillation - A cost-effectiveness analysis. J Clin Pharmacol. 2011;51(9):1334.
  143. Zecchin M, Bardari S, Vitali Serdoz L, et al. Anticoagulant therapy in patients with atrial fibrillation according to CHA2DS2 VASc score: What will change?. Europace. 2011;13(Suppl.3)

Population Is Not Patients With Nonvalvular Atrial Fibrillation-2012

  1. al-Khadra AS. Implantation of pacemakers and implantable cardioverter defibrillators in orally anticoagulated patients. Pacing Clin Electrophysiol. 2003;26(1Pt2):511–4. PMID: 12687880. [PubMed: 12687880]
  2. Alonso A, Tang W, Agarwal SK, et al. Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: The ARIC study. Int J Cardiol. 2012;155(2):217–22. PMID: 20965585. [PMC free article: PMC3025309] [PubMed: 20965585]
  3. Andersen KK, Olsen TS. Reduced poststroke mortality in patients with stroke and atrial fibrillation treated with anticoagulants: results from a Danish quality-control registry of 22,179 patients with ischemic stroke. Stroke. 2007;38(2):259–63. PMID: 17194876. [PubMed: 17194876]
  4. Bande D, Hossain S, Newman W, et al. Incidence of thromboembolic and bleeding complications in anticoagulated patients undergoing colonoscopy - A retrospective study. Am J Gastroenterol. 2011;106(Suppl.2):S523–4.
  5. Blacker DJ, Wijdicks EF, McClelland RL. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology. 2003;61(7):964–8. PMID: 14557569. [PubMed: 14557569]
  6. Brandt RR, Neumann T, Neuzner J, et al. Transcatheter closure of atrial septal defect and patent foramen ovale in adult patients using the Amplatzer occlusion device: no evidence for thrombus deposition with antiplatelet agents. J Am Soc Echocardiogr. 2002;15(10Pt1):1094–8. PMID: 12373252. [PubMed: 12373252]
  7. Cano O, Munoz B, Tejada D, et al. Evaluation of a new standardized protocol for the perioperative management of chronically anticoagulated patients receiving implantable cardiac arrhythmia devices. Heart Rhythm. 2012;9(3):361–7. PMID: 22001709. [PubMed: 22001709]
  8. Chan TY, Miu KY. Hemorrhagic complications of anticoagulant therapy in Chinese patients. J Chin Med Assoc. 2004;67(2):55–62. PMID: 15146899. [PubMed: 15146899]
  9. Chandratheva A, Geraghty OC, Luengo-Fernandez R, et al. ABCD2 score predicts severity rather than risk of early recurrent events after transient ischemic attack. Stroke. 2010;41(5):851–6. PMID: 20299668. [PubMed: 20299668]
  10. Cheng A, Nazarian S, Brinker JA, et al. Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial. Heart Rhythm. 2011;8(4):536–40. PMID: 21147261. [PubMed: 21147261]
  11. Chung N, Jeon HK, Lien LM, et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost. 2011;105(3):535–44. PMID: 21136011. [PubMed: 21136011]
  12. Constans M, Santamaria A, Mateo J, et al. Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy. Int J Clin Pract. 2007;61(2):212–7. PMID: 17263709. [PubMed: 17263709]
  13. Corrado G, Sgalambro A, Mantero A, et al. Thromboembolic risk in atrial flutter. The FLASIEC (FLutter Atriale Societa Italiana di Ecografia Cardiovascolare) multicentre study. Eur Heart J. 2001;22(12):1042–51. PMID: 11428839. [PubMed: 11428839]
  14. Dayani PN, Grand MG. Maintenance of warfarin anticoagulation for patients undergoing vitreoretinal surgery. Arch Ophthalmol. 2006;124(11):1558–65. PMID: 17102002. [PubMed: 17102002]
  15. de Souza MV, Duarte MM, Coeli CM, et al. Atrial fibrillation & hyperthyroidism: relation between transesophageal markers of a thrombogenic milieu and clinical risk factors for thromboembolism. Clin Endocrinol (Oxf). 2011;76(3):448–53. PMID: 21950838. [PubMed: 21950838]
  16. Deerhake JP, Merz JC, Cooper JV, et al. The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials. J Thromb Thrombolysis. 2007;23(2):107–13. PMID: 17221327. [PubMed: 17221327]
  17. Dotan ZA, Mor Y, Leibovitch I, et al. The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction. J Urol. 2002;168(2):610–3; discussion 614. PMID: 12131319. [PubMed: 12131319]
  18. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164(12):1319–26. PMID: 15226166. [PubMed: 15226166]
  19. Eisele R, Melzer N, Englert C, et al. Bridging with the Low molecular weight heparin certoparin in patients requiring temporary discontinuation of oral anticoagulation - the non-interventional, retrospective REMEMBER study. Thromb Res. 2012; 130(5):788–92. PMID: 22281069. [PubMed: 22281069]
  20. Evans A, Perez I, Yu G, et al. Secondary stroke prevention in atrial fibrillation: lessons from clinical practice. Stroke. 2000;31(9):2106–11. PMID: 10978038. [PubMed: 10978038]
  21. Finlay M, Sawhney V, Schilling R, et al. Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy. J Cardiovasc Electrophysiol. 2010;21(2):150–4. PMID: 19793142. [PubMed: 19793142]
  22. Fjeldheim R, Welch J, Koo J. A retrospective review of short-term outcomes after switching patients from clopidogrel to alternative antiplatelet therapy. Hosp Pharm. 2009;44(12):1103–11.
  23. Flanigan DC, Muchow R, Orwin J, et al. Arthroscopy on anticoagulated patients: A retrospective evaluation of postoperative complications. Orthopedics. 2010;33(2):82–6. PMID: 20192141. [PubMed: 20192141]
  24. Fu AD, McDonald HR, Williams DF, et al. Anticoagulation with warfarin in vitreoretinal surgery. Retina. 2007;27(3):290–5. PMID: 17460583. [PubMed: 17460583]
  25. Fukuda Y, Yoshida T, Inage T, et al. Long-term results of the maze procedure on left ventricular function for persistent atrial fibrillation associated with mitral valve disease. Heart Vessels. 2012;27(1):53–7. PMID: 21331619. [PubMed: 21331619]
  26. Gronefeld GC, Wegener F, Israel CW, et al. Thromboembolic risk of patients referred for radiofrequency catheter ablation of typical atrial flutter without prior appropriate anticoagulation therapy. Pacing Clin Electrophysiol. 2003;26(1Pt2):323–7. PMID: 12687838. [PubMed: 12687838]
  27. Halbritter KM, Wawer A, Beyer J, et al. Bridging anticoagulation for patients on long-term vitamin-K-antagonists. A prospective 1 year registry of 311 episodes. J Thromb Haemost. 2005;3(12):2823–5. PMID: 16359528. [PubMed: 16359528]
  28. Halkes PH, van Gijn J, Kappelle LJ, et al. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol. 2007;6(2):115–24. PMID: 17239798. [PubMed: 17239798]
  29. Hallevi H, Albright KC, Martin-Schild S, et al. Anticoagulation after cardioembolic stroke: to bridge or not to bridge?. Arch Neurol. 2008;65(9):1169–73. PMID: 18625852. [PMC free article: PMC2678170] [PubMed: 18625852]
  30. Handke M, Harloff A, Hetzel A, et al. Left atrial appendage flow velocity as a quantitative surrogate parameter for thromboembolic risk: determinants and relationship to spontaneous echocontrast and thrombus formation-a transesophageal echocardiographic study in 500 patients with cerebral ischemia. J Am Soc Echocardiogr. 2005;18(12):1366–72. PMID: 16376768. [PubMed: 16376768]
  31. Inatomi Y, Kimura K, Yonehara T, et al. DWI abnormalities and clinical characteristics in TIA patients. Neurology. 2004;62(3):376–80. PMID: 14872016. [PubMed: 14872016]
  32. Jessup DB, Coletti AT, Muhlestein JB, et al. Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy. Catheter Cardiovasc Interv. 2003;60(2):180–4. PMID: 14517922. [PubMed: 14517922]
  33. Kagansky N, Knobler H, Rimon E, et al. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med. 2004;164(18):2044–50. PMID: 15477441. [PubMed: 15477441]
  34. Kanderian AS, Gillinov AM, Pettersson GB, et al. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. J Am Coll Cardiol. 2008;52(11):924–9. PMID: 18772063. [PubMed: 18772063]
  35. Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007;28(6):726–32. PMID: 17267456. [PubMed: 17267456]
  36. Khositseth A, Cabalka AK, Sweeney JP, et al. Transcatheter Amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism. Mayo Clin Proc. 2004;79(1):35–41. PMID: 14708946. [PubMed: 14708946]
  37. Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol. 2006;18(4):162–4. PMID: 16729401. [PubMed: 16729401]
  38. Krane LS, Laungani R, Satyanarayana R, et al. Robotic-assisted radical prostatectomy in patients receiving chronic anticoagulation therapy: role of perioperative bridging. Urology. 2008;72(6):1351–5. PMID: 19041033. [PubMed: 19041033]
  39. Krumsdorf U, Ostermayer S, Billinger K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol. 2004;43(2):302–9. PMID: 14736453. [PubMed: 14736453]
  40. Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention: A Nationwide Cohort Study. Circulation. 2012;126(10):1185–93.PMID: 22869839. [PubMed: 22869839]
  41. Lavitola Pde L, Spina GS, Sampaio RO, et al. Bleeding during oral anticoagulant therapy: warning against a greater hazard. Arq Bras Cardiol. 2009;93(2):174–9. PMID: 19838496. [PubMed: 19838496]
  42. Lawrentschuk N, Kariappa S, Kaye AH. Spontaneous intracerebral haemorrhages-warfarin as a risk factor. J Clin Neurosci. 2003;10(5):550–2. PMID: 12948457. [PubMed: 12948457]
  43. Leitman M, Sidenko S, Peleg E, et al. Improved detection of spontaneous echo contrast in the aorta with tissue Doppler imaging. Echocardiography. 2004;21(6):503–8. PMID: 15298685. [PubMed: 15298685]
  44. Leung CS and Tam KM. Antithrombotic treatment of atrial fibrillation in a regional hospital in Hong Kong. Hong Kong Med J. 2003;9(3):179–85. PMID: 12777653. [PubMed: 12777653]
  45. Long AL, Bendz L, Horvath MM, et al. Characteristics of ambulatory anticoagulant adverse drug events: A descriptive study. Thromb J. 2010;8:5. PMID: 20167114. [PMC free article: PMC2843659] [PubMed: 20167114]
  46. Lopes RD, Elliott LE, White HD, et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J. 2009;30(16):2019–28. PMID: 19502623. [PMC free article: PMC2764954] [PubMed: 19502623]
  47. MacDonald LA, Meyers S, Bennett CL, et al. Post-cardiac catheterization access site complications and low-molecular -weight heparin following cardiac catheterization. J Invasive Cardiol. 2003;15(2):60–2. PMID: 12556615. [PubMed: 12556615]
  48. Malato A, Saccullo G, Lo Coco L, et al. Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin. J Thromb Haemost. 2010;8(1):107–13. PMID: 19817996. [PubMed: 19817996]
  49. Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010;363(17):1608–20. PMID: 20961244. [PubMed: 20961244]
  50. Mattichak SJ, Reed PS, Gallagher MJ, et al. Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction. J Interv Cardiol. 2005;18(3):163–6. PMID: 15966919. [PubMed: 15966919]
  51. McGrath ER, Kapral MK, Fang J, et al. Which Risk Factors Are More Associated With Ischemic Stroke Than Intracerebral Hemorrhage in Patients With Atrial Fibrillation?. Stroke. 2012;43(8):2048–54. PMID: 22618379. [PubMed: 22618379]
  52. Nguyen MC, Lim YL, Walton A, et al. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. Eur Heart J. 2007;28(14):1717–22. PMID: 17562671. [PubMed: 17562671]
  53. Nikolsky E, Mehran R, Dangas GD, et al. Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). Am J Cardiol. 2012;109(6):831–8. PMID: 22196778. [PubMed: 22196778]
  54. Omran H, Bauersachs R, Rubenacker S, et al. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost. 2012;108(1):65–73. PMID: 22534746. [PubMed: 22534746]
  55. Ono A, Fujita T. Low-intensity anticoagulation for stroke prevention in elderly patients with atrial fibrillation: efficacy and safety in actual clinical practice. J Clin Neurosci. 2005;12(8):891–4. PMID: 16271478. [PubMed: 16271478]
  56. Orford JL, Fasseas P, Melby S, et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J. 2004;147(3):463–7. PMID: 14999195. [PubMed: 14999195]
  57. Parvathaneni L, Mahenthiran J, Jacob S, et al. Comparison of tissue Doppler dynamics to Doppler flow in evaluating left atrial appendage function by transesophageal echocardiography. Am J Cardiol. 2005;95(8):1011–4. PMID: 15820180. [PubMed: 15820180]
  58. Perez-Gomez F, Alegria E, Berjon J, et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol. 2004;44(8):1557–66. PMID: 15489085. [PubMed: 15489085]
  59. Perez-Gomez F, Iriarte JA, Zumalde J, et al. Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial. Eur Heart J. 2007;28(8):996–1003. PMID: 17158523. [PubMed: 17158523]
  60. Phan TG, Koh M, Wijdicks EF. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol. 2000;57(12):1710–3. PMID: 11115236. [PubMed: 11115236]
  61. Poci D, Hartford M, Karlsson T, et al. Role of the CHADS2 score in acute coronary syndromes - risk of subsequent death or stroke in patients with and without atrial fibrillation. Chest. 2012;141(6):1431–40. PMID: 22016485. [PubMed: 22016485]
  62. Pozzoli M, Selva A, Skouse D, et al. Visualization of left atrial appendage and assessment of its function by transthoracic second harmonic imaging and contrast-enhanced pulsed Doppler. Eur J Echocardiogr. 2002;3(1):13–23. PMID: 12067529. [PubMed: 12067529]
  63. Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008;102(12):1618–23. PMID: 19064015. [PubMed: 19064015]
  64. Rubboli A, Magnavacchi P, Guastaroba P, et al. Antithrombotic management and 1-year outcome of patients on oral anticoagulation undergoing coronary stent implantation (from the Registro Regionale Angioplastiche Emilia-Romagna Registry). Am J Cardiol. 2012;109(10):1411–7. PMID: 22342850. [PubMed: 22342850]
  65. Saccullo G, Malato A, Raso S, et al. Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin. Am J Hematol. 2012;87(4):388–91. PMID: 22374861. [PubMed: 22374861]
  66. Saokaew S, Sapoo U, Nathisuwan S, et al. Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand. Int J Clin Pharm. 2012;34(1):105–12. PMID: 22203442. [PubMed: 22203442]
  67. Sarafoff N, Ndrepepa G, Mehilli J, et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med. 2008;264(5):472–80. PMID: 18624903. [PubMed: 18624903]
  68. Saxena R, Lewis S, Berge E, et al. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke. 2001;32(10):2333–7. PMID: 11588322. [PubMed: 11588322]
  69. Silverman IE, Kiernan FJ, Kelsey AM, et al. Initial experience with a transcatheter septal closure system for secondary stroke prevention in patients with interatrial septal defects. Conn Med. 2003;67(3):135–44. PMID: 12687787. [PubMed: 12687787]
  70. Sorescu D, Turk RJ, Cain M, et al. Clinical and transthoracic echocardiographic predictors of abnormal transesophageal findings in patients with suspected cardiac source of embolism. Am J Med Sci. 2003;326(1):31–4. PMID: 12861123. [PubMed: 12861123]
  71. Spyropoulos AC, Frost FJ, Hurley JS, et al. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest. 2004;125(5):1642–50. PMID: 15136371. [PubMed: 15136371]
  72. Spyropoulos AC, Turpie AG, Dunn AS, et al. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost. 2006;4(6):1246–52. PMID: 16706967. [PubMed: 16706967]
  73. Stahrenberg R, Edelmann F, Haase B, et al. Transthoracic echocardiography to rule out paroxysmal atrial fibrillation as a cause of stroke or transient ischemic attack. Stroke. 2011;42(12):3643–5. PMID: 21998056. [PubMed: 21998056]
  74. Udell JA, Wang JT, Gladstone DJ, et al. Anticoagulation after anterior myocardial infarction and the risk of stroke. PLoS One. 2010;5(8):e12150. PMID: 20730096. [PMC free article: PMC2921337] [PubMed: 20730096]
  75. Vincelj J, Sokol I, Jaksic O. Prevalence and clinical significance of left atrial spontaneous echo contrast detected by transesophageal echocardiography. Echocardiography. 2002;19(4):319–24. PMID: 12047783. [PubMed: 12047783]
  76. Yarmohammadi H, Varr BC, Puwanant S, et al. Role of CHADS(2) Score in Evaluation of Thromboembolic Risk and Mortality in Patients With Atrial Fibrillation Undergoing Direct Current Cardioversion (from the ACUTE Trial Substudy). Am J Cardiol. 2012;110(2):222–6. PMID: 22503581. [PubMed: 22503581]
  77. Zanetti G, Kartalas-Goumas I, Montanari E, et al. Extracorporeal shockwave lithotripsy in patients treated with antithrombotic agents. J Endourol. 2001;15(3):237–41. PMID: 11339387. [PubMed: 11339387]

No Intervention/Comparator of Interest-2012

  1. Abdelhafiz AH, Wheeldon NM. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic. Clin Ther. 2004;26(9):1470–8. PMID: 15531009. [PubMed: 15531009]
  2. Abdelhafiz AH, Wheeldon NM. Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice. Am J Geriatr Pharmacother. 2008;6(1):1–11. PMID: 18396243. [PubMed: 18396243]
  3. Ad N, Henry L, Hunt S, et al. Do we increase the operative risk by adding the Cox Maze III procedure to aortic valve replacement and coronary artery bypass surgery?. J Thorac Cardiovasc Surg. 2012;143(4):936–43. PMID: 22244503. [PubMed: 22244503]
  4. Ahmed I, Gertner E, Nelson WB, et al. Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation. Heart Rhythm. 2010;7(6):745–9. PMID: 20176137. [PubMed: 20176137]
  5. Akdeniz B, Turker S, Ozturk V, et al. Cardioversion under the guidance of transesophageal echochardiograhy in persistent atrial fibrillation: results with low molecular weight heparin. Int J Cardiol. 2005;98(1):49–55. PMID: 15676166. [PubMed: 15676166]
  6. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293(6):690–8. PMID: 15701910. [PubMed: 15701910]
  7. Alcalay J. Cutaneous surgery in patients receiving warfarin therapy. Dermatol Surg. 2001;27(8):756–8. PMID: 11493301. [PubMed: 11493301]
  8. Angeloni G, Alberti S, Romagnoli E, et al. Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study. Intern Emerg Med. 2011;6(2):117–23. PMID: 21082292. [PubMed: 21082292]
  9. Asbach S, Biermann J, Bode C, et al. Early Heparin Administration Reduces Risk for Left Atrial Thrombus Formation during Atrial Fibrillation Ablation Procedures. Cardiol Res Pract. 2011;2011:615087. PMID: 21747989. [PMC free article: PMC3130977] [PubMed: 21747989]
  10. Attaran S, Saleh HZ, Shaw M, et al. Does the outcome improve after radiofrequency ablation for atrial fibrillation in patients undergoing cardiac surgery? A propensity-matched comparison. Eur J Cardiothorac Surg. 2012;41(4):806–10; discussion 810-1. PMID: 22219413. [PubMed: 22219413]
  11. Azoulay L, Dell’aniello S, Simon T, et al. Warfarin and the risk of major bleeding events in patients with atrial fibrillation: A population-based study. Eur Heart J. 2011;32(Suppl.1):671–2.
  12. Bai R, Horton RP, L DIB, et al. Intraprocedural and Long-Term Incomplete Occlusion of the Left Atrial Appendage Following Placement of the WATCHMAN Device: A Single Center Experience. J Cardiovasc Electrophysiol. 2012;23(5):455–61. PMID: 22082312. [PubMed: 22082312]
  13. Bai R, Horton RP, L DIB, et al. Intraprocedural and long-term incomplete occlusion of the left atrial appendage following placement of the WATCHMAN device: a single center experience. J Cardiovasc Electrophysiol. 2012;23(5):455–61. PMID: 22082312. [PubMed: 22082312]
  14. Bayard YL, Omran H, Neuzil P, et al. PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. EuroIntervention. 2010;6(2):220–6. PMID: 20562072. [PubMed: 20562072]
  15. Bechtold H, Gunzenhauser D, Sawitzki H, et al. Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion. Z Kardiol. 2003;92(7):532–9. PMID: 12883837. [PubMed: 12883837]
  16. Bernhardt P, Schmidt H, Hammerstingl C, et al. Patients at high risk with atrial fibrillation: a prospective and serial follow-up during 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J Am Soc Echocardiogr. 2005;18(9):919–24. PMID: 16153514. [PubMed: 16153514]
  17. Bernhardt P, Schmidt H, Sommer T, et al. Atrial fibrillation - patients at high risk for cerebral embolism. Clin Res Cardiol. 2006;95(3):148–53. PMID: 16598527. [PubMed: 16598527]
  18. Berwaerts J, Webster J. Analysis of risk factors involved in oral-anticoagulant-related intracranial haemorrhages. QJM. 2000;93(8):513–21. PMID: 10924533. [PubMed: 10924533]
  19. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med. 2000;133(9):687–95. PMID: 11074901. [PubMed: 11074901]
  20. Billett HH, Scorziello BA, Giannattasio ER, et al. Low molecular weight heparin bridging for atrial fibrillation: is VTE thromboprophylaxis the major benefit?. J Thromb Thrombolysis. 2010;30(4):479–85. PMID: 20405168. [PubMed: 20405168]
  21. Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37(4):1070–4. PMID: 16528001. [PubMed: 16528001]
  22. Blackshear JL, Johnson WD, Odell JA, et al. Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation. J Am Coll Cardiol. 2003;42(7):1249–52. PMID: 14522490. [PubMed: 14522490]
  23. Block PC, Burstein S, Casale PN, et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovasc Interv. 2009;2(7):594–600. PMID: 19628179. [PubMed: 19628179]
  24. Bollmann A, Husser D, Lindgren A, et al. Atrial fibrillatory rate and risk of stroke in atrial fibrillation. Europace. 2009;11(5):582–6. PMID: 19287016. [PubMed: 19287016]
  25. Boriani G, Botto GL, Padeletti L, et al. Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke. 2011;42(6):1768–70. PMID: 21493904. [PubMed: 21493904]
  26. Boulanger L, Hauch O, Friedman M, et al. Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation. Ann Pharmacother. 2006;40(6):1024–9. PMID: 16735649. [PubMed: 16735649]
  27. Bover R, Perez-Gomez F, Maluenda MP, et al. Long-term follow-up of atrial fibrillation patients in the NASPEAF study. Prospective evaluation of different antiplatelet treatments. Rev Esp Cardiol. 2009;62(9):992–1000. PMID: 19712620. [PubMed: 19712620]
  28. Cha MJ, Oh GC, Hahn S, et al. Thromboembolic risk evaluation in patients with atrial fibrillation using a modified CHADS(2) scoring system. J Cardiovasc Electrophysiol. 2012;23(2):155–62. PMID: 21955174. [PubMed: 21955174]
  29. Chae SH, Froehlich J, Morady F, et al. Prevalence and predictors of warfarin use in patients with atrial fibrillation at low or intermediate risk and relation to thromboembolic events. Clin Cardiol. 2011;34(10):640–4. PMID: 21994084. [PMC free article: PMC6652735] [PubMed: 21994084]
  30. Chan KE, Lazarus JM, Thadhani R, et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20(10):2223–33. PMID: 19713308. [PMC free article: PMC2754104] [PubMed: 19713308]
  31. Connolly SJ, Eikelboom JW, Ng J, et al. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med. 2011;155(9):579–86. PMID: 22041946. [PubMed: 22041946]
  32. Conway DS, Pearce LA, Chin BS, et al. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation. 2003;107(25):3141–5. PMID: 12796127. [PubMed: 12796127]
  33. Copland M, Walker ID, Tait RC. Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med. 2001;161(17):2125–8. PMID: 11570942. [PubMed: 11570942]
  34. Corbi IS, Dantas RA, Pelegrino FM, et al. Health related quality of life of patients undergoing oral anticoagulation therapy. Rev Lat Am Enfermagem. 2011;19(4):865–73. PMID: 21876937. [PubMed: 21876937]
  35. Corrado G, Beretta S, Sormani L, et al. Prevalence of atrial thrombi in patients with atrial fibrillation/flutter and subtherapeutic anticoagulation prior to cardioversion. Eur J Echocardiogr. 2004;5(4):257–61. PMID: 15219540. [PubMed: 15219540]
  36. Corrado G, Santarone M, Beretta S, et al. Early cardioversion of atrial fibrillation and atrial flutter guided by transoesophageal echocardiography: a single centre 8.5-year experience. Europace. 2000;2(2):119–26. PMID: 11225938. [PubMed: 11225938]
  37. Currie CJ, Jones M, Goodfellow J, et al. Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin. Heart. 2006;92(2):196–200. PMID: 15883133. [PMC free article: PMC1860757] [PubMed: 15883133]
  38. Currie CJ, McEwan P, Emmas C, et al. Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population. Curr Med Res Opin. 2005;21(12):1905–13. PMID: 16368039. [PubMed: 16368039]
  39. Damonte AA, Costantini C, Montenegro M, et al. Percutaneous closure of the left atrial appendage with the Amplatzer Cardiac Plug: Initial Latin American experience. J Am Coll Cardiol. 2011;58(20):B192.
  40. Darkow T, Vanderplas AM, Lew KH, et al. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin. 2005;21(10):1583–94. PMID: 16238898. [PubMed: 16238898]
  41. Das AK, Willcoxson PD, Corrado OJ, et al. The impact of long-term warfarin on the quality of life of elderly people with atrial fibrillation. Age Ageing. 2007;36(1):95–7. PMID: 16799180. [PubMed: 16799180]
  42. De Caterina R, Connolly SJ, Pogue J, et al. Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. Eur Heart J. 2010;31(17):2133–40. PMID: 20685676. [PubMed: 20685676]
  43. Di Biase L, Burkhardt JD, Mohanty P, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation. 2010;121(23):2550–6. PMID: 20516376. [PubMed: 20516376]
  44. DiMarco JP, Flaker G, Waldo AL, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149(4):650–6. PMID: 15990748. [PubMed: 15990748]
  45. Douketis JD, Arneklev K, Goldhaber SZ, et al. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med. 2006;166(8):853–9. PMID: 16636210. [PubMed: 16636210]
  46. Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost. 2007;5(11):2211–8. PMID: 17697140. [PubMed: 17697140]
  47. Ederhy S, Di Angelantonio E, Dufaitre G, et al. C-reactive protein and transesophageal echocardiographic markers of thromboembolism in patients with atrial fibrillation. Int J Cardiol. 2012;159(1):40–6. PMID: 21402418. [PubMed: 21402418]
  48. Edvardsson N, Juul-Moller S, Omblus R, et al. Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. J Intern Med. 2003;254(1):95–101. PMID: 12823646. [PubMed: 12823646]
  49. Elliott DJ, Zhao L, Jasper SE, et al. Health status outcomes after cardioversion for atrial fibrillation: results from the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Trial. Am Heart J. 2008;156(2):374.e1–6. PMID: 18657673. [PubMed: 18657673]
  50. Evans A, Perez I, Yu G, et al. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation?. Stroke. 2001;32(12):2828–32. PMID: 11739981. [PubMed: 11739981]
  51. Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010;122(22):2246–53. PMID: 21147728. [PubMed: 21147728]
  52. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141(10):745–52. PMID: 15545674. [PubMed: 15545674]
  53. Fang MC, Go AS, Chang Y, et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke. 2012;43(7):1795–9. PMID: 22539546. [PMC free article: PMC3383879] [PubMed: 22539546]
  54. Fang MC, Go AS, Hylek EM, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006;54(8):1231–6. PMID: 16913990. [PMC free article: PMC3534958] [PubMed: 16913990]
  55. Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005;112(12):1687–91. PMID: 16157766. [PMC free article: PMC3522521] [PubMed: 16157766]
  56. Flaker GC, Gruber M, Connolly SJ, et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J. 2006;152(5):967–73. PMID: 17070169. [PubMed: 17070169]
  57. Flaker GC, Pogue J, Yusuf S, et al. Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3(3):277–83. PMID: 20233976. [PubMed: 20233976]
  58. Friberg L, Benson L, Rosenqvist M, et al. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ. 2012;344:e3522. PMID: 22653980. [PMC free article: PMC3365143] [PubMed: 22653980]
  59. Friberg L, Benson L, Rosenqvist M, et al. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: Nationwide retrospective cohort study. BMJ. 2012; 344:e3522. PMID: 22653980. [PMC free article: PMC3365143] [PubMed: 22653980]
  60. Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106(5):968–77. PMID: 21901239. [PubMed: 21901239]
  61. Gautam S, John RM, Stevenson WG, et al. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22(3):248–54. PMID: 20812929. [PubMed: 20812929]
  62. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. JAMA. 2003;290(20):2685–92. PMID: 14645310. [PubMed: 14645310]
  63. Gomberg-Maitland M, Wenger NK, Feyzi J, et al. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J. 2006;27(16):1947–53. PMID: 16774980. [PubMed: 16774980]
  64. Gorin L, Fauchier L, Nonin E, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thromb Haemost. 2010;103(4):833–40. PMID: 20135077. [PubMed: 20135077]
  65. Guerin A, Lin J, Jhaveri M, et al. Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy. Int J Cardiol. 2012. PMID: 22336254. [PubMed: 22336254]
  66. Guerios EE, Schmid M, Gloekler S, et al. Left atrial appendage closure with the Amplatzer Cardiac Plug in patients with atrial fibrillation. Arq Bras Cardiol. 2012;98(6):528–36. PMID: 22584492. [PubMed: 22584492]
  67. Guiot A, Jongnarangsin K, Chugh A, et al. Anticoagulant Therapy and Risk of Cerebrovascular Events After Catheter Ablation of Atrial Fibrillation in the Elderly. J Cardiovasc Electrophysiol. 2011;23(1):36–43. PMID: 21806701. [PubMed: 21806701]
  68. Guo Y, Wu Q, Zhang L, et al. Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?. Clin Interv Aging. 2010;5:157–62. PMID: 20517485. [PMC free article: PMC2877526] [PubMed: 20517485]
  69. Ha SI, Choi DH, Ki YJ, et al. Stroke prediction using mean platelet volume in patients with atrial fibrillation. Platelets. 2011;22(6):408–14. PMID: 21599611. [PubMed: 21599611]
  70. Hakalahti A, Uusimaa P, Ylitalo K, et al. Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment. Europace. 2011;13(5):640–5. PMID: 21398311. [PubMed: 21398311]
  71. Halbfass P, Janko S, Dorwarth U, et al. Dilemma of antithrombotic therapy in anticoagulated atrial fibrillation patients squeezed between thrombosis and bleeding events: a single-centre experience. Europace. 2009;11(7):957–60. PMID: 19493910. [PubMed: 19493910]
  72. Harley CR, Riedel AA, Hauch O, et al. Anticoagulation therapy in patients with chronic atrial fibrillation: a retrospective claims data analysis. Curr Med Res Opin. 2005;21(2):215–22. PMID: 15801992. [PubMed: 15801992]
  73. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 2000;35(1):183–7. PMID: 10636278. [PubMed: 10636278]
  74. He H, Kang J, Tao H, et al. Conventional oral anticoagulation may not replace prior transesophageal echocardiography for the patients with planned catheter ablation for atrial fibrillation. J Interv Card Electrophysiol. 2009;24(1):19–26. PMID: 18982437. [PubMed: 18982437]
  75. Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012;125(13):1605–16. PMID: 22374183. [PubMed: 22374183]
  76. Hori M, Connolly SJ, Ezekowitz MD, et al. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation-sub-analysis in Japanese population in RE-LY trial. Circ J. 2011;75(4):800–5. PMID: 21436594. [PubMed: 21436594]
  77. Humphries J, Phillips K. First 12 months experience and clinical outcomes after Watchman® left atrial appendage occlusion procedure: Case series in a single centre. Heart Lung Circul. 2011;20(Suppl.2):S126.
  78. Hussein AA, Martin DO, Saliba W, et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm. 2009;6(10):1425–9. PMID: 19968920. [PubMed: 19968920]
  79. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689–96. PMID: 17515465. [PubMed: 17515465]
  80. Hylek EM, Frison L, Henault LE, et al. Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. Stroke. 2008;39(11):3009–14. PMID: 18703812. [PubMed: 18703812]
  81. Indredavik B, Rohweder G, Lydersen S. Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation. J Intern Med. 2005;258(2):133–44. PMID: 16018790. [PubMed: 16018790]
  82. Jaffer AK, Ahmed M, Brotman DJ, et al. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. J Thromb Thrombolysis. 2005;20(1):11–6. PMID: 16133889. [PubMed: 16133889]
  83. Jang SW, Rho TH, Kim DB, et al. Optimal antithrombotic strategy in patients with atrial fibrillation after coronary stent implantation. Korean Circ J. 2011;41(10):578–82. PMID: 22125556. [PMC free article: PMC3221899] [PubMed: 22125556]
  84. Joffe HV, Goldhaber SZ. Effectiveness and safety of long-term anticoagulation of patients >/=90 years of age with atrial fibrillation. Am J Cardiol. 2002;90(12):1397–8. PMID: 12480055. [PubMed: 12480055]
  85. Johnson CE, Lim WK, Workman BS. People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up. J Am Geriatr Soc. 2005;53(4):655–9. PMID: 15817013. [PubMed: 15817013]
  86. Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart. 2005;91(4):472–7. PMID: 15772203. [PMC free article: PMC1768813] [PubMed: 15772203]
  87. Kalra L, Yu G, Perez I, et al. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ. 2000;320(7244):1236–9. PMID: 10797031. [PMC free article: PMC27364] [PubMed: 10797031]
  88. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344(19):1411–20. PMID: 11346805. [PubMed: 11346805]
  89. Klem I, Wehinger C, Schneider B, et al. Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up. Diabetes Metab Res Rev. 2003;19(4):320–8. PMID: 12879410. [PubMed: 12879410]
  90. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004;110(12):1658–63. PMID: 15364803. [PubMed: 15364803]
  91. Kukula K, Klopotowski M, Konka M, et al. Left atrial appendage occlusion using the PLAATO system in high-risk patients with atrial fibrillation - Long-term follow-up. Postepy Kardiol Interwencyjnej. 2009;5(2):51–7.
  92. Lai HM, Aronow WS, Kalen P, et al. Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renovasc Dis. 2009;2:33–7. PMID: 21694919. [PMC free article: PMC3108764] [PubMed: 21694919]
  93. Lam YY, Yip GW, Yu CM, et al. Left atrial appendage closure with Amplatzer cardiac plug for stroke prevention in atrial fibrillation: Initial Asia-Pacific experience. Catheter Cardiovasc Interv. 2011;78(1):S173. PMID: 21542102. [PubMed: 21542102]
  94. Lee SJ, Shin DH, Hwang HJ, et al. Bleeding risk and major adverse events in patients with previous ulcer on oral anticoagulation therapy. Am J Cardiol. 2012;110(3):373–7. PMID: 22516526. [PubMed: 22516526]
  95. Leiria TLL, Pellanda L, Miglioranza MH, et al. Warfarin and phenprocoumon: Experience of an Outpatient Anticoagulation Clinic. Arq Bras Cardiol. 2010;94(1):40–3. [PubMed: 20414525]
  96. Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. Thromb Res. 2011;127(2):91–9. PMID: 21172721. [PubMed: 21172721]
  97. Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J. 2009;30(23):2897–907. PMID: 19690349. [PMC free article: PMC2785945] [PubMed: 19690349]
  98. Lorgat F, Pudney E, Van Deventer H, et al. Robotically controlled ablation for atrial fibrillation: The first real-world experience in Africa with the Hansen robotic system. Cardiovasc J Afr. 2012;23(5):274–80. PMID: 22447186. [PMC free article: PMC3721926] [PubMed: 22447186]
  99. Mahe I, Bergmann JF, Chassany O, et al. A multicentric prospective study in usual care: D-dimer and cardiovascular events in patients with atrial fibrillation. Thromb Res. 2012;129(6):693–9. PMID: 21917302. [PubMed: 21917302]
  100. Mahe I, Grenard AS, Joyeux N, et al. Management of oral anticoagulant in clinical practice: a retrospective study of 187 patients. J Gerontol A Biol Sci Med Sci. 2004;59(12):1339–42. PMID: 15699536. [PubMed: 15699536]
  101. Majunke N, Daehnert I, Sick P, et al. Long-term outcome of percutaneous closure of the left atrial appendage with the watchman device. Eur Heart J. 2011;32(Suppl.1):467–8.
  102. Masaki N, Suzuki M, Matsumura A, et al. Quality of warfarin control affects the incidence of stroke in elderly patients with atrial fibrillation. Intern Med. 2010;49(16):1711–6. PMID: 20720347. [PubMed: 20720347]
  103. Mendell J, Basavapathrisni R, Swcaringen D, et al. Thorough qtiqtc study with edoxaban to evaluate effect of therapeutic and supratherapeutic exposure on QTC interval duration en healthy subjects. J Clin Pharmacol. 2009;49(9):1122.
  104. Mendell J, Basavapathruni R, Swearingen D, et al. Thorough QT/QTc study eith edoxaban to evaluate effect of therapeutic and supratherapeutic exposure on QTc interval duration in healthy subjects. Basic Clin Pharmacol Toxicol. 2009;105(Suppl.1):53.
  105. Naganuma M, Shiga T, Sato K, et al. Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: A single-center observational study. Thromb Res. 2012;130(1):21–6. PMID: 22137743. [PubMed: 22137743]
  106. Nakagawa K, Hirai T, Takashima S, et al. Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation. Am J Cardiol. 2011;107(6):912–6. PMID: 21247518. [PubMed: 21247518]
  107. Njaastad AM, Abildgaard U, Lassen JF. Gains and losses of warfarin therapy as performed in an anticoagulation clinic. J Intern Med. 2006;259(3):296–304. PMID: 16476107. [PubMed: 16476107]
  108. Nozawa T, Asanoi H, Inoue H. Instability of anticoagulation intensity contributes to occurrence of ischemic stroke in patients with non-rheumatic atrial fibrillation. Jpn Circ J. 2001;65(5):404–8. PMID: 11357868. [PubMed: 11357868]
  109. Nozawa T, Inoue H, Hirai T, et al. D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol. 2006;109(1):59–65. PMID: 15992948. [PubMed: 15992948]
  110. O’Hara GE, Charbonneau L, Chandler M, et al. Comparison of management patterns and clinical outcomes in patients with atrial fibrillation in Canada and the United States (from the analysis of the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] database). Am J Cardiol. 2005;96(6):815–21. PMID: 16169368. [PubMed: 16169368]
  111. Olsson SB, Rasmussen LH, Tveit A, et al. Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost. 2010;103(3):604–12. PMID: 20076850. [PubMed: 20076850]
  112. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362(9397):1691–8. PMID: 14643116. [PubMed: 14643116]
  113. Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol. 2005;46(1):9–14. PMID: 15992628. [PubMed: 15992628]
  114. Oude Velthuis B, Stevenhagen J, van Opstal JM, et al. Continuation of vitamin K antagonists as acceptable anticoagulation regimen in patients undergoing pulmonary vein isolation. Neth Heart J. 2012;20(1):12–5. PMID: 22161077. [PMC free article: PMC3247635] [PubMed: 22161077]
  115. Paciaroni M, Agnelli G, Ageno W, et al. Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. Atherosclerosis. 2010;212(2):564–6. PMID: 20599199. [PubMed: 20599199]
  116. Park JW, Leithauser B, Gerk U, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO) for stroke prevention in atrial fibrillation: 2-year outcomes. J Invasive Cardiol. 2009;21(9):446–50. PMID: 19726815. [PubMed: 19726815]
  117. Park JW, Sievert H, Schillinger W, et al. Interim data from AMPLATZER® Cardiac Plug registry. J Am Coll Cardiol. 2011;58(20):B33.
  118. Parkash R, Wee V, Gardner MJ, et al. The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study. Can J Cardiol. 2007;23(6):457–61. PMID: 17487290. [PMC free article: PMC2650665] [PubMed: 17487290]
  119. Pearce LA, Hart RG, Halperin JL. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med. 2000;109(1):45–51. PMID: 10936477. [PubMed: 10936477]
  120. Penado S, Cano M, Acha O, et al. Atrial fibrillation as a risk factor for stroke recurrence. Am J Med. 2003;114(3):206–10. PMID: 12637135. [PubMed: 12637135]
  121. Pengo V, Cucchini U, Denas G, et al. Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation. Thromb Haemost. 2010;103(2):442–9. PMID: 20076843. [PubMed: 20076843]
  122. Perera V, Bajorek BV, Matthews S, et al. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing. 2009;38(2):156–62. PMID: 19151165. [PubMed: 19151165]
  123. Pet M, Robertson JO, Bailey M, et al. The impact of CHADS(2) score on late stroke after the Cox maze procedure. J Thorac Cardiovasc Surg. 2012. PMID: 22818126. [PMC free article: PMC4369384] [PubMed: 22818126]
  124. Pichette M, Stevens LM, Noiseux N, et al. Effectiveness of warfarin therapy for atrial fibrillation in a real world population. Can J Cardiol. 2011;27(5):S122.
  125. Poli D, Antonucci E, Grifoni E, et al. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol. 2009;54(11):999–1002. PMID: 19729116. [PubMed: 19729116]
  126. Poli D, Antonucci E, Grifoni E, et al. Low bleeding risk of very old atrial fibrillation women on VKA treatment: Results from a prospective collaborative study. on behalf of the ad hoc Study Group of FCSA. Eur Heart J. 2011;32(Suppl.1):8.
  127. Poli D, Antonucci E, Grifoni E, et al. Risk of bleeding in low-risk atrial fibrillation patients on warfarin waiting for elective cardioversion. Thromb Res. 2012;129(5):588–90. PMID: 21975030. [PubMed: 21975030]
  128. Poli D, Antonucci E, Lombardi A, et al. Low incidence of hemorrhagic complications of oral anticoagulant therapy in patients with atrial fibrillation in the daily practice of an anticoagulation clinic. Ital Heart J. 2003;4(1):44–7. PMID: 12690920. [PubMed: 12690920]
  129. Poli D, Antonucci E, Lombardi A, et al. Management of oral anticoagulant therapy in the real practice of an anticoagulation clinic: focus on atrial fibrillation. Blood Coagul Fibrinolysis. 2005;16(7):491–4. PMID: 16175008. [PubMed: 16175008]
  130. Rasmussen LH, Larsen TB, Due KM, et al. Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: The Danish Diet, Cancer and Health Cohort study. J Thromb Haemost. 2011;9(7):1301–7. PMID: 21535388. [PubMed: 21535388]
  131. Raunso J, Selmer C, Olesen JB, et al. Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur Heart J. 2012;33(15):1886–92. PMID: 22199117. [PubMed: 22199117]
  132. Raunsoe J, Andersen SS, Lamberts M, et al. Increased risk of bleeding during combination therapy with warfarin and ibuprofen in a large population with atrial fibrillation. Eur Heart J. 2011;32(Suppl.1):264–5.
  133. Reynolds MR, Gunnarsson CL, Hunter TD, et al. Health outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation results of a propensity-matched analysis. Circ Cardiovasc Qual Outcomes. 2012;5(2):171–81. PMID: 22373904. [PubMed: 22373904]
  134. Rodes-Cabau J, Champagne J, Bernier M, et al. Transcatheter left atrial appendage closure in high-risk patients with atrial fibrillation who are not eligible for long-term anticoagulation therapy: Initial experience with the amplatzer cardiac plug. Can J Cardiol. 2011;27(5):S160.
  135. Roijer A, Eskilsson J, Olsson B. Transoesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Selection of a low-risk group for immediate cardioversion. Eur Heart J. 2000;21(10):837–47. PMID: 10781356. [PubMed: 10781356]
  136. Rossillo A, Bonso A, Themistoclakis S, et al. Role of anticoagulation therapy after pulmonary vein antrum isolation for atrial fibrillation treatment. J Cardiovasc Med (Hagerstown). 2008;9(1):51–5. PMID: 18268419. [PubMed: 18268419]
  137. Roy B, Desai RV, Mujib M, et al. Effect of Warfarin on Outcomes in Septuagenarian Patients With Atrial Fibrillation. Am J Cardiol. 2012;109(3):370–7. PMID: 22118824. [PMC free article: PMC3390022] [PubMed: 22118824]
  138. Ruigomez A, Garcia Rodriguez LA, Johansson S, et al. Risk of cerebrovascular accident after a first diagnosis of atrial fibrillation. Clin Cardiol. 2007;30(12):624–8. PMID: 18069679. [PMC free article: PMC6653054] [PubMed: 18069679]
  139. Ruiz Ortiz M, Romo E, Mesa D, et al. Outcomes and safety of antithrombotic treatment in patients aged 80 years or older with nonvalvular atrial fibrillation. Am J Cardiol. 2011;107(10):1489–93. PMID: 21420049. [PubMed: 21420049]
  140. Saad EB, d’Avila A, Costa IP, et al. Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS2 score &lt;/=3: a long-term outcome study. Circ Arrhythm Electrophysiol. 2011;4(5):615–21. PMID: 21841192. [PubMed: 21841192]
  141. Sadanaga T, Kohsaka S, Mitamura H, et al. Elevated B-type natriuretic peptide level as a marker of subsequent thromboembolic events in patients with atrial fibrillation. Heart Vessels. 2011;26(5):530–5. PMID: 21188387. [PubMed: 21188387]
  142. Sandhu RK, Bakal JA, Ezekowitz JA, et al. Risk stratification schemes, anticoagulation use and outcomes: The risk - Treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. Heart. 2011;97(24):2046–50. PMID: 22076011. [PubMed: 22076011]
  143. Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006;37(2):447–51. PMID: 16385088. [PubMed: 16385088]
  144. Scaglione M, Blandino A, Raimondo C, et al. Impact of Ablation Catheter Irrigation Design on Silent Cerebral Embolism After Radiofrequency Catheter Ablation of Atrial Fibrillation:Results from a Pilot Study. J Cardiovasc Electrophysiol. 2012;23(8):801–5. PMID: 22494043. [PubMed: 22494043]
  145. Scherr D, Dalal D, Spragg D, et al. Incidence and predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation. Eur Heart J. 2011;32(Suppl.1):805.
  146. Schultz KT, Bungard TJ. Dosing options for decreasing the time to achieve therapeutic anticoagulation when reinitiating warfarin: A case series. Pharmacotherapy. 2011;31(8):793–805. PMID: 21923606. [PubMed: 21923606]
  147. Seidl K, Rameken M, Drogemuller A, et al. Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen Observational Cardioversion Study. J Am Coll Cardiol. 2002;39(9):1436–42. PMID: 11985904. [PubMed: 11985904]
  148. Shen AY, Yao JF, Brar SS, et al. Racial/Ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation. Stroke. 2008;39(10):2736–43. PMID: 18635860. [PubMed: 18635860]
  149. Shen AY, Yao JF, Brar SS, et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50(4):309–15. PMID: 17659197. [PubMed: 17659197]
  150. Sherman DG, Kim SG, Boop BS, et al. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med. 2005;165(10):1185–91. PMID: 15911734. [PubMed: 15911734]
  151. Shin HW, Kim H, Son J, et al. Tissue Doppler imaging as a prognostic marker for cardiovascular events in heart failure with preserved ejection fraction and atrial fibrillation. J Am Soc Echocardiogr. 2010;23(7):755–61. PMID: 20620861. [PubMed: 20620861]
  152. Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2007;49(13):1490–5. PMID: 17397680. [PubMed: 17397680]
  153. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151(5):297–305. PMID: 19721017. [PMC free article: PMC2777526] [PubMed: 19721017]
  154. Sorino M, Colonna P, De Luca L, et al. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study). J Cardiovasc Med (Hagerstown). 2007;8(12):1034–42. PMID: 18163016. [PubMed: 18163016]
  155. Stenestrand U, Lindback J, Wallentin L. Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Circulation. 2005;112(21):3225–31. PMID: 16301355. [PubMed: 16301355]
  156. Sun Y, Hu D, Li K, et al. Predictors of stroke risk in native Chinese with nonrheumatic atrial fibrillation: retrospective investigation of hospitalized patients. Clin Cardiol. 2009;32(2):76–81. PMID: 19215006. [PMC free article: PMC6652905] [PubMed: 19215006]
  157. Suzuki S, Yamashita T, Kato T, et al. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ J. 2007;71(5):761–5. PMID: 17457005. [PubMed: 17457005]
  158. Tangelder MJ, Frison L, Weaver D, et al. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial. Am Heart J. 2008;155(2):382–7. PMID: 18215612. [PubMed: 18215612]
  159. Tebbe U, Oeckinghaus R, Appel KF, et al. AFFECT: a prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation. Clin Res Cardiol. 2008;97(6):389–96. PMID: 18322636. [PubMed: 18322636]
  160. Thambidorai SK, Murray RD, Parakh K, et al. Utility of transesophageal echocardiography in identification of thrombogenic milieu in patients with atrial fibrillation (an ACUTE ancillary study). Am J Cardiol. 2005;96(7):935–41. PMID: 16188520. [PubMed: 16188520]
  161. Themistoclakis S, Corrado A, Marchlinski FE, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol. 2010;55(8):735–43. PMID: 20170810. [PubMed: 20170810]
  162. Tincani E, Baldini P, Crowther MA, et al. Bleeding rates in patients older than 90 years of age on vitamin K antagonist therapy for nonvalvular atrial fibrillation. Blood Coagul Fibrinolysis. 2009;20(1):47–51. PMID: 20523164. [PubMed: 20523164]
  163. Tinkler K, Cullinane M, Kaposzta Z, et al. Asymptomatic embolisation in non-valvular atrial fibrillation and its relationship to anticoagulation therapy. Eur J Ultrasound. 2002;15(1-2):21–7. PMID: 12044849. [PubMed: 12044849]
  164. Tinmouth AH, Morrow BH, Cruickshank MK, et al. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother. 2001;35(6):669–74. PMID: 11408982. [PubMed: 11408982]
  165. Torn M, Cannegieter SC, Bollen WL, et al. Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch Intern Med. 2009;169(13):1203–9. PMID: 19597069. [PubMed: 19597069]
  166. Toumanides S, Sideris EB, Agricola T, et al. Transcatheter patch occlusion of the left atrial appendage using surgical adhesives in high-risk patients with atrial fibrillation. J Am Coll Cardiol. 2011;58(21):2236–40. PMID: 22078431. [PubMed: 22078431]
  167. Trullas-Vila JC, Bisbe-Company J, Freitas-Ramirez A, et al. Ten-year experience with acenocoumarol treatment in an ambulatory cohort of Spanish patients. J Thromb Thrombolysis. 2009;28(4):436–43. PMID: 19225864. [PubMed: 19225864]
  168. Ussia GP, Mule M, Cammalleri V, et al. Percutaneous closure of left atrial appendage to prevent embolic events in high-risk patients with chronic atrial fibrillation. Catheter Cardiovasc Interv. 2009;74(2):217–22. PMID: 19472361. [PubMed: 19472361]
  169. Vazquez E, Sanchez-Perales C, Garcia-Cortes MJ, et al. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants?. Int J Cardiol. 2003;87(2-3):135–9; discussion 139-41. PMID: 12559531. [PubMed: 12559531]
  170. Viles-Gonzalez JF, Reddy VY, Petru J, et al. Incomplete occlusion of the left atrial appendage with the percutaneous left atrial appendage transcatheter occlusion device is not associated with increased risk of stroke. J Interv Card Electrophysiol. 2012;33(1):69–75. PMID: 21947786. [PubMed: 21947786]
  171. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975–83. PMID: 20801496. [PubMed: 20801496]
  172. Weigner MJ, Thomas LR, Patel U, et al. Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. Am J Med. 2001;110(9):694–702. PMID: 11403753. [PubMed: 11403753]
  173. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167(3):239–45. PMID: 17296878. [PubMed: 17296878]
  174. Wieloch M, Sjalander A, Frykman V, et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J. 2011;32(18):2282–9. PMID: 21616951. [PubMed: 21616951]
  175. Wiesholzer M, Harm F, Tomasec G, et al. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol. 2001;21(1):35–9. PMID: 11275630. [PubMed: 11275630]
  176. Winkelmayer WC, Liu J, Setoguchi S, et al. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol. 2011;6(11):2662–8. PMID: 21959598. [PMC free article: PMC3206003] [PubMed: 21959598]
  177. Winkle RA, Mead RH, Engel G, et al. The Use of Dabigatran Immediately After Atrial Fibrillation Ablation. J Cardiovasc Electrophysiol. 2012;23(3):264–8. PMID: 21955008. [PubMed: 21955008]
  178. Wysokinski WE, McBane RD, Daniels PR, et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc. 2008;83(6):639–45. PMID: 18533080. [PubMed: 18533080]
  179. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med. 2001;40(12):1183–8. PMID: 11813841. [PubMed: 11813841]

No Outcomes of Interest-2012

  1. Abe Y, Asakura T, Gotou J, et al. Prediction of embolism in atrial fibrillation: classification of left atrial thrombi by transesophageal echocardiography. Jpn Circ J. 2000;64(6):411–5. PMID: 10875730. [PubMed: 10875730]
  2. Alessandri N, Mariani S, Ciccaglioni A, et al. Thrombus formation in the left atrial appendage in the course of atrial fibrillation. Eur Rev Med Pharmacol Sci. 2003;7(3):65–73. PMID: 14650642. [PubMed: 14650642]
  3. Ali A, Bailey C and Abdelhafiz AH. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis. Age Ageing. 2012;41(5):681–4. PMID: 22378612. [PubMed: 22378612]
  4. Anonymous. Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan. - Subanalysis of the J-RHYTHM Registry. Circ J. 2011;75(10):2357–62. PMID: 21791869. [PubMed: 21791869]
  5. Audebert HJ, Schenk B, Schenkel J, et al. Impact of prestroke oral anticoagulation on severity and outcome of ischemic and hemorrhagic stroke in patients with atrial fibrillation. Cerebrovasc Dis. 2010;29(5):476–83. PMID: 20299787. [PubMed: 20299787]
  6. Berisha B, Gashi M, Krasniqi X, et al. Limitations of CHADS2 scoring system in predicting stroke risk-need to change the age criteria. Med Arh. 2011;65(1):27–9. PMID: 21534448. [PubMed: 21534448]
  7. Bernhardt P, Schmidt H, Hammerstingl C, et al. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J Am Coll Cardiol. 2005;45(11):1807–12. PMID: 15936610. [PubMed: 15936610]
  8. Bernhardt P, Schmidt H, Hammerstingl C, et al. Fate of left atrial thrombi in patients with atrial fibrillation determined by transesophageal echocardiography and cerebral magnetic resonance imaging. Am J Cardiol. 2004;94(6):801–4. PMID: 15374795. [PubMed: 15374795]
  9. Cemri M, Timurkaynak T, Ozdemir M, et al. Effects of left ventricular systolic dysfunction on left atrial appendage and left atrial functions in patients with chronic nonvalvular atrial fibrillation. Acta Cardiol. 2002;57(2):101–5. PMID: 12003255. [PubMed: 12003255]
  10. Chan PS, Maddox TM, Tang F, et al. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J Cardiol. 2011;108(8):1136–40. PMID: 21798501. [PMC free article: PMC3584710] [PubMed: 21798501]
  11. Chao TF, Liu CJ, Chen SJ, et al. Atrial fibrillation and the risk of ischemic stroke: Does it still matter in patients with a CHA2DS2-VASc score of 0 or 1?. Stroke. 2012;43(10):2551–5. PMID: 22871677. [PubMed: 22871677]
  12. Chilukuri K, Mayer SA, Scherr D, et al. Transoesophageal echocardiography predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation. Europace. 2010;12(11):1543–9. PMID: 20682553. [PubMed: 20682553]
  13. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118(20):2029–37. PMID: 18955670. [PubMed: 18955670]
  14. Conway DS, Buggins P, Hughes E, et al. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation. Am J Cardiol. 2004;93(11):1368–73, A6. PMID: 15165916. [PubMed: 15165916]
  15. Daccarett M, Badger TJ, Akoum N, et al. Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol. 2011;57(7):831–8. PMID: 21310320. [PMC free article: PMC3124509] [PubMed: 21310320]
  16. Di Angelantonio E, Ederhy S, Benyounes N, et al. Comparison of transesophageal echocardiographic identification of embolic risk markers in patients with lone versus non-lone atrial fibrillation. Am J Cardiol. 2005;95(5):592–6. PMID: 15721097. [PubMed: 15721097]
  17. Di Biase L, Gaita F, Salvetti I, et al. Left atrial appendage morphology correlates with a reduced risk for stroke in patients with AF. Eur Heart J. 2011;32(Suppl.1):7.
  18. Di Biase L, Santangeli P, Anselmino M, et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation?: results from a multicenter study. J Am Coll Cardiol. 2012;60(6):531–8. PMID: 22858289. [PubMed: 22858289]
  19. Dinh T, Baur LH, Pisters R, et al. Feasibility of TEE-guided stroke risk assessment in atrial fibrillation-background, aims, design and baseline data of the TIARA pilot study. Neth Heart J. 2011;19(5):214–22. PMID: 21541835. [PMC free article: PMC3087029] [PubMed: 21541835]
  20. Dores H, Cardiga R, Ferreira R, et al. Atrial fibrillation and thromboembolic risk: what is the extent of adherence to guidelines in clinical practice?. Rev Port Cardiol. 2011;30(2):171–80. PMID: 21553610. [PubMed: 21553610]
  21. Ellis DJ, Usman MH, Milner PG, et al. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation. 2009;120(12):1029–35, 2 p following 1035. PMID: 19738136. [PubMed: 19738136]
  22. Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157(5):805–10, 810e1–2. PMID: 19376304. [PubMed: 19376304]
  23. Fonseca N, Caetano F, Santos J, et al. Transesophageal echocardiography-guided cardioversion of atrial fibrillation. Selection of a low-risk group for immediate cardioversion. Rev Port Cardiol. 2004;23(3):365–75. PMID: 15185562. [PubMed: 15185562]
  24. Friberg L, Rosenqvist M and Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125(19):2298–307. PMID: 22514252. [PubMed: 22514252]
  25. Fukuda S, Watanabe H, Shimada K, et al. Left atrial thrombus and prognosis after anticoagulation therapy in patients with atrial fibrillation. J Cardiol. 2011;58(3):266–77. PMID: 21824749. [PubMed: 21824749]
  26. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110(16):2287–92. PMID: 15477396. [PubMed: 15477396]
  27. Gaita F, Caponi D, Pianelli M, et al. Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation. 2010;122(17):1667–73. PMID: 20937975. [PubMed: 20937975]
  28. Ghate SR, Biskupiak JE, Ye X, et al. Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis. Ann Pharmacother. 2011;45(6):701–12. PMID: 21666081. [PubMed: 21666081]
  29. Giralt-Steinhauer E, Cuadrado-Godia E, Ois A, et al. Comparison between CHADS (2) and CHA (2) DS (2)-VASc score in a stroke cohort with atrial fibrillation. Eur J Neurol. 2012. PMID: 22834861. [PubMed: 22834861]
  30. Go AS, Hylek EM, Phillips KA, et al. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation. 2000;102(1):11–3. PMID: 10880408. [PubMed: 10880408]
  31. Gupta S, Wagner JS, Goren A, et al. The risk of stroke and preventative steps among patients diagnosed with atrial fibrillation in the United States. Value Health. 2011;14(3):A45.
  32. Haeusler KG, Konieczny M, Endres M, et al. Impact of anticoagulation before stroke on stroke severity and long-term survival. Int J Stroke. 2011. PMID: 22111868. [PubMed: 22111868]
  33. Hanna IR, Kolm P, Martin R, et al. Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO): six-month echocardiographic follow-up. J Am Coll Cardiol. 2004;43(10):1868–72. PMID: 15145113. [PubMed: 15145113]
  34. Ho LY, Siu CW, Yue WS, et al. Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial fibrillation and hypertension. J Hum Hypertens. 2011;25(5):304–10. PMID: 20596062. [PubMed: 20596062]
  35. Hoppensteadt D, Fareed J, Klein AL, et al. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation. Am J Cardiol. 2008;102(7):842–6. PMID: 18805108. [PubMed: 18805108]
  36. Igarashi Y, Kasai H, Yamashita F, et al. Lipoprotein(a), left atrial appendage function and thromboembolic risk in patients with chronic nonvalvular atrial fibrillation. Jpn Circ J. 2000;64(2):93–8. PMID: 10716521. [PubMed: 10716521]
  37. Ilercil A, Kondapaneni J, Hla A, et al. Influence of age on left atrial appendage function in patients with nonvalvular atrial fibrillation. Clin Cardiol. 2001;24(1):39–44. PMID: 11195605. [PMC free article: PMC6654982] [PubMed: 11195605]
  38. Ilic LM, Goldenberg EM. CHADS2 score predicts time interval free of atrial fibrillation in patients with symptomatic paroxysmal atrial fibrillation. Int J Cardiol. 2010;145(3):576–7. PMID: 20580106. [PubMed: 20580106]
  39. Inoue H, Atarashi H. Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation. Am J Cardiol. 2000;86(8):852–5. PMID: 11024400. [PubMed: 11024400]
  40. Inoue H, Nozawa T, Hirai T, et al. Sex-related differences in the risk factor profile and medications of patients with atrial fibrillation recruited in J-TRACE. Circ J. 2010;74(4):650–4. PMID: 20173301. [PubMed: 20173301]
  41. Ito T, Suwa M, Kobashi A, et al. Integrated backscatter assessment of left atrial spontaneous echo contrast in chronic nonvalvular atrial fibrillation: relation with clinical and echocardiographic parameters. J Am Soc Echocardiogr. 2000;13(7):666–73. PMID: 10887351. [PubMed: 10887351]
  42. Ito T, Suwa M, Nakamura T, et al. Quantification of left atrial appendage spontaneous echo contrast in patients with chronic nonalvular atrial fibrillation. J Cardiol. 2001;37(6):325–33. PMID: 11433808. [PubMed: 11433808]
  43. Jorge E, Pereira FS, Baptista R, et al. Anticoagulation in elderly patients with atrial fibrillation from the guidelines to the daily medical practice ORIGINAL (NON-ENGLISH) TITLE Terapeutica anti trombotica no idoso com fibrilhacao auricular das guidelines a pratica clinica. Acta Med Port. 2011;24(Suppl.2):293–300. PMID: 22849915. [PubMed: 22849915]
  44. Kamath S, Blann AD, Chin BS, et al. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol. 2002;40(3):484–90. PMID: 12142115. [PubMed: 12142115]
  45. Kaneko K, Hirono O, Fatema K, et al. Direct evidence that sustained dysfunction of left atrial appendage contributes to the occurrence of cardiogenic brain embolism in patients with paroxysmal atrial fibrillation. Intern Med. 2003;42(11):1077–83. PMID: 14686745. [PubMed: 14686745]
  46. Kawabata H, Pan X, Simon T, et al. Examining the association between discontinuation of warfarin and preceding bleeding, during or resulting in hospitalization, in patients with atrial fibrillation. Eur Heart J. 2011;32(Suppl.1):466.
  47. Khumri TM, Idupulapati M, Rader VJ, et al. Clinical and echocardiographic markers of mortality risk in patients with atrial fibrillation. Am J Cardiol. 2007;99(12):1733–6. PMID: 17560884. [PubMed: 17560884]
  48. King A. Atrial fibrillation: Is dabigatran cost-effective compared with warfarin in patients with AF?. Nat Rev Cardiol. 2011;9(1):3. PMID: 22124320. [PubMed: 22124320]
  49. Kleemann T, Becker T, Strauss M, et al. Prevalence and clinical impact of left atrial thrombus and dense spontaneous echo contrast in patients with atrial fibrillation and low CHADS2 score. Eur J Echocardiogr. 2009;10(3):383–8. PMID: 18835820. [PubMed: 18835820]
  50. Klein AL, Murray RD, Grimm RA, et al. Bleeding complications in patients with atrial fibrillation undergoing cardioversion randomized to transesophageal echocardiographically guided and conventional anticoagulation therapies. Am J Cardiol. 2003;92(2):161–5. PMID: 12860217. [PubMed: 12860217]
  51. Laguna P, Martin A, Del Arco C, et al. Differences among clinical classification schemes for predicting stroke in atrial fibrillation: implications for therapy in daily practice. Acad Emerg Med. 2005;12(9):828–34. PMID: 16141016. [PubMed: 16141016]
  52. Lam YY, Yip GW, Yu CM, et al. Left atrial appendage closure with AMPLATZER cardiac plug for stroke prevention in atrial fibrillation: initial Asia-Pacific experience. Catheter Cardiovasc Interv. 2012;79(5):794–800. PMID: 21542102. [PubMed: 21542102]
  53. Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke. 2000;31(4):828–33. PMID: 10753983. [PubMed: 10753983]
  54. Lidell C, Svedberg LE, Lindell P, et al. Clopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation. Thromb Haemost. 2003;89(5):842–6. PMID: 12719782. [PubMed: 12719782]
  55. Lin LY, Lee CH, Yu CC, et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation- a nation wide database analysis. Atherosclerosis. 2011;217(1):292–5. PMID: 21513938. [PubMed: 21513938]
  56. Maehama T, Okura H, Imai K, et al. Usefulness of CHADS2 score to predict C-reactive protein, left atrial blood stasis, and prognosis in patients with nonrheumatic atrial fibrillation. Am J Cardiol. 2010;106(4):535–8. PMID: 20691312. [PubMed: 20691312]
  57. Maltagliati A, Pepi M, Tamborini G, et al. Usefulness of multiplane transesophageal echocardiography in the recognition of artifacts and normal anatomical variants that may mimic left atrial thrombi in patients with atrial fibrillation. Ital Heart J. 2003;4(11):797–802. PMID: 14699710. [PubMed: 14699710]
  58. Mason PK, Lake DE, DiMarco JP, et al. Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. Am J Med. 2012;125(6):603.e1–6. PMID: 22502952. [PMC free article: PMC4555351] [PubMed: 22502952]
  59. McBane RD, Hodge DO, Wysokinski WE. Clinical and echocardiographic measures governing thromboembolism destination in atrial fibrillation. Thromb Haemost. 2008;99(5):951–5. PMID: 18449427. [PubMed: 18449427]
  60. Meier B, Palacios I, Windecker S, et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv. 2003;60(3):417–22. PMID: 14571497. [PubMed: 14571497]
  61. Mortada ME, Chandrasekaran K, Nangia V, et al. Periprocedural anticoagulation for atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2008;19(4):362–6. PMID: 18284509. [PubMed: 18284509]
  62. Muller I, Massberg S, Zierhut W, et al. Effects of aspirin and clopidogrel versus oral anticoagulation on platelet function and on coagulation in patients with nonvalvular atrial fibrillation (CLAFIB). Pathophysiol Haemost Thromb. 2002;32(1):16–24. PMID: 12214159. [PubMed: 12214159]
  63. Naccarelli GV, Panaccio MP, Cummins G, et al. CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients. Am J Cardiol. 2012;109(10):1526–33. PMID: 22360819. [PubMed: 22360819]
  64. Nakagawa K, Hirai T, Shinokawa N, et al. Aortic spontaneous echocardiographic contrast and hemostatic markers in patients with nonrheumatic atrial fibrillation. Chest. 2002;121(2):500–5. PMID: 11834664. [PubMed: 11834664]
  65. Ohyama H, Hosomi N, Takahashi T, et al. Comparison of magnetic resonance imaging and transesophageal echocardiography in detection of thrombus in the left atrial appendage. Stroke. 2003;34(10):2436–9. PMID: 12970519. [PubMed: 12970519]
  66. Okada Y, Shibazaki K, Kimura K, et al. Brain natriuretic peptide is a marker associated with thrombus in stroke patients with atrial fibrillation. J Neurol Sci. 2011;301(1-2):86–9. PMID: 21094497. [PubMed: 21094497]
  67. Olshansky B, Heller EN, Mitchell LB, et al. Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? Results from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. J Am Coll Cardiol. 2005;45(12):2026–33. PMID: 15963405. [PubMed: 15963405]
  68. Olsson LG, Swedberg K, Lappas G, et al. Trends in stroke incidence after hospitalization for atrial fibrillation in Sweden 1987 to 2006. Int J Cardiol. 2012. PMID: 22464487. [PubMed: 22464487]
  69. Omran H, Hardung D, Schmidt H, et al. Mechanical occlusion of the left atrial appendage. J Cardiovasc Electrophysiol. 2003;14:(9 Suppl):S56–9. PMID: 12950520. [PubMed: 12950520]
  70. Ozer N, Tokgozoglu L, Ovunc K, et al. Left atrial appendage function in patients with cardioembolic stroke in sinus rhythm and atrial fibrillation. J Am Soc Echocardiogr. 2000;13(7):661–5. PMID: 10887350. [PubMed: 10887350]
  71. Palm F, Kleemann T, Dos Santos M, et al. Stroke due to atrial fibrillation in a population-based stroke registry (Ludwigshafen Stroke Study) CHADS(2), CHA(2) DS(2) -VASc score, underuse of oral anticoagulation, and implications for preventive measures. Eur J Neurol. 2012. PMID: 22788384. [PubMed: 22788384]
  72. Parikh MG, Aziz Z, Krishnan K, et al. Usefulness of Transesophageal Echocardiography to Confirm Clinical Utility of CHA2DS2-VASc and CHADS2 Scores in Atrial Flutter. Am J Cardiol. 2012;109(4):550–5. PMID: 22133753. [PubMed: 22133753]
  73. Pengo V, Legnani C, Noventa F, et al. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost. 2001;85(3):418–22. PMID: 11307807. [PubMed: 11307807]
  74. Pink J, Lane S, Pirmohamed M, et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: Quantitative benefit-harm and economic analyses. BMJ. 2011; 343:d6333. PMID: 22042753. [PMC free article: PMC3204867] [PubMed: 22042753]
  75. Poli D, Antonucci E, Marcucci R, et al. Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score. Thromb Res. 2007;121(3):347–52. PMID: 17597186. [PubMed: 17597186]
  76. Poli D, Antonucci E, Marcucci R, et al. The quality of anticoagulation on functional outcome and mortality for TIA/stroke in atrial fibrillation patients. Int J Cardiol. 2009;132(1):109–13. PMID: 18180057. [PubMed: 18180057]
  77. Providencia R, Botelho A, Trigo J, et al. Possible refinement of clinical thromboembolism assessment in patients with atrial fibrillation using echocardiographic parameters. Europace. 2012;14(1):36–45. PMID: 21868410. [PubMed: 21868410]
  78. Providencia R, Paiva L, Faustino A, et al. Cardiac troponin I: Prothrombotic risk marker in non-valvular atrial fibrillation. Int J Cardiol. 2012. PMID: 22353438. [PubMed: 22353438]
  79. Providencia RA, Botelho A, Trigo J, et al. May echocardiographic data improve CHADS2 risk score?. Eur Heart J. 2011;32(Suppl.1):322.
  80. Providencia RA, Trigo J, Botelho A, et al. Left atrial deformation for stroke risk prediction in atrial fibrillation: How and where?. Eur Heart J. 2011;32(Suppl.1):562–3.
  81. Puwanant S, Varr BC, Shrestha K, et al. Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation. J Am Coll Cardiol. 2009;54(22):2032–9. PMID: 19926009. [PubMed: 19926009]
  82. Rader VJ, Khumri TM, Idupulapati M, et al. Clinical predictors of left atrial thrombus and spontaneous echocardiographic contrast in patients with atrial fibrillation. J Am Soc Echocardiogr. 2007;20(10):1181–5. PMID: 17566700. [PubMed: 17566700]
  83. Ren JF, Marchlinski FE, Callans DJ. Left atrial thrombus associated with ablation for atrial fibrillation: identification with intracardiac echocardiography. J Am Coll Cardiol. 2004;43(10):1861–7. PMID: 15145112. [PubMed: 15145112]
  84. Ren JF, Marchlinski FE, Callans DJ, et al. Increased intensity of anticoagulation may reduce risk of thrombus during atrial fibrillation ablation procedures in patients with spontaneous echo contrast. J Cardiovasc Electrophysiol. 2005;16(5):474–7. PMID: 15877616. [PubMed: 15877616]
  85. Rodriguez-Manero M, Cordero A, Bertomeu-Gonzalez V, et al. Impact of new criteria for anticoagulant treatment in atrial fibrillation. Rev Esp Cardiol. 2011;64(8):649–53. PMID: 21652133. [PubMed: 21652133]
  86. Roldan V, Marin F, Diaz J, et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost. 2012;10(8):1500–7. PMID: 22681487. [PubMed: 22681487]
  87. Saha SK, Anderson PL, Caracciolo G, et al. Global left atrial strain correlates with CHADS2 risk score in patients with atrial fibrillation. J Am Soc Echocardiogr. 2011;24(5):506–12. PMID: 21477990. [PubMed: 21477990]
  88. Salazar DE, Mendell J, Kastrissios H, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012;107(5):925–34. PMID: 22398655. [PubMed: 22398655]
  89. Salzberg SP, Plass A, Emmert MY, et al. Left atrial appendage clip occlusion: early clinical results. J Thorac Cardiovasc Surg. 2010;139(5):1269–74. PMID: 19880144. [PubMed: 19880144]
  90. Sato S, Yazawa Y, Itabashi R, et al. Pre-admission CHADS2 score is related to severity and outcome of stroke. J Neurol Sci. 2011;307(1-2):149–52. PMID: 21570092. [PubMed: 21570092]
  91. Schmidt H, von der Recke G, Illien S, et al. Prevalence of left atrial chamber and appendage thrombi in patients with atrial flutter and its clinical significance. J Am Coll Cardiol. 2001;38(3):778–84. PMID: 11527633. [PubMed: 11527633]
  92. Schrickel JW, Lickfett L, Lewalter T, et al. Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation. Europace. 2010;12(1):52–7. PMID: 19933517. [PubMed: 19933517]
  93. Shinokawa N, Hirai T, Takashima S, et al. A transesophageal echocardiographic study on risk factors for stroke in elderly patients with atrial fibrillation: a comparison with younger patients. Chest. 2001;120(3):840–6. PMID: 11555518. [PubMed: 11555518]
  94. Shinokawa N, Hirai T, Takashima S, et al. Relation of transesophageal echocardiographic findings to subtypes of cerebral infarction in patients with atrial fibrillation. Clin Cardiol. 2000;23(7):517–22. PMID: 10894440. [PMC free article: PMC6654812] [PubMed: 10894440]
  95. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation. 2002;105(16):1887–9. PMID: 11997272. [PubMed: 11997272]
  96. Singer DE, Chang Y, Fang MC, et al. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes. 2009;2(4):297–304. PMID: 20031854. [PMC free article: PMC2801892] [PubMed: 20031854]
  97. Siracuse JJ, Robich MP, Gautam S, et al. Antiplatelet agents, warfarin, and epidemic intracranial hemorrhage. Surgery. 2010;148(4):724–9; discussion 729-30. PMID: 20727562. [PubMed: 20727562]
  98. Smith SA, Binkley PF, Foraker RE, et al. The Role of Repeat Transesophageal Echocardiography in Patients without Atrial Thrombus Prior to Cardioversion or Ablation. J Am Soc Echocardiogr. 2012;25(10):1106–12. PMID: 22749434. [PMC free article: PMC3742543] [PubMed: 22749434]
  99. Somme D, Corvol A, Lazarovici C, et al. Clinical usefulness in geriatric patients of combining CHADS2 and HEMORR2HAGES scores to guide antithrombotic prophylaxis in atrial fibrillation. Aging Clin Exp Res. 2010;22(4):289–94. PMID: 19996707. [PubMed: 19996707]
  100. Tafur AJ, McBane R, 2nd, Wysokinski WE, et al. Predictors of Major Bleeding in Peri-Procedural Anticoagulation Management. J Thromb Haemost. 2012;10(2):261–7. PMID: 22123000. [PubMed: 22123000]
  101. Takada T, Yasaka M, Nagatsuka K, et al. Blood flow in the left atrial appendage and embolic stroke in nonvalvular atrial fibrillation. Eur Neurol. 2001;46(3):148–52. PMID: 11598333. [PubMed: 11598333]
  102. Thomson R, Eccles M, Wood R, et al. A cautionary note on data sources for evidence-based clinical decisions: warfarin and stroke prevention. Med Decis Making. 2007;27(4):438–47. PMID: 17641140. [PubMed: 17641140]
  103. Valocik G, Kamp O, Mihciokur M, et al. Assessment of the left atrial appendage mechanical function by three-dimensional echocardiography. Eur J Echocardiogr. 2002;3(3):207–13. PMID: 12144840. [PubMed: 12144840]
  104. van Walraven C, Hart RG, Wells GA, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med. 2003;163(8):936–43. PMID: 12719203. [PubMed: 12719203]
  105. Vazquez E, Sanchez-Perales C, Borrego F, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J. 2000;140(6):886–90. PMID: 11099992. [PubMed: 11099992]
  106. Vene N, Mavri A, Kosmelj K, et al. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost. 2003;90(6):1163–72. PMID: 14652652. [PubMed: 14652652]
  107. Viles-Gonzalez JF, Kar S, Douglas P, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol. 2012;59(10):923–9. PMID: 22381428. [PubMed: 22381428]
  108. von der Recke G, Schmidt H, Illien S, et al. Use of transesophageal contrast echocardiography for excluding left atrial appendage thrombi in patients with atrial fibrillation before cardioversion. J Am Soc Echocardiogr. 2002;15(10 Pt 2):1256–61. PMID: 12411914. [PubMed: 12411914]
  109. Wallvik J, Sjalander A, Johansson L, et al. Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scand J Prim Health Care. 2007;25(2):123–8. PMID: 17497491. [PMC free article: PMC3379747] [PubMed: 17497491]
  110. Wang TD, Chen WJ, Su SS, et al. Increased levels of tissue plasminogen activator antigen and factor VIII activity in nonvalvular atrial fibrillation: relation to predictors of thromboembolism. J Cardiovasc Electrophysiol. 2001;12(8):877–84. PMID: 11523531. [PubMed: 11523531]
  111. Weber R, Weimar C, Wanke I, et al. Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy. Stroke. 2012;43(2):350–5. PMID: 22267825. [PMC free article: PMC3266606] [PubMed: 22267825]
  112. Wehinger C, Stollberger C, Langer T, et al. Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke. 2001;32(10):2246–52. PMID: 11588308. [PubMed: 11588308]
  113. Wilke T, Groth A, Mueller S, et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost. 2012;107(6):1053–65. PMID: 22398417. [PubMed: 22398417]
  114. Wysokinski WE, Ammash N, Sobande F, et al. Predicting left atrial thrombi in atrial fibrillation. Am Heart J. 2010;159(4):665–71. PMID: 20362727. [PubMed: 20362727]
  115. Zoppo F, Brandolino G, Berton A, et al. Predictors of left atrium appendage clot detection despite on-target warfarin prevention for atrial fibrillation. J Interv Card Electrophysiol. 2012;35(2):151–8. PMID: 22869388. [PubMed: 22869388]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (5.8M)

In this Page

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...